{"id":2232,"date":"2021-07-08T14:02:11","date_gmt":"2021-07-08T12:02:11","guid":{"rendered":"https:\/\/www.crct-inserm.fr\/v2\/?page_id=2232"},"modified":"2024-03-13T10:24:47","modified_gmt":"2024-03-13T09:24:47","slug":"nolymit","status":"publish","type":"page","link":"https:\/\/www.crct-inserm.fr\/nolymit\/","title":{"rendered":"NoLymIT"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”a00720d8-8e3f-4b20-83b7-6d54485f541c” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”694d3d5d-3e0a-4cd1-b2ba-4eea0d99d5b4″ background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/07\/image-header.png” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”8292df69-9d3c-4423-ab4f-a4755f6c1135″ width_tablet=”85%” width_phone=”” width_last_edited=”on|phone” custom_padding_last_edited=”off|desktop” header_font_size_phone=”31px” global_colors_info=”{}”]<\/p>\n

\u00c9quipe
Camille LAURENT<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ header_2_font=”Open Sans||||||||” global_colors_info=”{}”]<\/p>\n

NoLymIT<\/strong> :<\/h2>\n

Nouvelles immunoth\u00e9rapies <\/strong>contre les lymphomes<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” width=”50%” custom_padding=”23px|||||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/LOGO-TOUCAN-Horizontal.png” title_text=”LOGO-TOUCAN-Horizontal” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font_size=”22px” custom_margin=”30px|||||” custom_padding=”||3px|||” global_colors_info=”{}”]<\/p>\n

Le laboratoire d\u2019Excellence Toulouse Cancer est un projet qui vise \u00e0 comprendre les m\u00e9canismes de r\u00e9sistance et de rechute dans les cancers.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(43,135,218,0) 50%|#f2efef 50%” background_color_gradient_start=”rgba(43,135,218,0)” background_color_gradient_start_position=”50%” background_color_gradient_end=”#f2efef” background_color_gradient_end_position=”0%” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_row disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” disabled=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=FkQuawiGWUw” image_src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/video.jpg” _builder_version=”4.16″ _module_preset=”default” width=”80%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

Les sp\u00e9cificit\u00e9s<\/strong><\/h2>\n

de notre axe de recherche<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Nos travaux portent sur la r\u00e9ponse immunitaire inn\u00e9e et adaptative dans le lymphome avec une mention sp\u00e9ciale sur l\u2019\u00e9tude des lymphocytes T\u03b3\u03b4 et des m\u00e9canismes de r\u00e9gulation de l’expression des immune checkpoints.<\/p>\n

R\u00e9cemment, nous avons introduit des techniques de Single Cell RNAseq et d\u00e9velopp\u00e9s des outils bionformatiques nous permettant d\u2019explorer le statut fonctionnel et le stade de maturation\/diff\u00e9renciation des effecteurs cytotoxiques \u00e0 l\u2019\u00e9chelle unicellulaire dans des \u00e9chantillons ganglionnaires ou sanguins de patient atteints de lymphome.<\/p>\n

L\u2019acc\u00e8s privil\u00e9gi\u00e9e aux diff\u00e9rentes cohortes de patients atteints de lymphomes nous a \u00e9galement permis d\u2019identifier des biomarqueurs de r\u00e9ponse dans les lymphomes et la mise en place d\u2019une plateforme de criblage dans des mod\u00e8les 3D issus d\u2019\u00e9chantillons de patients atteints de lymphomes.<\/p>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Lymphome B\/LLC<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”5px||5px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

microenvironnement & gamma delta T cells<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

m\u00e9canismes d\u2019immuno-\u00e9chappement & r\u00e9gulation post-transcriptionnelle des immune checkpoints<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

biomarqueurs de r\u00e9ponse\/progression<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

mod\u00e8les 3D<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

criblages th\u00e9rapeutiques<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

single cell RNAseq<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

\u00a0 outils bioinformatiques<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

DES PROJETS<\/strong>
DE RECHERCHE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” posts_number=”6″ include_categories=”118″ use_manual_excerpt=”off” show_more=”on” show_author=”off” show_date=”off” show_categories=”off” masonry_tile_background_color=”#f2efef” _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|800|||||||” header_font_size=”20px” body_font_size=”20px” read_more_text_color=”#5EC7ED” read_more_font_size=”20px” read_more_line_height=”3em” background_enable_color=”off” border_width_all=”0px” global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES FOCUS<\/strong>
DE L\u2019\u00c9QUIPE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 50%|rgba(174,227,246,0) 50%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”#ffffff” background_color_gradient_start_position=”50%” background_color_gradient_end=”rgba(174,227,246,0)” background_color_gradient_end_position=”0%” background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/Filets-bleu-actu.png” background_size=”contain” background_position=”bottom_center” custom_padding=”0px|||||” saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|desktop” header_4_font_size_tablet=”” header_4_font_size_phone=”” header_4_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

D\u00e9couvrir<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”994″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” _builder_version=”4.16″ _module_preset=”412cf9f9-c22e-468d-92e3-f93d454642a9″ header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_color_all_image=”#ffffff” border_width_bottom_image=”15px” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-3px||false|false” global_colors_info=”{}”]<\/p>\n

Comprendre<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1155″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” show_image_tablet=”” show_image_phone=”” show_image_last_edited=”on|phone” disabled_on=”off|off|off” _builder_version=”4.19.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” global_colors_info=”{}”]<\/p>\n

Participer<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1253,1319″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][et_pb_row disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

En live<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_code _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]\n\n

\n\t\n \n
\n \n
\n

\n CRCT-Oncopole<\/span>\n <\/span>\n Suivre<\/span>\n \n <\/path><\/svg>1,220<\/span>\n <\/path><\/svg>1,117<\/span>\n <\/span>\n <\/p>\n

\n Compte officiel du Centre de Recherches en Canc\u00e9rologie de Toulouse <\/p>\n <\/div>\n

\n
\n <\/path><\/svg> <\/div>\n \"crctoncopole\"\n <\/div>\n <\/a>\n<\/div>\n\n
\n \n
\n\n \n
\n
\n \n \"crctoncopole;\n <\/a>\n \n CRCT-Oncopole<\/a>\n @crctoncopole<\/a>\n \n \t\t ·<\/span>\n\t
\n 21 Ao\u00fbt 1693609681678217706<\/span><\/a>\n <\/div>\n <\/div>\n
\n <\/path><\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Castelnau-Montratier c\u00e9l\u00e8bre la lutte contre le cancer. Jeudi 24 ao\u00fbt 2023 conf\u00e9rence avec Fr\u00e9d\u00e9ric Chibon responsable de l'\u00e9quipe @OncoSarc du @crctoncopole accompagn\u00e9 de Gwena\u00ebl Ferron et Martin Gauthier oncologue @IUCTOncopole
\nD\u00e9couvrir l'\u00e9quipe
\n\u27a1\ufe0fhttps:\/\/www.crct-inserm.fr\/oncosarc\/ <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg>
<\/path><\/svg><\/div>\n \n \"Image\n \n Image du flux Twitter.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> R\u00e9pondre sur Twitter 1693609681678217706<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweeter sur Twitter 1693609681678217706<\/span>\n 0<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> J\u2019aime sur Twitter 1693609681678217706<\/span>\n 6<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 1693609681678217706<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n <\/div>\n\n Voir plus<\/span><\/a>\n\n<\/span>\n<\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

PRODUCTIONS SCIENTIFIQUES<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PUBLICATIONS 2024″ open=”on” open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2024<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-5392e5eafc5e3186b69c42a8be34fa3b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z2EF6TD8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Latg%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELatg%26%23xE9%3B%2C%20Adrien%2C%20Mehdi%20Krim%2C%20Lavinia%20Vija%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20and%20Slimane%20Zerdoud.%20%26%23x201C%3BDiffuse%20Bone%20Uptake%20of%20131%20I%20and%20Effect%20on%20Blood%20Counts%20in%20a%20Patient%20With%20Papillary%20Thyroid%20Carcinoma%20and%20Chronic%20Lymphocytic%20Leukemia.%26%23x201D%3B%20%3Ci%3EClinical%20Nuclear%20Medicine%3C%5C%2Fi%3E%2049%2C%20no.%204%20%28April%201%2C%202024%29%3A%20340%26%23x2013%3B41.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLU.0000000000005119%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLU.0000000000005119%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diffuse%20Bone%20Uptake%20of%20131%20I%20and%20Effect%20on%20Blood%20Counts%20in%20a%20Patient%20With%20Papillary%20Thyroid%20Carcinoma%20and%20Chronic%20Lymphocytic%20Leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Latg%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Krim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lavinia%22%2C%22lastName%22%3A%22Vija%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Slimane%22%2C%22lastName%22%3A%22Zerdoud%22%7D%5D%2C%22abstractNote%22%3A%22A%2057-year-old%20woman%20with%20history%20of%20chronic%20lymphocytic%20leukemia%20was%20referred%20to%20our%20center%20for%20adjuvant%20131%20I%20therapy%20following%20complete%20thyroidectomy%20for%20differentiated%20thyroid%20cancer.%20Posttherapeutic%20scintigraphy%20revealed%20atypical%20diffuse%20osteomedullar%20uptake.%20A%20major%20drop%20in%20lymphocyte%20count%20was%20observed%2C%20from%20117.7%20g%5C%2FL%20to%204.8%20g%5C%2FL%208%20weeks%20after%20131%20I%20therapy.%20Bone%20marrow%20uptake%20is%20presumed%20to%20be%20related%20to%20tracer%20sequestration%20in%20leukemic%20cells.%20White%20blood%20cell%20count%20normalization%20suggests%20a%20high%20sensitivity%20of%20leukemic%20cells%20to%20beta%20emission.%20This%20scintigraphic%20pattern%20may%20act%20as%20a%20pitfall%20for%20nuclear%20medicine%20physician.%22%2C%22date%22%3A%222024-04-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FRLU.0000000000005119%22%2C%22ISSN%22%3A%221536-0229%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T09%3A31%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22XXECIEUS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tchernonog%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETchernonog%2C%20Emmanuelle%2C%20Aline%20Moignet%2C%20Am%26%23xE9%3Blie%20Anota%2C%20Sophie%20Bernard%2C%20Guy%20Bouguet%2C%20Fanny%20Colin%2C%20Catherine%20Rioufol%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20and%20Emmanuel%20Gyan.%20%26%23x201C%3BHealth-Related%20Quality%20of%20Life%20in%20Patients%20with%20Hematologic%20Malignancies%20Treated%20with%20Chimeric%20Antigen%20Receptor%20T-Cell%20Therapy%3A%20Review%20and%20Current%20Progress.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%2C%20March%207%2C%202024.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282363%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282363%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Health-related%20quality%20of%20life%20in%20patients%20with%20hematologic%20malignancies%20treated%20with%20chimeric%20antigen%20receptor%20T-cell%20therapy%3A%20review%20and%20current%20progress%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Tchernonog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Moignet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Anota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Bouguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Rioufol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Gyan%22%7D%5D%2C%22abstractNote%22%3A%22Chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20therapy%20has%20transformed%20the%20care%20of%20patients%20with%20relapsed%5C%2Frefractory%20B-cell%20derived%20hematologic%20malignancies.%20To%20date%2C%20six%20CAR%20T-cell%20therapies%2C%20targeting%20either%20CD19%20or%20B-cell%20maturation%20antigen%2C%20have%20received%20regulatory%20approval.%20Along%20with%20the%20promising%20survival%20benefit%2C%20CAR%20T-cell%20therapy%20is%20associated%20with%20potentially%20lifethreatening%20adverse%20events%20%28AE%29%2C%20including%20cytokine%20release%20syndrome%20and%20immune%20effector%20cellassociated%20neurotoxicity%20syndrome.%20While%20clinical%20trials%20evaluating%20CAR%20T-cell%20therapy%20consistently%20report%20the%20incidence%20of%20these%20AE%2C%20most%20trials%20do%20not%20collect%20health-related%20quality%20of%20life%20%28HRQoL%29%20data.%20As%20such%2C%20the%20impact%20of%20CAR%20T-cell%20therapy%20process%20and%20related%20AE%20on%20the%20physical%20and%20psychological%20well-being%20of%20patients%20remains%20uncertain.%20HRQoL%20and%20other%20patientreported%20outcome%20%28PRO%29%20assessments%20in%20patients%20with%20relapsed%20or%20refractory%20hematologic%20malignancies%20are%20of%20utmost%20importance%2C%20as%20individuals%20may%20have%20unmet%20needs%20and%20a%20high%20demand%20for%20tolerable%20therapy%20if%20a%20cure%20is%20not%20obtained.%20In%20addition%2C%20it%20is%20important%20to%20standardize%20methods%20of%20data%20collection%20to%20better%20assess%20the%20impact%20of%20CAR%20T-cell%20therapy%20on%20quality%20of%20life%2C%20optimize%20patient%20care%20and%20costs%2C%20and%20enable%20comparison%20between%20different%20studies.%20We%20conducted%20a%20literature%20search%20up%20to%20June%202023%20to%20identify%20the%20HRQoL%20tools%20used%20in%20clinical%20trials%20and%20in%20realworld%20studies%20investigating%20CAR%20T-cell%20therapy%20in%20patients%20with%20lymphomas%20or%20leukemias.%20In%20the%20present%20comprehensive%20review%2C%20we%20summarize%20the%20most%20commonly%20used%20CAR%20T-cell%20specific%20and%20non-specific%20HRQoL%20tools%20and%20discuss%20how%20the%20use%20of%20HRQoL%20and%20other%20PRO%20tools%20may%20be%20optimized.%22%2C%22date%22%3A%222024-03-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2022.282363%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T09%3A32%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22XJZMEPQR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dartigeas%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDartigeas%2C%20Caroline%2C%20Anne%20Quinquenel%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Marie-Sarah%20Dilhuydy%2C%20Bruno%20Anglaret%2C%20Borhane%20Slama%2C%20Katell%20Le%20Du%2C%20et%20al.%20%26%23x201C%3BFinal%20Results%20on%20Effectiveness%20and%20Safety%20of%20Ibrutinib%20in%20Patients%20with%20Chronic%20Lymphocytic%20Leukemia%20from%20the%20Non-Interventional%20FIRE%20Study.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Hematology%3C%5C%2Fi%3E%2C%20March%206%2C%202024.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00277-024-05666-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00277-024-05666-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Final%20results%20on%20effectiveness%20and%20safety%20of%20Ibrutinib%20in%20patients%20with%20chronic%20lymphocytic%20leukemia%20from%20the%20non-interventional%20FIRE%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dartigeas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quinquenel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Sarah%22%2C%22lastName%22%3A%22Dilhuydy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Anglaret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Borhane%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katell%22%2C%22lastName%22%3A%22Le%20Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Tardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Tchernonog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Orfeuvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Voillat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Val%5Cu00e8re%22%2C%22lastName%22%3A%22Malfuson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Dupuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Deslandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Feugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Leblond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22FIRE%20Investigators%20Group%22%7D%5D%2C%22abstractNote%22%3A%22We%20conducted%20an%20observational%20study%20%28FIRE%29%20to%20understand%20the%20effectiveness%20and%20safety%20outcomes%20of%20ibrutinib%20in%20patients%20with%20chronic%20lymphocytic%20leukemia%20%28CLL%29%20in%20France%2C%20after%20a%20maximum%20follow-up%20of%20five%20years.%20Patients%20were%20included%20according%20to%20the%20French%20marketing%20authorization%20in%202016%20%28i.e.%20patients%20with%20relapsed%20or%20refractory%20CLL%20or%20to%20previously%20untreated%20CLL%20patients%20with%20deletion%2017p%20and%5C%2For%20tumor%20protein%20p53%20mutations%20unsuitable%20for%20chemoimmunotherapy%29%20and%20could%20have%20initiated%20ibrutinib%20more%20than%2030%5Cu00a0days%20prior%20their%20enrolment%20in%20the%20study%20%28i.e.%20retrospective%20patients%29%20or%20between%2030%5Cu00a0days%20before%20and%2014%5Cu00a0days%20after%20their%20enrolment%20%28i.e.%20prospective%20patients%29.%20The%20results%20showed%20that%20in%20the%20effectiveness%20population%20%28N%5Cu2009%3D%5Cu2009388%29%2C%20the%20median%20progression-free%20survival%20%28PFS%29%20was%2053.1%20%2895%25%20CI%3A%2044.5-60.5%29%20months%20for%20retrospective%20patients%20and%2052.9%20%2895%25%20CI%3A%2040.3-60.6%29%20months%20for%20prospective%20patients%20and%20no%20difference%20was%20shown%20between%20the%20PFS%20of%20patients%20who%20had%20at%20least%20one%20dose%20reduction%20versus%20the%20PFS%20of%20patients%20without%20dose%20reduction%20%28p%5Cu2009%3D%5Cu20090.7971%20for%20retrospective%20and%20p%5Cu2009%3D%5Cu20090.3163%20for%20prospective%20patients%29.%20For%20both%20retrospective%20and%20prospective%20patients%2C%20the%20median%20overall%20survival%20was%20not%20reached.%20The%20most%20frequent%20treatment-emergent%20adverse%20event%20of%20interest%20was%20infections%20%2857.6%25%20retrospective%3B%2071.4%25%20prospective%29.%20A%20total%20of%2014.6%25%20of%20the%20retrospective%20patients%20and%2022.4%25%20of%20the%20prospective%20patients%20had%20an%20adverse%20event%20leading%20to%20death.%20Our%20findings%20on%20effectiveness%20were%20consistent%20with%20other%20studies%20and%20the%20fact%20that%20patients%20with%20dose%20reductions%20had%20similar%20PFS%20than%20patients%20without%20dose%20reduction%20is%20reassuring.%20No%20additional%20safety%20concerns%20than%20those%20already%20mentioned%20in%20previous%20studies%20could%20be%20noticed.Trial%20registration%5Cu00a0ClinicalTrials.gov%2C%20NCT03425591.%20Registered%201%20February%202018%20-%20Retrospectively%20registered.%22%2C%22date%22%3A%222024-03-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00277-024-05666-3%22%2C%22ISSN%22%3A%221432-0584%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T09%3A32%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22MS5KHT6T%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rey-Barroso%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERey-Barroso%2C%20Javier%2C%20Alice%20Munaretto%2C%20Nelly%20Rouqui%26%23xE9%3B%2C%20Aur%26%23xE9%3Blie%20Mougel%2C%20Malika%20Chassan%2C%20S%26%23xE9%3Bbastien%20Gadat%2C%20Oc%26%23xE9%3Bane%20Dewingle%2C%20et%20al.%20%26%23x201C%3BLymphocyte%20Migration%20and%20Retention%20Properties%20Affected%20by%20Ibrutinib%20in%20Chronic%20Lymphocytic%20Leukemia.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%20109%2C%20no.%203%20%28March%201%2C%202024%29%3A%20809%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282466%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282466%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lymphocyte%20migration%20and%20retention%20properties%20affected%20by%20ibrutinib%20in%20chronic%20lymphocytic%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Rey-Barroso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Munaretto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Rouqui%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Mougel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malika%22%2C%22lastName%22%3A%22Chassan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Gadat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oc%5Cu00e9ane%22%2C%22lastName%22%3A%22Dewingle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Poincloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Cadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22The%20Bruton%20tyrosine%20kinase%20%28BTK%29%20inhibitor%20ibrutinib%20is%20widely%20used%20for%20treatment%20of%20patients%20with%20relapsed%5C%2Frefractory%20or%20treatment-na%5Cu00efve%20chronic%20lymphocytic%20leukemia%20%28CLL%29.%20A%20prominent%20effect%20of%20ibrutinib%20is%20to%20disrupt%20the%20retention%20of%20CLL%20cells%20from%20supportive%20lymphoid%20tissues%2C%20by%20altering%20BTK-dependent%20adhesion%20and%20migration.%20To%20further%20explore%20the%20mechanism%20of%20action%20of%20ibrutinib%20and%20its%20potential%20impact%20on%20non-leukemic%20cells%2C%20we%20quantified%20multiple%20motility%20and%20adhesion%20parameters%20of%20human%20primary%20CLL%20cells%20and%20non-leukemic%20lymphoid%20cells.%20In%20vitro%2C%20ibrutinib%20affected%20CCL19-%2C%20CXCL12-%20and%20CXCL13-evoked%20migration%20behavior%20of%20CLL%20cells%20and%20non-neoplastic%20lymphocytes%2C%20by%20reducing%20both%20motility%20speed%20and%20directionality.%20De-phosphorylation%20of%20BTK%20induced%20by%20ibrutinib%20in%20CLL%20cells%20was%20associated%20with%20defective%20polarization%20over%20fibronectin%20and%20inability%20to%20assemble%20the%20immunological%20synapse%20upon%20B-cell%20receptor%20engagement.%20In%20patients%27%20samples%20collected%20during%20a%206-month%20monitoring%20of%20therapy%2C%20chemokine-evoked%20migration%20was%20repressed%20in%20CLL%20cells%20and%20marginally%20reduced%20in%20T%20cells.%20This%20was%20accompanied%20by%20profound%20modulation%20of%20the%20expression%20of%20chemokine%20receptors%20and%20adhesion%20molecules.%20Remarkably%2C%20the%20relative%20expression%20of%20the%20receptors%20governing%20lymph%20node%20entry%20%28CCR7%29%20versus%20exit%20%28S1PR1%29%20stood%20out%20as%20a%20reliable%20predictive%20marker%20of%20the%20clinically%20relevant%20treatment-induced%20lymphocytosis.%20Together%2C%20our%20data%20reveal%20a%20multifaceted%20modulation%20of%20motility%20and%20adhesive%20properties%20of%20ibrutinib%20on%20both%20CLL%20leukemic%20cell%20and%20T-cell%20populations%20and%20point%20to%20intrinsic%20differences%20in%20CLL%20recirculation%20properties%20as%20an%20underlying%20cause%20for%20variability%20in%20treatment%20response.%22%2C%22date%22%3A%222024-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2022.282466%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T10%3A19%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22QYQBXB2C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brun%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrun%2C%20Aurore%2C%20Loic%20Ysebaert%2C%20Lucie%20Oberic%2C%20Laurence%20Lamant%2C%20and%20Vincent%20Sibaud.%20%26%23x201C%3BAssessment%20of%20Seasonality%20in%20Eosinophilic%20Dermatosis%20of%20Haematological%20Malignancy.%26%23x201D%3B%20%3Ci%3EActa%20Dermato-Venereologica%3C%5C%2Fi%3E%20104%20%28February%2019%2C%202024%29%3A%20adv15768.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2340%5C%2Factadv.v104.15768%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2340%5C%2Factadv.v104.15768%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20Seasonality%20in%20Eosinophilic%20Dermatosis%20of%20Haematological%20Malignancy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Sibaud%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-02-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2340%5C%2Factadv.v104.15768%22%2C%22ISSN%22%3A%221651-2057%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T09%3A31%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22BMYILRMA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Camus%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECamus%2C%20Vincent%2C%20Catherine%20Thieblemont%2C%20Philippe%20Gaulard%2C%20Morgane%20Cheminant%2C%20Rene-Olivier%20Casasnovas%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Gandhi%20Laurent%20Damaj%2C%20et%20al.%20%26%23x201C%3BRomidepsin%20Plus%20Cyclophosphamide%2C%20Doxorubicin%2C%20Vincristine%2C%20and%20Prednisone%20Versus%20Cyclophosphamide%2C%20Doxorubicin%2C%20Vincristine%2C%20and%20Prednisone%20in%20Patients%20With%20Previously%20Untreated%20Peripheral%20T-Cell%20Lymphoma%3A%20Final%20Analysis%20of%20the%20Ro-CHOP%20Trial.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%3C%5C%2Fi%3E%2C%20February%2016%2C%202024%2C%20JCO2301687.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.23.01687%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.23.01687%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Romidepsin%20Plus%20Cyclophosphamide%2C%20Doxorubicin%2C%20Vincristine%2C%20and%20Prednisone%20Versus%20Cyclophosphamide%2C%20Doxorubicin%2C%20Vincristine%2C%20and%20Prednisone%20in%20Patients%20With%20Previously%20Untreated%20Peripheral%20T-Cell%20Lymphoma%3A%20Final%20Analysis%20of%20the%20Ro-CHOP%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Camus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Cheminant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rene-Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gandhi%20Laurent%22%2C%22lastName%22%3A%22Damaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Matteo%22%2C%22lastName%22%3A%22Pica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Won%20Seog%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soon%20Thye%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Andre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norma%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Jesus%22%2C%22lastName%22%3A%22Penarrubia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%20B.%22%2C%22lastName%22%3A%22Staber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Trotman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22H%5Cu00fcttmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittorio%22%2C%22lastName%22%3A%22Stefoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandra%22%2C%22lastName%22%3A%22Tucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Fogarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Abraham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wajed%22%2C%22lastName%22%3A%22Abarah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatiha%22%2C%22lastName%22%3A%22Belmecheri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Ribrag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Helene%22%2C%22lastName%22%3A%22Delfau-Larue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-S%5Cu00e9gol%5Cu00e8ne%22%2C%22lastName%22%3A%22Cottereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Itti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ju%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Delarue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22de%20Leval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%5D%2C%22abstractNote%22%3A%22Clinical%20trials%20frequently%20include%20multiple%20end%20points%20that%20mature%20at%20different%20times.%20The%20initial%20report%2C%20typically%20based%20on%20the%20primary%20end%20point%2C%20may%20be%20published%20when%20key%20planned%20co-primary%20or%20secondary%20analyses%20are%20not%20yet%20available.%20Clinical%20Trial%20Updates%20provide%20an%20opportunity%20to%20disseminate%20additional%20results%20from%20studies%2C%20published%20in%20JCO%20or%20elsewhere%2C%20for%20which%20the%20primary%20end%20point%20has%20already%20been%20reported.The%20primary%20analysis%20of%20the%20Ro-CHOP%20phase%20III%20randomized%20controlled%20trial%20%28ClinicalTrials.gov%20identifier%3A%20NCT01796002%29%20established%20that%20romidepsin%20%28Ro%29%20plus%20cyclophosphamide%2C%20doxorubicin%2C%20vincristine%2C%20prednisone%20%28CHOP%29%20did%20not%20yield%20an%20increased%20efficacy%20compared%20with%20CHOP%20alone%20as%20first-line%20treatment%20of%20peripheral%20T-cell%20lymphoma.%20We%20report%20the%20planned%20final%20analysis%205%20years%20after%20the%20last%20patient%20enrolled.%20With%20a%20median%20follow-up%20of%206%20years%2C%20median%20progression-free%20survival%20%28PFS%29%20was%2012.0%20months%20compared%20with%2010.2%20months%20%28hazard%20ratio%20%5BHR%5D%2C%200.79%20%5B95%25%20CI%2C%200.62%20to%201.005%5D%3B%20P%20%3D%20.054%29%2C%20while%20median%20overall%20survival%20was%2062.2%20months%20%2835.7-86.6%20months%29%20and%2043.8%20months%20%2830.1-70.2%20months%3B%20HR%2C%200.88%20%5B95%25%20CI%2C%200.68%20to%201.14%5D%3B%20P%20%3D%20.324%29%20in%20the%20Ro-CHOP%20and%20CHOP%20arms%2C%20respectively.%20In%20an%20exploratory%20analysis%2C%20the%20median%20PFS%20in%20the%20centrally%20reviewed%20follicular%20helper%20T-cell%20lymphoma%20subgroup%20was%20significantly%20longer%20in%20the%20Ro-CHOP%20arm%20%2819.5%20v%2010.6%20months%2C%20HR%2C%200.703%20%5B95%25%20CI%2C%200.502%20to%200.985%5D%3B%20P%20%3D%20.039%29.%20Second-line%20treatments%20were%20given%20to%20251%20patients%20with%20a%20median%20PFS2%20and%20OS2%20after%20relapse%20or%20progression%20of%203.3%20months%20and%2011.5%20months%2C%20respectively.%20Within%20the%20limits%20of%20highly%20heterogeneous%20second-line%20treatments%2C%20no%20specific%20regimen%20seemed%20to%20provide%20superior%20disease%20control.%20However%2C%20a%20potential%20benefit%20was%20observed%20with%20brentuximab%20vedotin%20in%20association%20with%20chemotherapy%20even%20after%20excluding%20anaplastic%20large-cell%20lymphoma%20subtype%20or%20after%20adjusting%20for%20histology%20and%20international%20prognostic%20index%20in%20a%20multivariate%20model%20%28HR%20for%20PFS%2C%200.431%20%5B95%25%20CI%2C%200.238%20to%200.779%5D%3B%20P%20%3D%20.005%29.%22%2C%22date%22%3A%222024-02-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.23.01687%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T09%3A30%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22I3RBDBK5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krug%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKrug%2C%20Adrien%2C%20Marie%20Tosolini%2C%20Blandine%20Madji%20Hounoum%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Roger%20Geiger%2C%20Matteo%20Pecoraro%2C%20Patrick%20Emond%2C%20et%20al.%20%26%23x201C%3BInhibition%20of%20Choline%20Metabolism%20in%20an%20Angioimmunoblastic%20T-Cell%20Lymphoma%20Preclinical%20Model%20Reveals%20a%20New%20Metabolic%20Vulnerability%20as%20Possible%20Target%20for%20Treatment.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Experimental%20%26amp%3B%20Clinical%20Cancer%20Research%3A%20CR%3C%5C%2Fi%3E%2043%2C%20no.%201%20%28February%206%2C%202024%29%3A%2043.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13046-024-02952-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13046-024-02952-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibition%20of%20choline%20metabolism%20in%20an%20angioimmunoblastic%20T-cell%20lymphoma%20preclinical%20model%20reveals%20a%20new%20metabolic%20vulnerability%20as%20possible%20target%20for%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Krug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blandine%22%2C%22lastName%22%3A%22Madji%20Hounoum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Geiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matteo%22%2C%22lastName%22%3A%22Pecoraro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Emond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Ehrland%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Verhoeyen%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Angioimmunoblastic%20T-cell%20lymphoma%20%28AITL%29%20is%20a%20malignancy%20with%20very%20poor%20survival%20outcome%2C%20in%20urgent%20need%20of%20more%20specific%20therapeutic%20strategies.%20The%20drivers%20of%20malignancy%20in%20this%20disease%20are%20CD4%2B%20follicular%20helper%20T%20cells%20%28Tfh%29.%20The%20metabolism%20of%20these%20malignant%20Tfh%20cells%20was%20not%20yet%20elucidated.%20Therefore%2C%20we%20decided%20to%20identify%20their%20metabolic%20requirements%20with%20the%20objective%20to%20propose%20a%20novel%20therapeutic%20option.%5CnMETHODS%3A%20To%20reveal%20the%20prominent%20metabolic%20pathways%20used%20by%20the%20AITL%20lymphoma%20cells%2C%20we%20relied%20on%20metabolomic%20and%20proteomic%20analysis%20of%20murine%20AITL%20%28mAITL%29%20T%20cells%20isolated%20from%20our%20established%20mAITL%20model.%20We%20confirmed%20these%20results%20using%20AITL%20patient%20and%20healthy%20T%20cell%20expression%20data.%5CnRESULTS%3A%20Strikingly%2C%20the%20mAITL%20Tfh%20cells%20were%20highly%20dependent%20on%20the%20second%20branch%20of%20the%20Kennedy%20pathway%2C%20the%20choline%20lipid%20pathway%2C%20responsible%20for%20the%20production%20of%20the%20major%20membrane%20constituent%20phosphatidylcholine.%20Moreover%2C%20gene%20expression%20data%20from%20Tfh%20cells%20isolated%20from%20AITL%20patient%20tumors%2C%20confirmed%20the%20upregulation%20of%20the%20choline%20lipid%20pathway.%20Several%20enzymes%20involved%20in%20this%20pathway%20such%20as%20choline%20kinase%2C%20catalyzing%20the%20first%20step%20in%20the%20phosphatidylcholine%20pathway%2C%20are%20upregulated%20in%20multiple%20tumors%20other%20than%20AITL.%20Here%20we%20showed%20that%20treatment%20of%20our%20mAITL%20preclinical%20mouse%20model%20with%20a%20fatty%20acid%20oxydation%20inhibitor%2C%20significantly%20increased%20their%20survival%20and%20even%20reverted%20the%20exhausted%20CD8%20T%20cells%20in%20the%20tumor%20into%20potent%20cytotoxic%20anti-tumor%20cells.%20Specific%20inhibition%20of%20Chok%5Cu03b1%20confirmed%20the%20importance%20of%20the%20phosphatidylcholine%20production%20pathway%20in%20neoplastic%20CD4%5Cu2009%2B%5Cu2009T%20cells%2C%20nearly%20eradicating%20mAITL%20Tfh%20cells%20from%20the%20tumors.%20Finally%2C%20the%20same%20inhibitor%20induced%20in%20human%20AITL%20lymphoma%20biopsies%20cell%20death%20of%20the%20majority%20of%20the%20hAITL%20PD-1high%20neoplastic%20cells.%5CnCONCLUSION%3A%20Our%20results%20suggest%20that%20interfering%20with%20choline%20metabolism%20in%20AITL%20reveals%20a%20specific%20metabolic%20vulnerability%20and%20might%20represent%20a%20new%20therapeutic%20strategy%20for%20these%20patients.%22%2C%22date%22%3A%222024-02-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13046-024-02952-w%22%2C%22ISSN%22%3A%221756-9966%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-02-13T10%3A16%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22ID6RWANU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carbo-Meix%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECarbo-Meix%2C%20Anna%2C%20Francesca%20Guijarro%2C%20Luojun%20Wang%2C%20Marta%20Grau%2C%20Romina%20Royo%2C%20Gerard%20Frigola%2C%20Heribert%20Playa-Albinyana%2C%20et%20al.%20%26%23x201C%3BBCL3%20Rearrangements%20in%20B-Cell%20Lymphoid%20Neoplasms%20Occur%20in%20Two%20Breakpoint%20Clusters%20Associated%20with%20Different%20Diseases.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%20109%2C%20no.%202%20%28February%201%2C%202024%29%3A%20493%26%23x2013%3B508.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2023.283209%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2023.283209%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22BCL3%20rearrangements%20in%20B-cell%20lymphoid%20neoplasms%20occur%20in%20two%20breakpoint%20clusters%20associated%20with%20different%20diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Carbo-Meix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Guijarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luojun%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Grau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romina%22%2C%22lastName%22%3A%22Royo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Frigola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heribert%22%2C%22lastName%22%3A%22Playa-Albinyana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20M.%22%2C%22lastName%22%3A%22Buhler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillem%22%2C%22lastName%22%3A%22Clot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marti%22%2C%22lastName%22%3A%22Duran-Ferrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junyan%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%22%2C%22lastName%22%3A%22Granada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Joao%22%2C%22lastName%22%3A%22Baptista%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose-Tomas%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blanca%22%2C%22lastName%22%3A%22Espinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Puiggros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Tapia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Bandiera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriella%22%2C%22lastName%22%3A%22De%20Canal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Bonoldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fina%22%2C%22lastName%22%3A%22Climent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inmaculada%22%2C%22lastName%22%3A%22Ribera-Cortada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Fernandez-Caballero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esmeralda%22%2C%22lastName%22%3A%22De%20la%20Banda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janilson%22%2C%22lastName%22%3A%22Do%20Nascimento%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Pineda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolors%22%2C%22lastName%22%3A%22Vela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rozman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Aymerich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucrecia%22%2C%22lastName%22%3A%22Yanez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesus%20Xavier%22%2C%22lastName%22%3A%22Ortin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esperanza%22%2C%22lastName%22%3A%22Tuset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorsten%22%2C%22lastName%22%3A%22Zenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20R.%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20H.%22%2C%22lastName%22%3A%22Swerdlow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20I.%22%2C%22lastName%22%3A%22Martin-Subero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolors%22%2C%22lastName%22%3A%22Colomer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estella%22%2C%22lastName%22%3A%22Matutes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Bea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolors%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferran%22%2C%22lastName%22%3A%22Nadeu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elias%22%2C%22lastName%22%3A%22Campo%22%7D%5D%2C%22abstractNote%22%3A%22The%20t%2814%3B19%29%28q32%3Bq13%29%20often%20juxtaposes%20BCL3%20with%20immunoglobulin%20heavy%20chain%20%28IGH%29%20resulting%20in%20overexpression%20of%20the%20gene.%20In%20contrast%20to%20other%20oncogenic%20translocations%2C%20BCL3%20rearrangement%20%28BCL3-R%29%20has%20been%20associated%20with%20a%20broad%20spectrum%20of%20lymphoid%20neoplasms.%20Here%20we%20report%20an%20integrative%20whole-genome%20sequence%2C%20transcriptomic%2C%20and%20DNA%20methylation%20analysis%20of%2013%20lymphoid%20neoplasms%20with%20BCL3-R.%20The%20resolution%20of%20the%20breakpoints%20at%20single%20base-pair%20revealed%20that%20they%20occur%20in%20two%20clusters%20at%205%27%20%28n%3D9%29%20and%203%27%20%28n%3D4%29%20regions%20of%20BCL3%20associated%20with%20two%20different%20biological%20and%20clinical%20entities.%20Both%20breakpoints%20were%20mediated%20by%20aberrant%20class%20switch%20recombination%20of%20the%20IGH%20locus.%20However%2C%20the%205%27%20breakpoints%20%28upstream%29%20juxtaposed%20BCL3%20next%20to%20an%20IGH%20enhancer%20leading%20to%20overexpression%20of%20the%20gene%20whereas%20the%203%27%20breakpoints%20%28downstream%29%20positioned%20BCL3%20outside%20the%20influence%20of%20the%20IGH%20and%20were%20not%20associated%20with%20its%20expression.%20Upstream%20BCL3-R%20tumors%20had%20unmutated%20IGHV%2C%20trisomy%2012%2C%20and%20mutated%20genes%20frequently%20seen%20in%20chronic%20lymphocytic%20leukemia%20%28CLL%29%20but%20had%20an%20atypical%20CLL%20morphology%2C%20immunophenotype%2C%20DNA%20methylome%2C%20and%20expression%20profile%20that%20differ%20from%20conventional%20CLL.%20In%20contrast%2C%20downstream%20BCL3-R%20neoplasms%20were%20atypical%20splenic%20or%20nodal%20marginal%20zone%20lymphomas%20%28MZL%29%20with%20mutated%20IGHV%2C%20complex%20karyotypes%20and%20mutated%20genes%20typical%20of%20MZL.%20Two%20of%20the%20latter%20four%20tumors%20transformed%20to%20a%20large%20B-cell%20lymphoma.%20We%20designed%20a%20novel%20fluorescence%20in%20situ%20hybridization%20assay%20that%20recognizes%20the%20two%20different%20breakpoints%20and%20validated%20these%20findings%20in%2017%20independent%20tumors.%20Overall%2C%20upstream%20or%20downstream%20breakpoints%20of%20BCL3-R%20are%20mainly%20associated%20with%20two%20subtypes%20of%20lymphoid%20neoplasms%20with%20different%20%28epi%29genomic%2C%20expression%2C%20and%20clinicopathological%20features%20resembling%20atypical%20CLL%20and%20MZL%2C%20respectively.%22%2C%22date%22%3A%222024-02-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2023.283209%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A08%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22T8T7U8HR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ghesqui%5Cu00e8res%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-23%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGhesqui%26%23xE8%3Bres%2C%20Herv%26%23xE9%3B%2C%20Fanny%20Cherblanc%2C%20Aur%26%23xE9%3Blien%20Belot%2C%20Sophie%20Micon%2C%20Krimo%20K.%20Bouabdallah%2C%20Cyril%20Esnault%2C%20Luc-Matthieu%20Fornecker%2C%20et%20al.%20%26%23x201C%3BChallenges%20for%20Quality%20and%20Utilization%20of%20Real-World%20Data%20for%20Diffuse%20Large%20B-Cell%20Lymphoma%20in%20REALYSA%2C%20a%20LYSA%20Cohort.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%208%2C%20no.%202%20%28January%2023%2C%202024%29%3A%20296%26%23x2013%3B308.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023010798%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023010798%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20for%20quality%20and%20utilization%20of%20real-world%20data%20for%20diffuse%20large%20B-cell%20lymphoma%20in%20REALYSA%2C%20a%20LYSA%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Cherblanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Belot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Micon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krimo%20K.%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Esnault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc-Matthieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katia%22%2C%22lastName%22%3A%22Thokagevistk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Bonjour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fontanet%22%2C%22lastName%22%3A%22Bijou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Haioun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Morineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gandhi%22%2C%22lastName%22%3A%22Damaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Tessoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thi%5Cu00e9blemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Chauchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Gressin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Fruchart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Labour%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Fouillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lionne-Huyghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Lebras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandy%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Leyronnas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Guieze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roch%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Dr%5Cu00e9nou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fitoussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Detourmignies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Abraham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Soussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Matteo%22%2C%22lastName%22%3A%22Pica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Fogarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Cony-Makhoul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Bernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Le%20Guyader-Peyrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Monnereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Boissard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Camus%22%7D%5D%2C%22abstractNote%22%3A%22Real-world%20data%20%28RWD%29%20are%20essential%20to%20complement%20clinical%20trial%20%28CT%29%20data%2C%20but%20major%20challenges%20remain%2C%20such%20as%20data%20quality.%20REal%20world%20dAta%20in%20LYmphoma%20and%20Survival%20in%20Adults%20%28REALYSA%29%20is%20a%20prospective%20noninterventional%20multicentric%20cohort%20started%20in%202018%20that%20included%20patients%20newly%20diagnosed%20with%20lymphoma%20in%20France.%20Herein%20is%20a%20proof-of-concept%20analysis%20on%20patients%20with%20first-line%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%20to%20%281%29%20evaluate%20the%20capacity%20of%20the%20cohort%20to%20provide%20robust%20data%20through%20a%20multistep%20validation%20process%3B%20%282%29%20assess%20the%20consistency%20of%20the%20results%3B%20and%20%283%29%20conduct%20an%20exploratory%20transportability%20assessment%20of%202%20recent%20phase%203%20CTs%20%28POLARIX%20and%20SENIOR%29.%20The%20analysis%20population%20comprised%20645%20patients%20with%20DLBCL%20included%20before%2031%20March%202021%20who%20received%20immunochemotherapy%20and%20for%20whom%203589%20queries%20were%20generated%2C%20resulting%20in%20high%20data%20completeness%20%28%3C4%25%20missing%20data%29.%20Median%20age%20was%2066%20years%2C%20with%20mostly%20advanced-stage%20disease%20and%20high%20international%20prognostic%20index%20%28IPI%29%20score.%20Treatments%20were%20mostly%20rituximab%2C%20cyclophosphamide%2C%20doxorubicin%20hydrochloride%2C%20vincristine%2C%20and%20prednisone%20%28R-CHOP%2075%25%29%20and%20reduced%20dose%20R-CHOP%20%2813%25%29.%20Estimated%201-year%20event-free%20survival%20%28EFS%29%20and%20overall%20survival%20rates%20were%2077.9%25%20and%2090.0%25%2C%20respectively%20%28median%20follow-up%2C%209.9%5Cu00a0months%29.%20Regarding%20transportability%2C%20when%20applying%20the%20CT%27s%20main%20inclusion%20criteria%20%28age%2C%20performance%20status%2C%20and%20IPI%29%2C%20outcomes%20seemed%20comparable%20between%20patients%20in%20REALYSA%20and%20standard%20arms%20of%20POLARIX%20%281-year%20progression-free%20survival%2079.8%25%20vs%2079.8%25%29%20and%20SENIOR%20%281-year%20EFS%2C%2064.5%25%20vs%2060.0%25%29.%20With%20its%20rigorous%20data%20validation%20process%2C%20REALYSA%20provides%20high-quality%20RWD%2C%20thus%20constituting%20a%20platform%20for%20numerous%20scientific%20purposes.%20The%20REALYSA%20study%20was%20registered%20at%20www.clinicaltrials.gov%20as%20%23NCT03869619.%22%2C%22date%22%3A%222024-01-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2023010798%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-11T14%3A17%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22XA7WBQQF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cottereau%20et%20al.%22%2C%22parsedDate%22%3A%222024-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECottereau%2C%20A.%20S.%2C%20L.%20Rebaud%2C%20J.%20Trotman%2C%20P.%20Feugier%2C%20L.%20J.%20Nastoupil%2C%20E.%20Bachy%2C%20I.%20W.%20Flinn%2C%20et%20al.%20%26%23x201C%3BMetabolic%20Tumor%20Volume%20Predicts%20Outcome%20in%20Patients%20with%20Advanced%20Stage%20Follicular%20Lymphoma%20from%20the%20RELEVANCE%20Trial.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%3C%5C%2Fi%3E%2035%2C%20no.%201%20%28January%202024%29%3A%20130%26%23x2013%3B37.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2023.10.121%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2023.10.121%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20tumor%20volume%20predicts%20outcome%20in%20patients%20with%20advanced%20stage%20follicular%20lymphoma%20from%20the%20RELEVANCE%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%22%2C%22lastName%22%3A%22Cottereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Rebaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Trotman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Feugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20J.%22%2C%22lastName%22%3A%22Nastoupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20W.%22%2C%22lastName%22%3A%22Flinn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Haioun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20L.%22%2C%22lastName%22%3A%22Bartlett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Tilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Portugues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Buvat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Meignan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Morschhauser%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20investigated%20the%20prognostic%20value%20of%20baseline%20positron%20emission%20tomography%20%28PET%29%20parameters%20for%20patients%20with%20treatment-na%5Cu00efve%20follicular%20lymphoma%20%28FL%29%20in%20the%20phase%20III%20RELEVANCE%20trial%2C%20comparing%20the%20immunomodulatory%20combination%20of%20lenalidomide%20and%20rituximab%20%28R2%29%20versus%20R-chemotherapy%20%28R-chemo%29%2C%20with%20both%20regimens%20followed%20by%20R%20maintenance%20therapy.%5CnPATIENTS%20AND%20METHODS%3A%20Baseline%20characteristics%20of%20the%20entire%20PET-evaluable%20population%20%28n%5Cu00a0%3D%20406%5C%2F1032%29%20were%20well%20balanced%20between%20treatment%20arms.%20The%20maximal%20standard%20uptake%20value%20%28SUVmax%29%20and%20the%20standardized%20maximal%20distance%20between%20tow%20lesions%20%28SDmax%29%20were%20extracted%2C%20the%20standardized%20distance%20between%20two%20lesions%20the%20furthest%20apart%2C%20were%20extracted.%20The%20total%20metabolic%20tumor%20volume%20%28TMTV%29%20was%20computed%20using%20the%2041%25%20SUVmax%20method.%5CnRESULTS%3A%20With%20a%20median%20follow-up%20of%206.5%20years%2C%20the%206-year%20progression-free%20survival%20%28PFS%29%20was%2057.8%25%2C%20the%20median%20TMTV%20was%20284%20cm3%2C%20SUVmax%20was%2011.3%20and%20SDmax%20was%200.32%20m-1%2C%20with%20no%20significant%20difference%20between%20arms.%20High%20TMTV%20%28%3E510%20cm3%29%20and%20FLIPI%20were%20associated%20with%20an%20inferior%20PFS%20%28P%5Cu00a0%3D%200.013%20and%20P%5Cu00a0%3D%200.006%2C%20respectively%29%2C%20whereas%20SUVmax%20and%20SDmax%20were%20not%20%28P%5Cu00a0%3D%200.08%20and%20P%5Cu00a0%3D%200.12%2C%20respectively%29.%20In%20multivariable%20analysis%2C%20follicular%20lymphoma%20international%20prognostic%20index%20%28FLIPI%29%20and%20TMTV%20remained%20significantly%20associated%20with%20PFS%20%28P%5Cu00a0%3D%200.0119%20and%20P%5Cu00a0%3D%200.0379%2C%20respectively%29.%20These%20two%20adverse%20factors%20combined%20stratified%20the%20overall%20population%20into%20three%20risk%20groups%3A%20patients%20with%20no%20risk%20factors%20%2840%25%29%2C%20with%20one%20factor%20%2844%25%29%2C%20or%20with%20both%20%2816%25%29%2C%20with%20a%206-year%20PFS%20of%2067.7%25%2C%2054.5%25%2C%20and%2041.0%25%2C%20respectively.%20No%20significant%20interaction%20between%20treatment%20arms%20and%20TMTV%20or%20FLIPI%20%28P%5Cu00a0%3D%5Cu00a00.31%20or%20P%5Cu00a0%3D%200.59%2C%20respectively%29%20was%20observed.%20The%20high-risk%20group%20%28high%20TMTV%20and%20FLIPI%203-5%29%20had%20a%20similar%20PFS%20in%20both%20arms%20%28P%5Cu00a0%3D%200.45%29%20with%20a%20median%20PFS%20of%2068.4%25%20in%20the%20R-chemo%20arm%20versus%2071.4%25%20in%20the%20R2%20arm.%5CnCONCLUSIONS%3A%20Baseline%20TMTV%20is%20predictive%20of%20PFS%2C%20independently%20of%20FLIPI%2C%20in%20patients%20with%20advanced%20FL%20even%20in%20the%20context%20of%20antibody%20maintenance.%22%2C%22date%22%3A%222024-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2023.10.121%22%2C%22ISSN%22%3A%221569-8041%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-03-13T10%3A19%3A14Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Latgé, Adrien, Mehdi Krim, Lavinia Vija, Loïc Ysebaert, and Slimane Zerdoud. “Diffuse Bone Uptake of 131 I and Effect on Blood Counts in a Patient With Papillary Thyroid Carcinoma and Chronic Lymphocytic Leukemia.” Clinical Nuclear Medicine<\/i> 49, no. 4 (April 1, 2024): 340–41. https:\/\/doi.org\/10.1097\/RLU.0000000000005119<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tchernonog, Emmanuelle, Aline Moignet, Amélie Anota, Sophie Bernard, Guy Bouguet, Fanny Colin, Catherine Rioufol, Loïc Ysebaert, and Emmanuel Gyan. “Health-Related Quality of Life in Patients with Hematologic Malignancies Treated with Chimeric Antigen Receptor T-Cell Therapy: Review and Current Progress.” Haematologica<\/i>, March 7, 2024. https:\/\/doi.org\/10.3324\/haematol.2022.282363<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dartigeas, Caroline, Anne Quinquenel, Loïc Ysebaert, Marie-Sarah Dilhuydy, Bruno Anglaret, Borhane Slama, Katell Le Du, et al. “Final Results on Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia from the Non-Interventional FIRE Study.” Annals of Hematology<\/i>, March 6, 2024. https:\/\/doi.org\/10.1007\/s00277-024-05666-3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rey-Barroso, Javier, Alice Munaretto, Nelly Rouquié, Aurélie Mougel, Malika Chassan, Sébastien Gadat, Océane Dewingle, et al. “Lymphocyte Migration and Retention Properties Affected by Ibrutinib in Chronic Lymphocytic Leukemia.” Haematologica<\/i> 109, no. 3 (March 1, 2024): 809–23. https:\/\/doi.org\/10.3324\/haematol.2022.282466<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Brun, Aurore, Loic Ysebaert, Lucie Oberic, Laurence Lamant, and Vincent Sibaud. “Assessment of Seasonality in Eosinophilic Dermatosis of Haematological Malignancy.” Acta Dermato-Venereologica<\/i> 104 (February 19, 2024): adv15768. https:\/\/doi.org\/10.2340\/actadv.v104.15768<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Camus, Vincent, Catherine Thieblemont, Philippe Gaulard, Morgane Cheminant, Rene-Olivier Casasnovas, Loïc Ysebaert, Gandhi Laurent Damaj, et al. “Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/i>, February 16, 2024, JCO2301687. https:\/\/doi.org\/10.1200\/JCO.23.01687<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Krug, Adrien, Marie Tosolini, Blandine Madji Hounoum, Jean-Jacques Fournié, Roger Geiger, Matteo Pecoraro, Patrick Emond, et al. “Inhibition of Choline Metabolism in an Angioimmunoblastic T-Cell Lymphoma Preclinical Model Reveals a New Metabolic Vulnerability as Possible Target for Treatment.” Journal of Experimental & Clinical Cancer Research: CR<\/i> 43, no. 1 (February 6, 2024): 43. https:\/\/doi.org\/10.1186\/s13046-024-02952-w<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Carbo-Meix, Anna, Francesca Guijarro, Luojun Wang, Marta Grau, Romina Royo, Gerard Frigola, Heribert Playa-Albinyana, et al. “BCL3 Rearrangements in B-Cell Lymphoid Neoplasms Occur in Two Breakpoint Clusters Associated with Different Diseases.” Haematologica<\/i> 109, no. 2 (February 1, 2024): 493–508. https:\/\/doi.org\/10.3324\/haematol.2023.283209<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ghesquières, Hervé, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K. Bouabdallah, Cyril Esnault, Luc-Matthieu Fornecker, et al. “Challenges for Quality and Utilization of Real-World Data for Diffuse Large B-Cell Lymphoma in REALYSA, a LYSA Cohort.” Blood Advances<\/i> 8, no. 2 (January 23, 2024): 296–308. https:\/\/doi.org\/10.1182\/bloodadvances.2023010798<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cottereau, A. S., L. Rebaud, J. Trotman, P. Feugier, L. J. Nastoupil, E. Bachy, I. W. Flinn, et al. “Metabolic Tumor Volume Predicts Outcome in Patients with Advanced Stage Follicular Lymphoma from the RELEVANCE Trial.” Annals of Oncology: Official Journal of the European Society for Medical Oncology<\/i> 35, no. 1 (January 2024): 130–37. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.121<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2023″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2023<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-56a77c49f0ab65c1d2b438e2f7e5d297%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22JJ5GLA9S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Sascha%20Dietrich%2C%20and%20Karin%20Tarte.%20%26%23x201C%3BCell%20Crosstalk%20within%20Lymphoma%20Tumor%20Microenvironment%3A%20Follicular%20Lymphoma%20as%20a%20Paradigm.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%2C%20December%2014%2C%202023%2C%20blood.2023021000.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2023021000%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2023021000%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cell%20crosstalk%20within%20lymphoma%20tumor%20microenvironment%3A%20follicular%20lymphoma%20as%20a%20paradigm%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sascha%22%2C%22lastName%22%3A%22Dietrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%22%2C%22lastName%22%3A%22Tarte%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20is%20an%20indolent%20yet%20incurable%20germinal%20center%20B-cell%20lymphoma%20retaining%20a%20characteristic%20follicular%20architecture.%20FL%20tumor%20B%20cells%20are%20highly%20dependent%20on%20direct%20and%20indirect%20interactions%20with%20a%20specific%20and%20complex%20tumor%20microenvironment%20%28TME%29.%20Great%20progress%20has%20been%20recently%20made%20in%20describing%20the%20heterogeneity%20and%20dynamics%20of%20FL-TME%20and%20in%20depicting%20how%20tumor%20clonal%20and%20functional%20heterogeneity%20rely%20on%20the%20integration%20of%20TME-related%20signals.%20Specifically%2C%20FL-TME%20is%20enriched%20for%20exhausted%20cytotoxic%20T%20cells%2C%20immunosuppressive%20regulatory%20T%20cells%20of%20various%20origins%2C%20and%20follicular%20helper%20T%20cells%20overexpressing%20B%20cell%20and%20TME%20reprogramming%20factors.%20FL%20stromal%20cells%20have%20also%20emerged%20as%20crucial%20determinants%20of%20tumor%20growth%20and%20remodeling%2C%20with%20a%20key%20role%20for%20deregulated%20chemokines%20and%20extracellular%20matrix%20composition.%20Finally%2C%20tumor%20associated%20macrophages%20play%20a%20dual%20function%2C%20contributing%20to%20FL%20cell%20phagocytosis%20and%20to%20FL%20cell%20survival%20through%20BCR%20long-lasting%20activation.%20The%20resulting%20tumor-permissive%20niches%20show%20additional%20layers%20of%20site-to-site%20and%20kinetic%20heterogeneity%2C%20which%20raise%20questions%20about%20the%20niche%20of%20FL-committed%20precursor%20cells%20supporting%20early%20lymphomagenesis%2C%20clonal%20evolution%2C%20relapse%2C%20and%20transformation.%20In%20turn%2C%20FL%20B%20cell%20genetic%20and%20non-genetic%20determinants%20drive%20the%20reprogramming%20of%20FL%20immune%20and%20stromal%20TME.%20Therefore%2C%20offering%20a%20functional%20picture%20of%20the%20dynamic%20crosstalk%20between%20FL%20cells%20and%20TME%20holds%20the%20promise%20of%20identifying%20the%20mechanisms%20of%20therapy%20resistance%2C%20stratifying%20patients%2C%20and%20developing%20new%20therapeutic%20approaches%20capable%20of%20eradicating%20FL%20disease%20in%20its%20different%20ecosystems.%22%2C%22date%22%3A%222023-12-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2023021000%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-11T14%3A16%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22YJRWALQV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Niemann%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ENiemann%2C%20Carsten%20U.%2C%20Talha%20Munir%2C%20Carol%20Moreno%2C%20Carolyn%20Owen%2C%20George%20A.%20Follows%2C%20Ohad%20Benjamini%2C%20Ann%20Janssens%2C%20et%20al.%20%26%23x201C%3BFixed-Duration%20Ibrutinib-Venetoclax%20versus%20Chlorambucil-Obinutuzumab%20in%20Previously%20Untreated%20Chronic%20Lymphocytic%20Leukaemia%20%28GLOW%29%3A%204-Year%20Follow-up%20from%20a%20Multicentre%2C%20Open-Label%2C%20Randomised%2C%20Phase%203%20Trial.%26%23x201D%3B%20%3Ci%3EThe%20Lancet.%20Oncology%3C%5C%2Fi%3E%2024%2C%20no.%2012%20%28December%202023%29%3A%201423%26%23x2013%3B33.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1470-2045%2823%2900452-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1470-2045%2823%2900452-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fixed-duration%20ibrutinib-venetoclax%20versus%20chlorambucil-obinutuzumab%20in%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%20%28GLOW%29%3A%204-year%20follow-up%20from%20a%20multicentre%2C%20open-label%2C%20randomised%2C%20phase%203%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%20U.%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Talha%22%2C%22lastName%22%3A%22Munir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carol%22%2C%22lastName%22%3A%22Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%22%2C%22lastName%22%3A%22Owen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20A.%22%2C%22lastName%22%3A%22Follows%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ohad%22%2C%22lastName%22%3A%22Benjamini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Janssens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark-David%22%2C%22lastName%22%3A%22Levin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tadeusz%22%2C%22lastName%22%3A%22Robak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Simkovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergey%22%2C%22lastName%22%3A%22Voloshin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Vorobyev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Munci%22%2C%22lastName%22%3A%22Yagci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keqin%22%2C%22lastName%22%3A%22Qi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qianya%22%2C%22lastName%22%3A%22Qi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lori%22%2C%22lastName%22%3A%22Parisi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srimathi%22%2C%22lastName%22%3A%22Srinivasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natasha%22%2C%22lastName%22%3A%22Schuier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Baeten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Howes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donne%20Bennett%22%2C%22lastName%22%3A%22Caces%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnon%20P.%22%2C%22lastName%22%3A%22Kater%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20GLOW%20study%2C%20fixed-duration%20ibrutinib-venetoclax%20showed%20superior%20progression-free%20survival%20versus%20chlorambucil-obinutuzumab%20in%20patients%20with%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%20who%20were%20older%20or%20had%20comorbidities%2C%20or%20both%2C%20at%20a%20median%20follow%20up%20of%2027%5Cu00b77%20months.%20In%20this%20Article%2C%20we%20report%20updated%20outcomes%20from%20GLOW%20after%20a%2046-month%20median%20follow-up.%5CnMETHODS%3A%20GLOW%20was%20a%20randomised%2C%20multicentre%2C%20phase%203%20study%20done%20at%2067%20hospital%20centres%20across%2014%20countries.%20Patients%20aged%2065%20years%20and%20older%20or%2018-64%20years%20with%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%20and%20a%20cumulative%20illness%20rating%20scale%20score%20of%20more%20than%206%20or%20creatinine%20clearance%20less%20than%2070%20mL%5C%2Fmin%2C%20or%20both%2C%20and%20an%20Eastern%20Cooperative%20Oncology%20Group%20performance%20status%20of%202%20or%20less%20were%20randomly%20assigned%20%281%3A1%29%20via%20an%20interactive%20web%20system%20with%20permuted%20blocks%20%28block%20size%20of%20four%29%20and%20stratified%20by%20IGHV%20mutational%20status%20and%20the%20presence%20of%20del11q%20aberration%20to%20the%20ibrutinib-venetoclax%20group%20%28three%20cycles%20of%20ibrutinib%20lead-in%20%5B420%20mg%5C%2Fday%2C%20orally%5D%2C%20followed%20by%2012%20cycles%20of%20ibrutinib%20plus%20venetoclax%20%5B400%20mg%5C%2Fday%2C%20orally%2C%20including%20a%205-week%20dose%20ramp-up%5D%29%20or%20the%20chlorambucil-obinutuzumab%20group%20%28six%20cycles%20of%20chlorambucil%20%5B0%5Cu00b75%20mg%5C%2Fkg%2C%20orally%2C%20on%20days%201%20and%2015%20of%20each%20cycle%5D%2C%20and%20obinutuzumab%20%5B1000%20mg%2C%20intravenously%2C%20on%20days%201%20%28or%20100%20mg%20on%20day%201%20and%20900%20mg%20on%20day%202%29%2C%208%2C%20and%2015%20of%20cycle%201%20and%20day%201%20of%20cycles%202-6%5D%29.%20The%20primary%20endpoint%20was%20progression-free%20survival%20in%20the%20intention-to-treat%20population%2C%20assessed%20by%20an%20independent%20review%20committee.%20The%20safety%20population%20included%20all%20randomised%20patients%20who%20received%20at%20least%20one%20dose%20of%20the%20study%20treatment.%20This%20study%20is%20registered%20with%20ClinicalTrials.gov%20%28NCT03462719%29%20and%20the%20EU%20Clinical%20Trials%20Register%20%28EudraCT%202017-004699-77%29.%5CnFINDINGS%3A%20Between%20May%204%2C%202018%2C%20and%20April%205%2C%202019%2C%20211%20patients%20%28122%20%5B58%25%5D%20were%20male%20and%2089%20%5B42%25%5D%20were%20female%29%20were%20randomly%20assigned%20to%20receive%20ibrutinib-venetoclax%20%28n%3D106%29%20or%20chlorambucil-obinutuzumab%20%28n%3D105%29.%20At%20a%20median%20of%2046%20months%20%28IQR%2043-47%29%20of%20follow-up%2C%20progression-free%20survival%20remained%20superior%20for%20the%20ibrutinib-venetoclax%20group%20%28hazard%20ratio%200%5Cu00b7214%20%5B95%25%20CI%200%5Cu00b7138-0%5Cu00b7334%5D%3B%20p%3C0%5Cu00b70001%29%3B%2042-month%20progression-free%20survival%20rates%20were%2074%5Cu00b76%25%20%2895%25%20CI%2065%5Cu00b70-82%5Cu00b70%29%20for%20ibrutinib-venetoclax%20and%2024%5Cu00b78%25%20%2816%5Cu00b75-34%5Cu00b71%29%20for%20chlorambucil-obinutuzumab.%20Following%20the%20primary%20analysis%2C%20one%20patient%20in%20the%20chlorambucil-obinutuzumab%20group%20had%20a%20serious%20adverse%20event%20of%20myelodysplastic%20syndrome.%20Treatment-related%20deaths%20were%20reported%20in%20one%20patient%20receiving%20ibrutinib-venetoclax%20%28cardiac%20failure%2C%20pneumonia%2C%20and%20sinus%20node%20dysfunction%29%20and%20in%20one%20patient%20receiving%20chlorambucil-obinutuzumab%20%28pneumonia%29.%20There%20were%2015%20deaths%20in%20the%20ibrutinib-venetoclax%20group%20%28of%20which%20three%20were%20due%20to%20post-treatment%20infections%29%20and%2030%20deaths%20in%20the%20chlorambucil-obinutuzumab%20group%20%28of%20which%2010%20were%20due%20to%20post-treatment%20infections%29.%5CnINTERPRETATION%3A%20After%204%20years%20of%20follow-up%2C%20ibrutinib-venetoclax%20continues%20to%20significantly%20prolong%20progression-free%20survival%20%28vs%20chemoimmunotherapy%29%20in%20patients%20with%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%2C%20supporting%20its%20use%20as%20a%20first-line%20option.%5CnFUNDING%3A%20Janssen%20Research%20%26%20Development%20and%20Pharmacyclics.%22%2C%22date%22%3A%222023-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1470-2045%2823%2900452-7%22%2C%22ISSN%22%3A%221474-5488%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-11T14%3A16%3A40Z%22%7D%7D%2C%7B%22key%22%3A%222JNLFXLR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carras%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECarras%2C%20Sylvain%2C%20Alexia%20Torroja%2C%20Anouk%20Emadali%2C%20Emilie%20Montaut%2C%20Nicolas%20Daguindau%2C%20Adrian%20Tempescul%2C%20Anne%20Moreau%2C%20et%20al.%20%26%23x201C%3BLong-Term%20Analysis%20of%20the%20RiBVD%20Phase%20II%20Trial%20Reveals%20the%20Unfavorable%20Impact%20of%20TP53%20Mutations%20and%20Hypoalbuminemia%20in%20Older%20Adults%20with%20Mantle%20Cell%20Lymphoma%3B%20for%20the%20LYSA%20Group.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%2C%20November%2030%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2023.283724%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2023.283724%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20analysis%20of%20the%20RiBVD%20phase%20II%20trial%20reveals%20the%20unfavorable%20impact%20of%20TP53%20mutations%20and%20hypoalbuminemia%20in%20older%20adults%20with%20mantle%20cell%20lymphoma%3B%20for%20the%20LYSA%20group%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Carras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Torroja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouk%22%2C%22lastName%22%3A%22Emadali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Montaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Daguindau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%22%2C%22lastName%22%3A%22Tempescul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Tchernonog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Schmitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roch%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dartigeas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Barbieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Selim%22%2C%22lastName%22%3A%22Corm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Banos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Fouillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jehan%22%2C%22lastName%22%3A%22Dupuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%22%2C%22lastName%22%3A%22Macro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joel%22%2C%22lastName%22%3A%22Fleury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clementine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghandi%22%2C%22lastName%22%3A%22Damaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Feugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%20Matthieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%22%2C%22lastName%22%3A%22Chabrot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Dorvaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krimo%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandy%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reda%22%2C%22lastName%22%3A%22Garidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Voillat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Morineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Pierre%22%2C%22lastName%22%3A%22Moles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hacene%22%2C%22lastName%22%3A%22Zerazhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Fontan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazid%22%2C%22lastName%22%3A%22Arkam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magda%22%2C%22lastName%22%3A%22Alexis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Delwail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Vilque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Burroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Callanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Le%20Gouill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Gressin%22%7D%5D%2C%22abstractNote%22%3A%22Between%202011%20and%202012%2C%20a%20phase%20II%20trial%20evaluated%20the%20use%20of%20the%20RiBVD%20%28Rituximab%2C%20Bendamustine%2C%20Velcade%20and%20Dexamethasone%29%20combination%20as%20first-line%20treatment%20for%20mantle%20cell%20lymphoma%20%28MCL%29%20patients%20aged%20over%2065.%20We%20have%20now%20re-examined%20the%20classic%20prognostic%20factors%2C%20adding%20an%20assessment%20of%20the%20mutation%20status%20of%20TP53.%20Patients%20%28n%3D74%3B%20median%20age%2073%20years%29%20were%20treated%20with%20the%20RiBVD%20combination.%20Median%20Progression%20Free%20Survival%20%28mPFS%29%20was%2079%20months%2C%20and%20median%20Overall%20Survival%20%28mOS%29%20was%20111%20months.%20TP53%20mutation%20status%20was%20available%20for%2054%5C%2F74%20%2873%25%29%20patients.%20TP53%20mutations%20%28TP53mt%29%20were%20found%20in%2012%20patients%20%2822.2%25%29.%20In%20multivariate%20analysis%2C%20among%20the%20prognostic%20factors%20%28PF%29%20evaluated%2C%20only%20TP53mt%20and%20an%20albumin%20level%20below%203.6%20g%5C%2FdL%20%28Alb%3C3.6%20g%5C%2FdL%29%20were%20independently%20associated%20with%20a%20shorter%20mPFS.%20A%20hazard%20ratio%20%28HR%29%20of%203.16%20%281.3-9.9%2C%20p%3D0.014%29%20was%20obtained%20for%20TP53mt%20versus%20TP53wt%2C%20and%203.6%20%281.39-9.5%2C%20p%3D0.009%29%20for%20Alb%3C3.6%20g%5C%2FdL%20vs%20Alb%5Cu22653.6%20g%5C%2FdL.%20In%20terms%20of%20mOS%2C%20multivariate%20analysis%20identified%20three%20PFs%3A%20TP53mt%20%28HR%3A%205.9%20%281.77-19.5%2C%20p%3D0.004%29%29%2C%20Alb%3C3.6%20g%5C%2FdL%20%28HR%3A%205.2%20%281.46-18.5%2C%20p%3D0.011%29%29%2C%20and%20ECOG%3D2%20%28HR%3A%203.7%20%281.31-10.6%2C%20p%3D0.014%29%29.%20Finally%2C%20a%20score%20combining%20TP53%20status%20and%20albumin%20level%20distinguished%20three%20populations%20based%20on%20the%20presence%20of%200%2C%201%2C%20or%202%20PF.%20For%20these%20populations%2C%20mPFS%20was%207.8%20years%2C%2028%20months%20and%202.5%20months%2C%20respectively.%20Our%20prolonged%20follow-up%20confirmed%20the%20efficacy%20of%20the%20RiBVD%20regimen%2C%20comparing%20it%20favorably%20to%20other%20regimens.%20TP53mt%20and%20hypoalbuminemia%20emerge%20as%20strong%20PF%20that%20can%20be%20easily%20integrated%20into%20prognostic%20scores%20for%20older%20adult%20patients%20with%20MCL.%22%2C%22date%22%3A%222023-11-30%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2023.283724%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-11T14%3A16%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22HL8AXBF2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Houot%20et%20al.%22%2C%22parsedDate%22%3A%222023-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHouot%2C%20Roch%2C%20Emmanuel%20Bachy%2C%20Guillaume%20Cartron%2C%20Fran%26%23xE7%3Bois-Xavier%20Gros%2C%20Franck%20Morschhauser%2C%20Lucie%20Oberic%2C%20Thomas%20Gastinne%2C%20et%20al.%20%26%23x201C%3BAxicabtagene%20Ciloleucel%20as%20Second-Line%20Therapy%20in%20Large%20B%20Cell%20Lymphoma%20Ineligible%20for%20Autologous%20Stem%20Cell%20Transplantation%3A%20A%20Phase%202%20Trial.%26%23x201D%3B%20%3Ci%3ENature%20Medicine%3C%5C%2Fi%3E%2029%2C%20no.%2010%20%28October%202023%29%3A%202593%26%23x2013%3B2601.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-023-02572-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-023-02572-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Axicabtagene%20ciloleucel%20as%20second-line%20therapy%20in%20large%20B%20cell%20lymphoma%20ineligible%20for%20autologous%20stem%20cell%20transplantation%3A%20a%20phase%202%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roch%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Xavier%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Gastinne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Feugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Dul%5Cu00e9ry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Joris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Choquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Brisou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Cheminant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques-Olivier%22%2C%22lastName%22%3A%22Bay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%20Llamas%22%2C%22lastName%22%3A%22Gutierrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Menard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%22%2C%22lastName%22%3A%22Tarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Delfau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Portugues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Itti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Palard-Novello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Blanc-Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yassine%22%2C%22lastName%22%3A%22Al%20Tabaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Bailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%5D%2C%22abstractNote%22%3A%22Axicabtagene%20ciloleucel%20%28axi-cel%29%20demonstrated%20superior%20efficacy%20compared%20to%20standard%20of%20care%20as%20second-line%20therapy%20in%20patients%20with%20high-risk%20relapsed%5C%2Frefractory%20%28R%5C%2FR%29%20large%20B%20cell%20lymphoma%20%28LBCL%29%20considered%20eligible%20for%20autologous%20stem%20cell%20transplantation%20%28ASCT%29%3B%20however%2C%20in%20clinical%20practice%2C%20roughly%20half%20of%20patients%20with%20R%5C%2FR%20LBCL%20are%20deemed%20unsuitable%20candidates%20for%20ASCT.%20The%20efficacy%20of%20axi-cel%20remains%20to%20be%20ascertained%20in%20transplant-ineligible%20patients.%20ALYCANTE%2C%20an%20open-label%2C%20phase%202%20study%2C%20evaluated%20axi-cel%20as%20a%20second-line%20therapy%20in%2062%20patients%20with%20R%5C%2FR%20LBCL%20who%20were%20considered%20ineligible%20for%20ASCT.%20The%20primary%20end%20point%20was%20investigator-assessed%20complete%20metabolic%20response%20at%203%20months%20from%20the%20axi-cel%20infusion.%20Key%20secondary%20end%20points%20included%20progression-free%20survival%2C%20overall%20survival%20and%20safety.%20The%20study%20met%20its%20primary%20end%20point%20with%20a%20complete%20metabolic%20response%20of%2071.0%25%20%2895%25%20confidence%20interval%2C%2058.1-81.8%25%29%20at%203%20months.%20With%20a%20median%20follow-up%20of%2012.0%20months%20%28range%2C%202.1-17.9%29%2C%20median%20progression-free%20survival%20was%2011.8%20months%20%2895%25%20confidence%20interval%2C%208.4-not%20reached%29%20and%20overall%20survival%20was%20not%20reached.%20There%20was%20no%20unexpected%20toxicity.%20Grade%203-4%20cytokine%20release%20syndrome%20and%20neurologic%20events%20occurred%20in%208.1%25%20and%2014.5%25%20of%20patients%2C%20respectively.%20These%20results%20support%20axi-cel%20as%20second-line%20therapy%20in%20patients%20with%20R%5C%2FR%20LBCL%20ineligible%20for%20ASCT.%20ClinicalTrials.gov%20Identifier%3A%20NCT04531046%20.%22%2C%22date%22%3A%222023-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41591-023-02572-5%22%2C%22ISSN%22%3A%221546-170X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-11T14%3A17%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22TVYQFI5H%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Faria%20et%20al.%22%2C%22parsedDate%22%3A%222023-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFaria%2C%20Carla%2C%20Fabien%20Gava%2C%20Pauline%20Gravelle%2C%20Juan%20Garcia%20Valero%2C%20Celia%20Doba%26%23xF1%3Bo-L%26%23xF3%3Bpez%2C%20Nathalie%20Van%20Acker%2C%20Cathy%20Quelen%2C%20et%20al.%20%26%23x201C%3BPatient-Derived%20Lymphoma%20Spheroids%20Integrating%20Immune%20Tumor%20Microenvironment%20as%20Preclinical%20Follicular%20Lymphoma%20Models%20for%20Personalized%20Medicine.%26%23x201D%3B%20%3Ci%3EJournal%20for%20Immunotherapy%20of%20Cancer%3C%5C%2Fi%3E%2011%2C%20no.%2010%20%28October%202023%29%3A%20e007156.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2023-007156%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2023-007156%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patient-derived%20lymphoma%20spheroids%20integrating%20immune%20tumor%20microenvironment%20as%20preclinical%20follicular%20lymphoma%20models%20for%20personalized%20medicine%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carla%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Gava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Garcia%22%2C%22lastName%22%3A%22Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celia%22%2C%22lastName%22%3A%22Doba%5Cu00f1o-L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Van%20Acker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%22%2C%22lastName%22%3A%22Quelen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Jalowicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Gal%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Follicular%20lymphoma%20%28FL%29%2C%20the%20most%20common%20indolent%20non-Hodgkin%27s%20Lymphoma%2C%20is%20a%20heterogeneous%20disease%20and%20a%20paradigm%20of%20the%20contribution%20of%20immune%20tumor%20microenvironment%20to%20disease%20onset%2C%20progression%2C%20and%20therapy%20resistance.%20Patient-derived%20models%20are%20scarce%20and%20fail%20to%20reproduce%20immune%20phenotypes%20and%20therapeutic%20responses.%5CnMETHODS%3A%20To%20capture%20disease%20heterogeneity%20and%20microenvironment%20cues%2C%20we%20developed%20a%20patient-derived%20lymphoma%20spheroid%20%28FL-PDLS%29%20model%20culturing%20FL%20cells%20from%20lymph%20nodes%20%28LN%29%20with%20an%20optimized%20cytokine%20cocktail%20that%20mimics%20LN%20stimuli%20and%20maintains%20tumor%20cell%20viability.%5CnRESULTS%3A%20FL-PDLS%2C%20mainly%20composed%20of%20tumor%20B%20cells%20%2860%25%20on%20average%29%20and%20autologous%20T%20cells%20%2813%25%5Cu2009CD4%20and%203%25%5Cu2009CD8%20on%20average%2C%20respectively%29%2C%20rapidly%20organizes%20into%20patient-specific%20three-dimensional%20%283D%29%20structures%20of%20three%20different%20morphotypes%20according%20to%203D%20imaging%20analysis.%20RNAseq%20analysis%20indicates%20that%20FL-PDLS%20reproduces%20FL%20hallmarks%20with%20the%20overexpression%20of%20cell%20cycle%2C%20BCR%2C%20or%20mTOR%20signaling%20related%20gene%20sets.%20FL-PDLS%20also%20recapitulates%20the%20exhausted%20immune%20phenotype%20typical%20of%20FL-LN%2C%20including%20expression%20of%20BTLA%2C%20TIGIT%2C%20PD-1%2C%20TIM-3%2C%20CD39%20and%20CD73%20on%20CD3%2B%20T%20cells.%20These%20features%20render%20FL-PDLS%20an%20amenable%20system%20for%20immunotherapy%20testing.%20With%20this%20aim%2C%20we%20demonstrate%20that%20the%20combination%20of%20obinutuzumab%20%28anti-CD20%29%20and%20nivolumab%20%28anti-PD1%29%20reduces%20tumor%20load%20in%20a%20significant%20proportion%20of%20FL-PDLS.%20Interestingly%2C%20B%20cell%20depletion%20inversely%20correlates%20with%20the%20percentage%20of%20CD8%2B%20cells%20positive%20for%20PD-1%20and%20TIM-3.%5CnCONCLUSIONS%3A%20In%20summary%2C%20FL-PDLS%20is%20a%20robust%20patient-derived%203D%20system%20that%20can%20be%20used%20as%20a%20tool%20to%20mimic%20FL%20pathology%20and%20to%20test%20novel%20immunotherapeutic%20approaches%20in%20a%20context%20of%20personalized%20medicine.%22%2C%22date%22%3A%222023-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjitc-2023-007156%22%2C%22ISSN%22%3A%222051-1426%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222024-01-08T13%3A30%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22KV2LCIUV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fi%5Cu00e9vet%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFi%26%23xE9%3Bvet%2C%20Lo%26%23xEF%3Bc%2C%20Nicolas%20Espagnolle%2C%20Daniela%20Gerovska%2C%20David%20Bernard%2C%20Charlotte%20Syrykh%2C%20Camille%20Laurent%2C%20Pierre%20Layrolle%2C%20et%20al.%20%26%23x201C%3BSingle-Cell%20RNA%20Sequencing%20of%20Human%20Non-Hematopoietic%20Bone%20Marrow%20Cells%20Reveals%20a%20Unique%20Set%20of%20Inter-Species%20Conserved%20Biomarkers%20for%20Native%20Mesenchymal%20Stromal%20Cells.%26%23x201D%3B%20%3Ci%3EStem%20Cell%20Research%20%26amp%3B%20Therapy%3C%5C%2Fi%3E%2014%2C%20no.%201%20%28August%2030%2C%202023%29%3A%20229.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13287-023-03437-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13287-023-03437-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-cell%20RNA%20sequencing%20of%20human%20non-hematopoietic%20bone%20marrow%20cells%20reveals%20a%20unique%20set%20of%20inter-species%20conserved%20biomarkers%20for%20native%20mesenchymal%20stromal%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Fi%5Cu00e9vet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Espagnolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Gerovska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Layrolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22De%20Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Justo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Reina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Casteilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20J.%22%2C%22lastName%22%3A%22Ara%5Cu00fazo-Bravo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abderrahim%22%2C%22lastName%22%3A%22Naji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Deschaseaux%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Native%20bone%20marrow%20%28BM%29%20mesenchymal%20stem%5C%2Fstromal%20cells%20%28BM-MSCs%29%20participate%20in%20generating%20and%20shaping%20the%20skeleton%20and%20BM%20throughout%20the%20lifespan.%20Moreover%2C%20BM-MSCs%20regulate%20hematopoiesis%20by%20contributing%20to%20the%20hematopoietic%20stem%20cell%20niche%20in%20providing%20critical%20cytokines%2C%20chemokines%20and%20extracellular%20matrix%20components.%20However%2C%20BM-MSCs%20contain%20a%20heterogeneous%20cell%20population%20that%20remains%20ill-defined.%20Although%20studies%20on%20the%20taxonomy%20of%20native%20BM-MSCs%20in%20mice%20have%20just%20started%20to%20emerge%2C%20the%20taxonomy%20of%20native%20human%20BM-MSCs%20remains%20unelucidated.%5CnMETHODS%3A%20By%20using%20single-cell%20RNA%20sequencing%20%28scRNA-seq%29%2C%20we%20aimed%20to%20define%20a%20proper%20taxonomy%20for%20native%20human%20BM%20non-hematopoietic%20subsets%20including%20endothelial%20cells%20%28ECs%29%20and%20mural%20cells%20%28MCs%29%20but%20with%20a%20focal%20point%20on%20MSCs.%20To%20this%20end%2C%20transcriptomic%20scRNA-seq%20data%20were%20generated%20from%205%20distinct%20BM%20donors%20and%20were%20analyzed%20together%20with%20other%20transcriptomic%20data%20and%20with%20computational%20biology%20analyses%20at%20different%20levels%20to%20identify%2C%20characterize%20and%20classify%20distinct%20native%20cell%20subsets%20with%20relevant%20biomarkers.%5CnRESULTS%3A%20We%20could%20ascribe%20novel%20specific%20biomarkers%20to%20ECs%2C%20MCs%20and%20MSCs.%20Unlike%20ECs%20and%20MCs%2C%20MSCs%20exhibited%20an%20adipogenic%20transcriptomic%20pattern%20while%20co-expressing%20genes%20related%20to%20hematopoiesis%20support%20and%20multilineage%20commitment%20potential.%20Furthermore%2C%20by%20a%20comparative%20analysis%20of%20scRNA-seq%20of%20BM%20cells%20from%20humans%20and%20mice%2C%20we%20identified%20core%20genes%20conserved%20in%20both%20species.%20Notably%2C%20we%20identified%20MARCKS%2C%20CXCL12%2C%20PDGFRA%2C%20and%20LEPR%20together%20with%20adipogenic%20factors%20as%20archetypal%20biomarkers%20of%20native%20MSCs%20within%20BM.%20In%20addition%2C%20our%20data%20suggest%20some%20complex%20gene%20nodes%20regulating%20critical%20biological%20functions%20of%20native%20BM-MSCs%20together%20with%20a%20preferential%20commitment%20toward%20an%20adipocyte%20lineage.%5CnCONCLUSIONS%3A%20Overall%2C%20our%20taxonomy%20for%20native%20BM%20non-hematopoietic%20compartment%20provides%20an%20explicit%20depiction%20of%20gene%20expression%20in%20human%20ECs%2C%20MCs%20and%20MSCs%20at%20single-cell%20resolution.%20This%20analysis%20helps%20enhance%20our%20understanding%20of%20the%20phenotype%20and%20the%20complexity%20of%20biological%20functions%20of%20native%20human%20BM-MSCs.%22%2C%22date%22%3A%222023-08-30%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13287-023-03437-x%22%2C%22ISSN%22%3A%221757-6512%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A50%3A17Z%22%7D%7D%2C%7B%22key%22%3A%229JB4T4ZZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Quintanilla-Martinez%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQuintanilla-Martinez%2C%20Leticia%2C%20Camille%20Laurent%2C%20Lorinda%20Soma%2C%20Siok-Bian%20Ng%2C%20Fina%20Climent%2C%20Sarah%20L.%20Ondrejka%2C%20Alberto%20Zamo%2C%20et%20al.%20%26%23x201C%3BEmerging%20Entities%3A%20High-Grade%5C%2FLarge%20B-Cell%20Lymphoma%20with%2011q%20Aberration%2C%20Large%20B-Cell%20Lymphoma%20with%20IRF4%20Rearrangement%2C%20and%20New%20Molecular%20Subgroups%20in%20Large%20B-Cell%20Lymphomas%3A%20A%20Report%20of%20the%202022%20EA4HP%5C%2FSH%20Lymphoma%20Workshop.%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%2C%20August%209%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-023-03590-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-023-03590-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Emerging%20entities%3A%20high-grade%5C%2Flarge%20B-cell%20lymphoma%20with%2011q%20aberration%2C%20large%20B-cell%20lymphoma%20with%20IRF4%20rearrangement%2C%20and%20new%20molecular%20subgroups%20in%20large%20B-cell%20lymphomas%3A%20a%20report%20of%20the%202022%20EA4HP%5C%2FSH%20lymphoma%20workshop%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leticia%22%2C%22lastName%22%3A%22Quintanilla-Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorinda%22%2C%22lastName%22%3A%22Soma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siok-Bian%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fina%22%2C%22lastName%22%3A%22Climent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20L.%22%2C%22lastName%22%3A%22Ondrejka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Zamo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Wotherspoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22de%20Leval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Dirnhofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Leoncini%22%7D%5D%2C%22abstractNote%22%3A%22Emerging%20entities%20and%20molecular%20subgroups%20in%20large%20B-cell%20lymphomas%20%28LBCLs%29%20were%20discussed%20during%20the%202022%20European%20Association%20for%20Haematopathology%5C%2FSociety%20for%20Hematopathology%20workshop%20in%20Florence%2C%20Italy.%20This%20session%20focused%20on%20newly%20recognized%20diseases%20and%20their%20diagnostic%20challenges.%20High-grade%5C%2Flarge%20B-cell%20lymphoma%20with%2011q%20aberration%20%28HG%5C%2FLBCL-11q%29%20is%20defined%20by%20chromosome%2011q-gains%20and%20telomeric%20loss.%20FISH%20analysis%20is%20recommended%20for%20the%20diagnosis.%20HG%5C%2FLBCL-11q%20can%20occur%20in%20the%20setting%20of%20immunodeficiency%2C%20including%20ataxia-telangiectasia%2C%20and%20predominates%20in%20children.%20The%20morphological%20spectrum%20of%20these%20cases%20is%20broader%20than%20previously%20thought%20with%20often%20Burkitt-like%20morphology%20and%20coarse%20apoptotic%20bodies.%20It%20has%20a%20Burkitt-like%20immunophenotype%20%28CD10%2B%2C%20BCL6%2B%2C%20BCL2-%29%20but%20MYC%20expression%20is%20weak%20or%20negative%2C%20lacks%20MYC%20rearrangement%2C%20and%20is%20in%20contrast%20to%20Burkitt%20lymphoma%2050%25%20of%20the%20cases%20express%20LMO2.%20LBCL%20with%20IRF4%20rearrangement%20%28LBCL-IRF4%29%20occurs%20mainly%20in%20the%20pediatric%20population%20but%20also%20in%20adults.%20LBCL-IRF4%20has%20an%20excellent%20prognosis%2C%20with%20distinguishing%20molecular%20findings.%20IRF4%20rearrangements%2C%20although%20characteristic%20of%20this%20entity%2C%20are%20not%20specific%20and%20can%20be%20found%20in%20association%20with%20other%20chromosomal%20translocations%20in%20other%20large%20B-cell%20lymphomas.%20Other%20molecular%20subgroups%20discussed%20included%20primary%20bone%20diffuse%20large%20B-cell%20lymphoma%20%28PB-DLBCL%29%2C%20which%20has%20distinctive%20clinical%20presentation%20and%20molecular%20findings%2C%20and%20B-acute%20lymphoblastic%20leukemia%20%28B-ALL%29%20with%20IGH%3A%3AMYC%20translocation%20recently%20segregated%20from%20Burkitt%20lymphoma%20with%20TdT%20expression.%20This%20latter%20disorder%20has%20molecular%20features%20of%20precursor%20B-cells%2C%20often%20tetrasomy%201q%20and%20recurrent%20NRAS%20and%20KRAS%20mutations.%20In%20this%20report%2C%20novel%20findings%2C%20recommendations%20for%20diagnosis%2C%20open%20questions%2C%20and%20diagnostic%20challenges%20raised%20by%20the%20cases%20submitted%20to%20the%20workshop%20will%20be%20discussed.%22%2C%22date%22%3A%222023-08-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-023-03590-x%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A50%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22IMVSNCSG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Michallet%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMichallet%2C%20Anne-Sophie%2C%20R%26%23xE9%3Bmi%20Letestu%2C%20Magali%20Le%20Garff-Tavernier%2C%20Lydia%20Campos%2C%20Michel%20Ticchioni%2C%20Marie-Sarah%20Dilhuydy%2C%20Stephane%20Morisset%2C%20et%20al.%20%26%23x201C%3BA%20Fixed-Duration%20Immunochemotherapy%20Approach%20in%20CLL%3A%205.5-Year%20Results%20from%20the%20Phase%202%20ICLL-07%20FILO%20Trial.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%207%2C%20no.%2015%20%28August%208%2C%202023%29%3A%203936%26%23x2013%3B45.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2022009594%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2022009594%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20fixed-duration%20immunochemotherapy%20approach%20in%20CLL%3A%205.5-year%20results%20from%20the%20phase%202%20ICLL-07%20FILO%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Michallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Letestu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Le%20Garff-Tavernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Ticchioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Sarah%22%2C%22lastName%22%3A%22Dilhuydy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephane%22%2C%22lastName%22%3A%22Morisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Rouille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Mah%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamel%22%2C%22lastName%22%3A%22Laribi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Villemagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Ferrant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tournilhac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Delmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lysiane%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Leblond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Tomowiak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22de%20Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederique%22%2C%22lastName%22%3A%22Orsini-Piocelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Banos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Carassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%20Mathieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dartigeas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Truchan-Graczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Vilque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Th%5Cu00e9r%5Cu00e8se%20Aurran%22%2C%22lastName%22%3A%22Schleinitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Cymbalista%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Lepr%5Cu00eatre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22L%5Cu00e9vy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Nguyen-Khac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Feugier%22%7D%5D%2C%22abstractNote%22%3A%22In%20previously%20untreated%2C%20medically%20fit%20patients%20with%20chronic%20lymphocytic%20leukemia%20%28CLL%29%2C%20research%20is%20focused%20on%20developing%20fixed-duration%20strategies%20to%20improve%20long-term%20outcomes%20while%20sparing%20patients%20from%20serious%20toxicities.%20The%20ICLL-07%20trial%20evaluated%20a%20fixed-duration%20%2815-month%29%20immunochemotherapy%20approach%20in%20which%20after%20obinutuzumab-ibrutinib%20induction%20for%209%5Cu00a0months%2C%20patients%20%28n%5Cu00a0%3D%2010%29%20in%20complete%20remission%20%28CR%29%20with%20bone%20marrow%20%28BM%29%20measurable%20residual%20disease%20%28MRD%29%20%3C0.01%25%20continued%20only%20ibrutinib%20420%5Cu00a0mg%5C%2Fday%20for%206%20additional%20months%20%28I%20arm%29%2C%20whereas%20the%20majority%20%28n%5Cu00a0%3D%20115%29%20received%20up%20to%204%20cycles%20of%20fludarabine%5C%2Fcyclophosphamide-obinutuzumab%201000%5Cu00a0mg%20alongside%20the%20ibrutinib%20%28I-FCG%20arm%29.%20Primary%20analysis%20at%20month%2016%20showed%20that%2084%20of%20135%20%2862.2%25%29%20patients%20enrolled%20achieved%20CR%20with%20a%20BM%20MRD%20%3C0.01%25.%20Here%2C%20we%20report%20follow-up%20at%20median%2063%5Cu00a0months.%20Peripheral%20blood%20%28PB%29%20MRD%20was%20assessed%206%5Cu00a0monthly%20beyond%20the%20end%20of%20treatment%20using%20a%20highly%20sensitive%20%2810-6%29%20flow%20cytometry%20technique.%20In%20the%20I-FCG%20arm%2C%20the%20PB%20MRD%20%3C0.01%25%20rate%20%28low-level%20positive%20%3C0.01%25%20or%20undetectable%20with%20limit%20of%20detection%20%5Cu226410-4%29%20in%20evaluable%20patients%20was%20still%2092.5%25%20%2874%5C%2F80%29%20at%20month%2040%20and%2080.6%25%20%2850%5C%2F62%29%20at%20month%2064.%20No%20differences%20in%20the%20PB%20MRD%20status%20were%20apparent%20per%20to%20the%20IGHV%20mutational%20status.%20In%20the%20overall%20population%2C%204-year%20progression-free%20and%20overall%20survival%20rates%20were%2095.5%25%20and%2096.2%25%2C%20respectively.%20Twelve%20deaths%20occurred%20overall.%20Fourteen%20serious%20adverse%20events%20occurred%20beyond%20the%20end%20of%20treatment.%20Thus%2C%20our%20fixed-duration%20immunochemotherapy%20approach%20produced%20deep%20and%20sustained%20PB%20MRD%20responses%2C%20high%20survival%20rates%2C%20and%20low%20long-term%20toxicity.%20A%20randomized%20trial%20is%20needed%20to%20compare%20our%20immunochemotherapy%20approach%20with%20a%20chemotherapy-free%20strategy.%20This%20trial%20was%20registered%20at%20www.clinicaltrials.gov%20as%20%23NCT02666898.%22%2C%22date%22%3A%222023-08-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2022009594%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A51%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22QJXPL3HT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ousset%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOusset%2C%20L%26%23xE9%3Ba%2C%20Fran%26%23xE7%3Bois%20Vergez%2C%20Camille%20Laurent%2C%20Lucie%20Oberic%2C%20and%20Alban%20Canali.%20%26%23x201C%3BDiagnosis%20of%20Enteropathy-Associated%20T-Cell%20Lymphoma%20%28EATL%29%20on%20Peripheral%20Blood%3A%20A%20Pleiomorphic%20Morphology%20and%20an%20Unusual%20Immunophenotype.%26%23x201D%3B%20%3Ci%3EEJHaem%3C%5C%2Fi%3E%204%2C%20no.%203%20%28August%202023%29%3A%20861%26%23x2013%3B62.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjha2.733%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjha2.733%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20of%20enteropathy-associated%20T-cell%20lymphoma%20%28EATL%29%20on%20peripheral%20blood%3A%20A%20pleiomorphic%20morphology%20and%20an%20unusual%20immunophenotype%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Ousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alban%22%2C%22lastName%22%3A%22Canali%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjha2.733%22%2C%22ISSN%22%3A%222688-6146%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A54%3A48Z%22%7D%7D%2C%7B%22key%22%3A%227Y49BCTF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Maria%20Flores%2C%20Lo%26%23xEF%3Bc%20Chartier%2C%20Sarah%20Huet%2C%20Christopher%20R.%20Bolen%2C%20Jeffrey%20M.%20Venstrom%2C%20Catherine%20Chassagne-Cl%26%23xE9%3Bment%2C%20et%20al.%20%26%23x201C%3BLong-Term%20Follow-up%20Confirms%20the%20Favourable%20Prognostic%20Impact%20of%20High%20Numbers%20of%20Tumour%20Infiltrating%20CD3%20T-Cells%20in%20Follicular%20Lymphoma%20Patients%20Treated%20by%20Rituximab-Maintenance%20Regimen.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20202%2C%20no.%203%20%28August%202023%29%3A%20686%26%23x2013%3B89.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.18881%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.18881%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20follow-up%20confirms%20the%20favourable%20prognostic%20impact%20of%20high%20numbers%20of%20tumour%20infiltrating%20CD3%20T-cells%20in%20follicular%20lymphoma%20patients%20treated%20by%20rituximab-maintenance%20regimen%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Chartier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Huet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20R.%22%2C%22lastName%22%3A%22Bolen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20M.%22%2C%22lastName%22%3A%22Venstrom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Cl%5Cu00e9ment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Dartigues-Cuill%5Cu00e9res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Charlotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Tesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbjh.18881%22%2C%22ISSN%22%3A%221365-2141%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A51%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22BGJSIB3W%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Al%20Tabaa%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAl%20Tabaa%2C%20Yassine%2C%20Rene%20Oliver%20Casasnovas%2C%20Clio%20Baillet%2C%20Emmanuel%20Bachy%2C%20Emmanuelle%20Nicolas-Virelizier%2C%20Jean%20Marc%20Schiano%20De%20Colella%2C%20Clement%20Bailly%2C%20et%20al.%20%26%23x201C%3BProspective%20Evaluation%20of%20Lymphoma%20Response%20to%20Immunomodulatory%20Therapy%20Criteria%20in%20GATA%20Trial%20from%20the%20LYSA%20Group.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%207%2C%20no.%2014%20%28July%2025%2C%202023%29%3A%203735%26%23x2013%3B38.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023009911%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023009911%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prospective%20evaluation%20of%20lymphoma%20response%20to%20immunomodulatory%20therapy%20criteria%20in%20GATA%20trial%20from%20the%20LYSA%20group%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yassine%22%2C%22lastName%22%3A%22Al%20Tabaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rene%20Oliver%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clio%22%2C%22lastName%22%3A%22Baillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Nicolas-Virelizier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marc%22%2C%22lastName%22%3A%22Schiano%20De%20Colella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clement%22%2C%22lastName%22%3A%22Bailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Gyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remy%22%2C%22lastName%22%3A%22Gressin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Morineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Le%20Gouill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Tilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roch%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Herbaux%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-07-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2023009911%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A51%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22BIL9RS25%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Munir%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMunir%2C%20Talha%2C%20Carol%20Moreno%2C%20Carolyn%20Owen%2C%20George%20Follows%2C%20Ohad%20Benjamini%2C%20Ann%20Janssens%2C%20Mark-David%20Levin%2C%20et%20al.%20%26%23x201C%3BImpact%20of%20Minimal%20Residual%20Disease%20on%20Progression-Free%20Survival%20Outcomes%20After%20Fixed-Duration%20Ibrutinib-Venetoclax%20Versus%20Chlorambucil-Obinutuzumab%20in%20the%20GLOW%20Study.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%3C%5C%2Fi%3E%2041%2C%20no.%2021%20%28July%2020%2C%202023%29%3A%203689%26%23x2013%3B99.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.22.02283%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.22.02283%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Minimal%20Residual%20Disease%20on%20Progression-Free%20Survival%20Outcomes%20After%20Fixed-Duration%20Ibrutinib-Venetoclax%20Versus%20Chlorambucil-Obinutuzumab%20in%20the%20GLOW%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Talha%22%2C%22lastName%22%3A%22Munir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carol%22%2C%22lastName%22%3A%22Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%22%2C%22lastName%22%3A%22Owen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Follows%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ohad%22%2C%22lastName%22%3A%22Benjamini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Janssens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark-David%22%2C%22lastName%22%3A%22Levin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Osterborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tadeusz%22%2C%22lastName%22%3A%22Robak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Simkovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don%22%2C%22lastName%22%3A%22Stevens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergey%22%2C%22lastName%22%3A%22Voloshin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Vorobyev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Munci%22%2C%22lastName%22%3A%22Yagci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keqin%22%2C%22lastName%22%3A%22Qi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qianya%22%2C%22lastName%22%3A%22Qi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lori%22%2C%22lastName%22%3A%22Parisi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srimathi%22%2C%22lastName%22%3A%22Srinivasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natasha%22%2C%22lastName%22%3A%22Schuier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Baeten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Howes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donne%20Bennett%22%2C%22lastName%22%3A%22Caces%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%20U.%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnon%20P.%22%2C%22lastName%22%3A%22Kater%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20In%20GLOW%2C%20fixed-duration%20ibrutinib%20%2B%20venetoclax%20showed%20superior%20progression-free%20survival%20%28PFS%29%20versus%20chlorambucil%20%2B%20obinutuzumab%20in%20older%5C%2Fcomorbid%20patients%20with%20previously%20untreated%20chronic%20lymphocytic%20leukemia%20%28CLL%29.%20The%20current%20analysis%20describes%20minimal%20residual%20disease%20%28MRD%29%20kinetics%20and%20any%20potential%20predictive%20value%20for%20PFS%2C%20as%20it%20has%20not%20yet%20been%20evaluated%20for%20ibrutinib%20%2B%20venetoclax%20treatment.%5CnMETHODS%3A%20Undetectable%20MRD%20%28uMRD%29%20was%20assessed%20by%20next-generation%20sequencing%20at%20%3C1%20CLL%20cell%20per%2010%2C000%20%28%3C10-4%29%20and%20%3C1%20CLL%20cell%20per%20100%2C000%20%28%3C10-5%29%20leukocytes.%20PFS%20was%20analyzed%20by%20MRD%20status%20at%203%20months%20after%20treatment%20%28EOT%2B3%29.%5CnRESULTS%3A%20Ibrutinib%20%2B%20venetoclax%20achieved%20deeper%20uMRD%20%28%3C10-5%29%20rates%20in%20bone%20marrow%20%28BM%29%20and%20peripheral%20blood%20%28PB%29%2C%20respectively%2C%20in%2040.6%25%20and%2043.4%25%20of%20patients%20at%20EOT%2B3%20versus%207.6%25%20and%2018.1%25%20of%20patients%20receiving%20chlorambucil%20%2B%20obinutuzumab.%20Of%20these%20patients%2C%20uMRD%20%28%3C10-5%29%20in%20PB%20was%20sustained%20during%20the%20first%20year%20post-treatment%20%28EOT%2B12%29%20in%2080.4%25%20of%20patients%20receiving%20ibrutinib%20%2B%20venetoclax%20and%2026.3%25%20receiving%20chlorambucil%20%2B%20obinutuzumab.%20Patients%20with%20detectable%20MRD%20%28dMRD%3B%20%5Cu226510-4%29%20in%20PB%20at%20EOT%2B3%20were%20more%20likely%20to%20sustain%20MRD%20levels%20through%20EOT%2B12%20with%20ibrutinib%20%2B%20venetoclax%20versus%20chlorambucil%20%2B%20obinutuzumab.%20PFS%20rates%20at%20EOT%2B12%20were%20high%20among%20patients%20treated%20with%20ibrutinib%20%2B%20venetoclax%20regardless%20of%20MRD%20status%20at%20EOT%2B3%3A%2096.3%25%20and%2093.3%25%20in%20patients%20with%20uMRD%20%28%3C10-4%29%20and%20dMRD%20%28%5Cu226510-4%29%20in%20BM%2C%20respectively%2C%20versus%2083.3%25%20and%2058.7%25%20for%20patients%20receiving%20chlorambucil%20%2B%20obinutuzumab.%20PFS%20rates%20at%20EOT%2B12%20also%20remained%20high%20in%20patients%20with%20unmutated%20immunoglobulin%20heavy-chain%20variable%20region%20%28IGHV%29%20receiving%20ibrutinib%20%2B%20venetoclax%2C%20independent%20of%20MRD%20status%20in%20BM.%5CnCONCLUSION%3A%20Molecular%20and%20clinical%20relapses%20were%20less%20frequent%20during%20the%20first%20year%20post-treatment%20with%20ibrutinib%20%2B%20venetoclax%20versus%20chlorambucil%20%2B%20obinutuzumab%20regardless%20of%20MRD%20status%20at%20EOT%2B3%20and%20IGHV%20status.%20Even%20for%20patients%20not%20achieving%20uMRD%20%28%3C10-4%29%2C%20PFS%20rates%20remained%20high%20with%20ibrutinib%20%2B%20venetoclax%3B%20this%20is%20a%20novel%20finding%20and%20requires%20additional%20follow-up%20to%20confirm%20its%20persistence%20over%20time.%22%2C%22date%22%3A%222023-07-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.22.02283%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A52%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22ZKE9TN44%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeot%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeot%2C%20Anne%2C%20Vanessa%20Klapp%2C%20Elodie%20Viry%2C%20Susanne%20Gonder%2C%20Iria%20Fernandez%20Botana%2C%20Arnaud%20Blomme%2C%20Mohaned%20Benzarti%2C%20et%20al.%20%26%23x201C%3BInhibition%20of%20MYC%20Translation%20through%20Targeting%20of%20the%20Newly%20Identified%20PHB-EIF4F%20Complex%20as%20a%20Therapeutic%20Strategy%20in%20CLL.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20141%2C%20no.%2026%20%28June%2029%2C%202023%29%3A%203166%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022017839%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022017839%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibition%20of%20MYC%20translation%20through%20targeting%20of%20the%20newly%20identified%20PHB-eIF4F%20complex%20as%20a%20therapeutic%20strategy%20in%20CLL%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Largeot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Klapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Viry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanne%22%2C%22lastName%22%3A%22Gonder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iria%22%2C%22lastName%22%3A%22Fernandez%20Botana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Blomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohaned%22%2C%22lastName%22%3A%22Benzarti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Pierson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Duculty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petra%22%2C%22lastName%22%3A%22Marttila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Wierz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernesto%22%2C%22lastName%22%3A%22Gargiulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulia%22%2C%22lastName%22%3A%22Pagano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ning%22%2C%22lastName%22%3A%22An%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najla%22%2C%22lastName%22%3A%22El%20Hachem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Perez%20Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Supriya%22%2C%22lastName%22%3A%22Chakraborty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Hugues%22%2C%22lastName%22%3A%22Fran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Cortez%20Clemente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Berchem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitar%20G.%22%2C%22lastName%22%3A%22Efremov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunnar%22%2C%22lastName%22%3A%22Dittmar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martyna%22%2C%22lastName%22%3A%22Szpakowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andy%22%2C%22lastName%22%3A%22Chevign%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%20V.%22%2C%22lastName%22%3A%22Nazarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Helleday%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Close%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Meiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basile%22%2C%22lastName%22%3A%22Stamatopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22D%5Cu00e9saubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Paggetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Moussay%22%7D%5D%2C%22abstractNote%22%3A%22Dysregulation%20of%20messenger%20RNA%20%28mRNA%29%20translation%2C%20including%20preferential%20translation%20of%20mRNA%20with%20complex%205%27%20untranslated%20regions%20such%20as%20the%20MYC%20oncogene%2C%20is%20recognized%20as%20an%20important%20mechanism%20in%20cancer.%20Here%2C%20we%20show%20that%20both%20human%20and%20murine%20chronic%20lymphocytic%20leukemia%20%28CLL%29%20cells%20display%20a%20high%20translation%20rate%2C%20which%20is%20inhibited%20by%20the%20synthetic%20flavagline%20FL3%2C%20a%20prohibitin%20%28PHB%29-binding%20drug.%20A%20multiomics%20analysis%20performed%20in%20samples%20from%20patients%20with%20CLL%20and%20cell%20lines%20treated%20with%20FL3%20revealed%20the%20decreased%20translation%20of%20the%20MYC%20oncogene%20and%20of%20proteins%20involved%20in%20cell%20cycle%20and%20metabolism.%20Furthermore%2C%20inhibiting%20translation%20induced%20a%20proliferation%20arrest%20and%20a%20rewiring%20of%20MYC-driven%20metabolism.%20Interestingly%2C%20contrary%20to%20other%20models%2C%20the%20RAS-RAF-%28PHBs%29-MAPK%20pathway%20is%20neither%20impaired%20by%20FL3%20nor%20implicated%20in%20translation%20regulation%20in%20CLL%20cells.%20Here%2C%20we%20rather%20show%20that%20PHBs%20are%20directly%20associated%20with%20the%20eukaryotic%20initiation%20factor%20%28eIF%294F%20translation%20complex%20and%20are%20targeted%20by%20FL3.%20Knockdown%20of%20PHBs%20resembled%20FL3%20treatment.%20Importantly%2C%20inhibition%20of%20translation%20controlled%20CLL%20development%20in%5Cu00a0vivo%2C%20either%20alone%20or%20combined%20with%20immunotherapy.%20Finally%2C%20high%20expression%20of%20translation%20initiation-related%20genes%20and%20PHBs%20genes%20correlated%20with%20poor%20survival%20and%20unfavorable%20clinical%20parameters%20in%20patients%20with%20CLL.%20Overall%2C%20we%20demonstrated%20that%20translation%20inhibition%20is%20a%20valuable%20strategy%20to%20control%20CLL%20development%20by%20blocking%20the%20translation%20of%20several%20oncogenic%20pathways%20including%20MYC.%20We%20also%20unraveled%20a%20new%20and%20direct%20role%20of%20PHBs%20in%20translation%20initiation%2C%20thus%20creating%20new%20therapeutic%20opportunities%20for%20patients%20with%20CLL.%22%2C%22date%22%3A%222023-06-29%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2022017839%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A52%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22TZHYRQEP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonfiglio%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-27%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonfiglio%2C%20Silvia%2C%20Lesley-Ann%20Sutton%2C%20Viktor%20Ljungstr%26%23xF6%3Bm%2C%20Antonella%20Capasso%2C%20Tatjana%20Pandzic%2C%20Simone%20Westr%26%23xF6%3Bm%2C%20Hassan%20Foroughi-Asl%2C%20et%20al.%20%26%23x201C%3BBTK%20and%20PLCG2%20Remain%20Unmutated%20in%20One-Third%20of%20Patients%20with%20CLL%20Relapsing%20on%20Ibrutinib.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%207%2C%20no.%2012%20%28June%2027%2C%202023%29%3A%202794%26%23x2013%3B2806.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2022008821%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2022008821%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22BTK%20and%20PLCG2%20remain%20unmutated%20in%20one-third%20of%20patients%20with%20CLL%20relapsing%20on%20ibrutinib%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Bonfiglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lesley-Ann%22%2C%22lastName%22%3A%22Sutton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viktor%22%2C%22lastName%22%3A%22Ljungstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22Capasso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatjana%22%2C%22lastName%22%3A%22Pandzic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Westr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Foroughi-Asl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aron%22%2C%22lastName%22%3A%22Skaftason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Gellerbring%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lyander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Gandini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gianluca%22%2C%22lastName%22%3A%22Gaidano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Livio%22%2C%22lastName%22%3A%22Trentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Bonello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gianluigi%22%2C%22lastName%22%3A%22Reda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Csaba%22%2C%22lastName%22%3A%22B%5Cu00f6d%5Cu00f6r%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niki%22%2C%22lastName%22%3A%22Stavroyianni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantine%20S.%22%2C%22lastName%22%3A%22Tam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Marasca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Forconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panayiotis%22%2C%22lastName%22%3A%22Panayiotidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingo%22%2C%22lastName%22%3A%22Ringshausen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ozren%22%2C%22lastName%22%3A%22Jaksic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Frustaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunil%22%2C%22lastName%22%3A%22Iyengar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Coscia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20P.%22%2C%22lastName%22%3A%22Mulligan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Strugov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%22%2C%22lastName%22%3A%22Pavlovsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Walewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22%5Cu00d6sterborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Cortese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%22%2C%22lastName%22%3A%22Ranghetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panagiotis%22%2C%22lastName%22%3A%22Baliakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kostas%22%2C%22lastName%22%3A%22Stamatopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Scarf%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Rosenquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Ghia%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20with%20chronic%20lymphocytic%20leukemia%20%28CLL%29%20progressing%20on%20ibrutinib%20constitute%20an%20unmet%20need.%20Though%20Bruton%20tyrosine%20kinase%20%28BTK%29%20and%20PLCG2%20mutations%20are%20associated%20with%20ibrutinib%20resistance%2C%20their%20frequency%20and%20relevance%20to%20progression%20are%20not%20fully%20understood.%20In%20this%20multicenter%20retrospective%20observational%20study%2C%20we%20analyzed%2098%20patients%20with%20CLL%20on%20ibrutinib%20%2849%20relapsing%20after%20an%20initial%20response%20and%2049%20still%20responding%20after%20%5Cu22651%20year%20of%20continuous%20treatment%29%20using%20a%20next-generation%20sequencing%20%28NGS%29%20panel%20%281%25%20sensitivity%29%20comprising%2013%20CLL-relevant%20genes%20including%20BTK%20and%20PLCG2.%20BTK%20hotspot%20mutations%20were%20validated%20by%20droplet%20digital%20polymerase%20chain%20reaction%20%28ddPCR%29%20%280.1%25%20sensitivity%29.%20By%20integrating%20NGS%20and%20ddPCR%20results%2C%2032%20of%2049%20relapsing%20cases%20%2865%25%29%20carried%20at%20least%201%20hotspot%20BTK%20and%5C%2For%20PLCG2%20mutation%28s%29%3B%20in%206%20of%2032%2C%20BTK%20mutations%20were%20only%20detected%20by%20ddPCR%20%28variant%20allele%20frequency%20%5BVAF%5D%200.1%25%20to%201.2%25%29.%20BTK%5C%2FPLCG2%20mutations%20were%20also%20identified%20in%206%20of%2049%20responding%20patients%20%2812%25%3B%205%5C%2F6%20VAF%20%3C10%25%29%2C%20of%20whom%202%20progressed%20later.%20Among%20the%20relapsing%20patients%2C%20the%20BTK-mutated%20%28BTKmut%29%20group%20was%20enriched%20for%20EGR2%20mutations%2C%20whereas%20BTK-wildtype%20%28BTKwt%29%20cases%20more%20frequently%20displayed%20BIRC3%20and%20NFKBIE%20mutations.%20Using%20an%20extended%20capture-based%20panel%2C%20only%20BRAF%20and%20IKZF3%20mutations%20showed%20a%20predominance%20in%20relapsing%20cases%2C%20who%20were%20enriched%20for%20del%288p%29%20%28n%5Cu00a0%3D%2011%3B%203%20BTKwt%29.%20Finally%2C%20no%20difference%20in%20TP53%20mutation%20burden%20was%20observed%20between%20BTKmut%20and%20BTKwt%20relapsing%20cases%2C%20and%20ibrutinib%20treatment%20did%20not%20favor%20selection%20of%20TP53-aberrant%20clones.%20In%20conclusion%2C%20we%20show%20that%20BTK%5C%2FPLCG2%20mutations%20were%20absent%20in%20a%20substantial%20fraction%20%2835%25%29%20of%20a%20real-world%20cohort%20failing%20ibrutinib%2C%20and%20propose%20additional%20mechanisms%20contributing%20to%20resistance.%22%2C%22date%22%3A%222023-06-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2022008821%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A53%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22RCGCTB6A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Verstraete%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-16%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVerstraete%2C%20Nina%2C%20Malvina%20Marku%2C%20Marcin%20Domagala%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Arduin%2C%20Julie%20Bordenave%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Mary%20Poupot%2C%20and%20Vera%20Pancaldi.%20%26%23x201C%3BAn%20Agent-Based%20Model%20of%20Monocyte%20Differentiation%20into%20Tumour-Associated%20Macrophages%20in%20Chronic%20Lymphocytic%20Leukemia.%26%23x201D%3B%20%3Ci%3EIScience%3C%5C%2Fi%3E%2026%2C%20no.%206%20%28June%2016%2C%202023%29%3A%20106897.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.106897%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.106897%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22An%20agent-based%20model%20of%20monocyte%20differentiation%20into%20tumour-associated%20macrophages%20in%20chronic%20lymphocytic%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Verstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malvina%22%2C%22lastName%22%3A%22Marku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Arduin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bordenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%5D%2C%22abstractNote%22%3A%22Monocyte-derived%20macrophages%20help%20maintain%20tissue%20homeostasis%20and%20defend%20the%20organism%20against%20pathogens.%20In%20tumors%2C%20recent%20studies%20have%20uncovered%20complex%20macrophage%20populations%2C%20including%20tumor-associated%20macrophages%2C%20which%20support%20tumorigenesis%20through%20cancer%20hallmarks%20such%20as%20immunosuppression%2C%20angiogenesis%2C%20or%20matrix%20remodeling.%20In%20the%20case%20of%20chronic%20lymphocytic%20leukemia%2C%20these%20macrophages%20are%20known%20as%20nurse-like%20cells%20%28NLCs%29%20and%20they%20protect%20leukemic%20cells%20from%20spontaneous%20apoptosis%2C%20contributing%20to%20their%20chemoresistance.%20We%20propose%20an%20agent-based%20model%20of%20monocyte%20differentiation%20into%20NLCs%20upon%20contact%20with%20leukemic%20B%20cells%20in%5Cu00a0vitro.%20We%20performed%20patient-specific%20model%20optimization%20using%20cultures%20of%20peripheral%20blood%20mononuclear%20cells%20from%20patients.%20Using%20our%20model%2C%20we%20were%20able%20to%20reproduce%20the%20temporal%20survival%20dynamics%20of%20cancer%20cells%20in%20a%20patient-specific%20manner%20and%20to%20identify%20patient%20groups%20related%20to%20distinct%20macrophage%20phenotypes.%20Our%20results%20show%20a%20potentially%20important%20role%20of%20phagocytosis%20in%20the%20polarization%20process%20of%20NLCs%20and%20in%20promoting%20cancer%20cells%27%20enhanced%20survival.%22%2C%22date%22%3A%222023-06-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.isci.2023.106897%22%2C%22ISSN%22%3A%222589-0042%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%226FNA338P%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A55%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22ZSYUYEL9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Armand%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EArmand%2C%20Marine%2C%20Micha%26%23xEB%3Bl%20Degaud%2C%20Bruno%20Tesson%2C%20C%26%23xE9%3Bcile%20Laurent%2C%20Manon%20Vavasseur%2C%20M%26%23xE9%3Blanie%20Parisot%2C%20B%26%23xE9%3Bn%26%23xE9%3Bdicte%20Hoareau-Coudert%2C%20et%20al.%20%26%23x201C%3BExploring%20the%20Genetic%20Landscape%20of%20HCV-Related%20B-Cell%20Lymphomas%20Using%20Whole%20Exome%20Sequencing.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2037%2C%20no.%206%20%28June%202023%29%3A%201388%26%23x2013%3B91.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01868-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01868-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exploring%20the%20genetic%20landscape%20of%20HCV-related%20B-cell%20lymphomas%20using%20whole%20exome%20sequencing%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Armand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micha%5Cu00ebl%22%2C%22lastName%22%3A%22Degaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Tesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Vavasseur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Parisot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Hoareau-Coudert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danielle%22%2C%22lastName%22%3A%22Canioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marie%22%2C%22lastName%22%3A%22Michot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Charlotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Meignin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Gl%5Cu00e9hen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Hermine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Davi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Couronn%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-023-01868-2%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A54%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22Q9N2YHQI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Araujo-Ayala%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAraujo-Ayala%2C%20Ferran%2C%20C%26%23xE8%3Blia%20Doba%26%23xF1%3Bo-L%26%23xF3%3Bpez%2C%20Juan%20Garc%26%23xED%3Ba%20Valero%2C%20Ferran%20Nadeu%2C%20Fabien%20Gava%2C%20Carla%20Faria%2C%20Marine%20Norlund%2C%20et%20al.%20%26%23x201C%3BA%20Novel%20Patient-Derived%203D%20Model%20Recapitulates%20Mantle%20Cell%20Lymphoma%20Lymph%20Node%20Signaling%2C%20Immune%20Profile%20and%20in%20Vivo%20Ibrutinib%20Responses.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2037%2C%20no.%206%20%28June%202023%29%3A%201311%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01885-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01885-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20novel%20patient-derived%203D%20model%20recapitulates%20mantle%20cell%20lymphoma%20lymph%20node%20signaling%2C%20immune%20profile%20and%20in%20vivo%20ibrutinib%20responses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferran%22%2C%22lastName%22%3A%22Araujo-Ayala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e8lia%22%2C%22lastName%22%3A%22Doba%5Cu00f1o-L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferran%22%2C%22lastName%22%3A%22Nadeu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Gava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carla%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Norlund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Bernes-Lasserre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neus%22%2C%22lastName%22%3A%22Serrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heribert%22%2C%22lastName%22%3A%22Playa-Albinyana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rub%5Cu00e9n%22%2C%22lastName%22%3A%22Gim%5Cu00e9nez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22El%5Cu00edas%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armando%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Guillermo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolors%22%2C%22lastName%22%3A%22Colomer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Gal%5Cu00e1n%22%7D%5D%2C%22abstractNote%22%3A%22Mantle%20cell%20lymphoma%20%28MCL%29%2C%20a%20rare%20and%20aggressive%20B-cell%20non-Hodgkin%20lymphoma%2C%20mainly%20develops%20in%20the%20lymph%20node%20%28LN%29%20and%20creates%20a%20protective%20and%20immunosuppressive%20niche%20that%20facilitates%20tumor%20survival%2C%20proliferation%20and%20chemoresistance.%20To%20capture%20disease%20heterogeneity%20and%20tumor%20microenvironment%20%28TME%29%20cues%2C%20we%20have%20developed%20the%20first%20patient-derived%20MCL%20spheroids%20%28MCL-PDLS%29%20that%20recapitulate%20tumor%20oncogenic%20pathways%20and%20immune%20microenvironment%20in%20a%20multiplexed%20system%20that%20allows%20easy%20drug%20screening%2C%20including%20immunotherapies.%20MCL%20spheroids%2C%20integrated%20by%20tumor%20B%20cells%2C%20monocytes%20and%20autologous%20T-cells%20self-organize%20in%20disc-shaped%20structures%2C%20where%20B%20and%20T-cells%20maintain%20viability%20and%20proliferate%2C%20and%20monocytes%20differentiate%20into%20M2-like%20macrophages.%20RNA-seq%20analysis%20demonstrated%20that%20tumor%20cells%20recapitulate%20hallmarks%20of%20MCL-LN%20%28proliferation%2C%20NF-kB%20and%20BCR%29%2C%20with%20T%20cells%20exhibiting%20an%20exhaustion%20profile%20%28PD1%2C%20TIM-3%20and%20TIGIT%29.%20MCL-PDLS%20reproduces%20in%20vivo%20responses%20to%20ibrutinib%20and%20demonstrates%20that%20combination%20of%20ibrutinib%20with%20nivolumab%20%28anti-PD1%29%20may%20be%20effective%20in%20ibrutinib-resistant%20cases%20by%20engaging%20an%20immune%20response%20with%20increased%20interferon%20gamma%20and%20granzyme%20B%20release.%20In%20conclusion%2C%20MCL-PDLS%20recapitulates%20specific%20MCL-LN%20features%20and%20in%20vivo%20responses%20to%20ibrutinib%2C%20representing%20a%20robust%20tool%20to%20study%20MCL%20interaction%20with%20the%20immune%20TME%20and%20to%20perform%20drug%20screening%20in%20a%20patient-derived%20system%2C%20advancing%20toward%20personalized%20therapeutic%20approaches.%22%2C%22date%22%3A%222023-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-023-01885-1%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A52%3A45Z%22%7D%7D%2C%7B%22key%22%3A%2223UJ5M9Q%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Curdy%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECurdy%2C%20Nicolas%2C%20Olivia%20Lanvin%2C%20Juan-Pablo%20Cerapio%2C%20Fr%26%23xE9%3Bderic%20Pont%2C%20Marie%20Tosolini%2C%20Emeline%20Sarot%2C%20Carine%20Valle%2C%20et%20al.%20%26%23x201C%3BThe%20Proteome%20and%20Transcriptome%20of%20Stress%20Granules%20and%20P%20Bodies%20during%20Human%20T%20Lymphocyte%20Activation.%26%23x201D%3B%20%3Ci%3ECell%20Reports%3C%5C%2Fi%3E%2042%2C%20no.%203%20%28March%2028%2C%202023%29%3A%20112211.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2023.112211%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2023.112211%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20proteome%20and%20transcriptome%20of%20stress%20granules%20and%20P%20bodies%20during%20human%20T%20lymphocyte%20activation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Curdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan-Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Saint-Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Lhuillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%5D%2C%22abstractNote%22%3A%22Stress%20granules%20%28SGs%29%20and%20processing%20bodies%20%28PBs%29%20are%20membraneless%20cytoplasmic%20assemblies%20regulating%20mRNAs%20under%20environmental%20stress%20such%20as%20viral%20infections%2C%20neurological%20disorders%2C%20or%20cancer.%20Upon%20antigen%20stimulation%2C%20T%20lymphocytes%20mediate%20their%20immune%20functions%20under%20regulatory%20mechanisms%20involving%20SGs%20and%20PBs.%20However%2C%20the%20impact%20of%20T%5Cu00a0cell%20activation%20on%20such%20complexes%20in%20terms%20of%20formation%2C%20constitution%2C%20and%20relationship%20remains%20unknown.%20Here%2C%20by%20combining%20proteomic%2C%20transcriptomic%2C%20and%20immunofluorescence%20approaches%2C%20we%20simultaneously%20characterized%20the%20SGs%20and%20PBs%20from%20primary%20human%20T%20lymphocytes%20pre%20and%20post%20stimulation.%20The%20identification%20of%20the%20proteomes%20and%20transcriptomes%20of%20SGs%20and%20PBs%20indicate%20an%20unanticipated%20molecular%20and%20functional%20complementarity.%20Notwithstanding%2C%20these%20granules%20keep%20distinct%20spatial%20organizations%20and%20abilities%20to%20interact%20with%20mRNAs.%20This%20comprehensive%20characterization%20of%20the%20RNP%20granule%20proteomic%20and%20transcriptomic%20landscapes%20provides%20a%20unique%20resource%20for%20future%20investigations%20on%20SGs%20and%20PBs%20in%20T%20lymphocytes.%22%2C%22date%22%3A%222023-03-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.celrep.2023.112211%22%2C%22ISSN%22%3A%222211-1247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A27%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22W76WP533%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Walczak%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWalczak%2C%20Pierre%2C%20Sylvain%20Choquet%2C%20Jacques%20Dantal%2C%20David%20Boutboul%2C%20Felipe%20Suarez%2C%20Marine%20Baron%2C%20Veronique%20Morel%2C%20et%20al.%20%26%23x201C%3BPost-Transplantation%20Burkitt%20Lymphoma%3A%20A%20Retrospective%20Study%20of%2055%20Patients.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%2C%20March%209%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282297%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282297%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-transplantation%20Burkitt%20lymphoma%3A%20a%20retrospective%20study%20of%2055%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Walczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Choquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Dantal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Boutboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Suarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Baron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Cluzeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Touati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Elias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Nicolas-Virelizier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roch%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffroy%22%2C%22lastName%22%3A%22Venton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Jacquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Moles-Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Durot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noureddine%22%2C%22lastName%22%3A%22Balegroune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Ecotiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Guieze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Kamar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lionel%22%2C%22lastName%22%3A%22Couzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Roulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Ou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Caillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heiner%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%20Ulrich%22%2C%22lastName%22%3A%22Trappe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Roos-Weil%22%7D%5D%2C%22abstractNote%22%3A%22Not%20available.%22%2C%22date%22%3A%222023-03-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2022.282297%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A31%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22G652TSTF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Donzel%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDonzel%2C%20Marie%2C%20Juliette%20Fontaine%2C%20and%20Alexandra%20Traverse-Glehen.%20%26%23x201C%3B%5BHistoseminar%3A%20%26%23x2018%3BThe%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%26%23x2019%3B%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2043%2C%20no.%202%20%28March%202023%29%3A%20126%26%23x2013%3B31.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.016%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BHistoseminar%3A%20%5C%22The%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%5C%22%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Donzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2023.01.016%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-09-11T12%3A18%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22CBFZYY7R%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Xerri%20and%20Laurent%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EXerri%2C%20Luc%2C%20and%20Camille%20Laurent.%20%26%23x201C%3B%5BHistioseminar%3A%20%26%23xAB%3B%26%23xA0%3BThe%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%26%23xA0%3B%26%23xBB%3B.%20Case%20No.%204%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2043%2C%20no.%202%20%28March%202023%29%3A%20135%26%23x2013%3B38.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BHistioseminar%3A%20%5Cu00ab%5Cu00a0The%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%5Cu00a0%5Cu00bb.%20Case%20No.%204%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2023.01.005%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A31%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22AKJWT62N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Xerri%20and%20Laurent%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EXerri%2C%20Luc%2C%20and%20Camille%20Laurent.%20%26%23x201C%3B%5BHistoseminar%3A%20%26%23xAB%3B%26%23xA0%3BThe%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%26%23xA0%3B%26%23xBB%3B.%20Case%20No.%203%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2043%2C%20no.%202%20%28March%202023%29%3A%20132%26%23x2013%3B34.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.12.004%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.12.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BHistoseminar%3A%20%5Cu00ab%5Cu00a0The%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20myth%20or%20reality%3F%5Cu00a0%5Cu00bb.%20Case%20No.%203%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2022.12.004%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A30%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22LNKDZN93%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20and%20Laurent%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20and%20Camille%20Laurent.%20%26%23x201C%3B%5BHistoseminar%3A%20%26%23x2018%3BThe%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20Myth%20or%20reality%3F%26%23x2019%3B.%20Cases%20No.%205%20%26amp%3B%206%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2043%2C%20no.%202%20%28March%202023%29%3A%20139%26%23x2013%3B45.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.008%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2023.01.008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BHistoseminar%3A%20%5C%22The%20contribution%20of%20new%20molecular%20biology%20techniques%20in%20the%20diagnosis%20of%20lymphoma%3A%20Myth%20or%20reality%3F%5C%22.%20Cases%20No.%205%20%26%206%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2023.01.008%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A30%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22M5JTY5T9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pont%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPont%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Juan%20Pablo%20Cerapio%2C%20Pauline%20Gravelle%2C%20Laetitia%20Ligat%2C%20Carine%20Valle%2C%20Emeline%20Sarot%2C%20Marion%20Perrier%2C%20et%20al.%20%26%23x201C%3BSingle-Cell%20Spatial%20Explorer%3A%20Easy%20Exploration%20of%20Spatial%20and%20Multimodal%20Transcriptomics.%26%23x201D%3B%20%3Ci%3EBMC%20Bioinformatics%3C%5C%2Fi%3E%2024%2C%20no.%201%20%28January%2027%2C%202023%29%3A%2030.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12859-023-05150-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12859-023-05150-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-cell%20spatial%20explorer%3A%20easy%20exploration%20of%20spatial%20and%20multimodal%20transcriptomics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20development%20of%20single-cell%20technologies%20yields%20large%20datasets%20of%20information%20as%20diverse%20and%20multimodal%20as%20transcriptomes%2C%20immunophenotypes%2C%20and%20spatial%20position%20from%20tissue%20sections%20in%20the%20so-called%20%27spatial%20transcriptomics%27.%20Currently%20however%2C%20user-friendly%2C%20powerful%2C%20and%20free%20algorithmic%20tools%20for%20straightforward%20analysis%20of%20spatial%20transcriptomic%20datasets%20are%20scarce.%5CnRESULTS%3A%20Here%2C%20we%20introduce%20Single-Cell%20Spatial%20Explorer%2C%20an%20open-source%20software%20for%20multimodal%20exploration%20of%20spatial%20transcriptomics%2C%20examplified%20with%209%20human%20and%20murine%20tissues%20datasets%20from%204%20different%20technologies.%5CnCONCLUSIONS%3A%20Single-Cell%20Spatial%20Explorer%20is%20a%20very%20powerful%2C%20versatile%2C%20and%20interoperable%20tool%20for%20spatial%20transcriptomics%20analysis.%22%2C%22date%22%3A%222023-01-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12859-023-05150-1%22%2C%22ISSN%22%3A%221471-2105%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22EA5M9MPD%22%5D%2C%22dateModified%22%3A%222023-02-01T10%3A03%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22MY8VFLZP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rimailho%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERimailho%2C%20L%26%23xE9%3Ba%2C%20Carla%20Faria%2C%20Marcin%20Domagala%2C%20Camille%20Laurent%2C%20Christine%20Bezombes%2C%20and%20Mary%20Poupot.%20%26%23x201C%3B%26%23x393%3B%26%23x3B4%3B%20T%20Cells%20in%20Immunotherapies%20for%20B-Cell%20Malignancies.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2014%20%282023%29%3A%201200003.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2023.1200003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2023.1200003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5Cu03b3%5Cu03b4%20T%20cells%20in%20immunotherapies%20for%20B-cell%20malignancies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Rimailho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carla%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20advancements%20in%20therapy%20for%20B%20cell%20malignancies%20and%20the%20increase%20in%20long-term%20survival%20of%20patients%2C%20almost%20half%20of%20them%20lead%20to%20relapse.%20Combinations%20of%20chemotherapy%20and%20monoclonal%20antibodies%20such%20as%20anti-CD20%20leads%20to%20mixed%20outcomes.%20Recent%20developments%20in%20immune%20cell-based%20therapies%20are%20showing%20many%20encouraging%20results.%20%5Cu03b3%5Cu03b4%20T%20cells%2C%20with%20their%20potential%20of%20functional%20plasticity%20and%20their%20anti-tumoral%20properties%2C%20emerged%20as%20good%20candidates%20for%20cancer%20immunotherapies.%20The%20representation%20and%20the%20diversity%20of%20%5Cu03b3%5Cu03b4%20T%20cells%20in%20tissues%20and%20in%20the%20blood%2C%20in%20physiological%20conditions%20or%20in%20B-cell%20malignancies%20such%20as%20B%20cell%20lymphoma%2C%20chronic%20lymphoblastic%20leukemia%20or%20multiple%20myeloma%2C%20provides%20the%20possibility%20to%20manipulate%20them%20with%20immunotherapeutic%20approaches%20for%20these%20patients.%20In%20this%20review%2C%20we%20summarized%20several%20strategies%20based%20on%20the%20activation%20and%20tumor-targeting%20of%20%5Cu03b3%5Cu03b4%20T%20cells%2C%20optimization%20of%20expansion%20protocols%2C%20and%20development%20of%20gene-modified%20%5Cu03b3%5Cu03b4%20T%20cells%2C%20using%20combinations%20of%20antibodies%20and%20therapeutic%20drugs%20and%20adoptive%20cell%20therapy%20with%20autologous%20or%20allogenic%20%5Cu03b3%5Cu03b4%20T%20cells%20following%20potential%20genetic%20modifications.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2023.1200003%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%226FNA338P%22%5D%2C%22dateModified%22%3A%222023-09-06T07%3A53%3A15Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Laurent, Camille, Sascha Dietrich, and Karin Tarte. “Cell Crosstalk within Lymphoma Tumor Microenvironment: Follicular Lymphoma as a Paradigm.” Blood<\/i>, December 14, 2023, blood.2023021000. https:\/\/doi.org\/10.1182\/blood.2023021000<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Niemann, Carsten U., Talha Munir, Carol Moreno, Carolyn Owen, George A. Follows, Ohad Benjamini, Ann Janssens, et al. “Fixed-Duration Ibrutinib-Venetoclax versus Chlorambucil-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukaemia (GLOW): 4-Year Follow-up from a Multicentre, Open-Label, Randomised, Phase 3 Trial.” The Lancet. Oncology<\/i> 24, no. 12 (December 2023): 1423–33. https:\/\/doi.org\/10.1016\/S1470-2045(23)00452-7<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Carras, Sylvain, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, et al. “Long-Term Analysis of the RiBVD Phase II Trial Reveals the Unfavorable Impact of TP53 Mutations and Hypoalbuminemia in Older Adults with Mantle Cell Lymphoma; for the LYSA Group.” Haematologica<\/i>, November 30, 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283724<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Houot, Roch, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, et al. “Axicabtagene Ciloleucel as Second-Line Therapy in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: A Phase 2 Trial.” Nature Medicine<\/i> 29, no. 10 (October 2023): 2593–2601. https:\/\/doi.org\/10.1038\/s41591-023-02572-5<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Faria, Carla, Fabien Gava, Pauline Gravelle, Juan Garcia Valero, Celia Dobaño-López, Nathalie Van Acker, Cathy Quelen, et al. “Patient-Derived Lymphoma Spheroids Integrating Immune Tumor Microenvironment as Preclinical Follicular Lymphoma Models for Personalized Medicine.” Journal for Immunotherapy of Cancer<\/i> 11, no. 10 (October 2023): e007156. https:\/\/doi.org\/10.1136\/jitc-2023-007156<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Fiévet, Loïc, Nicolas Espagnolle, Daniela Gerovska, David Bernard, Charlotte Syrykh, Camille Laurent, Pierre Layrolle, et al. “Single-Cell RNA Sequencing of Human Non-Hematopoietic Bone Marrow Cells Reveals a Unique Set of Inter-Species Conserved Biomarkers for Native Mesenchymal Stromal Cells.” Stem Cell Research & Therapy<\/i> 14, no. 1 (August 30, 2023): 229. https:\/\/doi.org\/10.1186\/s13287-023-03437-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Quintanilla-Martinez, Leticia, Camille Laurent, Lorinda Soma, Siok-Bian Ng, Fina Climent, Sarah L. Ondrejka, Alberto Zamo, et al. “Emerging Entities: High-Grade\/Large B-Cell Lymphoma with 11q Aberration, Large B-Cell Lymphoma with IRF4 Rearrangement, and New Molecular Subgroups in Large B-Cell Lymphomas: A Report of the 2022 EA4HP\/SH Lymphoma Workshop.” Virchows Archiv: An International Journal of Pathology<\/i>, August 9, 2023. https:\/\/doi.org\/10.1007\/s00428-023-03590-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Michallet, Anne-Sophie, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, et al. “A Fixed-Duration Immunochemotherapy Approach in CLL: 5.5-Year Results from the Phase 2 ICLL-07 FILO Trial.” Blood Advances<\/i> 7, no. 15 (August 8, 2023): 3936–45. https:\/\/doi.org\/10.1182\/bloodadvances.2022009594<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ousset, Léa, François Vergez, Camille Laurent, Lucie Oberic, and Alban Canali. “Diagnosis of Enteropathy-Associated T-Cell Lymphoma (EATL) on Peripheral Blood: A Pleiomorphic Morphology and an Unusual Immunophenotype.” EJHaem<\/i> 4, no. 3 (August 2023): 861–62. https:\/\/doi.org\/10.1002\/jha2.733<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, Maria Flores, Loïc Chartier, Sarah Huet, Christopher R. Bolen, Jeffrey M. Venstrom, Catherine Chassagne-Clément, et al. “Long-Term Follow-up Confirms the Favourable Prognostic Impact of High Numbers of Tumour Infiltrating CD3 T-Cells in Follicular Lymphoma Patients Treated by Rituximab-Maintenance Regimen.” British Journal of Haematology<\/i> 202, no. 3 (August 2023): 686–89. https:\/\/doi.org\/10.1111\/bjh.18881<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Al Tabaa, Yassine, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Jean Marc Schiano De Colella, Clement Bailly, et al. “Prospective Evaluation of Lymphoma Response to Immunomodulatory Therapy Criteria in GATA Trial from the LYSA Group.” Blood Advances<\/i> 7, no. 14 (July 25, 2023): 3735–38. https:\/\/doi.org\/10.1182\/bloodadvances.2023009911<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Munir, Talha, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, et al. “Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/i> 41, no. 21 (July 20, 2023): 3689–99. https:\/\/doi.org\/10.1200\/JCO.22.02283<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeot, Anne, Vanessa Klapp, Elodie Viry, Susanne Gonder, Iria Fernandez Botana, Arnaud Blomme, Mohaned Benzarti, et al. “Inhibition of MYC Translation through Targeting of the Newly Identified PHB-EIF4F Complex as a Therapeutic Strategy in CLL.” Blood<\/i> 141, no. 26 (June 29, 2023): 3166–83. https:\/\/doi.org\/10.1182\/blood.2022017839<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bonfiglio, Silvia, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi-Asl, et al. “BTK and PLCG2 Remain Unmutated in One-Third of Patients with CLL Relapsing on Ibrutinib.” Blood Advances<\/i> 7, no. 12 (June 27, 2023): 2794–2806. https:\/\/doi.org\/10.1182\/bloodadvances.2022008821<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Verstraete, Nina, Malvina Marku, Marcin Domagala, Hélène Arduin, Julie Bordenave, Jean-Jacques Fournié, Loïc Ysebaert, Mary Poupot, and Vera Pancaldi. “An Agent-Based Model of Monocyte Differentiation into Tumour-Associated Macrophages in Chronic Lymphocytic Leukemia.” IScience<\/i> 26, no. 6 (June 16, 2023): 106897. https:\/\/doi.org\/10.1016\/j.isci.2023.106897<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Armand, Marine, Michaël Degaud, Bruno Tesson, Cécile Laurent, Manon Vavasseur, Mélanie Parisot, Bénédicte Hoareau-Coudert, et al. “Exploring the Genetic Landscape of HCV-Related B-Cell Lymphomas Using Whole Exome Sequencing.” Leukemia<\/i> 37, no. 6 (June 2023): 1388–91. https:\/\/doi.org\/10.1038\/s41375-023-01868-2<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Araujo-Ayala, Ferran, Cèlia Dobaño-López, Juan García Valero, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, et al. “A Novel Patient-Derived 3D Model Recapitulates Mantle Cell Lymphoma Lymph Node Signaling, Immune Profile and in Vivo Ibrutinib Responses.” Leukemia<\/i> 37, no. 6 (June 2023): 1311–23. https:\/\/doi.org\/10.1038\/s41375-023-01885-1<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Curdy, Nicolas, Olivia Lanvin, Juan-Pablo Cerapio, Fréderic Pont, Marie Tosolini, Emeline Sarot, Carine Valle, et al. “The Proteome and Transcriptome of Stress Granules and P Bodies during Human T Lymphocyte Activation.” Cell Reports<\/i> 42, no. 3 (March 28, 2023): 112211. https:\/\/doi.org\/10.1016\/j.celrep.2023.112211<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Walczak, Pierre, Sylvain Choquet, Jacques Dantal, David Boutboul, Felipe Suarez, Marine Baron, Veronique Morel, et al. “Post-Transplantation Burkitt Lymphoma: A Retrospective Study of 55 Patients.” Haematologica<\/i>, March 9, 2023. https:\/\/doi.org\/10.3324\/haematol.2022.282297<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Donzel, Marie, Juliette Fontaine, and Alexandra Traverse-Glehen. “[Histoseminar: ‘The contribution of new molecular biology techniques in the diagnosis of lymphoma: myth or reality?’].” Annales De Pathologie<\/i> 43, no. 2 (March 2023): 126–31. https:\/\/doi.org\/10.1016\/j.annpat.2023.01.016<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Xerri, Luc, and Camille Laurent. “[Histioseminar: « The contribution of new molecular biology techniques in the diagnosis of lymphoma: myth or reality? ». Case No. 4].” Annales De Pathologie<\/i> 43, no. 2 (March 2023): 135–38. https:\/\/doi.org\/10.1016\/j.annpat.2023.01.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Xerri, Luc, and Camille Laurent. “[Histoseminar: « The contribution of new molecular biology techniques in the diagnosis of lymphoma: myth or reality? ». Case No. 3].” Annales De Pathologie<\/i> 43, no. 2 (March 2023): 132–34. https:\/\/doi.org\/10.1016\/j.annpat.2022.12.004<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Syrykh, Charlotte, and Camille Laurent. “[Histoseminar: ‘The contribution of new molecular biology techniques in the diagnosis of lymphoma: Myth or reality?’. Cases No. 5 & 6].” Annales De Pathologie<\/i> 43, no. 2 (March 2023): 139–45. https:\/\/doi.org\/10.1016\/j.annpat.2023.01.008<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pont, Frédéric, Juan Pablo Cerapio, Pauline Gravelle, Laetitia Ligat, Carine Valle, Emeline Sarot, Marion Perrier, et al. “Single-Cell Spatial Explorer: Easy Exploration of Spatial and Multimodal Transcriptomics.” BMC Bioinformatics<\/i> 24, no. 1 (January 27, 2023): 30. https:\/\/doi.org\/10.1186\/s12859-023-05150-1<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rimailho, Léa, Carla Faria, Marcin Domagala, Camille Laurent, Christine Bezombes, and Mary Poupot. “Γδ T Cells in Immunotherapies for B-Cell Malignancies.” Frontiers in Immunology<\/i> 14 (2023): 1200003. https:\/\/doi.org\/10.3389\/fimmu.2023.1200003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2022″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.19.0″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2022<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-43709572d9d66496d13724f8d8655832%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22USYZDAAP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20Charlotte%20Chaouat%2C%20Elsa%20Poullot%2C%20Nadia%20Amara%2C%20Virginie%20Fataccioli%2C%20Marie%20Parrens%2C%20Alexandra%20Traverse-Glehen%2C%20et%20al.%20%26%23x201C%3BLymph%20Node%20Excisions%20Provide%20More%20Precise%20Lymphoma%20Diagnoses%20than%20Core%20Biopsies%3A%20A%20French%20Lymphopath%20Network%20Survey.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20140%2C%20no.%2024%20%28December%2015%2C%202022%29%3A%202573%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022015520%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022015520%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lymph%20node%20excisions%20provide%20more%20precise%20lymphoma%20diagnoses%20than%20core%20biopsies%3A%20a%20French%20Lymphopath%20network%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Chaouat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elsa%22%2C%22lastName%22%3A%22Poullot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Amara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Fataccioli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Parrens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry-Jo%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Lacheretz-Szablewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Copin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Chenard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22According%20to%20expert%20guidelines%2C%20lymph%20node%20surgical%20excision%20is%20the%20standard%20of%20care%20for%20lymphoma%20diagnosis.%20However%2C%20core%20needle%20biopsy%20%28CNB%29%20has%20become%20widely%20accepted%20as%20part%20of%20the%20lymphoma%20diagnostic%20workup%20over%20the%20past%20decades.%20The%20aim%20of%20this%20study%20was%20to%20present%20the%20largest%20multicenter%20inventory%20of%20lymph%20nodes%20sampled%20either%20by%20CNB%20or%20surgical%20excision%20in%20patients%20with%20suspected%20lymphoma%20and%20to%20compare%20their%20diagnostic%20performance%20in%20routine%20pathologic%20practice.%20We%20reviewed%2032%5Cu2009285%20cases%20registered%20in%20the%20French%20Lymphopath%20network%2C%20which%20provides%20a%20systematic%20expert%20review%20of%20all%20lymphoma%20diagnoses%20in%20France%2C%20and%20evaluated%20the%20percentage%20of%20CNB%20and%20surgical%20excision%20cases%20accurately%20diagnosed%20according%20to%20the%20World%20Health%20Organization%20classification.%20Although%20CNB%20provided%20a%20definitive%20diagnosis%20in%2092.3%25%20and%20seemed%20to%20be%20a%20reliable%20method%20of%20investigation%20for%20most%20patients%20with%20suspected%20lymphoma%2C%20it%20remained%20less%20conclusive%20than%20surgical%20excision%2C%20which%20provided%20a%20definitive%20diagnosis%20in%2098.1%25.%20Discordance%20rates%20between%20referral%20and%20expert%20diagnoses%20were%20higher%20on%20CNB%20%2823.1%25%29%20than%20on%20surgical%20excision%20%2821.2%25%3B%20P%5Cu00a0%3D%20.004%29%2C%20and%20referral%20pathologists%20provided%20more%20cases%20with%20unclassified%20lymphoma%20or%20equivocal%20lesion%20through%20CNB.%20In%20such%20cases%2C%20expert%20review%20improved%20the%20diagnostic%20workup%20by%20classifying%20%5Cu223c90%25%20of%20cases%2C%20with%20higher%20efficacy%20on%20surgical%20excision%20%2893.3%25%29%20than%20CNB%20%2881.4%25%3B%20P%5Cu00a0%3C%2010-6%29.%20Moreover%2C%20diagnostic%20concordance%20for%20reactive%20lesions%20was%20higher%20on%20surgical%20excision%20than%20CNB%20%28P%5Cu00a0%3D%20.009%29.%20Overall%2C%20although%20CNB%20accurately%20diagnoses%20lymphoma%20in%20most%20instances%2C%20it%20increases%20the%20risk%20of%20erroneous%20or%20nondefinitive%20conclusions.%20This%20large-scale%20survey%20also%20emphasizes%20the%20need%20for%20systematic%20expert%20review%20in%20cases%20of%20lymphoma%20suspicion%2C%20especially%20in%20those%20sampled%20by%20using%20CNB.%22%2C%22date%22%3A%222022-12-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2022015520%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-12-21T09%3A19%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22599EI8HF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trecourt%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETrecourt%2C%20Alexis%2C%20Marie%20Donzel%2C%20Juliette%20Fontaine%2C%20Herv%26%23xE9%3B%20Ghesqui%26%23xE8%3Bres%2C%20Laurent%20Jallade%2C%20Gabriel%20Antherieu%2C%20Camille%20Laurent%2C%20Claire%20Mauduit%2C%20and%20Alexsandra%20Traverse-Glehen.%20%26%23x201C%3BPlasticity%20in%20Classical%20Hodgkin%20Composite%20Lymphomas%3A%20A%20Systematic%20Review.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%2022%20%28November%2019%2C%202022%29%3A%205695.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14225695%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14225695%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasticity%20in%20Classical%20Hodgkin%20Composite%20Lymphomas%3A%20A%20Systematic%20Review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Trecourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Donzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Jallade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Antherieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexsandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%5D%2C%22abstractNote%22%3A%22The%20co-occurrence%20of%20several%20lymphomas%20in%20a%20patient%20defines%20composite%5C%2Fsynchronous%20lymphoma.%20A%20common%20cellular%20origin%20has%20been%20reported%20for%20both%20contingents%20of%20such%20entities.%20In%20the%20present%20review%2C%20we%20aimed%20to%20gather%20the%20available%20data%20on%20composite%20lymphomas%20associating%20a%20classical%20Hodgkin%20lymphoma%20%28cHL%29%20with%20another%20lymphoma%2C%20to%20better%20understand%20the%20plasticity%20of%20mature%20B%20and%20T-cells.%20This%20review%20highlights%20that%20%26gt%3B70%25%20of%20patients%20with%20a%20composite%20lymphoma%20are%20%5Cu226555%20years%20old%2C%20with%20a%20male%20predominance.%20The%20most%20reported%20associations%20are%20cHL%20with%20follicular%20lymphoma%20or%20diffuse%20large%20B-cell%20lymphoma%2C%20with%20over%20130%20cases%20reported.%20The%20cHL%20contingent%20is%20often%20of%20mixed%20cellularity%20type%2C%20with%20a%20more%20frequent%20focal%5C%2Fweak%20CD20%20expression%20%2830%25%20to%2055.6%25%29%20compared%20to%20de%20novo%20cHL%2C%20suggesting%20a%20particular%20pathophysiology.%20Moreover%2C%20Hodgkin%20cells%20may%20express%20specific%20markers%20of%20the%20associated%20lymphoma%20%28e.g.%2C%20BCL2%5C%2FBCL6%20for%20follicular%20lymphoma%20and%20Cyclin%20D1%20for%20mantle%20cell%20lymphoma%29%2C%20sometimes%20combined%20with%20common%20BCL2%5C%2FBCL6%20or%20CCND1%20rearrangements%2C%20respectively.%20In%20addition%2C%20both%20contingents%20may%20share%20similar%20IgH%5C%2FIgK%20rearrangements%20and%20identical%20pathogenic%20variants%2C%20reinforcing%20the%20hypothesis%20of%20a%20common%20clonal%20origin.%20Finally%2C%20cHL%20appears%20to%20be%20endowed%20with%20a%20greater%20plasticity%20than%20previously%20thought%2C%20supporting%20a%20common%20clonal%20origin%20and%20a%20transdifferentiation%20process%20during%20lymphomagenesis%20of%20composite%20lymphomas.%22%2C%22date%22%3A%222022-11-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14225695%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-11-28T09%3A37%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22QWWD357F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20James%20R.%20Cook%2C%20Tadashi%20Yoshino%2C%20Leticia%20Quintanilla-Martinez%2C%20and%20Elaine%20S.%20Jaffe.%20%26%23x201C%3BFollicular%20Lymphoma%20and%20Marginal%20Zone%20Lymphoma%3A%20How%20Many%20Diseases%3F%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%2C%20November%2017%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-022-03432-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-022-03432-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Follicular%20lymphoma%20and%20marginal%20zone%20lymphoma%3A%20how%20many%20diseases%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20R.%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tadashi%22%2C%22lastName%22%3A%22Yoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leticia%22%2C%22lastName%22%3A%22Quintanilla-Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elaine%20S.%22%2C%22lastName%22%3A%22Jaffe%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20and%20marginal%20zone%20lymphoma%20%28MZL%29%20are%20indolent%20mature%20B-cell%20neoplasms%20with%20variable%20clinical%20presentation%20and%20distinct%20histopathologic%20features.%20Recent%20advances%20in%20the%20biology%20and%20molecular%20characteristics%20of%20these%20lymphomas%20have%20further%20expanded%20our%20understanding%20of%20the%20heterogeneous%20nature%20of%20these%20lymphomas%2C%20with%20increasing%20recognition%20of%20specific%20disease%20entities%20within%20the%20broader%20categories%20of%20FL%20and%20MZL.%20Here%2C%20we%20discuss%20the%20conclusions%20of%20the%202022%20International%20Consensus%20Classification%20of%20Mature%20Lymphoid%20Neoplasms%20%282022%20ICC%29%20dealing%20with%20FL%2C%20and%20review%20differences%20with%20the%20proposed%20WHO%205th%20Edition%20classification.%20We%20review%20issues%20related%20to%20grading%20and%20alternative%20forms%20of%20FL%20especially%20those%20lacking%20the%20genetic%20hallmark%20of%20FL%2C%20the%20t%2814%3B18%29%20chromosomal%20alteration.%20Among%20them%2C%20t%2814%3B18%29-negative%20CD23%2B%5Cu2009follicle%20center%20lymphoma%20has%20been%20proposed%20by%20the%202022%20ICC%20as%20a%20provisional%20entity.%20Other%20follicle%20center-derived%20lymphomas%20such%20as%20pediatric-type%20follicular%20lymphoma%2C%20testicular%20follicular%20lymphoma%2C%20primary%20cutaneous%20follicle%20center%20lymphoma%2C%20and%20large%20B-cell%20lymphoma%20with%20IRF4%20rearrangement%20are%20considered%20distinct%20entities%20separate%20from%20conventional%20FL.%20Importantly%2C%20large%20B-cell%20lymphoma%20with%20IRF4%20rearrangement%20introduced%20as%20a%20provisional%20entity%20in%20the%20WHO%202017%20is%20upgraded%20to%20a%20definite%20entity%20in%20the%202022%20ICC.%20We%20also%20discuss%20diagnostic%20strategies%20for%20recognition%20of%20MZLs%20including%20splenic%20MZL%2C%20extranodal%20MZL%20%28MALT%20lymphoma%29%2C%20and%20primary%20nodal%20MZL.%20The%20importance%20of%20molecular%20studies%20in%20the%20distinction%20among%20marginal%20zone%20lymphoma%20subtypes%20is%20emphasized%2C%20as%20well%20as%20their%20value%20in%20the%20differential%20diagnosis%20with%20other%20B-cell%20lymphomas.%22%2C%22date%22%3A%222022-11-17%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-022-03432-2%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-12-14T13%3A51%3A18Z%22%7D%7D%2C%7B%22key%22%3A%224UGCF4JP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gondran%20and%20Ysebaert%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGondran%2C%20Camille%2C%20and%20Lo%26%23xEF%3Bc%20Ysebaert.%20%26%23x201C%3B%5BDrug%20approval%3A%20Mosunetuzumab%20-%20third-line%20therapy%20in%20follicular%20lymphoma%5D.%26%23x201D%3B%20%3Ci%3EBulletin%20Du%20Cancer%3C%5C%2Fi%3E%20109%2C%20no.%2011%20%28November%202022%29%3A%201105%26%23x2013%3B6.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2022.07.010%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2022.07.010%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BDrug%20approval%3A%20Mosunetuzumab%20-%20third-line%20therapy%20in%20follicular%20lymphoma%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Gondran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-11%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2022.07.010%22%2C%22ISSN%22%3A%221769-6917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-01-05T10%3A51%3A20Z%22%7D%7D%2C%7B%22key%22%3A%223N2SW3ZE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Phelippeau%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPhelippeau%2C%20Mona%2C%20Christine%20Lefebvre%2C%20Marie-Christine%20Jacob%2C%20Charlotte%20Syrykh%2C%20Julien%20Ghelfi%2C%20Sylvain%20Carras%2C%20Camille%20Laurent%2C%20Lysiane%20Molina%2C%20and%20S%26%23xE9%3Bverine%20Valmary-Degano.%20%26%23x201C%3B%5BDasatinib-induced%20follicular%20lymphoid%20hyperplasia%2C%20an%20entity%20to%20know%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2C%20October%2017%2C%202022%2C%20S0242-6498%2822%2900175-4.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.09.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.09.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BDasatinib-induced%20follicular%20lymphoid%20hyperplasia%2C%20an%20entity%20to%20know%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mona%22%2C%22lastName%22%3A%22Phelippeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Ghelfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Carras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lysiane%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Valmary-Degano%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoid%20hyperplasia%20induced%20by%20dasatinib%20is%20an%20entity%20recently%20described.%20It%20is%20sometimes%20difficult%20to%20rule%20out%20the%20diagnostic%20of%20small%20B-cell%20lymphoma.%20Usually%2C%20the%20node%20is%20swollen%2C%20with%20follicular%20architecture%20conserved%2C%20composed%20by%20germinal%20centers%20with%20variable%20size%20and%20shape%2C%20with%20a%20hight%20number%20of%20mitoses%20and%20tingible%20bodies%20macrophages%20inside.%20Follicular%20lymphoid%20hyperplasia%20is%20isolated%20or%20associated%20with%20multiple%20reactive%20patterns.%20The%20immunohistochemical%20profil%20of%20germinal%20centers%20is%20CD20%2B%2C%20CD10%2B%2C%20BCL6%2B%2C%20BCL2-.%20Swollen%20node%20disappears%20in%20a%20short%20time%20after%20dasatinib%20discontinuation.%20Clinicians%20and%20pathologists%20need%20to%20be%20aware%20of%20this%20entity%2C%20so%20as%20not%20to%20avoid%20mistakenly%20suspect%20lymphoma%20when%20lymphadenopathy%20occurs%20in%20a%20patient%20with%20chronic%20myeloid%20leukemia%20treated%20with%20dasatinib.%22%2C%22date%22%3A%222022-10-17%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2022.09.005%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A19%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22QLLEZVLY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bouclet%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBouclet%2C%20Florian%2C%20Daphn%26%23xE9%3B%20Krzisch%2C%20V%26%23xE9%3Bronique%20Leblond%2C%20C%26%23xE9%3Bcile%20Tomowiak%2C%20Kamel%20Laribi%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Olivier%20Tournilhac%2C%20et%20al.%20%26%23x201C%3B%5BWaldenstr%26%23xF6%3Bm%20disease%3A%20News%20and%20perspectives%20in%202022%5D.%26%23x201D%3B%20%3Ci%3EBulletin%20Du%20Cancer%3C%5C%2Fi%3E%2C%20October%2010%2C%202022%2C%20S0007-4551%2822%2900350-2.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2022.08.012%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2022.08.012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BWaldenstr%5Cu00f6m%20disease%3A%20News%20and%20perspectives%20in%202022%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Bouclet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daphn%5Cu00e9%22%2C%22lastName%22%3A%22Krzisch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Leblond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Tomowiak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamel%22%2C%22lastName%22%3A%22Laribi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tournilhac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dartigeas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Lepr%5Cu00eatre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Jondreville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22la%20participation%20de%20l%5Cu2019association%20Waldenstr%5Cu00f6m%20France%22%7D%5D%2C%22abstractNote%22%3A%22Waldenstr%5Cu00f6m%27s%20disease%20is%20a%20B-cell%20neoplasm%20characterized%20by%20the%20accumulation%20of%20lymphoplasmacytic%20cells%20%28LPCs%29%20in%20the%20bone%20marrow%2C%20and%20more%20rarely%20in%20the%20lymph%20nodes%20and%20the%20spleen%2C%20which%20produce%20a%20monoclonal%20immunoglobulin%20M%20%28IgM%29%20protein.%20The%20diagnosis%20requires%20the%20identification%20of%20LPCs%20in%20the%20bone%20marrow%2C%20using%20specific%20markers%20in%20flow%20cytometry.%20The%20MYD88L265P%20mutation%20is%20found%20in%2095%25%20of%20cases%20and%20the%20CXCR4%20mutation%20in%2030-40%25%20of%20cases.%20These%20markers%20must%20be%20sought%20because%20they%20have%20a%20diagnostic%20and%20prognostic%20role%2C%20and%20they%20might%20become%20predictive%20in%20the%20future.%20The%20clinical%20presentation%20is%20very%20variable%2C%20and%20includes%20anomalies%20related%20to%20the%20bone%20marrow%20infiltration%20of%20the%20LPCs%20%28such%20as%20anemia%29%2C%20but%20also%20anomalies%20of%20the%20physico-chemical%20and%5C%2For%20immunological%20activity%20of%20the%20overproduced%20IgM%20%28hyperviscosity%2C%20AL%20amyloidosis%2C%20cryoglobulinemia%2C%20anti-MAG%20neuropathies%2C%20etc.%29.%20Prognostic%20scores%20%28IPSSWM%29%20now%20make%20it%20possible%20to%20understand%20the%20prognosis%20of%20symptomatic%20WM%20requiring%20appropriate%20treatment.%20The%20therapeutic%20management%20depends%20on%20many%20parameters%2C%20such%20as%20the%20specific%20clinical%20presentation%2C%20the%20speed%20of%20evolution%20and%20of%20course%20the%20age%20and%20comorbidities.%20Immuno-chemotherapy%20is%20often%20the%201st%20line%20treatment%20%28rituximab-cyclophosphamide-dexamethasone%20%28RCD%29%20or%20bendamustine-rituximab%20%28BR%29%29%20but%20the%20role%20of%20targeted%20therapies%20is%20becoming%20preponderant.%20Bruton%20tyrosine%20kinase%20inhibitors%20%28BTKi%29%20are%20used%20today%20in%20first%20relapse.%20Other%20therapeutic%20perspectives%20will%20certainly%20allow%20us%20tomorrow%20to%20better%20understand%20this%20incurable%20chronic%20disease%2C%20such%20as%20new%20generations%20of%20BTKi%2C%20BCL2%20inhibitors%2C%20anti-CXCR4%2C%20bi-specific%20antibodies%2C%20and%20CAR-T%20cells.%22%2C%22date%22%3A%222022-10-10%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2022.08.012%22%2C%22ISSN%22%3A%221769-6917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A19%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22ICIHPS3F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Feldman%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFeldman%2C%20Andrew%20L.%2C%20Camille%20Laurent%2C%20Marina%20Narbaitz%2C%20Shigeo%20Nakamura%2C%20Wing%20C.%20Chan%2C%20Laurence%20de%20Leval%2C%20and%20Philippe%20Gaulard.%20%26%23x201C%3BClassification%20and%20Diagnostic%20Evaluation%20of%20Nodal%20T-%20and%20NK-Cell%20Lymphomas.%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%2C%20October%2010%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-022-03412-6%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-022-03412-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Classification%20and%20diagnostic%20evaluation%20of%20nodal%20T-%20and%20NK-cell%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20L.%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Narbaitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shigeo%22%2C%22lastName%22%3A%22Nakamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wing%20C.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22de%20Leval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%5D%2C%22abstractNote%22%3A%22Nodal%20T-%20and%20NK-cell%20lymphomas%20are%20among%20the%20most%20frequent%20T-cell%20malignancies%20and%20most%20subtypes%20have%20aggressive%20clinical%20behavior.%20Evolving%20understanding%20of%20the%20biology%20and%20molecular%20characteristics%20of%20these%20lymphomas%2C%20as%20well%20as%20the%20development%20of%20new%20precision%20therapy%20approaches%2C%20underscores%20the%20importance%20of%20ongoing%20updates%20to%20the%20classification%20and%20diagnostic%20evaluation%20of%20this%20group%20of%20malignancies.%20Here%2C%20we%20discuss%20the%20classification%20of%20nodal%20T-%20and%20NK-cell%20lymphomas%20based%20on%20the%202022%20International%20Consensus%20Classification%20of%20Mature%20Lymphoid%20Neoplasms%20%282022%20ICC%29.%20Lymphomas%20of%20T-follicular%20helper%20cell%20origin%20are%20now%20grouped%20into%20a%20single%20entity%2C%20follicular%20helper%20T-cell%20lymphoma%20%28TFH%20lymphoma%29%2C%20with%20three%20subtypes%20%28angioimmunoblastic-type%2C%20follicular-type%2C%20and%20not%20otherwise%20specified%29%2C%20reflecting%20their%20common%20cellular%20origin%20and%20shared%20molecular%20and%20clinical%20characteristics.%20Classification%20of%20anaplastic%20large%20cell%20lymphoma%20%28ALCL%29%20remains%20essentially%20unchanged%3B%20DUSP22-rearranged%20cases%20are%20now%20considered%20a%20genetic%20subtype%20of%20ALK-negative%20ALCL.%20Primary%20nodal%20EBV-positive%20T-%5C%2FNK-cell%20lymphoma%20is%20introduced%20as%20a%20new%20provisional%20entity%3B%20these%20cases%20were%20previously%20considered%20a%20variant%20of%20peripheral%20T-cell%20lymphoma%2C%20not%20otherwise%20specified%20%28PTCL%2C%20NOS%29.%20PTCL%2C%20NOS%20remains%20a%20diagnosis%20of%20exclusion%2C%20with%20evolving%20molecular%20data%20indicating%20the%20presence%20of%20distinct%20subgroups%2C%20including%20PTCL-TBX21%2C%20PTCL-GATA3%2C%20and%20EBV-negative%20cytotoxic%20PTCLs.%20We%20also%20discuss%20diagnostic%20strategies%20to%20facilitate%20the%202022%20ICC%20classification%20among%20nodal%20T-%20and%20NK-cell%20lymphomas%20and%20the%20distinction%20from%20nodal%20involvement%20by%20extranodal%20neoplasms.%22%2C%22date%22%3A%222022-10-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-022-03412-6%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-12-14T13%3A50%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22568IIU35%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lamaison%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-06%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELamaison%2C%20Claire%2C%20Juliette%20Ferrant%2C%20Pauline%20Gravelle%2C%20Alexandra%20Traverse-Glehen%2C%20Herv%26%23xE9%3B%20Ghesqui%26%23xE8%3Bres%2C%20Marie%20Tosolini%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20et%20al.%20%26%23x201C%3BHistological%20Subtypes%20Drive%20Distinct%20Prognostic%20Immune%20Signatures%20in%20Classical%20Hodgkin%20Lymphoma.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%2019%20%28October%206%2C%202022%29%3A%204893.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14194893%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14194893%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Histological%20Subtypes%20Drive%20Distinct%20Prognostic%20Immune%20Signatures%20in%20Classical%20Hodgkin%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Lamaison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Ferrant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20success%20of%20standard%20front-line%20chemotherapy%2C%2020%25%20of%20classical%20Hodgkin%20lymphoma%20%28cHL%29%20patients%20still%20relapse%20or%20have%20refractory%20disease%20%28r%5C%2Fr%29%2C%20and%20a%20subset%20of%20them%20die%20due%20to%20disease%20progression.%20There%20is%20a%20critical%20lack%20of%20predictive%20factors%20for%20early%20identification%20of%20those%20r%5C%2Fr%20patients%20who%20may%20benefit%20from%20new%20therapeutic%20strategies.%20This%20study%20aimed%20to%20evaluate%20the%20dynamic%20expression%20of%20586%20immune-related%20genes%20in%20a%20cohort%20of%2042%20cHL%20patients%20including%2030%20r%5C%2Fr%20cHL%20after%20first-line%20chemotherapy.%20Gene%20expression%20profiling%20%28GEP%29%20using%20NanoString%20technology%20identified%20a%2019-gene%20immune%20signature%20at%20diagnosis%20predictive%20of%20cHL%20relapse%2C%20but%20dependent%20on%20histological%20subtypes.%20Genes%20related%20to%20tumor%20survival%20were%20found%20upregulated%20while%20genes%20related%20to%20B-lineage%20were%20downregulated%20at%20diagnosis%20in%20r%5C%2Fr%20nodular%20sclerosis%20cHL.%20In%20contrast%20to%20the%20mixed-cellularity%20subtype%2C%20comparative%20GEP%20analyses%20between%20paired%20diagnosis%5C%2Frelapse%20biopsies%20of%20nodular%20sclerosis%20cHL%20showed%20118%20differentially%20expressed%20genes%2C%20supporting%20an%20immune%20contexture%20switch%20at%20relapse%20with%20upregulation%20of%20immunosuppressive%20cytokines%2C%20such%20as%20LGALS1%20and%20TGFB1%2C%20and%20downregulation%20of%20the%20T-cell%20co-stimulatory%20receptor%20ICOS.%20These%20results%20indicate%20that%20the%20predictive%20value%20of%20immune%20signature%20in%20cHL%20is%20strongly%20influenced%20by%20histological%20subtype%20which%20should%20be%20considered%20when%20assessing%20new%20immunotherapy%20target%20strategies.%22%2C%22date%22%3A%222022-10-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14194893%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-10-25T10%3A36%3A42Z%22%7D%7D%2C%7B%22key%22%3A%225VRWZT9W%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Morschhauser%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMorschhauser%2C%20Franck%2C%20Loretta%20Nastoupil%2C%20Pierre%20Feugier%2C%20Jean-Marc%20Schiano%20de%20Colella%2C%20Herv%26%23xE9%3B%20Tilly%2C%20Maria%20Lia%20Palomba%2C%20Emmanuel%20Bachy%2C%20et%20al.%20%26%23x201C%3BSix-Year%20Results%20From%20RELEVANCE%3A%20Lenalidomide%20Plus%20Rituximab%20%28R2%29%20Versus%20Rituximab-Chemotherapy%20Followed%20by%20Rituximab%20Maintenance%20in%20Untreated%20Advanced%20Follicular%20Lymphoma.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%3C%5C%2Fi%3E%2040%2C%20no.%2028%20%28October%201%2C%202022%29%3A%203239%26%23x2013%3B45.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.22.00843%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.22.00843%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Six-Year%20Results%20From%20RELEVANCE%3A%20Lenalidomide%20Plus%20Rituximab%20%28R2%29%20Versus%20Rituximab-Chemotherapy%20Followed%20by%20Rituximab%20Maintenance%20in%20Untreated%20Advanced%20Follicular%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loretta%22%2C%22lastName%22%3A%22Nastoupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Feugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Schiano%20de%20Colella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Tilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Lia%22%2C%22lastName%22%3A%22Palomba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Fruchart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20N.%22%2C%22lastName%22%3A%22Libby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rene-Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20W.%22%2C%22lastName%22%3A%22Flinn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Haioun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Maisonneuve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%20L.%22%2C%22lastName%22%3A%22Bartlett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamal%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Brice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Ribrag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Le%20Gouill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Daguindau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Matteo%22%2C%22lastName%22%3A%22Pica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%20Mart%5Cu00edn%22%2C%22lastName%22%3A%22Garc%5Cu00eda-Sancho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armondo%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Guillermo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Larouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%22%2C%22lastName%22%3A%22Ando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Gomes%20da%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wu%22%2C%22lastName%22%3A%22Kalung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%20H.%22%2C%22lastName%22%3A%22Sehn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koji%22%2C%22lastName%22%3A%22Izutsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Argyrios%22%2C%22lastName%22%3A%22Gkasiamis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%22%2C%22lastName%22%3A%22Crowe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%20H.%22%2C%22lastName%22%3A%22Fowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%5D%2C%22abstractNote%22%3A%22Clinical%20trials%20frequently%20include%20multiple%20end%20points%20that%20mature%20at%20different%20times.%20The%20initial%20report%2C%20typically%20based%20on%20the%20primary%20end%20point%2C%20may%20be%20published%20when%20key%20planned%20co-primary%20or%20secondary%20analyses%20are%20not%20yet%20available.%20Clinical%20Trial%20Updates%20provide%20an%20opportunity%20to%20disseminate%20additional%20results%20from%20studies%2C%20published%20in%20JCO%20or%20elsewhere%2C%20for%20which%20the%20primary%20end%20point%20has%20already%20been%20reported.The%20RELEVANCE%20trial%20%28ClinicalTrials.gov%20identifier%3A%20NCT01650701%29%20showed%20that%20lenalidomide%20plus%20rituximab%20%28R2%29%20provided%20similar%20efficacy%20to%20rituximab%20plus%20chemotherapy%20%28R-chemo%29%20in%20patients%20with%20advanced-stage%2C%20previously%20untreated%20follicular%20lymphoma%20%28FL%29.%20We%20report%20the%20second%20interim%20analysis%20of%20the%20RELEVANCE%20trial%20after%206%20years%20of%20follow-up.%20Patients%20with%20previously%20untreated%20grade%201-3a%20FL%20were%20assigned%201%3A1%20to%20R2%20or%20R-chemo%2C%20followed%20by%20rituximab%20maintenance.%20Coprimary%20end%20points%20were%20complete%20response%20%28confirmed%5C%2Funconfirmed%29%20at%20week%20120%20and%20progression-free%20survival%20%28PFS%29.%20At%20median%20follow-up%20of%2072%20months%2C%206-year%20PFS%20was%2060%25%20and%2059%25%20for%20R2%20and%20R-chemo%2C%20respectively%20%28hazard%20ratio%20%3D%201.03%20%5B95%25%20CI%2C%200.84%20to%201.27%5D%29.%20Six-year%20overall%20survival%20was%20estimated%20to%20be%2089%25%20in%20both%20groups.%20Median%20PFS%20and%20overall%20survival%20were%20not%20reached%20in%20either%20group.%20Overall%20response%20after%20progression%20was%2061%25%20and%2059%25%2C%20and%205-year%20estimated%20survival%20rate%20after%20progression%20was%2069%25%20and%2074%25%20in%20the%20R2%20and%20R-chemo%20groups%2C%20respectively.%20The%20transformation%20rate%20per%20year%20in%20the%20R2%20and%20R-chemo%20groups%20was%200.68%25%20and%200.45%25%2C%20and%20secondary%20primary%20malignancies%20occurred%20in%2011%25%20and%2013%25%20%28P%20%3D%20.34%29%2C%20respectively.%20No%20new%20safety%20signals%20were%20observed.%20R2%20continues%20to%20demonstrate%20comparable%2C%20durable%20efficacy%20and%20safety%20versus%20R-chemo%20in%20previously%20untreated%20patients%20with%20FL%20and%20provides%20an%20acceptable%20chemo-free%20alternative.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.22.00843%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A21%3A25Z%22%7D%7D%2C%7B%22key%22%3A%222P79YWUY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lapierre%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELapierre%2C%20L%26%23xE9%3Bopoldine%2C%20Charlotte%20Syrykh%2C%20Laetitia%20Largeaud%2C%20Bastien%20Cabarrou%2C%20Thomas%20Filleron%2C%20Lucie%20Oberic%2C%20Salim%20Kanoun%2C%20et%20al.%20%26%23x201C%3B%26%23x2018%3BAccelerated%20Phase%26%23x2019%3B%20Chronic%20Lymphocytic%20Leukemia%3A%20Still%20an%20Intermediate%20Risk%20Disease%20in%20the%20Era%20of%20Targeted%20Therapies.%26%23x201D%3B%20%3Ci%3EHematological%20Oncology%3C%5C%2Fi%3E%2040%2C%20no.%204%20%28October%202022%29%3A%20805%26%23x2013%3B8.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhon.2985%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhon.2985%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5C%22Accelerated%20phase%5C%22%20chronic%20lymphocytic%20leukemia%3A%20Still%20an%20intermediate%20risk%20disease%20in%20the%20era%20of%20targeted%20therapies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9opoldine%22%2C%22lastName%22%3A%22Lapierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Coster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Branco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Brechemier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Balardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fhon.2985%22%2C%22ISSN%22%3A%221099-1069%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A22%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22EJHWMRRF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Campo%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECampo%2C%20Elias%2C%20Elaine%20S.%20Jaffe%2C%20James%20R.%20Cook%2C%20Leticia%20Quintanilla-Martinez%2C%20Steven%20H.%20Swerdlow%2C%20Kenneth%20C.%20Anderson%2C%20Pierre%20Brousset%2C%20et%20al.%20%26%23x201C%3BThe%20International%20Consensus%20Classification%20of%20Mature%20Lymphoid%20Neoplasms%3A%20A%20Report%20from%20the%20Clinical%20Advisory%20Committee.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20140%2C%20no.%2011%20%28September%2015%2C%202022%29%3A%201229%26%23x2013%3B53.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022015851%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022015851%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20International%20Consensus%20Classification%20of%20Mature%20Lymphoid%20Neoplasms%3A%20a%20report%20from%20the%20Clinical%20Advisory%20Committee%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elias%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elaine%20S.%22%2C%22lastName%22%3A%22Jaffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20R.%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leticia%22%2C%22lastName%22%3A%22Quintanilla-Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20H.%22%2C%22lastName%22%3A%22Swerdlow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20C.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Cerroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22de%20Leval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Dirnhofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmet%22%2C%22lastName%22%3A%22Dogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20L.%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Falko%22%2C%22lastName%22%3A%22Fend%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20W.%22%2C%22lastName%22%3A%22Friedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Ghia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20M.%22%2C%22lastName%22%3A%22Horwitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20L.%22%2C%22lastName%22%3A%22King%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesus%22%2C%22lastName%22%3A%22San-Miguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20F.%22%2C%22lastName%22%3A%22Seymour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20P.%22%2C%22lastName%22%3A%22Treon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%20M.%22%2C%22lastName%22%3A%22Vose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Zucca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ranjana%22%2C%22lastName%22%3A%22Advani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Ansell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wing-Yan%22%2C%22lastName%22%3A%22Au%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Barrionuevo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leif%22%2C%22lastName%22%3A%22Bergsagel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wing%20C.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20I.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22d%27Amore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brunangelo%22%2C%22lastName%22%3A%22Falini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%20M.%22%2C%22lastName%22%3A%22Ghobrial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20R.%22%2C%22lastName%22%3A%22Goodlad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20G.%22%2C%22lastName%22%3A%22Gribben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20D.%22%2C%22lastName%22%3A%22Hsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brad%20S.%22%2C%22lastName%22%3A%22Kahl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Won-Seog%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaji%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%20S.%22%2C%22lastName%22%3A%22LaCasce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Lenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20P.%22%2C%22lastName%22%3A%22Leonard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20P.%22%2C%22lastName%22%3A%22Link%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armando%22%2C%22lastName%22%3A%22Lopez-Guillermo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Victoria%22%2C%22lastName%22%3A%22Mateos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Macintyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ari%20M.%22%2C%22lastName%22%3A%22Melnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shigeo%22%2C%22lastName%22%3A%22Nakamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Narbaitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Astrid%22%2C%22lastName%22%3A%22Pavlovsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%20A.%22%2C%22lastName%22%3A%22Pileri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Piris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Pro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Rajkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20T.%22%2C%22lastName%22%3A%22Rosen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgitta%22%2C%22lastName%22%3A%22Sander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%22%2C%22lastName%22%3A%22Sehn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%20A.%22%2C%22lastName%22%3A%22Shipp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonali%20M.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20M.%22%2C%22lastName%22%3A%22Staudt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Tousseyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wyndham%20H.%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tadashi%22%2C%22lastName%22%3A%22Yoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pier-Luigi%22%2C%22lastName%22%3A%22Zinzani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Dreyling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20N.%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20D.%22%2C%22lastName%22%3A%22Zelenetz%22%7D%5D%2C%22abstractNote%22%3A%22Since%20the%20publication%20of%20the%20Revised%20European-American%20Classification%20of%20Lymphoid%20Neoplasms%20in%201994%2C%20subsequent%20updates%20of%20the%20classification%20of%20lymphoid%20neoplasms%20have%20been%20generated%20through%20iterative%20international%20efforts%20to%20achieve%20broad%20consensus%20among%20hematopathologists%2C%20geneticists%2C%20molecular%20scientists%2C%20and%20clinicians.%20Significant%20progress%20has%20recently%20been%20made%20in%20the%20characterization%20of%20malignancies%20of%20the%20immune%20system%2C%20with%20many%20new%20insights%20provided%20by%20genomic%20studies.%20They%20have%20led%20to%20this%20proposal.%20We%20have%20followed%20the%20same%20process%20that%20was%20successfully%20used%20for%20the%20third%20and%20fourth%20editions%20of%20the%20World%20Health%20Organization%20Classification%20of%20Hematologic%20Neoplasms.%20The%20definition%2C%20recommended%20studies%2C%20and%20criteria%20for%20the%20diagnosis%20of%20many%20entities%20have%20been%20extensively%20refined.%20Some%20categories%20considered%20provisional%20have%20now%20been%20upgraded%20to%20definite%20entities.%20Terminology%20for%20some%20diseases%20has%20been%20revised%20to%20adapt%20nomenclature%20to%20the%20current%20knowledge%20of%20their%20biology%2C%20but%20these%20modifications%20have%20been%20restricted%20to%20well-justified%20situations.%20Major%20findings%20from%20recent%20genomic%20studies%20have%20impacted%20the%20conceptual%20framework%20and%20diagnostic%20criteria%20for%20many%20disease%20entities.%20These%20changes%20will%20have%20an%20impact%20on%20optimal%20clinical%20management.%20The%20conclusions%20of%20this%20work%20are%20summarized%20in%20this%20report%20as%20the%20proposed%20International%20Consensus%20Classification%20of%20mature%20lymphoid%2C%20histiocytic%2C%20and%20dendritic%20cell%20tumors.%22%2C%22date%22%3A%222022-09-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2022015851%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-12-14T13%3A52%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22Q8XA2WJE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Charlotte%20Syrykh%2C%20Maxime%20Hamon%2C%20Jos%26%23xE9%3B%20Ad%26%23xE9%3Bla%26%23xEF%3Bde%2C%20Arnaud%20Guille%2C%20Frederic%20Escudi%26%23xE9%3B%2C%20Gael%20Jalowicki%2C%20et%20al.%20%26%23x201C%3BResistance%20of%20B-Cell%20Lymphomas%20to%20CAR%20T-Cell%20Therapy%20Is%20Associated%20With%20Genomic%20Tumor%20Changes%20Which%20Can%20Result%20in%20Transdifferentiation.%26%23x201D%3B%20%3Ci%3EThe%20American%20Journal%20of%20Surgical%20Pathology%3C%5C%2Fi%3E%2046%2C%20no.%206%20%28June%201%2C%202022%29%3A%20742%26%23x2013%3B53.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001834%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001834%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Resistance%20of%20B-Cell%20Lymphomas%20to%20CAR%20T-Cell%20Therapy%20Is%20Associated%20With%20Genomic%20Tumor%20Changes%20Which%20Can%20Result%20in%20Transdifferentiation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Hamon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Ad%5Cu00e9la%5Cu00efde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Guille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Escudi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Jalowicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Fina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Bardet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lena%5Cu00efg%22%2C%22lastName%22%3A%22Mescam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%20J.%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Dartigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Parrens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sujobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Birnbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20impressive%20efficacy%20of%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20therapy%20%28CART%29%20in%20B-cell%20non-Hodgkin%20lymphomas%2C%20durable%20responses%20are%20uncommon.%20The%20histopathologic%20and%20molecular%20features%20associated%20with%20treatment%20failure%20are%20still%20largely%20unknown.%20Therefore%2C%20we%20have%20analyzed%2019%20sequential%20tumor%20samples%20from%209%20patients%2C%20prior%20anti-CD19%20CART%20%28pre-CART%29%20and%20at%20relapse%20%28post-CART%29%2C%20using%20immunohistochemistry%2C%20fluorescence%20in%20situ%20hybridization%2C%20array%20comparative%20genomic%20hybridization%2C%20next-generation%20DNA%20and%20RNA%20sequencing%2C%20and%20genome-scale%20DNA%20methylation.%20The%20initial%20diagnosis%20was%20diffuse%20large%20B-cell%20lymphoma%20%28n%3D6%29%2C%20double-hit%20high-grade%20B-cell%20lymphoma%20%28n%3D1%29%2C%20and%20Burkitt%20lymphoma%20%28n%3D2%29.%20Histopathologic%20features%20were%20mostly%20retained%20at%20relapse%20in%207%5C%2F9%20patients%2C%20except%20the%20frequent%20loss%20of%201%20or%20several%20B-cell%20markers.%20The%20remaining%202%20cases%20%281%20diffuse%20large%20B-cell%20lymphoma%20and%201%20Burkitt%20lymphoma%29%20displayed%20a%20dramatic%20phenotypic%20shift%20in%20post-CART%20tumors%2C%20with%20the%20drastic%20downfall%20of%20B-cell%20markers%20and%20emergence%20of%20T-cell%20or%20histiocytic%20markers%2C%20despite%20the%20persistence%20of%20identical%20clonal%20immunoglobulin%20gene%20rearrangements.%20The%20post-CART%20tumor%20with%20aberrant%20T-cell%20phenotype%20showed%20reduced%20mRNA%20expression%20of%20most%20B-cell%20genes%20with%20increased%20methylation%20of%20their%20promoter.%20Fluorescence%20in%20situ%20hybridization%20and%20comparative%20genomic%20hybridization%20showed%20global%20stability%20of%20chromosomal%20alterations%20in%20all%20paired%20samples%2C%20including%2017p%5C%2FTP53%20deletions.%20New%20pathogenic%20variants%20acquired%20in%20post-CART%20samples%20included%20mutations%20triggering%20the%20PI3K%20pathway%20%28PIK3R1%2C%20PIK3R2%2C%20PIK3C2G%29%20or%20associated%20with%20tumor%20aggressiveness%20%28KRAS%2C%20INPP4B%2C%20SF3B1%2C%20SYNE1%2C%20TBL1XR1%29.%20These%20results%20indicate%20that%20CART-resistant%20B-cell%20non-Hodgkin%20lymphomas%20display%20genetic%20remodeling%2C%20which%20may%20result%20in%20profound%20dysregulation%20of%20B-cell%20differentiation.%20Acquired%20mutations%20in%20the%20PI3K%20and%20KRAS%20pathways%20suggest%20that%20some%20targeted%20therapies%20could%20be%20useful%20to%20overcome%20CART%20resistance.%22%2C%22date%22%3A%222022-06-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001834%22%2C%22ISSN%22%3A%221532-0979%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A53%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22G5ZLC36Z%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Reshma%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-20%22%2C%22numChildren%22%3A5%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EReshma%2C%20Ismat%20Ara%2C%20Camille%20Franchet%2C%20Margot%20Gaspard%2C%20Radu%20Tudor%20Ionescu%2C%20Josiane%20Mothe%2C%20Sylvain%20Cussat-Blanc%2C%20Herv%26%23xE9%3B%20Luga%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3BFinding%20a%20Suitable%20Class%20Distribution%20for%20Building%20Histological%20Images%20Datasets%20Used%20in%20Deep%20Model%20Training-The%20Case%20of%20Cancer%20Detection.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Digital%20Imaging%3C%5C%2Fi%3E%2C%20April%2020%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10278-022-00618-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10278-022-00618-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Finding%20a%20Suitable%20Class%20Distribution%20for%20Building%20Histological%20Images%20Datasets%20Used%20in%20Deep%20Model%20Training-The%20Case%20of%20Cancer%20Detection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ismat%20Ara%22%2C%22lastName%22%3A%22Reshma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Gaspard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radu%20Tudor%22%2C%22lastName%22%3A%22Ionescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josiane%22%2C%22lastName%22%3A%22Mothe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Cussat-Blanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Luga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22The%20class%20distribution%20of%20a%20training%20dataset%20is%20an%20important%20factor%20which%20influences%20the%20performance%20of%20a%20deep%20learning-based%20system.%20Understanding%20the%20optimal%20class%20distribution%20is%20therefore%20crucial%20when%20building%20a%20new%20training%20set%20which%20may%20be%20costly%20to%20annotate.%20This%20is%20the%20case%20for%20histological%20images%20used%20in%20cancer%20diagnosis%20where%20image%20annotation%20requires%20domain%20experts.%20In%20this%20paper%2C%20we%20tackle%20the%20problem%20of%20finding%20the%20optimal%20class%20distribution%20of%20a%20training%20set%20to%20be%20able%20to%20train%20an%20optimal%20model%20that%20detects%20cancer%20in%20histological%20images.%20We%20formulate%20several%20hypotheses%20which%20are%20then%20tested%20in%20scores%20of%20experiments%20with%20hundreds%20of%20trials.%20The%20experiments%20have%20been%20designed%20to%20account%20for%20both%20segmentation%20and%20classification%20frameworks%20with%20various%20class%20distributions%20in%20the%20training%20set%2C%20such%20as%20natural%2C%20balanced%2C%20over-represented%20cancer%2C%20and%20over-represented%20non-cancer.%20In%20the%20case%20of%20cancer%20detection%2C%20the%20experiments%20show%20several%20important%20results%3A%20%28a%29%20the%20natural%20class%20distribution%20produces%20more%20accurate%20results%20than%20the%20artificially%20generated%20balanced%20distribution%3B%20%28b%29%20the%20over-representation%20of%20non-cancer%5C%2Fnegative%20classes%20%28healthy%20tissue%20and%5C%2For%20background%20classes%29%20compared%20to%20cancer%5C%2Fpositive%20classes%20reduces%20the%20number%20of%20samples%20which%20are%20falsely%20predicted%20as%20cancer%20%28false%20positive%29%3B%20%28c%29%20the%20least%20expensive%20to%20annotate%20non-ROI%20%28non-region-of-interest%29%20data%20can%20be%20useful%20in%20compensating%20for%20the%20performance%20loss%20in%20the%20system%20due%20to%20a%20shortage%20of%20expensive%20to%20annotate%20ROI%20data%3B%20%28d%29%20the%20multi-label%20examples%20are%20more%20useful%20than%20the%20single-label%20ones%20to%20train%20a%20segmentation%20model%3B%20and%20%28e%29%20when%20the%20classification%20model%20is%20tuned%20with%20a%20balanced%20validation%20set%2C%20it%20is%20less%20affected%20than%20the%20segmentation%20model%20by%20the%20class%20distribution%20of%20the%20training%20set.%22%2C%22date%22%3A%222022-04-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10278-022-00618-7%22%2C%22ISSN%22%3A%221618-727X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-10-24T13%3A31%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22LFUAVI7T%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Degbo%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDegbo%26%23xE9%3B%2C%20Yannick%2C%20R%26%23xE9%3Bmy%20Poupot%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BRepolarization%20of%20Unbalanced%20Macrophages%3A%20Unmet%20Medical%20Need%20in%20Chronic%20Inflammation%20and%20Cancer.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2023%2C%20no.%203%20%28January%2028%2C%202022%29%3A%201496.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms23031496%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms23031496%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Repolarization%20of%20Unbalanced%20Macrophages%3A%20Unmet%20Medical%20Need%20in%20Chronic%20Inflammation%20and%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Degbo%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22Monocytes%20and%20their%20tissue%20counterpart%20macrophages%20%28MP%29%20constitute%20the%20front%20line%20of%20the%20immune%20system.%20Indeed%2C%20they%20are%20able%20to%20rapidly%20and%20efficiently%20detect%20both%20external%20and%20internal%20danger%20signals%2C%20thereby%20activating%20the%20immune%20system%20to%20eradicate%20the%20disturbing%20biological%2C%20chemical%2C%20or%20physical%20agents.%20They%20are%20also%20in%20charge%20of%20the%20control%20of%20the%20immune%20response%20and%20account%20for%20the%20repair%20of%20the%20damaged%20tissues%2C%20eventually%20restoring%20tissue%20homeostasis.%20The%20balance%20between%20these%20dual%20activities%20must%20be%20thoroughly%20controlled%20in%20space%20and%20time.%20Any%20sustained%20unbalanced%20response%20of%20MP%20leads%20to%20pathological%20disorders%2C%20such%20as%20chronic%20inflammation%2C%20or%20favors%20cancer%20development%20and%20progression.%20In%20this%20review%2C%20we%20take%20advantage%20of%20our%20expertise%20in%20chronic%20inflammation%2C%20especially%20in%20rheumatoid%20arthritis%2C%20and%20in%20cancer%2C%20to%20highlight%20the%20pivotal%20role%20of%20MP%20in%20the%20physiopathology%20of%20these%20disorders%20and%20to%20emphasize%20the%20repolarization%20of%20unbalanced%20MP%20as%20a%20promising%20therapeutic%20strategy%20to%20control%20these%20diseases.%22%2C%22date%22%3A%222022-01-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms23031496%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-06-13T09%3A42%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22RGNBEBCV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Piedrafita%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPiedrafita%2C%20Alexis%2C%20Fran%26%23xE7%3Bois%20Vergez%2C%20Julie%20Belliere%2C%20Nais%20Prades%2C%20Magali%20Colombat%2C%20Antoine%20Huart%2C%20Jean-Baptiste%20Rieu%2C%20et%20al.%20%26%23x201C%3BSpectrum%20of%20Kidney%20Disorders%20Associated%20with%20T-Cell%20Immunoclones.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Medicine%3C%5C%2Fi%3E%2011%2C%20no.%203%20%28January%2025%2C%202022%29%3A%20604.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fjcm11030604%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fjcm11030604%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Spectrum%20of%20Kidney%20Disorders%20Associated%20with%20T-Cell%20Immunoclones%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Piedrafita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Belliere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nais%22%2C%22lastName%22%3A%22Prades%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Colombat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Huart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Del%20Bello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Kamar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Chauveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ribes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Faguer%22%7D%5D%2C%22abstractNote%22%3A%22Large%20granular%20T-cell%20leukemia%20is%20a%20clonal%20hematological%20condition%20often%20associated%20with%20autoimmune%20disorders.%20Whether%20small-sized%20T-cell%20clones%20that%20are%20otherwise%20asymptomatic%20can%20promote%20immune%20kidney%20disorders%20remains%20elusive.%20In%20this%20monocentric%20retrospective%20cohort%20in%20a%20tertiary%20referral%20center%20in%20France%2C%20we%20reviewed%20characteristics%20of%2029%20patients%20with%20T-cell%20clone%20proliferation%20and%20autoimmune%20kidney%20disorders.%20Next-generation%20sequencing%20of%20the%20T-cell%20receptor%20of%20circulating%20T-cells%20was%20performed%20in%20a%20subset%20of%20patients.%20The%20T-cell%20clones%20were%20detected%20owing%20to%20systematic%20screening%20%28mean%20count%200.32%20%5Cu00d7%20109%5C%2FL%2C%20range%200.13-3.7%29.%20Strikingly%2C%20a%20common%20phenotype%20of%20acute%20interstitial%20nephropathy%20was%20observed%20in%2022%20patients%20%28median%20estimated%20glomerular%20filtration%20rate%20at%20presentation%20of%2022%20mL%5C%2Fmin%5C%2F1.73%20m2%20%28range%200-56%29%29.%20Kidney%20biopsies%20showed%20polymorphic%20inflammatory%20cell%20infiltration%20%28predominantly%20CD3%2B%20T-cells%2C%20most%20of%20them%20demonstrating%20positive%20phospho-STAT3%20staining%29%20and%20non-necrotic%20granuloma%20in%20six%20cases.%20Immune-mediated%20glomerulopathy%20only%20or%20in%20combination%20with%20acute%20interstitial%20nephropathy%20was%20identified%20in%20eight%20patients.%20Next-generation%20sequencing%20%28n%20%3D%2013%29%20identified%20a%20major%20T-cell%20clone%20representing%20more%20than%201%25%20of%20the%20T-cell%20population%20in%20all%20but%20two%20patients.%20None%20had%20a%20mutation%20of%20STAT3.%20Twenty%20patients%20%2869%25%29%20had%20two%20or%20more%20extra-kidney%20autoimmune%20diseases.%20Acute%20interstitial%20nephropathies%20were%20controlled%20with%20corticosteroids%2C%20cyclosporin%20A%2C%20or%20tofacitinib.%20Thus%2C%20we%20showed%20that%20small-sized%20T-cell%20clones%20%28i.e.%2C%20without%20lymphocytosis%29%20undetectable%20without%20specific%20screening%20are%20associated%20with%20various%20immune%20kidney%20disorders%2C%20including%20a%20previously%20unrecognized%20phenotype%20characterized%20by%20severe%20inflammatory%20kidney%20fibrosis%20and%20lymphocytic%20JAK%5C%2FSTAT%20activation.%22%2C%22date%22%3A%222022-01-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fjcm11030604%22%2C%22ISSN%22%3A%222077-0383%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A53%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22QBQ4UHU6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bachy%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBachy%2C%20Emmanuel%2C%20Vincent%20Camus%2C%20Catherine%20Thieblemont%2C%20David%20Sibon%2C%20Ren%26%23xE9%3B-Olivier%20Casasnovas%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Gandhi%20Damaj%2C%20et%20al.%20%26%23x201C%3BRomidepsin%20Plus%20CHOP%20Versus%20CHOP%20in%20Patients%20With%20Previously%20Untreated%20Peripheral%20T-Cell%20Lymphoma%3A%20Results%20of%20the%20Ro-CHOP%20Phase%20III%20Study%20%28Conducted%20by%20LYSA%29.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%3C%5C%2Fi%3E%2040%2C%20no.%203%20%28January%2020%2C%202022%29%3A%20242%26%23x2013%3B51.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.21.01815%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.21.01815%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Romidepsin%20Plus%20CHOP%20Versus%20CHOP%20in%20Patients%20With%20Previously%20Untreated%20Peripheral%20T-Cell%20Lymphoma%3A%20Results%20of%20the%20Ro-CHOP%20Phase%20III%20Study%20%28Conducted%20by%20LYSA%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Camus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Sibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9-Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gandhi%22%2C%22lastName%22%3A%22Damaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Matteo%22%2C%22lastName%22%3A%22Pica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Won%20Seog%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soon%20Thye%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%20Mart%5Cu00edn%22%2C%22lastName%22%3A%22Garc%5Cu00eda-Sancho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Jesus%22%2C%22lastName%22%3A%22Penarrubia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%20B.%22%2C%22lastName%22%3A%22Staber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Trotman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22H%5Cu00fcttmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittorio%22%2C%22lastName%22%3A%22Stefoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Helene%22%2C%22lastName%22%3A%22Delfau-Larue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22de%20Leval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Meignan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ju%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Delarue%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Romidepsin%2C%20a%20histone%20deacetylase%20inhibitor%2C%20has%20demonstrated%20activity%20in%20relapsed%20or%20refractory%20peripheral%20T-cell%20lymphoma%20%28PTCL%29%20as%20a%20single%20agent.%20Cyclophosphamide%2C%20doxorubicin%2C%20vincristine%2C%20and%20prednisone%20%28CHOP%29%20therapy%20is%20widely%20used%20as%20first-line%20treatment%20of%20PTCL%3B%20however%2C%20it%20has%20limited%20efficacy.%20Results%20from%20a%20phase%20Ib%20and%20II%20study%20showed%20the%20feasibility%20of%20combining%20romidepsin%20with%20CHOP%20%28Ro-CHOP%29.%5CnMETHODS%3A%20This%20study%20is%20a%20randomized%20phase%20III%20study%20of%20Ro-CHOP%20versus%20CHOP%20in%20adult%20patients%20with%20previously%20untreated%20PTCL.%20All%20patients%20received%20CHOP%20in%203-week%20cycles%20for%20six%20cycles.%20Romidepsin%2C%2012%20mg%5C%2Fm2%2C%20was%20administered%20intravenously%20over%20a%204-hour%20period%20on%20days%201%20and%208%20of%20each%203-week%20cycle%20for%20six%20cycles.%20The%20primary%20end%20point%20was%20progression-free%20survival%20%28PFS%29%20according%20to%20International%20Working%20Group%201999%20criteria.%5CnRESULTS%3A%20Between%20January%202013%20and%20December%202017%2C%20421%20patients%20were%20enrolled%20%28Ro-CHOP%2C%20n%20%3D%20211%3B%20CHOP%2C%20n%20%3D%20210%29.%20The%20median%20PFS%20for%20Ro-CHOP%20versus%20CHOP%20was%2012.0%20months%20%2895%25%20CI%2C%209.0%20to%2025.8%29%20versus%2010.2%20months%20%2895%25%20CI%2C%207.4%20to%2013.2%29%20with%20a%20hazard%20ratio%20of%200.81%20%28P%20%3D%20.096%29.%20In%20the%20Ro-CHOP%20versus%20CHOP%20arms%2C%20the%20median%20overall%20survival%20was%2051.8%20versus%2042.9%20months%20and%20the%20objective%20response%20rate%20was%2063%25%20versus%2060%25%20with%20complete%20response%20plus%20unconfirmed%20complete%20response%20rates%20of%2041%25%20versus%2037%25%20%28P%20%3E%20.1%20in%20all%20comparisons%29%2C%20respectively.%20Grade%203%20or%204%20treatment-emergent%20adverse%20events%20occurring%20in%20%5Cu2265%2030%25%20of%20patients%20in%20the%20Ro-CHOP%20arm%20included%20thrombocytopenia%20%2850%25%20v%2010%25%20in%20the%20Ro-CHOP%20v%20CHOP%20arms%2C%20respectively%29%2C%20neutropenia%20%2849%25%20v%2033%25%29%2C%20anemia%20%2847%25%20v%2017%25%29%2C%20and%20leukopenia%20%2832%25%20v%2020%25%29.%5CnCONCLUSION%3A%20The%20addition%20of%20romidepsin%20to%20CHOP%20did%20not%20improve%20PFS%2C%20response%20rates%2C%20nor%20overall%20survival%20and%20increased%20the%20frequency%20for%20grade%20%5Cu2265%203%20treatment-emergent%20adverse%20events.%20Ro-CHOP%20does%20not%20represent%20a%20significant%20advance%20in%20the%20standard%20of%20care%20for%20patients%20with%20previously%20untreated%20PTCL.%22%2C%22date%22%3A%222022-01-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.21.01815%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A54%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22CPISWKS3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rossi%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-01%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERossi%2C%20C%26%23xE9%3Bdric%2C%20Marie%20Tosolini%2C%20Pauline%20Gravelle%2C%20Sarah%20Pericart%2C%20Salim%20Kanoun%2C%20Solene%20Evrard%2C%20Julia%20Gilhodes%2C%20et%20al.%20%26%23x201C%3BBaseline%20SUVmax%20Is%20Related%20to%20Tumor%20Cell%20Proliferation%20and%20Patient%20Outcome%20in%20Follicular%20Lymphoma.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%20107%2C%20no.%201%20%28January%201%2C%202022%29%3A%20221%26%23x2013%3B30.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2020.263194%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2020.263194%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Baseline%20SUVmax%20is%20related%20to%20tumor%20cell%20proliferation%20and%20patient%20outcome%20in%20follicular%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Pericart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solene%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Amara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Selim%22%2C%22lastName%22%3A%22Ramla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippine%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Tabouret-Viaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9-Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20is%20the%20most%20common%20indolent%20lymphoma.%20Despite%20the%20clear%20benefit%20of%20CD20-based%20therapy%2C%20a%20subset%20of%20FL%20patients%20still%20progress%20to%20aggressive%20lymphoma.%20Thus%2C%20identifying%20early%20biomarkers%20that%20incorporate%20PET%20metrics%20could%20be%20helpful%20to%20identify%20patients%20with%20a%20high%20risk%20of%20treatment%20failure%20with%20Rituximab.%20We%20retrospectively%20included%20a%20total%20of%20132%20untreated%20FL%20patients%20separated%20into%20training%20and%20validation%20cohorts.%20Optimal%20threshold%20of%20baseline%20SUVmax%20was%20first%20determined%20in%20the%20training%20cohort%20%28n%3D48%29%20to%20predict%20progression-free%20survival%20%28PFS%29.%20The%20PET%20results%20were%20investigated%20along%20with%20the%20tumor%20and%20immune%20microenvironment%2C%20which%20were%20determined%20by%20immunochemistry%20and%20transcriptome%20studies%20involving%20gene%20set%20enrichment%20analyses%20and%20immune%20cell%20deconvolution%2C%20together%20with%20the%20tumor%20mutation%20profile.%20We%20report%20that%20baseline%20SUVmax%20%3E14.5%20was%20associated%20with%20poorer%20PFS%20than%20baseline%20SUVmax%20%5Cu226414.5%20%28HR%3D0.28%3B%20p%3D0.00046%29.%20Neither%20immune%20T-cell%20infiltration%20nor%20immune%20checkpoint%20expression%20were%20associated%20with%20baseline%20PET%20metrics.%20By%20contrast%2C%20FL%20samples%20with%20Ki-67%20staining%20%5Cu226510%25%20showed%20enrichment%20of%20cell%20cycle%5C%2FDNA%20genes%20%28p%3D0.013%29%20and%20significantly%20higher%20SUVmax%20values%20%28p%3D0.007%29.%20Despite%20similar%20oncogenic%20pathway%20alterations%20in%20both%20SUVmax%20groups%20of%20FL%20samples%2C%204%20out%20of%205%20cases%20harboring%20the%20infrequent%20FOXO1%20transcription%20factor%20mutation%20were%20seen%20in%20FL%20patients%20with%20SUVmax%20%3E14.5.%20Thus%2C%20high%20baseline%20SUVmax%20reflects%20FL%20tumor%20proliferation%20and%2C%20together%20with%20Ki-67%20proliferative%20index%2C%20can%20be%20used%20to%20identify%20patients%20at%20risk%20of%20early%20relapse%20with%20R-chemotherapy.%22%2C%22date%22%3A%222022-01-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2020.263194%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%223U3NWA3K%22%5D%2C%22dateModified%22%3A%222022-12-14T13%3A54%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22IQDP7G9B%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trecourt%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETrecourt%2C%20Alexis%2C%20Claire%20Mauduit%2C%20Vanessa%20Szablewski%2C%20Juliette%20Fontaine%2C%20Brigitte%20Balme%2C%20Marie%20Donzel%2C%20Camille%20Laurent%2C%20et%20al.%20%26%23x201C%3BPlasticity%20of%20Mature%20B%20Cells%20Between%20Follicular%20and%20Classic%20Hodgkin%20Lymphomas%3A%20A%20Series%20of%2022%20Cases%20Expanding%20the%20Spectrum%20of%20Transdifferentiation.%26%23x201D%3B%20%3Ci%3EThe%20American%20Journal%20of%20Surgical%20Pathology%3C%5C%2Fi%3E%2046%2C%20no.%201%20%28January%201%2C%202022%29%3A%2058%26%23x2013%3B70.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001780%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001780%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasticity%20of%20Mature%20B%20Cells%20Between%20Follicular%20and%20Classic%20Hodgkin%20Lymphomas%3A%20A%20Series%20of%2022%20Cases%20Expanding%20the%20Spectrum%20of%20Transdifferentiation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Trecourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Szablewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Balme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Donzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sesques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Emile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Cl%5Cu00e9ment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Genestier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20and%20classic%20Hodgkin%20lymphoma%20can%20be%20associated%20in%20composite%20and%5C%2For%20sequential%20lymphomas.%20Common%20IGH%20and%20BCL2%20rearrangements%20have%20already%20been%20identified%20between%20both%20contingents%20of%20these%20entities%2C%20but%20mutation%20profiles%20have%20not%20yet%20been%20investigated.%20The%20main%20objective%20of%20this%20study%20was%20to%20analyze%20the%20transdifferentiation%20process%20that%20may%20occur%20between%20Hodgkin%20and%20follicular%20contingents%20in%20sequential%20and%20composite%20lymphomas%20to%20better%20characterize%20these%20entities.%20From%202004%20to%202020%2C%20a%20retrospective%20multicentric%20study%20was%20performed%2C%20including%209%20composite%20and%2013%20sequential%20lymphomas.%20Clinical%20data%20were%20retrospectively%20collected.%20Fluorescent%20in%20situ%20hybridization%20of%20BCL2%20and%20BCL6%20rearrangements%2C%20polymerase%20chain%20reaction%20of%20IGH%20and%20IGK%20rearrangements%2C%20next-generation%20sequencing%20of%20IGK%20rearrangement%2C%20and%20targeted%20next-generation%20sequencing%20%28TNGS%29%20on%20a%20panel%20of%20genes%20frequently%20mutated%20in%20lymphomas%20were%20performed%20on%20each%20contingent%20of%20composite%20and%20sequential%20lymphomas.%20For%20TNGS%2C%20each%20contingent%20was%20isolated%20by%20laser%20capture%20microdissection.%20Clinical%20presentation%20and%20evolution%20were%20more%20aggressive%20in%20sequential%20than%20composite%20lymphomas.%20By%20fluorescent%20in%20situ%20hybridization%2C%20common%20rearrangements%20of%20BCL6%20and%20BCL2%20were%20identified%20between%20both%20contingents.%20Similarly%2C%20a%20common%20clonal%20relationship%20was%20established%20by%20evaluating%20IGH%20and%20IGK%20rearrangement%20by%20polymerase%20chain%20reaction%20or%20next-generation%20sequencing.%20By%20TNGS%2C%20the%20same%20pathogenic%20variants%20were%20identified%20in%20both%20contingents%20in%20the%20following%20genes%3A%20CREBBP%2C%20KMT2D%2C%20BCL2%2C%20EP300%2C%20SF3B1%2C%20SOCS1%2C%20ARID1A%2C%20and%20BCOR.%20Specific%20pathogenic%20variants%20for%20each%20contingent%20were%20also%20identified%3A%20XPO1%20for%20Hodgkin%20lymphoma%20contingent%20and%20FOXO1%2C%20TNFRSF14%20for%20follicular%20lymphoma%20contingent.%20This%20study%20reinforces%20the%20hypothesis%20of%20a%20transdifferentiation%20process%20between%20Hodgkin%20and%20follicular%20contingent%20of%20sequential%5C%2Fcomposite%20lymphomas.%22%2C%22date%22%3A%222022-01-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001780%22%2C%22ISSN%22%3A%221532-0979%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A52%3A49Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Syrykh, Charlotte, Charlotte Chaouat, Elsa Poullot, Nadia Amara, Virginie Fataccioli, Marie Parrens, Alexandra Traverse-Glehen, et al. “Lymph Node Excisions Provide More Precise Lymphoma Diagnoses than Core Biopsies: A French Lymphopath Network Survey.” Blood<\/i> 140, no. 24 (December 15, 2022): 2573–83. https:\/\/doi.org\/10.1182\/blood.2022015520<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Trecourt, Alexis, Marie Donzel, Juliette Fontaine, Hervé Ghesquières, Laurent Jallade, Gabriel Antherieu, Camille Laurent, Claire Mauduit, and Alexsandra Traverse-Glehen. “Plasticity in Classical Hodgkin Composite Lymphomas: A Systematic Review.” Cancers<\/i> 14, no. 22 (November 19, 2022): 5695. https:\/\/doi.org\/10.3390\/cancers14225695<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, James R. Cook, Tadashi Yoshino, Leticia Quintanilla-Martinez, and Elaine S. Jaffe. “Follicular Lymphoma and Marginal Zone Lymphoma: How Many Diseases?” Virchows Archiv: An International Journal of Pathology<\/i>, November 17, 2022. https:\/\/doi.org\/10.1007\/s00428-022-03432-2<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gondran, Camille, and Loïc Ysebaert. “[Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].” Bulletin Du Cancer<\/i> 109, no. 11 (November 2022): 1105–6. https:\/\/doi.org\/10.1016\/j.bulcan.2022.07.010<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Phelippeau, Mona, Christine Lefebvre, Marie-Christine Jacob, Charlotte Syrykh, Julien Ghelfi, Sylvain Carras, Camille Laurent, Lysiane Molina, and Séverine Valmary-Degano. “[Dasatinib-induced follicular lymphoid hyperplasia, an entity to know].” Annales De Pathologie<\/i>, October 17, 2022, S0242-6498(22)00175-4. https:\/\/doi.org\/10.1016\/j.annpat.2022.09.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bouclet, Florian, Daphné Krzisch, Véronique Leblond, Cécile Tomowiak, Kamel Laribi, Loïc Ysebaert, Olivier Tournilhac, et al. “[Waldenström disease: News and perspectives in 2022].” Bulletin Du Cancer<\/i>, October 10, 2022, S0007-4551(22)00350-2. https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.012<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Feldman, Andrew L., Camille Laurent, Marina Narbaitz, Shigeo Nakamura, Wing C. Chan, Laurence de Leval, and Philippe Gaulard. “Classification and Diagnostic Evaluation of Nodal T- and NK-Cell Lymphomas.” Virchows Archiv: An International Journal of Pathology<\/i>, October 10, 2022. https:\/\/doi.org\/10.1007\/s00428-022-03412-6<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lamaison, Claire, Juliette Ferrant, Pauline Gravelle, Alexandra Traverse-Glehen, Hervé Ghesquières, Marie Tosolini, Cédric Rossi, et al. “Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.” Cancers<\/i> 14, no. 19 (October 6, 2022): 4893. https:\/\/doi.org\/10.3390\/cancers14194893<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Morschhauser, Franck, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, et al. “Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/i> 40, no. 28 (October 1, 2022): 3239–45. https:\/\/doi.org\/10.1200\/JCO.22.00843<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lapierre, Léopoldine, Charlotte Syrykh, Laetitia Largeaud, Bastien Cabarrou, Thomas Filleron, Lucie Oberic, Salim Kanoun, et al. “‘Accelerated Phase’ Chronic Lymphocytic Leukemia: Still an Intermediate Risk Disease in the Era of Targeted Therapies.” Hematological Oncology<\/i> 40, no. 4 (October 2022): 805–8. https:\/\/doi.org\/10.1002\/hon.2985<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Campo, Elias, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, et al. “The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.” Blood<\/i> 140, no. 11 (September 15, 2022): 1229–53. https:\/\/doi.org\/10.1182\/blood.2022015851<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, Charlotte Syrykh, Maxime Hamon, José Adélaïde, Arnaud Guille, Frederic Escudié, Gael Jalowicki, et al. “Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.” The American Journal of Surgical Pathology<\/i> 46, no. 6 (June 1, 2022): 742–53. https:\/\/doi.org\/10.1097\/PAS.0000000000001834<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Reshma, Ismat Ara, Camille Franchet, Margot Gaspard, Radu Tudor Ionescu, Josiane Mothe, Sylvain Cussat-Blanc, Hervé Luga, and Pierre Brousset. “Finding a Suitable Class Distribution for Building Histological Images Datasets Used in Deep Model Training-The Case of Cancer Detection.” Journal of Digital Imaging<\/i>, April 20, 2022. https:\/\/doi.org\/10.1007\/s10278-022-00618-7<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Degboé, Yannick, Rémy Poupot, and Mary Poupot. “Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and Cancer.” International Journal of Molecular Sciences<\/i> 23, no. 3 (January 28, 2022): 1496. https:\/\/doi.org\/10.3390\/ijms23031496<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Piedrafita, Alexis, François Vergez, Julie Belliere, Nais Prades, Magali Colombat, Antoine Huart, Jean-Baptiste Rieu, et al. “Spectrum of Kidney Disorders Associated with T-Cell Immunoclones.” Journal of Clinical Medicine<\/i> 11, no. 3 (January 25, 2022): 604. https:\/\/doi.org\/10.3390\/jcm11030604<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bachy, Emmanuel, Vincent Camus, Catherine Thieblemont, David Sibon, René-Olivier Casasnovas, Loïc Ysebaert, Gandhi Damaj, et al. “Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/i> 40, no. 3 (January 20, 2022): 242–51. https:\/\/doi.org\/10.1200\/JCO.21.01815<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rossi, Cédric, Marie Tosolini, Pauline Gravelle, Sarah Pericart, Salim Kanoun, Solene Evrard, Julia Gilhodes, et al. “Baseline SUVmax Is Related to Tumor Cell Proliferation and Patient Outcome in Follicular Lymphoma.” Haematologica<\/i> 107, no. 1 (January 1, 2022): 221–30. https:\/\/doi.org\/10.3324\/haematol.2020.263194<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Trecourt, Alexis, Claire Mauduit, Vanessa Szablewski, Juliette Fontaine, Brigitte Balme, Marie Donzel, Camille Laurent, et al. “Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.” The American Journal of Surgical Pathology<\/i> 46, no. 1 (January 1, 2022): 58–70. https:\/\/doi.org\/10.1097\/PAS.0000000000001780<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2021″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2021<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-d8011078903093727cabbb2206cbcd13%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228YSDNVNF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Domagala%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-21%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDomagala%2C%20Marcin%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Laetitia%20Ligat%2C%20Frederic%20Lopez%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Camille%20Laurent%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BIL-10%20Rescues%20CLL%20Survival%20through%20Repolarization%20of%20Inflammatory%20Nurse-like%20Cells.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%201%20%28December%2021%2C%202021%29%3A%2016.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14010016%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14010016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22IL-10%20Rescues%20CLL%20Survival%20through%20Repolarization%20of%20Inflammatory%20Nurse-like%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22Tumor-associated%20macrophages%20%28TAMs%29%20in%20chronic%20lymphocytic%20leukemia%20%28CLL%29%20are%20also%20called%20nurse-like%20cells%20%28NLC%29%2C%20and%20confer%20survival%20signals%20through%20the%20release%20of%20soluble%20factors%20and%20cellular%20contacts.%20While%20in%20most%20patient%20samples%20the%20presence%20of%20NLC%20in%20co-cultures%20guarantees%20high%20viability%20of%20leukemic%20cells%20in%20vitro%2C%20in%20some%20cases%20this%20protective%20effect%20is%20absent.%20These%20macrophages%20are%20characterized%20by%20an%20%5C%22M1-like%20phenotype%5C%22.%20We%20show%20here%20that%20their%20reprogramming%20towards%20an%20M2-like%20phenotype%20%28tumor-supportive%29%20with%20IL-10%20leads%20to%20an%20increase%20in%20leukemic%20cell%20survival.%20Inflammatory%20cytokines%2C%20such%20as%20TNF%2C%20are%20also%20able%20to%20depolarize%20M2-type%20protective%20NLC%20%28decreasing%20CLL%20cell%20viability%29%2C%20an%20effect%20which%20is%20countered%20by%20IL-10%20or%20blocking%20antibodies.%20Interestingly%2C%20both%20IL-10%20and%20TNF%20are%20implied%20in%20the%20pathophysiology%20of%20CLL%20and%20their%20elevated%20level%20is%20associated%20with%20bad%20prognosis.%20We%20propose%20that%20the%20molecular%20balance%20between%20these%20two%20cytokines%20in%20CLL%20niches%20plays%20an%20important%20role%20in%20the%20maintenance%20of%20the%20protective%20phenotype%20of%20NLCs%2C%20and%20therefore%20in%20the%20survival%20of%20CLL%20cells.%22%2C%22date%22%3A%222021-12-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14010016%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-17T15%3A54%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22HYY4IUBM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lapierre%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELapierre%2C%20Leopoldine%2C%20Sarah%20Pericart%2C%20Caroline%20Protin%2C%20Cecile%20Borel%2C%20Loic%20Ysebaert%2C%20Camille%20Laurent%2C%20and%20Lucie%20Oberic.%20%26%23x201C%3BNivolumab%20in%20Refractory%20Cerebral%20Relapse%20of%20Hodgkin%26%23x2019%3Bs%20Lymphoma.%26%23x201D%3B%20%3Ci%3ELeukemia%20%26amp%3B%20Lymphoma%3C%5C%2Fi%3E%2062%2C%20no.%2012%20%28December%202021%29%3A%203063%26%23x2013%3B65.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2021.1950711%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2021.1950711%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nivolumab%20in%20refractory%20cerebral%20relapse%20of%20Hodgkin%27s%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leopoldine%22%2C%22lastName%22%3A%22Lapierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Pericart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%22%2C%22lastName%22%3A%22Borel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F10428194.2021.1950711%22%2C%22ISSN%22%3A%221029-2403%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A04%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22IAXYF6IN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-23%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20Pauline%20Gorez%2C%20Sarah%20P%26%23xE9%3Bricart%2C%20David%20Grand%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Escudi%26%23xE9%3B%2C%20Bastien%20Cabarrou%2C%20Lucie%20Ob%26%23xE9%3Bric%2C%20et%20al.%20%26%23x201C%3BMolecular%20Diagnosis%20of%20T-Cell%20Lymphoma%3A%20A%20Correlative%20Study%20of%20PCR-Based%20T-Cell%20Clonality%20Assessment%20and%20Targeted%20NGS.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%205%2C%20no.%2022%20%28November%2023%2C%202021%29%3A%204590%26%23x2013%3B93.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005249%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005249%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20diagnosis%20of%20T-cell%20lymphoma%3A%20a%20correlative%20study%20of%20PCR-based%20T-cell%20clonality%20assessment%20and%20targeted%20NGS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gorez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Escudi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%20M.%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22Immunomorphological%20diagnosis%20of%20T-cell%20lymphoma%20%28TCL%29%20may%20be%20challenging%2C%20especially%20on%20needle%20biopsies.%20Multiplex%20polymerase%20chain%20reaction%20%28PCR%29%20assays%20to%20assess%20T-cell%20receptor%20%28TCR%29%20gene%20rearrangements%20are%20now%20widely%20used%20to%20detect%20T-cell%20clones%20and%20provide%20diagnostic%20support.%20However%2C%20PCR%20assays%20detect%20only%2080%25%20of%20TCL%2C%20and%20clonal%20lymphocyte%20populations%20may%20also%20appear%20in%20nonneoplastic%20conditions.%20More%20recently%2C%20targeted%20next-generation%20sequencing%20%28t-NGS%29%20technologies%20have%20been%20deployed%20to%20improve%20lymphoma%20classification.%20To%20the%20best%20of%20our%20knowledge%2C%20the%20comparison%20of%20these%20techniques%27%20performance%20in%20TCL%20diagnosis%20has%20not%20been%20reported%20yet.%20In%20this%20study%2C%2082%20TCL%20samples%20and%2025%20nonneoplastic%20T-cell%20infiltrates%20were%20divided%20into%202%20cohorts%20%28test%20and%20validation%29%20and%20analyzed%20with%20both%20multiplex%20PCR%20and%20t-NGS%20to%20investigate%20TCR%20gene%20rearrangements%20and%20somatic%20mutations%2C%20respectively.%20The%20detection%20of%20mutations%20appeared%20to%20be%20more%20specific%20%28100.0%25%29%20than%20T-cell%20clonality%20assessment%20%2841.7%25-45.5%25%29%2C%20whereas%20no%20differences%20were%20observed%20in%20terms%20of%20sensitivity%20%2895.1%25-97.4%25%29.%20Furthermore%2C%20t-NGS%20provided%20a%20reliable%20basis%20for%20TCL%20diagnosis%20in%20samples%20with%20partially%20degraded%20DNA%20that%20was%20impossible%20to%20assess%20with%20PCR.%20Finally%2C%20although%20multiplex%20PCR%20assays%20appeared%20to%20be%20less%20specific%20than%20t-NGS%2C%20both%20techniques%20remain%20complementary%2C%20as%20PCR%20recovered%20some%20t-NGS%20negative%20cases.%22%2C%22date%22%3A%222021-11-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2021005249%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A36%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22YM56SARY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cerapio%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECerapio%2C%20Juan%20Pablo%2C%20Marion%20Perrier%2C%20Fr%26%23xE9%3Bderic%20Pont%2C%20Marie%20Tosolini%2C%20Camille%20Laurent%2C%20St%26%23xE9%3Bphane%20Bertani%2C%20and%20Jean-Jacques%20Fournie.%20%26%23x201C%3BSingle-Cell%20RNAseq%20Profiling%20of%20Human%20%26%23x393%3B%26%23x3B4%3B%20T%20Lymphocytes%20in%20Virus-Related%20Cancers%20and%20COVID-19%20Disease.%26%23x201D%3B%20%3Ci%3EViruses%3C%5C%2Fi%3E%2013%2C%20no.%2011%20%28November%203%2C%202021%29%3A%202212.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fv13112212%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fv13112212%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-Cell%20RNAseq%20Profiling%20of%20Human%20%5Cu03b3%5Cu03b4%20T%20Lymphocytes%20in%20Virus-Related%20Cancers%20and%20COVID-19%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Bertani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fournie%22%7D%5D%2C%22abstractNote%22%3A%22The%20detailed%20characterization%20of%20human%20%5Cu03b3%5Cu03b4%20T%20lymphocyte%20differentiation%20at%20the%20single-cell%20transcriptomic%20%28scRNAseq%29%20level%20in%20tumors%20and%20patients%20with%20coronavirus%20disease%202019%20%28COVID-19%29%20requires%20both%20a%20reference%20differentiation%20trajectory%20of%20%5Cu03b3%5Cu03b4%20T%20cells%20and%20a%20robust%20mapping%20method%20for%20additional%20%5Cu03b3%5Cu03b4%20T%20lymphocytes.%20Here%2C%20we%20incepted%20such%20a%20method%20to%20characterize%20thousands%20of%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20from%20%28n%20%3D%2095%29%20patients%20with%20cancer%20or%20adult%20and%20pediatric%20COVID-19%20disease.%20We%20found%20that%20cancer%20patients%20with%20human%20papillomavirus-positive%20head%20and%20neck%20squamous%20cell%20carcinoma%20and%20Epstein-Barr%20virus-positive%20Hodgkin%27s%20lymphoma%20have%20%5Cu03b3%5Cu03b4%20tumor-infiltrating%20T%20lymphocytes%20that%20are%20more%20prone%20to%20recirculate%20from%20the%20tumor%20and%20avoid%20exhaustion.%20In%20COVID-19%2C%20both%20TCRV%5Cu03b39%20and%20TCRV%5Cu03b3non9%20subsets%20of%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20relocalize%20from%20peripheral%20blood%20mononuclear%20cells%20%28PBMC%29%20to%20the%20infected%20lung%20tissue%2C%20where%20their%20advanced%20differentiation%2C%20tissue%20residency%2C%20and%20exhaustion%20reflect%20T%20cell%20activation.%20Although%20severe%20COVID-19%20disease%20increases%20both%20recruitment%20and%20exhaustion%20of%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20in%20infected%20lung%20lesions%20but%20not%20blood%2C%20the%20anti-IL6R%20therapy%20with%20Tocilizumab%20promotes%20%5Cu03b3%5Cu03b4%20T%20lymphocyte%20differentiation%20in%20patients%20with%20COVID-19.%20PBMC%20from%20pediatric%20patients%20with%20acute%20COVID-19%20disease%20display%20similar%20%5Cu03b3%5Cu03b4%20T%20cell%20lymphopenia%20to%20that%20seen%20in%20adult%20patients.%20However%2C%20blood%20%5Cu03b3%5Cu03b4%20T%20cells%20from%20children%20with%20the%20COVID-19-related%20multisystem%20inflammatory%20syndrome%20are%20not%20lymphodepleted%2C%20but%20they%20are%20differentiated%20as%20in%20healthy%20PBMC.%20These%20findings%20suggest%20that%20some%20virus-induced%20memory%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20durably%20persist%20in%20the%20blood%20of%20adults%20and%20could%20subsequently%20infiltrate%20and%20recirculate%20in%20tumors.%22%2C%22date%22%3A%222021-11-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fv13112212%22%2C%22ISSN%22%3A%221999-4915%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A46%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22EFHYTYNI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Caputo%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECaputo%2C%20Sandrine%20M.%2C%20Lisa%20Golmard%2C%20M%26%23xE9%3Blanie%20L%26%23xE9%3Bone%2C%20Francesca%20Damiola%2C%20Marine%20Guillaud-Bataille%2C%20Fran%26%23xE7%3Boise%20Revillion%2C%20Etienne%20Rouleau%2C%20et%20al.%20%26%23x201C%3BClassification%20of%20101%20BRCA1%20and%20BRCA2%20Variants%20of%20Uncertain%20Significance%20by%20Cosegregation%20Study%3A%20A%20Powerful%20Approach.%26%23x201D%3B%20%3Ci%3EAmerican%20Journal%20of%20Human%20Genetics%3C%5C%2Fi%3E%20108%2C%20no.%2010%20%28October%207%2C%202021%29%3A%201907%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajhg.2021.09.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajhg.2021.09.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Classification%20of%20101%20BRCA1%20and%20BRCA2%20variants%20of%20uncertain%20significance%20by%20cosegregation%20study%3A%20A%20powerful%20approach%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%20M.%22%2C%22lastName%22%3A%22Caputo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Golmard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22L%5Cu00e9one%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Damiola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Guillaud-Bataille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Revillion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Rouleau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Derive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Buisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Basset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathias%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Vilquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Garrec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Privat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Gay-Bellile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khadija%22%2C%22lastName%22%3A%22Abidallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Airaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Allary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Barouk-Simonet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Belotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Benigni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20R.%22%2C%22lastName%22%3A%22Benusiglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Berthemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Berthet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ophelie%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22B%5Cu00e9zieau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bidart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves-Jean%22%2C%22lastName%22%3A%22Bignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Birot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Blanluet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amelie%22%2C%22lastName%22%3A%22Bloucard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johny%22%2C%22lastName%22%3A%22Bombled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Bonadona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Bonnet-Dupeyron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Boulaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavie%22%2C%22lastName%22%3A%22Boulouard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Bouras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Violaine%22%2C%22lastName%22%3A%22Bourdon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afane%22%2C%22lastName%22%3A%22Brahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Brayotel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Bressac%20de%20Paillerets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Bronnec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Bubien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Buecher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Cabaret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Carriere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Chiesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Chieze-Val%5Cu00e9ro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Cohen-Haguenauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chrystelle%22%2C%22lastName%22%3A%22Colas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Collonge-Rame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Conoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Coulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Coupier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Crivelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronica%22%2C%22lastName%22%3A%22Cusin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22De%20Pauw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Dehainault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Delhomelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Capucine%22%2C%22lastName%22%3A%22Delnatte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Demontety%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Denizeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Devulder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Dreyfus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20Dubois%22%2C%22lastName%22%3A%22d%27Enghein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Durlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Dussart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Fajac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Fekairi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Fert-Ferrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Fi%5Cu00e9vet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Fouillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Mouret-Fourme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Gauthier-Villars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Gesta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Goldbarg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Goussot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erell%22%2C%22lastName%22%3A%22Guillerm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Hardouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Heude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Houdayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Ingster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Jacquot-Sawka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalie%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Krieger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofiane%22%2C%22lastName%22%3A%22Lacoste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hakima%22%2C%22lastName%22%3A%22Lallaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Larbre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Laug%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%22%2C%22lastName%22%3A%22Le%20Guyadec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Le%20Mentec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Lecerf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Le%20Gall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9reng%5Cu00e8re%22%2C%22lastName%22%3A%22Legendre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Legrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e9lina%22%2C%22lastName%22%3A%22Legros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Lejeune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosette%22%2C%22lastName%22%3A%22Lidereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Lignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Limacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22null%22%2C%22lastName%22%3A%22Doriane%20Livon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarab%22%2C%22lastName%22%3A%22Lizard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Longy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Lortholary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Macquere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Mailliez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Malsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Margot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Mari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Maugard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Meira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Menjard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Moli%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Moncoutier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Moretta-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoe%22%2C%22lastName%22%3A%22Nevi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thien-Vu%22%2C%22lastName%22%3A%22Nguyen%20Minh%20Tuan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tetsuro%22%2C%22lastName%22%3A%22Noguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Nogu%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florine%22%2C%22lastName%22%3A%22Oca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornel%22%2C%22lastName%22%3A%22Popovici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Prieur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Raad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Rey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Ricou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Salle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Saule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Sevenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatoumata%22%2C%22lastName%22%3A%22Simaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hagay%22%2C%22lastName%22%3A%22Sobol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Voreak%22%2C%22lastName%22%3A%22Suybeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Tennevet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henrique%22%2C%22lastName%22%3A%22Tenreiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Tinat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Turbiez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Uhrhammer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Vande%20Perre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Vaur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Venat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Viellard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Charlotte%22%2C%22lastName%22%3A%22Villy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Warcoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Yvard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zattara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Caron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lasset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Remenieras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Boutry-Kryza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Cast%5Cu00e9ra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Stoppa-Lyonnet%22%7D%5D%2C%22abstractNote%22%3A%22Up%20to%2080%25%20of%20BRCA1%20and%20BRCA2%20genetic%20variants%20remain%20of%20uncertain%20clinical%20significance%20%28VUSs%29.%20Only%20variants%20classified%20as%20pathogenic%20or%20likely%20pathogenic%20can%20guide%20breast%20and%20ovarian%20cancer%20prevention%20measures%20and%20treatment%20by%20PARP%20inhibitors.%20We%20report%20the%20first%20results%20of%20the%20ongoing%20French%20national%20COVAR%20%28cosegregation%20variant%29%20study%2C%20the%20aim%20of%20which%20is%20to%20classify%20BRCA1%5C%2F2%20VUSs.%20The%20classification%20method%20was%20a%20multifactorial%20model%20combining%20different%20associations%20between%20VUSs%20and%20cancer%2C%20including%20cosegregation%20data.%20At%20this%20time%2C%20among%20the%20653%20variants%20selected%2C%20101%20%2815%25%29%20distinct%20variants%20shared%20by%201%2C624%20families%20were%20classified%20as%20pathogenic%5C%2Flikely%20pathogenic%20or%20benign%5C%2Flikely%20benign%20by%20the%20COVAR%20study.%20Sixty-six%20of%20the%20101%20%2865%25%29%20variants%20classified%20by%20COVAR%20would%20have%20remained%20VUSs%20without%20cosegregation%20data.%20Of%20note%2C%20among%20the%2034%20variants%20classified%20as%20pathogenic%20by%20COVAR%2C%2016%20remained%20VUSs%20or%20likely%20pathogenic%20when%20following%20the%20ACMG%5C%2FAMP%20variant%20classification%20guidelines.%20Although%20the%20initiation%20and%20organization%20of%20cosegregation%20analyses%20require%20a%20considerable%20effort%2C%20the%20growing%20number%20of%20available%20genetic%20tests%20results%20in%20an%20increasing%20number%20of%20families%20sharing%20a%20particular%20variant%2C%20and%20thereby%20increases%20the%20power%20of%20such%20analyses.%20Here%20we%20demonstrate%20that%20variant%20cosegregation%20analyses%20are%20a%20powerful%20tool%20for%20the%20classification%20of%20variants%20in%20the%20BRCA1%5C%2F2%20breast-ovarian%20cancer%20predisposition%20genes.%22%2C%22date%22%3A%222021-10-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ajhg.2021.09.003%22%2C%22ISSN%22%3A%221537-6605%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A40%3A27Z%22%7D%7D%2C%7B%22key%22%3A%2265NXX7J3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Jos%26%23xE9%3B%20Ad%26%23xE9%3Bla%26%23xEF%3Bde%2C%20Arnaud%20Guille%2C%20Bruno%20Tesson%2C%20Elodie%20Gat%2C%20Solene%20Evrard%2C%20Frederic%20Escudi%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BHigh-Grade%20Follicular%20Lymphomas%20Exhibit%20Clinicopathologic%2C%20Cytogenetic%2C%20and%20Molecular%20Diversity%20Extending%20Beyond%20Grades%203A%20and%203B.%26%23x201D%3B%20%3Ci%3EThe%20American%20Journal%20of%20Surgical%20Pathology%3C%5C%2Fi%3E%2045%2C%20no.%2010%20%28October%201%2C%202021%29%3A%201324%26%23x2013%3B36.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001726%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001726%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-grade%20Follicular%20Lymphomas%20Exhibit%20Clinicopathologic%2C%20Cytogenetic%2C%20and%20Molecular%20Diversity%20Extending%20Beyond%20Grades%203A%20and%203B%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Ad%5Cu00e9la%5Cu00efde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Guille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Tesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solene%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Escudi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danielle%22%2C%22lastName%22%3A%22Canioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Fabiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Meignin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Clement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Dartigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Parrens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Huet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Birnbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Lymphoma%20Study%20Association%20%28LYSA%29%22%7D%5D%2C%22abstractNote%22%3A%22Although%20follicular%20lymphoma%20%28FL%29%20is%20usually%20graded%20as%20FL1-2%2C%20FL3A%2C%20and%20FL3B%2C%20some%20borderline%20cases%20can%20be%20observed%20and%20led%20us%20to%20investigate%20the%20clinicopathologic%20diversity%20of%20grade%203%20FL%20%28FL3%29.%20Among%202449%20FL%20patients%20enrolled%20in%20Lymphoma%20Study%20Association%20%28LYSA%29%20trials%2C%201921%20cases%20with%20sufficient%20material%20underwent%20a%20central%20pathologic%20review.%20The%20resulting%20diagnoses%20comprised%2089.6%25%20FL1-2%20%28n%3D1723%29%2C%207.2%25%20FL3A%20%28n%3D138%29%2C%20and%200.5%25%20purely%20follicular%20FL3B%20%28n%3D9%29.%20The%20remaining%2051%20unclassifiable%20cases%20%282.7%25%29%20exhibited%20high-grade%20features%20but%20did%20not%20meet%20WHO%20criteria%20for%20either%20FL3A%20or%20FL3B%3B%20and%20were%20considered%20as%20%5C%22unconventional%5C%22%20high-grade%20FL%20%28FL3U%29.%20FL3U%20morphological%20pattern%20consisted%20of%20nodular%20proliferation%20of%20large%20cleaved%20cells%20or%20small-sized%20to%20medium-sized%20blast%20cells.%20Compared%20with%20FL3A%2C%20FL3U%20exhibited%20higher%20MUM1%20and%20Ki67%20expression%2C%20less%20BCL2%20breaks%20and%20more%20BCL6%20rearrangements%2C%20together%20with%20a%20higher%20number%20of%20cases%20without%20any%20BCL2%2C%20BCL6%20or%20MYC%20rearrangement.%20FL3U%20harbored%20less%20frequent%20mutations%20in%20BCL2%2C%20KMT2D%2C%20KMT2B%2C%20and%20CREBBP%20than%20FL3A.%20MYC%20and%20BCL2%20were%20less%20frequently%20mutated%20in%20FL3U%20than%20FL3B.%20Rituximab%20cyclophosphamide%2C%20doxorubicin%2C%20vincristine%2C%20and%20prednisone%20treated%20FL3U%20patients%20had%20a%20worse%20survival%20than%20FL1-2%20patients%20with%20similar%20follicular%20lymphoma%20international%20prognostic%20index%20and%20treatment.%20These%20results%20suggest%20that%20high-grade%20FLs%20encompass%20a%20heterogeneous%20spectrum%20of%20tumors%20with%20variable%20morphology%20and%20genomic%20alterations%2C%20including%20FL3U%20cases%20that%20do%20not%20strictly%20fit%20WHO%20criteria%20for%20either%20FL3A%20or%20FL3B%2C%20and%20display%20a%20worse%20outcome%20than%20FL1-2.%20The%20distinction%20of%20FL3U%20may%20be%20useful%20to%20allow%20a%20better%20comprehension%20of%20high-grade%20FLs%20and%20to%20design%20clinical%20trials.%22%2C%22date%22%3A%222021-10-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001726%22%2C%22ISSN%22%3A%221532-0979%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A38%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22E52CY92N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Oberic%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOberic%2C%20Lucie%2C%20Faustine%20Delzor%2C%20Caroline%20Protin%2C%20Sophie%20Perriat%2C%20Camille%20Laurent%2C%20Ana%26%23xEF%3Bs%20Grand%2C%20Jean%20Marie%20Canonge%2C%20et%20al.%20%26%23x201C%3BBrentuximab%20Vedotin%20in%20Real%20Life%2C%20a%20Seven%20Year%20Experience%20in%20Patients%20with%20Refractory%5C%2FRelapsed%20CD30%2B%20T%20Cell%20Lymphoma.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Oncology%20Pharmacy%20Practice%3A%20Official%20Publication%20of%20the%20International%20Society%20of%20Oncology%20Pharmacy%20Practitioners%3C%5C%2Fi%3E%2027%2C%20no.%207%20%28October%202021%29%3A%201730%26%23x2013%3B35.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1078155220968615%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1078155220968615%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Brentuximab%20vedotin%20in%20real%20life%2C%20a%20seven%20year%20experience%20in%20patients%20with%20refractory%5C%2Frelapsed%20CD30%2B%20T%20cell%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faustine%22%2C%22lastName%22%3A%22Delzor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Perriat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marie%22%2C%22lastName%22%3A%22Canonge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Borel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Brentuximab%20vedotin%20%28Bv%29%20has%20been%20approved%20for%20the%20treatment%20of%20Refractory%5C%2FRelapsed%20%28R%5C%2FR%29%20Anaplastic%20Large%20Cell%20Lymphomas%20%28ALCL%29%20and%20cutaneous%20T-Cell%20Lymphomas%2C%20but%20is%20also%20effective%20in%20other%20CD30%2B%20malignancies.%20We%20report%20here%20the%20outcomes%20of%20patients%20with%20various%20R%5C%2FR%20Peripheral%20T%20Cell%20Lymphoma%20%28PTCL%29%20treated%20with%20Bv%20in%20real%20life%20practice.%5CnMETHOD%3A%20This%20was%20a%20retrospective%2C%20single-center%20study%20based%20on%20medical%20records%20of%20patients%20with%20R%5C%2FR%20PTCL%20treated%20either%20with%20Bv%20alone%20or%20in%20combination%20with%20chemotherapy.%5CnRESULTS%3A%20Among%2027%20patients%20treated%20with%20Bv%2C%20neutropenia%20was%20the%20main%20serious%20adverse%20event%20observed%20in%20particular%20when%20Bv%20was%20used%20as%20combination%20treatment.%20The%20complete%20Response%20Rates%20%28CRR%29%20was%2040.7%25%3B%20it%20was%20significantly%20improved%20when%20Bv%20was%20used%20as%20combination%20treatment.%20The%20majority%20of%20eligible%20patients%20%287%5C%2F10%29%20underwent%20Stem%20Cell%20Transplantation.%20Median%20Progression%20Free%20Survival%20%28PFS%29%20and%20Overall%20Survival%20%28OS%29%20were%205.2%5Cu2009months%20and%2012.5%5Cu2009months%20respectively.%5CnCONCLUSION%3A%20Our%20current%20study%20shows%20that%20Bv%20used%20in%20combination%20with%20chemotherapy%20provides%20a%20high%20CRR%20and%20thereby%20allows%20SCT%20in%20R%5C%2FR%20PTCL.%20The%20use%20of%20Bv%20treatments%20in%20this%20setting%20warrants%20further%20investigation.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1078155220968615%22%2C%22ISSN%22%3A%221477-092X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A02%3A36Z%22%7D%7D%2C%7B%22key%22%3A%224DPRNVW5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laval%5Cu00e9e%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaval%26%23xE9%3Be%2C%20Margot%2C%20Nicolas%20Curdy%2C%20Camille%20Laurent%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20and%20Don-Marc%20Franchini.%20%26%23x201C%3BCancer%20Cell%20Adaptability%3A%20Turning%20Ribonucleoprotein%20Granules%20into%20Targets.%26%23x201D%3B%20%3Ci%3ETrends%20in%20Cancer%3C%5C%2Fi%3E%207%2C%20no.%2010%20%28October%202021%29%3A%20902%26%23x2013%3B15.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.trecan.2021.05.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.trecan.2021.05.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20cell%20adaptability%3A%20turning%20ribonucleoprotein%20granules%20into%20targets%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Laval%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Curdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%5D%2C%22abstractNote%22%3A%22Stress%20granules%20%28SGs%29%20and%20processing%20bodies%20%28P-bodies%29%20are%20membraneless%20cytoplasmic%20condensates%20of%20ribonucleoproteins%20%28RNPs%29.%20They%20both%20regulate%20RNA%20fate%20under%20physiological%20and%20pathological%20conditions%2C%20and%20are%20thereby%20involved%20in%20the%20regulation%20and%20maintenance%20of%20cellular%20integrity.%20During%20tumorigenesis%2C%20cancer%20cells%20use%20these%20granules%20to%20thrive%2C%20to%20adapt%20to%20the%20harsh%20conditions%20of%20the%20tumor%20microenvironment%20%28TME%29%2C%20and%20to%20protect%20themselves%20from%20anticancer%20treatments.%20This%20ability%20to%20provide%20multiple%20outcomes%20not%20only%20makes%20RNP%20granules%20promising%20targets%20for%20cancer%20therapy%20but%20also%20emphasizes%20the%20need%20for%20more%20knowledge%20about%20the%20biology%20of%20these%20granules%20to%20achieve%20clinical%20use.%20In%20this%20review%20we%20focus%20on%20the%20role%20of%20RNP%20granules%20in%20cancer%2C%20and%20on%20how%20their%20composition%20and%20regulation%20might%20be%20used%20to%20elaborate%20therapeutic%20strategies.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.trecan.2021.05.006%22%2C%22ISSN%22%3A%222405-8025%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A41%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22U6WPBU7P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Polivka%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPolivka%2C%20Laura%2C%20Veronique%20Parietti%2C%20Julie%20Bruneau%2C%20Erinn%20Soucie%2C%20Marine%20Madrange%2C%20Elisa%20Bayard%2C%20Rachel%20Rignault%2C%20et%20al.%20%26%23x201C%3BThe%20Association%20of%20Greig%20Syndrome%20and%20Mastocytosis%20Reveals%20the%20Involvement%20of%20Hedgehog%20Pathway%20in%20Advanced%20Mastocytosis.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%2C%20August%2023%2C%202021%2C%20blood.2020010207.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020010207%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020010207%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20association%20of%20Greig%20syndrome%20and%20mastocytosis%20reveals%20the%20involvement%20of%20hedgehog%20pathway%20in%20advanced%20mastocytosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Polivka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Parietti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bruneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erinn%22%2C%22lastName%22%3A%22Soucie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Madrange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Bayard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Rignault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danielle%22%2C%22lastName%22%3A%22Canioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Fraitag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22F%5Cu00e9roul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Tissandier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Rossignol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Frenzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Cagnard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%22%2C%22lastName%22%3A%22Meni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassiba%22%2C%22lastName%22%3A%22Bouktit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Florence%22%2C%22lastName%22%3A%22Collange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%22%2C%22lastName%22%3A%22Gougoula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Parisot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Bader-Meunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Livideanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Arock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smail%22%2C%22lastName%22%3A%22Hadj-Rabia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrich%22%2C%22lastName%22%3A%22R%5Cu00fcther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Dubreuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bodemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Hermine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Maouche-Chretien%22%7D%5D%2C%22abstractNote%22%3A%22Mastocytosis%20is%20a%20heterogeneous%20disease%20characterized%20by%20an%20abnormal%20accumulation%20of%20mast%20cells%20%28MCs%29%20in%20one%20or%20several%20organs.%20Although%20a%20somatic%20KIT%20D816V%20mutation%20is%20detected%20in%20~85%25%20of%20patients%2C%20attempts%20to%20demonstrate%20its%20oncogenic%20effect%20alone%20have%20repeatedly%20failed%2C%20suggesting%20that%20additional%20pathways%20are%20involved%20in%20MC%20transformation.%20From%20three%20children%20presenting%20with%20both%20Greig%20cephalopolysyndactyly%20syndrome%20%28GCPS%2C%20MIM%23175700%29%20and%20congenital%20mastocytosis%2C%20we%20demonstrated%20the%20involvement%20of%20the%20hedgehog%20%28Hh%29%20pathway%20in%20mastocytosis.%20GCPS%20is%20an%20extremely%20rare%20syndrome%20resulting%20from%20haploinsufficiency%20of%20GLI3%2C%20the%20major%20repressor%20of%20Hh%20family%20members.%20From%20these%20familial%20cases%20of%20mastocytosis%2C%20we%20demonstrate%20that%20the%20Hh%20pathway%20is%20barely%20active%20in%20normal%20primary%20MCs%20and%20overactive%20in%20neoplastic%20MCs.%20We%20show%20that%20GLI3%20and%20KIT%20mutations%20have%20a%20synergistic%2C%20tumorigenic%20effect%20on%20the%20onset%20of%20mastocytosis%20in%20a%20GCPS%20mouse%20model.%20Finally%2C%20we%20show%20that%20Hh%20inhibitors%20suppress%20neoplastic%20MC%20proliferation%20in%20vitro%20and%20extend%20the%20survival%20time%20of%20aggressive%20systemic%20mastocytosis%20%28ASM%29%20mice.%20This%20work%20revealed%2C%20for%20the%20first%20time%2C%20the%20involvement%20of%20Hh%20signaling%20in%20the%20pathophysiology%20of%20mastocytosis%20and%20demonstrated%20the%20cooperative%20effects%20of%20the%20KIT%20and%20Hh%20oncogenic%20pathways%20in%20ASM%2C%20leading%20to%20the%20identification%20of%20new%20promising%20therapeutic%20targets.%22%2C%22date%22%3A%222021-08-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2020010207%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A56%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22L5GMW8SB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franchet%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFranchet%2C%20Camille%2C%20Lounes%20Djerroudi%2C%20Aur%26%23xE9%3Blie%20Maran-Gonzalez%2C%20Olivia%20Abramovici%2C%20Martine%20Antoine%2C%20V%26%23xE9%3Bronique%20Becette%2C%20Anca%20Berghian%2C%20et%20al.%20%26%23x201C%3B%5B2021%26%23xA0%3Bupdate%20of%20the%20GEFPICS%26%23x2019%3B%20recommendations%20for%20HER2%26%23xA0%3Bstatus%20assessment%20in%20invasive%20breast%20cancer%20in%20France%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2C%20August%2012%2C%202021%2C%20S0242-6498%2821%2900191-7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2021.07.014%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2021.07.014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5B2021%5Cu00a0update%20of%20the%20GEFPICS%27%20recommendations%20for%20HER2%5Cu00a0status%20assessment%20in%20invasive%20breast%20cancer%20in%20France%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lounes%22%2C%22lastName%22%3A%22Djerroudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Maran-Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Abramovici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Antoine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Becette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anca%22%2C%22lastName%22%3A%22Berghian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Blanc-Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Brabencova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Charafe-Jauffret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Chenard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Dauplat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Delr%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00eblle%22%2C%22lastName%22%3A%22Duprez-Paumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Fleury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Ghnassia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Haudebourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Leroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebtan%22%2C%22lastName%22%3A%22MacGrogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Mathieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Michenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Penault-Llorca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Poulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%20Marie%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Roger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Russ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Tixier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Treilleux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Valent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Verriele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Vincent-Salomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Arnould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Lacroix-Triki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22pour%20le%20GEFPICS%22%7D%5D%2C%22abstractNote%22%3A%22The%20last%20international%20guidelines%20on%20HER2%20determination%20in%20breast%20cancer%20have%20been%20updated%20in%202018%20by%20the%20American%20Society%20of%20Clinical%20Oncology%20and%20College%20of%20American%20Pathologists%2C%20on%20the%20basis%20of%20a%20twenty-year%20practice%20and%20results%20of%20numerous%20clinical%20trials.%20Moreover%2C%20the%20emerging%20HER2-low%20concept%20for%201%2B%20and%202%2B%20non%20amplified%20breast%20cancers%20lead%20to%20refine%20French%20practices%20for%20HER2%20status%20assessment.%20The%20GEFPICS%20group%2C%20composed%20of%20expert%20pathologists%2C%20herein%20presents%20the%20latest%20French%20recommendations%20for%20HER2%20status%20evaluation%20in%20breast%20cancer%2C%20taking%20into%20account%20the%20ASCO%5C%2FCAP%20guidelines%20and%20introducing%20the%20HER2-low%20concept.%20In%20the%20era%20of%20personalized%20medicine%2C%20HER2%20status%20assessment%20remains%20one%20of%20the%20most%20important%20biomarkers%20in%20breast%20cancer%20and%20its%20quality%20guaranties%20the%20optimal%20patients%27%20care.%20French%20pathologists%27%20commitment%20in%20theranostic%20biomarker%20quality%20is%20more%20than%20ever%20required%20to%20provide%20the%20most%20efficient%20cares%20in%20oncology.%22%2C%22date%22%3A%222021-08-12%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2021.07.014%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A54%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22TBR6Q7DE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bezombes%20and%20P%5Cu00e9rez-Gal%5Cu00e1n%22%2C%22parsedDate%22%3A%222021-07-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBezombes%2C%20Christine%2C%20and%20Patricia%20P%26%23xE9%3Brez-Gal%26%23xE1%3Bn.%20%26%23x201C%3BImmunotherapies%20in%20Non-Hodgkin%26%23x2019%3Bs%20Lymphoma.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%2014%20%28July%2020%2C%202021%29%3A%203625.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13143625%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13143625%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immunotherapies%20in%20Non-Hodgkin%27s%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Gal%5Cu00e1n%22%7D%5D%2C%22abstractNote%22%3A%22Immune-based%20therapies%20mobilize%20the%20immune%20system%20to%20promote%20or%20restore%20an%20effective%20antitumor%20immune%20response%20%5B...%5D.%22%2C%22date%22%3A%222021-07-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13143625%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-17T15%3A53%3A29Z%22%7D%7D%2C%7B%22key%22%3A%227BQ8M6UL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20Sarah%20P%26%23xE9%3Bricart%2C%20Claire%20Lamaison%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Escudi%26%23xE9%3B%2C%20Pierre%20Brousset%2C%20and%20Camille%20Laurent.%20%26%23x201C%3BEpstein-Barr%20Virus-Associated%20T-%20and%20NK-Cell%20Lymphoproliferative%20Diseases%3A%20A%20Review%20of%20Clinical%20and%20Pathological%20Features.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%2013%20%28July%201%2C%202021%29%3A%203315.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13133315%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13133315%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epstein-Barr%20Virus-Associated%20T-%20and%20NK-Cell%20Lymphoproliferative%20Diseases%3A%20A%20Review%20of%20Clinical%20and%20Pathological%20Features%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Lamaison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Escudi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22Epstein-Barr%20virus%20%28EBV%29%20is%20a%20ubiquitous%20virus%20detected%20in%20up%20to%2095%25%20of%20the%20general%20population.%20Most%20people%20are%20asymptomatic%2C%20while%20some%20may%20develop%20a%20wide%20range%20of%20EBV-associated%20lymphoproliferative%20disorders%20%28LPD%29.%20Among%20them%2C%20EBV-positive%20T%5C%2FNK%20LPD%20are%20uncommon%20diseases%20defined%20by%20the%20proliferation%20of%20T-%20or%20NK-cells%20infected%20by%20EBV.%20The%202017%20World%20Health%20Organization%20%28WHO%29%20classification%20recognizes%20the%20following%20entities%20characterized%20by%20different%20outcomes%3A%20chronic%20active%20EBV%20infection%20of%20T-%20or%20NK-cell%20types%20%28cutaneous%20and%20systemic%20forms%29%2C%20systemic%20EBV-positive%20T-cell%20lymphoma%20of%20childhood%2C%20EBV-positive%20aggressive%20NK-cell%20leukemia%2C%20extra%20nodal%20NK%5C%2FT-cell%20lymphoma%20nasal%20type%2C%20and%20the%20new%20provisional%20entity%20known%20as%20primary%20EBV-positive%20nodal%20T%5C%2FNK-cell%20lymphoma.%20In%20addition%2C%20EBV%20associated-hemophagocytic%20lymphohistiocytosis%20is%20part%20of%20EBV-positive%20T%5C%2FNK%20LPD%2C%20but%20has%20not%20been%20included%20in%20the%20WHO%20classification%20due%20to%20its%20reactive%20nature.%20Despite%20novel%20insights%20from%20high-throughput%20molecular%20studies%2C%20EBV-positive%20NK%5C%2FT-cell%20LPD%20diagnoses%20remain%20challenging%2C%20especially%20because%20of%20their%20rarity%20and%20overlap.%20Until%20now%2C%20an%20accurate%20EBV-positive%20NK%5C%2FT%20LPD%20diagnosis%20has%20been%20based%20on%20its%20clinical%20presentation%20and%20course%20correlated%20with%20its%20histological%20features.%20This%20review%20aims%20to%20summarize%20clinical%2C%20pathological%20and%20molecular%20features%20of%20EBV-positive%20T%5C%2FNK%20LPD%20subtypes%20and%20to%20provide%20an%20overview%20of%20new%20understandings%20regarding%20these%20rare%20disorders.%22%2C%22date%22%3A%222021-07-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13133315%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A48%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22EMCUDVLJ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laplagne%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-28%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaplagne%2C%20Chlo%26%23xE9%3B%2C%20Laetitia%20Ligat%2C%20Juliet%20Foote%2C%20Frederic%20Lopez%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Camille%20Laurent%2C%20Salvatore%20Valitutti%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BSelf-Activation%20of%20V%26%23x3B3%3B9V%26%23x3B4%3B2%20T%20Cells%20by%20Exogenous%20Phosphoantigens%20Involves%20TCR%20and%20Butyrophilins.%26%23x201D%3B%20%3Ci%3ECellular%20%26amp%3B%20Molecular%20Immunology%3C%5C%2Fi%3E%2C%20June%2028%2C%202021.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41423-021-00720-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41423-021-00720-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Self-activation%20of%20V%5Cu03b39V%5Cu03b42%20T%20cells%20by%20exogenous%20phosphoantigens%20involves%20TCR%20and%20butyrophilins%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Laplagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliet%22%2C%22lastName%22%3A%22Foote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salvatore%22%2C%22lastName%22%3A%22Valitutti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22The%20high%20cytotoxic%20activity%20of%20V%5Cu03b39V%5Cu03b42%20T%20lymphocytes%20against%20tumor%20cells%20makes%20them%20useful%20candidates%20in%20anticancer%20therapies.%20However%2C%20the%20molecular%20mechanism%20of%20their%20activation%20by%20phosphoantigens%20%28PAgs%29%20is%20not%20completely%20known.%20Many%20studies%20have%20depicted%20the%20mechanism%20of%20V%5Cu03b39V%5Cu03b42%20T-cell%20activation%20by%20PAg-sensed%20accessory%20cells%2C%20such%20as%20immune%20presenting%20cells%20or%20tumor%20cells.%20In%20this%20study%2C%20we%20demonstrated%20that%20pure%20resting%20V%5Cu03b39V%5Cu03b42%20T%20lymphocytes%20can%20self-activate%20through%20exogenous%20PAgs%2C%20involving%20their%20TCR%20and%20the%20butyrophilins%20BTN3A1%20and%20BTN2A1.%20This%20is%20the%20first%20time%20that%20these%20three%20molecules%2C%20concurrently%20expressed%20at%20the%20plasma%20membrane%20of%20V%5Cu03b39V%5Cu03b42%20T%20cells%2C%20have%20been%20shown%20to%20be%20involved%20together%20on%20the%20same%20and%20unique%20T%20cell%20during%20PAg%20activation.%20Moreover%2C%20the%20use%20of%20probucol%20to%20stimulate%20the%20inhibition%20of%20this%20self-activation%20prompted%20us%20to%20propose%20that%20ABCA-1%20could%20be%20implicated%20in%20the%20transfer%20of%20exogenous%20PAgs%20inside%20V%5Cu03b39V%5Cu03b42%20T%20cells%20before%20activating%20them%20through%20membrane%20clusters%20formed%20by%20%5Cu03b39TCR%2C%20BTN3A1%20and%20BTN2A1.%20The%20self-activation%20of%20V%5Cu03b39V%5Cu03b42%20T%20cells%2C%20which%20leads%20to%20self-killing%2C%20can%20therefore%20participate%20in%20the%20failure%20of%20%5Cu03b3%5Cu03b4%20T%20cell-based%20therapies%20with%20exogenous%20PAgs%20and%20should%20be%20taken%20into%20account.%22%2C%22date%22%3A%222021-06-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41423-021-00720-w%22%2C%22ISSN%22%3A%222042-0226%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22UNNZZUAJ%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A10%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22ASEHR4MC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Sarah%20P%26%23xE9%3Bricart%2C%20Sol%26%23xE8%3Bne%20M.%20Evrard%2C%20Fabienne%20Meggetto%2C%20Salim%20Kanoun%2C%20Pierre%20Brousset%2C%20and%20Camille%20Laurent.%20%26%23x201C%3BALK-Positive%20Histiocytosis%20Associated%20with%20Chronic%20Lymphocytic%20Leukaemia%5C%2FSmall%20Lymphocytic%20Lymphoma%3A%20A%20Multitarget%20Response%20under%20Ibrutinib.%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%20478%2C%20no.%204%20%28April%202021%29%3A%20779%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-020-02937-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-020-02937-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ALK-positive%20histiocytosis%20associated%20with%20chronic%20lymphocytic%20leukaemia%5C%2Fsmall%20lymphocytic%20lymphoma%3A%20a%20multitarget%20response%20under%20ibrutinib%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%20M.%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Meggetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22ALK-positive%20histiocytosis%20is%20a%20recently%20described%20entity%20with%20few%20reported%20cases%20in%20literature.%20Herein%2C%20we%20report%20an%20unusual%20case%20of%20ALK-positive%20histiocytosis%20showing%20an%20Erdheim-Chester%20disease%20%28ECD%29-like%20presentation%2C%20occurring%20in%20a%2037-year-old%20woman%20with%20a%202-year%20history%20of%20chronic%20lymphocytic%20leukaemia%20%28CLL%29.%20Our%20CLL%20patient%20relapsed%206%5Cu00a0months%20after%20the%20end%20of%20fludarabine%2C%20cyclophosphamide%20and%20rituximab%20frontline%20therapy%20and%20complained%20of%20lower%20limb%20pains.%20A%20bone%20marrow%20biopsy%20was%20performed%20and%20showed%20concomitant%20CLL%5C%2Fsmall%20lymphocytic%20lymphoma%20and%20ALK-positive%20histiocytosis%20with%20an%20identical%20immunoglobulin%20heavy-chain%20gene%20rearrangement%20in%20both%20neoplasms%2C%20suggesting%20clonal%20relationship.%20After%204%5Cu00a0years%20under%20ibrutinib%20therapy%2C%20our%20patient%20remains%20free%20of%20both%20diseases.%20This%20report%20extends%20the%20spectrum%20of%20composite%20hematolymphoid%20neoplasms%20and%20shows%20that%20ALK%20rearrangement%20should%20be%20considered%20in%20all%20histiocytosis%20subtypes.%20Moreover%2C%20both%20tumours%20eradication%20under%20ibrutinib%20suggests%20that%20BTK%20inhibitors%20may%20also%20be%20effective%20in%20histiocytic%20neoplasms.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-020-02937-y%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22VDZ48X5N%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A51%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22SLHNI5AW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bommier%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBommier%2C%20C%26%23xF4%3Bme%2C%20Claire%20Mauduit%2C%20Juliette%20Fontaine%2C%20Estelle%20Bourbon%2C%20Pierre%20Sujobert%2C%20Sarah%20Huet%2C%20Lucile%20Baseggio%2C%20et%20al.%20%26%23x201C%3BReal-Life%20Targeted%20next-Generation%20Sequencing%20for%20Lymphoma%20Diagnosis%20over%201%26%23xA0%3BYear%20from%20the%20French%20Lymphoma%20Network.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Haematology%3C%5C%2Fi%3E%2C%20March%2025%2C%202021.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.17395%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.17395%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-life%20targeted%20next-generation%20sequencing%20for%20lymphoma%20diagnosis%20over%201%5Cu00a0year%20from%20the%20French%20Lymphoma%20Network%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00f4me%22%2C%22lastName%22%3A%22Bommier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Bourbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sujobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Huet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Baseggio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Hayette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%5D%2C%22abstractNote%22%3A%22As%20the%20impact%20of%20targeted%20next-generation%20sequencing%20%28TNGS%29%20on%20daily%20diagnosis%20has%20not%20been%20evaluated%2C%20we%20performed%20TNGS%20%2846%20genes%29%20on%20lymphomas%20of%20unclear%20subtype%20following%20expert%20haematopathological%20review.%20The%20potential%20impact%20on%20patient%20care%20and%20modifications%20of%20final%20diagnosis%20were%20divided%20into%20major%20and%20minor%20changes%20according%20to%20the%20European%20Society%20of%20Medical%20Oncology%20%28ESMO%29%20guidelines.%20Among%20229%20patients%20%5B19%20primary%20central%20nervous%20system%20lymphomas%20%28PCNSL%29%2C%2048%20large%20B-cell%20lymphomas%20%28LBCLs%29%2C%2089%20small%20BCLs%20%28SBCLs%29%2C%20seven%20Hodgkin%20lymphomas%20%28HL%29%2C%2066%20T-cell%20lymphomas%5D%2C%20the%20overall%20concordance%20rate%20of%20histological%20and%20TNGS%20diagnosis%20was%2089%5Cu00b75%25.%20TNGS%20confirmed%20the%20histological%20diagnosis%20in%20144%20cases%20%2862%5Cu00b79%25%29%2C%20changed%20the%20diagnosis%20in%2024%20cases%20%2810%5Cu00b75%25%29%20and%20did%20not%20help%20to%20clarify%20diagnosis%20in%2061%20cases%20%2826%5Cu00b77%25%29.%20Modifications%20to%20the%20final%20diagnosis%20had%20a%20clinical%20impact%20on%20patient%20care%20in%208%5Cu00b73%25%20of%20cases.%20Diagnostic%20modifications%20occurred%20in%20all%20types%20of%20lymphoma%20except%20in%20PCNSL%20and%20HL%3B%20the%20modification%20rate%20was%2014%5Cu00b76%25%20in%20SBCL%20and%2012%5Cu00b75%25%20in%20LBCL.%20While%20comparing%20informative%20and%20uninformative%20cases%2C%20no%20differences%20were%20found%20in%20terms%20of%20DNA%20amplification%2C%20quality%20or%20depth%20of%20sequencing%20and%20biopsy%20type.%20The%20present%20study%20highlights%20that%20TNGS%20may%20directly%20contribute%20to%20a%20more%20accurate%20diagnosis%20in%20difficult-to-diagnose%20lymphomas%2C%20thus%20improving%20the%20clinical%20management%20in%20routine%20practice.%22%2C%22date%22%3A%222021-03-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbjh.17395%22%2C%22ISSN%22%3A%221365-2141%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A24%3A40Z%22%7D%7D%2C%7B%22key%22%3A%229E3XBVNW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gava%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGava%2C%20Fabien%2C%20Carla%20Faria%2C%20Pauline%20Gravelle%2C%20Juan%20G.%20Valero%2C%20C%26%23xE8%3Blia%20Doba%26%23xF1%3Bo-L%26%23xF3%3Bpez%2C%20Renaud%20Morin%2C%20Marine%20Norlund%2C%20et%20al.%20%26%23x201C%3B3D%20Model%20Characterization%20by%202D%20and%203D%20Imaging%20in%20t%2814%3B18%29-Positive%20B-NHL%3A%20Perspectives%20for%20In%20Vitro%20Drug%20Screens%20in%20Follicular%20Lymphoma.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%207%20%28March%2024%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13071490%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13071490%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%223D%20Model%20Characterization%20by%202D%20and%203D%20Imaging%20in%20t%2814%3B18%29-Positive%20B-NHL%3A%20Perspectives%20for%20In%20Vitro%20Drug%20Screens%20in%20Follicular%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Gava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carla%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e8lia%22%2C%22lastName%22%3A%22Doba%5Cu00f1o-L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Norlund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bordenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Pieruccioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Rouquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alba%22%2C%22lastName%22%3A%22Matas-C%5Cu00e9spedes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Gal%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20is%20an%20indolent%20B%20cell%20lymphoproliferative%20disorder%20of%20transformed%20follicular%20center%20B%20cells%2C%20which%20accounts%20for%2020-30%20percent%20of%20all%20non-Hodgkin%20lymphoma%20%28NHL%29%20cases.%20Great%20advances%20have%20been%20made%20to%20identify%20the%20most%20relevant%20targets%20for%20precision%20therapy.%20However%2C%20no%20relevant%20models%20for%20in%20vitro%20studies%20have%20been%20developed%20or%20characterized%20in%20depth.%20To%20this%20purpose%2C%20we%20generated%20a%203D%20cell%20model%20from%20t%2814%3B18%29-positive%20B-NHL%20cell%20lines%20cultured%20in%20ultra-low%20attachment%2096-well%20plates.%20Morphological%20features%20and%20cell%20growth%20behavior%20were%20evaluated%20by%20classical%20microscopy%20%282D%20imaging%29%20and%20response%20to%20treatment%20with%20different%20drugs%20was%20evaluated%20by%20a%20high-content%20analysis%20system%20to%20determine%20the%20robustness%20of%20the%20model.%20We%20show%20that%20the%20ultra-low%20attachment%20%28ULA%29%20method%20allows%20the%20development%20of%20regular%2C%20spherical%20and%20viable%20ULA-multicellular%20aggregates%20of%20lymphoma%20cells%20%28MALC%29.%20However%2C%20discrepancies%20in%20the%20results%20obtained%20after%202D%20imaging%20analyses%20on%20drug-treated%20ULA-MALC%20prompted%20us%20to%20develop%203D%20imaging%20and%20specific%20analyses.%20We%20show%20by%20using%20light%20sheet%20microscopy%20and%20specifically%20developed%203D%20imaging%20algorithms%20that%203D%20imaging%20and%20dedicated%20analyses%20are%20necessary%20to%20characterize%20morphological%20properties%20of%203D%20models%20and%20drug%20effects.%20This%20study%20proposes%20a%20new%20method%2C%20but%20also%20imaging%20tools%20and%20informatic%20solutions%2C%20developed%20for%20FL%20necessary%20for%20future%20preclinical%20studies.%22%2C%22date%22%3A%222021-03-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13071490%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A36%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22RXZ7LHVS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cerapio%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECerapio%2C%20Juan%20Pablo%2C%20Agn%26%23xE8%3Bs%20Marchio%2C%20Luis%20Cano%2C%20Ignacio%20L%26%23xF3%3Bpez%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20B%26%23xE9%3Batrice%20R%26%23xE9%3Bgnault%2C%20Sandro%20Casavilca-Zambrano%2C%20et%20al.%20%26%23x201C%3BGlobal%20DNA%20Hypermethylation%20Pattern%20and%20Unique%20Gene%20Expression%20Signature%20in%20Liver%20Cancer%20from%20Patients%20with%20Indigenous%20American%20Ancestry.%26%23x201D%3B%20%3Ci%3EOncotarget%3C%5C%2Fi%3E%2012%2C%20no.%205%20%28March%202%2C%202021%29%3A%20475%26%23x2013%3B92.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.18632%5C%2Foncotarget.27890%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.18632%5C%2Foncotarget.27890%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20DNA%20hypermethylation%20pattern%20and%20unique%20gene%20expression%20signature%20in%20liver%20cancer%20from%20patients%20with%20Indigenous%20American%20ancestry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Marchio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Cano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22R%5Cu00e9gnault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandro%22%2C%22lastName%22%3A%22Casavilca-Zambrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eloy%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Dejean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Bertani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Pineau%22%7D%5D%2C%22abstractNote%22%3A%22Hepatocellular%20carcinoma%20%28HCC%29%20usually%20afflicts%20individuals%20in%20their%20maturity%20after%20a%20protracted%20liver%20disease.%20Contrasting%20with%20this%20pattern%2C%20the%20age%20structure%20of%20HCC%20in%20Andean%20people%20displays%20a%20bimodal%20distribution%20with%20half%20of%20the%20patients%20developing%20HCC%20in%20adolescence%20and%20early%20adulthood.%20To%20deepen%20our%20understanding%20of%20the%20molecular%20determinants%20of%20the%20disease%20in%20this%20population%2C%20we%20conducted%20an%20integrative%20analysis%20of%20gene%20expression%20and%20DNA%20methylation%20in%20HCC%20developed%20by%2074%20Peruvian%20patients%2C%20including%2039%20adolescents%20and%20young%20adults.%20While%20genome-wide%20hypomethylation%20is%20considered%20as%20a%20paradigm%20in%20human%20HCCs%2C%20our%20analysis%20revealed%20that%20Peruvian%20tumors%20are%20associated%20with%20a%20global%20DNA%20hypermethylation.%20Moreover%2C%20pathway%20enrichment%20analysis%20of%20transcriptome%20data%20characterized%20an%20original%20combination%20of%20signatures.%20Peruvian%20HCC%20forgoes%20canonical%20activations%20of%20IGF2%2C%20Notch%2C%20Ras%5C%2FMAPK%2C%20and%20TGF-%5Cu03b2%20signals%20to%20depend%20instead%20on%20Hippo%5C%2FYAP1%2C%20MYC%2C%20and%20Wnt%5C%2F%5Cu03b2-catenin%20pathways.%20These%20signatures%20delineate%20a%20homogeneous%20subtype%20of%20liver%20tumors%20at%20the%20interface%20of%20the%20proliferative%20and%20non-proliferative%20classes%20of%20HCCs.%20Remarkably%2C%20the%20development%20of%20this%20HCC%20subtype%20occurs%20in%20patients%20with%20one%20of%20the%20four%20Native%20American%20mitochondrial%20haplogroups%20A-D.%20Finally%2C%20integrative%20characterization%20revealed%20that%20Peruvian%20HCC%20is%20apparently%20controlled%20by%20the%20PRC2%20complex%20that%20mediates%20cell%20reprogramming%20with%20massive%20DNA%20methylation%20modulating%20gene%20expression%20and%20pinpointed%20retinoid%20signaling%20as%20a%20potential%20target%20for%20epigenetic%20therapy.%22%2C%22date%22%3A%222021-03-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.18632%5C%2Foncotarget.27890%22%2C%22ISSN%22%3A%221949-2553%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A49%3A29Z%22%7D%7D%2C%7B%22key%22%3A%226I3Q8DZS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ghesqui%5Cu00e8res%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGhesqui%26%23xE8%3Bres%2C%20Herv%26%23xE9%3B%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20Fanny%20Cherblanc%2C%20Sandra%20Le%20Guyader-Peyrou%2C%20Fontanet%20Bijou%2C%20Pierre%20Sujobert%2C%20Pascale%20Fabbro-Peray%2C%20et%20al.%20%26%23x201C%3BA%20French%20Multicentric%20Prospective%20Prognostic%20Cohort%20with%20Epidemiological%2C%20Clinical%2C%20Biological%20and%20Treatment%20Information%20to%20Improve%20Knowledge%20on%20Lymphoma%20Patients%3A%20Study%20Protocol%20of%20the%20%26%23x2018%3BREal%20World%20DAta%20in%20LYmphoma%20and%20Survival%20in%20Adults%26%23x2019%3B%20%28REALYSA%29%20Cohort.%26%23x201D%3B%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2021%2C%20no.%201%20%28March%202%2C%202021%29%3A%20432.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10433-4%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10433-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20French%20multicentric%20prospective%20prognostic%20cohort%20with%20epidemiological%2C%20clinical%2C%20biological%20and%20treatment%20information%20to%20improve%20knowledge%20on%20lymphoma%20patients%3A%20study%20protocol%20of%20the%20%5C%22REal%20world%20dAta%20in%20LYmphoma%20and%20survival%20in%20adults%5C%22%20%28REALYSA%29%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Cherblanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Le%20Guyader-Peyrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fontanet%22%2C%22lastName%22%3A%22Bijou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sujobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Fabbro-Peray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Bernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Belot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Chartier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc-Matthieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Baldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krimo%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Morineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Le%20Gouill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Morschhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Haioun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gandhi%22%2C%22lastName%22%3A%22Damaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guidez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Labour%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fitoussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Lebras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Gressin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Monnereau%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Age-adjusted%20lymphoma%20incidence%20rates%20continue%20to%20rise%20in%20France%20since%20the%20early%2080%27s%2C%20although%20rates%20have%20slowed%20since%202010%20and%20vary%20across%20subtypes.%20Recent%20improvements%20in%20patient%20survival%20in%20major%20lymphoma%20subtypes%20at%20population%20level%20raise%20new%20questions%20about%20patient%20outcomes%20%28i.e.%20quality%20of%20life%2C%20long-term%20sequelae%29.%20Epidemiological%20studies%20have%20investigated%20factors%20related%20to%20lymphoma%20risk%2C%20but%20few%20have%20addressed%20the%20extent%20to%20which%20socioeconomic%20status%2C%20social%20institutional%20context%20%28i.e.%20healthcare%20system%29%2C%20social%20relationships%2C%20environmental%20context%20%28exposures%29%2C%20individual%20behaviours%20%28lifestyle%29%20or%20genetic%20determinants%20influence%20lymphoma%20outcomes%2C%20especially%20in%20the%20general%20population.%20Moreover%2C%20the%20knowledge%20of%20the%20disease%20behaviour%20mainly%20obtained%20from%20clinical%20trials%20data%20is%20partly%20biased%20because%20of%20patient%20selection.%5CnMETHODS%3A%20The%20REALYSA%20%28%5C%22REal%20world%20dAta%20in%20LYmphoma%20and%20Survival%20in%20Adults%5C%22%29%20study%20is%20a%20real-life%20multicentric%20cohort%20set%20up%20in%20French%20areas%20covered%20by%20population-based%20cancer%20registries%20to%20study%20the%20prognostic%20value%20of%20epidemiological%2C%20clinical%20and%20biological%20factors%20with%20a%20prospective%209-year%20follow-up.%20We%20aim%20to%20include%206000%20patients%20over%204%20to%205%5Cu2009years.%20Adult%20patients%20without%20lymphoma%20history%20and%20newly%20diagnosed%20with%20one%20of%20the%20following%207%20lymphoma%20subtypes%20%28diffuse%20large%20B-cell%2C%20follicular%2C%20marginal%20zone%2C%20mantle%20cell%2C%20Burkitt%2C%20Hodgkin%2C%20mature%20T-cell%29%20are%20invited%20to%20participate%20during%20a%20medical%20consultation%20with%20their%20hematologist.%20Exclusion%20criteria%20are%3A%20having%20already%20received%20anti-lymphoma%20treatment%20%28except%20pre-phase%29%20and%20having%20a%20documented%20HIV%20infection.%20Patients%20are%20treated%20according%20to%20the%20standard%20practice%20in%20their%20center.%20Clinical%20data%2C%20including%20treatment%20received%2C%20are%20extracted%20from%20patients%27%20medical%20records.%20Patients%27%20risk%20factors%20exposures%20and%20other%20epidemiological%20data%20are%20obtained%20at%20baseline%20by%20filling%20out%20a%20questionnaire%20during%20an%20interview%20led%20by%20a%20clinical%20research%20assistant.%20Biological%20samples%20are%20collected%20at%20baseline%20and%20during%20treatment.%20A%20virtual%20tumor%20biobank%20is%20constituted%20for%20baseline%20tumor%20samples.%20Follow-up%20data%2C%20both%20clinical%20and%20epidemiological%2C%20are%20collected%20every%206%5Cu2009months%20in%20the%20first%203%5Cu2009years%20and%20every%20year%20thereafter.%5CnDISCUSSION%3A%20This%20cohort%20constitutes%20an%20innovative%20platform%20for%20clinical%2C%20biological%2C%20epidemiological%20and%20socio-economic%20research%20projects%20and%20provides%20an%20opportunity%20to%20improve%20knowledge%20on%20factors%20associated%20to%20outcome%20of%20lymphoma%20patients%20in%20real%20life.%5CnTRIAL%20REGISTRATION%3A%202018-A01332-53%2C%20ClinicalTrials.gov%20identifier%3A%20NCT03869619%20.%22%2C%22date%22%3A%222021-03-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-021-10433-4%22%2C%22ISSN%22%3A%221471-2458%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A38%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22HJ4DUV73%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poupot%22%2C%22parsedDate%22%3A%222021-02-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPoupot%2C%20Mary.%20%26%23x201C%3BWhy%20Target%20Innate%20Immune%20Cells%20in%20Cancers%3F%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%204%20%28February%209%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13040690%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13040690%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Why%20Target%20Innate%20Immune%20Cells%20in%20Cancers%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22The%20immune%20system%20is%20a%20smart%20way%20to%20fight%20cancer%2C%20with%20its%20precise%20targeting%20of%20cancer%20cells%20sparing%20healthy%20cells%20%5B...%5D.%22%2C%22date%22%3A%222021-02-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13040690%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A10%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22W2E6VEUE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Curdy%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECurdy%2C%20Nicolas%2C%20Olivia%20Lanvin%2C%20Sarah%20Cadot%2C%20Camille%20Laurent%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20and%20Don-Marc%20Franchini.%20%26%23x201C%3BStress%20Granules%20in%20the%20Post-Transcriptional%20Regulation%20of%20Immune%20Cells.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Cell%20and%20Developmental%20Biology%3C%5C%2Fi%3E%208%20%28February%202%2C%202021%29%3A%20611185.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcell.2020.611185%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcell.2020.611185%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stress%20Granules%20in%20the%20Post-transcriptional%20Regulation%20of%20Immune%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Curdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Cadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20cell%20activation%20triggers%20transcriptional%20and%20translational%20programs%20eliciting%20cellular%20processes%2C%20such%20as%20differentiation%20or%20proliferation%2C%20essential%20for%20an%20efficient%20immune%20response.%20These%20dynamic%20processes%20require%20an%20intricate%20orchestration%20of%20regulatory%20mechanisms%20to%20control%20the%20precise%20spatiotemporal%20expression%20of%20proteins.%20Post-transcriptional%20regulation%20ensures%20the%20control%20of%20messenger%20RNA%20metabolism%20and%20appropriate%20translation.%20Among%20these%20post-transcriptional%20regulatory%20mechanisms%2C%20stress%20granules%20participate%20in%20the%20control%20of%20protein%20synthesis.%20Stress%20granules%20are%20ribonucleoprotein%20complexes%20that%20form%20upon%20stress%2C%20typically%20under%20control%20of%20the%20integrated%20stress%20response.%20Such%20structures%20assemble%20upon%20stimulation%20of%20immune%20cells%20where%20they%20control%20selective%20translational%20programs%20ensuring%20the%20establishment%20of%20accurate%20effector%20functions.%20In%20this%20review%2C%20we%20summarize%20the%20current%20knowledge%20about%20post-transcriptional%20regulation%20in%20immune%20cells%20and%20highlight%20the%20role%20of%20stress%20sensors%20and%20stress%20granules%20in%20such%20regulation.%22%2C%22date%22%3A%2202%5C%2F02%5C%2F2021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcell.2020.611185%22%2C%22ISSN%22%3A%222296-634X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A53%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22GI99ZBA9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Burlet%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBurlet%2C%20B%26%23xE9%3Bn%26%23xE9%3Bdicte%2C%20Selim%20Ramla%2C%20Cyril%20Fournier%2C%20Maria%20Jimena%20Abrey-Recalde%2C%20Camille%20Sauter%2C%20Marie-Lorraine%20Chr%26%23xE9%3Btien%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20et%20al.%20%26%23x201C%3BIdentification%20of%20Novel%2C%20Clonally%20Stable%2C%20Somatic%20Mutations%20Targeting%20Transcription%20Factors%20PAX5%20and%20NKX2-3%2C%20the%20Epigenetic%20Regulator%20LRIF1%2C%20and%20BRAF%20in%20a%20Case%20of%20Atypical%20B-Cell%20Chronic%20Lymphocytic%20Leukemia%20Harboring%20a%20t%2814%3B18%29%28Q32%3BQ21%29.%26%23x201D%3B%20%3Ci%3ECold%20Spring%20Harbor%20Molecular%20Case%20Studies%3C%5C%2Fi%3E%207%2C%20no.%201%20%28February%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2Fmcs.a005934%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2Fmcs.a005934%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identification%20of%20novel%2C%20clonally%20stable%2C%20somatic%20mutations%20targeting%20transcription%20factors%20PAX5%20and%20NKX2-3%2C%20the%20epigenetic%20regulator%20LRIF1%2C%20and%20BRAF%20in%20a%20case%20of%20atypical%20B-cell%20chronic%20lymphocytic%20leukemia%20harboring%20a%20t%2814%3B18%29%28q32%3Bq21%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Burlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Selim%22%2C%22lastName%22%3A%22Ramla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Jimena%22%2C%22lastName%22%3A%22Abrey-Recalde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Sauter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Lorraine%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannis%22%2C%22lastName%22%3A%22Duffourd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Ragot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Buriller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Tournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Chapusot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Nadal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Racine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Guy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-No%5Cu00ebl%22%2C%22lastName%22%3A%22Bastie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Caillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Albuisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Broccardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Thieblemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Delva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Maynadi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Aucagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20B.%22%2C%22lastName%22%3A%22Callanan%22%7D%5D%2C%22abstractNote%22%3A%22Diagnosis%20of%20B-cell%20chronic%20lymphocytic%20leukemia%20%28B-CLL%29%20is%20usually%20straightforward%2C%20involving%20clinical%2C%20immunophenotypic%20%28Matutes%20score%29%2C%20and%20%28immuno%29genetic%20analyses%20%28to%20refine%20patient%20prognosis%20for%20treatment%29.%20CLL%20cases%20with%20atypical%20presentation%20%28e.g.%2C%20Matutes%20%5Cu2264%203%29%20are%20also%20encountered%2C%20and%20for%20these%20diseases%2C%20biology%20and%20prognostic%20impact%20are%20less%20clear.%20Here%20we%20report%20the%20genomic%20characterization%20of%20a%20case%20of%20atypical%20B-CLL%20in%20a%2070-yr-old%20male%20patient%3B%20B-CLL%20cells%20showed%20a%20Matutes%20score%20of%203%2C%20chromosomal%20translocation%20t%2814%3B18%29%28q32%3Bq21%29%20%28BCL2%5C%2FIGH%29%2C%20mutated%20IGHV%2C%20deletion%2017p%2C%20and%20mutations%20in%20BCL2%2C%20NOTCH1%20%28subclonal%29%2C%20and%20TP53%20%28subclonal%29.%20Quite%20strikingly%2C%20a%20novel%20PAX5%20mutation%20that%20was%20predicted%20to%20be%20loss%20of%20function%20was%20also%20seen.%20Exome%20sequencing%20identified%2C%20in%20addition%2C%20a%20potentially%20actionable%20BRAF%20mutation%2C%20together%20with%20novel%20somatic%20mutations%20affecting%20the%20homeobox%20transcription%20factor%20NKX2-3%2C%20known%20to%20control%20B-lymphocyte%20development%20and%20homing%2C%20and%20the%20epigenetic%20regulator%20LRIF1%2C%20which%20is%20implicated%20in%20chromatin%20compaction%20and%20gene%20silencing.%20Neither%20NKX2-3%20nor%20LRIF1%20mutations%2C%20predicted%20to%20be%20loss%20of%20function%2C%20have%20previously%20been%20reported%20in%20B-CLL.%20Sequencing%20confirmed%20the%20presence%20of%20these%20mutations%20together%20with%20BCL2%2C%20NOTCH1%2C%20and%20BRAF%20mutations%2C%20with%20the%20t%2814%3B18%29%28q32%3Bq21%29%20translocation%2C%20in%20the%20initial%20diagnostic%20sample%20obtained%2012%20yr%20prior.%20This%20is%20suggestive%20of%20a%20role%20for%20these%20novel%20mutations%20in%20B-CLL%20initiation%20and%20stable%20clonal%20evolution%2C%20including%20upon%20treatment%20withdrawal.%20This%20case%20extends%20the%20spectrum%20of%20atypical%20B-CLL%20with%20t%2814%3B18%29%28q32%3Bq21%29%20and%20highlights%20the%20value%20of%20more%20global%20precision%20genomics%20for%20patient%20follow-up%20and%20treatment%20in%20these%20patients.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2Fmcs.a005934%22%2C%22ISSN%22%3A%222373-2873%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A26%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22QPCESS3E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Quelen%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQuelen%2C%20Cathy%2C%20David%20Grand%2C%20Emeline%20Sarot%2C%20Laurence%20Brugi%26%23xE8%3Bres%2C%20David%20Sibon%2C%20Anne%20Pradines%2C%20Camille%20Laurent%2C%20Pierre%20Brousset%2C%20and%20Laurence%20Lamant.%20%26%23x201C%3BMinimal%20Residual%20Disease%20Monitoring%20Using%20a%203%26%23x2019%3BALK%20Universal%20Probe%20Assay%20in%20ALK-Positive%20Anaplastic%20Large-Cell%20Lymphoma%3A%20DdPCR%2C%20an%20Attractive%20Alternative%20Method%20to%20Real-Time%20Quantitative%20PCR.%26%23x201D%3B%20%3Ci%3EThe%20Journal%20of%20Molecular%20Diagnostics%3A%20JMD%3C%5C%2Fi%3E%2023%2C%20no.%202%20%28February%202021%29%3A%20131%26%23x2013%3B39.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jmoldx.2020.11.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jmoldx.2020.11.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Minimal%20Residual%20Disease%20Monitoring%20Using%20a%203%27ALK%20Universal%20Probe%20Assay%20in%20ALK-Positive%20Anaplastic%20Large-Cell%20Lymphoma%3A%20ddPCR%2C%20an%20Attractive%20Alternative%20Method%20to%20Real-Time%20Quantitative%20PCR%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%22%2C%22lastName%22%3A%22Quelen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Sibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Pradines%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%5D%2C%22abstractNote%22%3A%22In%20ALK-positive%20anaplastic%20large-cell%20lymphomas%2C%20positive%20qualitative%20PCR%20for%20NPM1-anaplastic%20lymphoma%20kinase%20%28ALK%29%20in%20peripheral%20blood%20and%5C%2For%20bone%20marrow%20at%20diagnosis%20and%20during%20treatment%20are%20associated%20with%20a%20higher%20risk%20of%20treatment%20failure.%20Real-time%20quantitative%20PCR%20allows%20identification%20of%20very%20high%20risk%20patients.%20However%2C%20this%20latter%20technique%20initially%20designed%20for%20patients%20with%20lymphomas%20carrying%20the%20most%20frequent%20NPM1-ALK%20translocation%20necessitates%20calibration%20curves%2C%20limiting%20interlaboratory%20reproducibility.%20An%20ALK%20universal%20quantitative%20PCR%20based%20on%203%27ALK%20transcript%20amplification%20was%20designed%20to%20allow%20the%20detection%20of%20all%20ALK%20fusion%20transcripts.%20The%20absolute%20concordance%20of%203%27ALK%20quantitative%20PCR%20results%20were%20validated%20with%20the%20routine%20NPM1-ALK%20qualitative%20and%20quantitative%20PCR%20on%2046%20samples.%20The%20universality%20of%20ALK%20fusion%20transcript%20detection%20also%20was%20validated%20on%20TPM3-%2C%20ALO17-%2C%20and%20ATIC-ALK-positive%20samples%2C%20and%20the%20EML4-ALK-positive%20cell%20line.%20Digital%20droplet%20PCR%20using%20the%203%27ALK%20universal%20probe%20showed%20highly%20concordant%20results%20with%203%27ALK%20universal%20quantitative%20PCR.%20A%20major%20benefit%20of%20digital%20droplet%20PCR%20is%20a%20reduced%20experimental%20set-up%20compared%20with%20quantitative%20PCR%2C%20without%20generation%20of%20standard%20curves%2C%20leading%20to%20a%20reliable%20protocol%20for%20multilaboratory%20validation%20in%20multicenter%20clinical%20trials%20essential%20for%20this%20rare%20pathology.%20Our%20ALK%20universal%20method%20could%20be%20used%20for%20the%20screening%20of%20ALK%20fusion%20transcripts%20in%20liquid%20biopsy%20specimens%20of%20other%20ALK-positive%20tumors%2C%20including%20non-small%20cell%20lung%20carcinomas.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jmoldx.2020.11.002%22%2C%22ISSN%22%3A%221943-7811%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A57%3A00Z%22%7D%7D%2C%7B%22key%22%3A%226WVH2A33%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Domagala%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDomagala%2C%20Marcin%2C%20Chlo%26%23xE9%3B%20Laplagne%2C%20Edouard%20Leveque%2C%20Camille%20Laurent%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Eric%20Espinosa%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BCancer%20Cells%20Resistance%20Shaping%20by%20Tumor%20Infiltrating%20Myeloid%20Cells.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%202%20%28January%206%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13020165%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13020165%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20Cells%20Resistance%20Shaping%20by%20Tumor%20Infiltrating%20Myeloid%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Laplagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Leveque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Espinosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22Interactions%20between%20malignant%20cells%20and%20neighboring%20stromal%20and%20immune%20cells%20profoundly%20shape%20cancer%20progression.%20New%20forms%20of%20therapies%20targeting%20these%20cells%20have%20revolutionized%20the%20treatment%20of%20cancer.%20However%2C%20in%20order%20to%20specifically%20address%20each%20population%2C%20it%20was%20essential%20to%20identify%20and%20understand%20their%20individual%20roles%20in%20interaction%20between%20malignant%20cells%2C%20and%20the%20formation%20of%20the%20tumor%20microenvironment%20%28TME%29.%20In%20this%20review%2C%20we%20focus%20on%20the%20myeloid%20cell%20compartment%2C%20a%20prominent%2C%20and%20heterogeneous%20group%20populating%20TME%2C%20which%20can%20initially%20exert%20an%20anti-tumoral%20effect%2C%20but%20with%20time%20actively%20participate%20in%20disease%20progression.%20Macrophages%2C%20dendritic%20cells%2C%20neutrophils%2C%20myeloid-derived%20suppressor%20cells%2C%20mast%20cells%2C%20eosinophils%2C%20and%20basophils%20act%20alone%20or%20in%20concert%20to%20shape%20tumor%20cells%20resistance%20through%20cellular%20interaction%20and%5C%2For%20release%20of%20soluble%20factors%20favoring%20survival%2C%20proliferation%2C%20and%20migration%20of%20tumor%20cells%2C%20but%20also%20immune-escape%20and%20therapy%20resistance.%22%2C%22date%22%3A%222021-01-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13020165%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A55%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22UV5Q4HZY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cerapio%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECerapio%2C%20Juan-Pablo%2C%20Marion%20Perrier%2C%20Camille-Charlotte%20Balan%26%23xE7%3Ba%2C%20Pauline%20Gravelle%2C%20Fr%26%23xE9%3Bderic%20Pont%2C%20Christel%20Devaud%2C%20Don-Marc%20Franchini%2C%20et%20al.%20%26%23x201C%3BPhased%20Differentiation%20of%20%26%23x393%3B%26%23x3B4%3B%20T%20and%20T%20CD8%20Tumor-Infiltrating%20Lymphocytes%20Revealed%20by%20Single-Cell%20Transcriptomics%20of%20Human%20Cancers.%26%23x201D%3B%20%3Ci%3EOncoimmunology%3C%5C%2Fi%3E%2010%2C%20no.%201%20%282021%29%3A%201939518.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2021.1939518%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2021.1939518%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phased%20differentiation%20of%20%5Cu03b3%5Cu03b4%20T%20and%20T%20CD8%20tumor-infiltrating%20lymphocytes%20revealed%20by%20single-cell%20transcriptomics%20of%20human%20cancers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan-Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22F%5Cu00e9liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fournie%22%7D%5D%2C%22abstractNote%22%3A%22%5Cu03b3%5Cu03b4%20T%20lymphocytes%20diverge%20from%20conventional%20T%20CD8%20lymphocytes%20for%20ontogeny%2C%20homing%2C%20and%20antigen%20specificity%2C%20but%20whether%20their%20differentiation%20in%20tumors%20also%20deviates%20was%20unknown.%20Using%20innovative%20analyses%20of%20our%20original%20and%20~150%20published%20single-cell%20RNA%20sequencing%20datasets%20validated%20by%20phenotyping%20of%20human%20tumors%20and%20murine%20models%2C%20here%20we%20present%20the%20first%20high-resolution%20view%20of%20human%20%5Cu03b3%5Cu03b4%20T%20cell%20differentiation%20in%20cancer.%20While%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20prominently%20encompass%20TCRV%5Cu03b39%20cells%20more%20differentiated%20than%20T%20CD8%20in%20healthy%20donor%27s%20blood%2C%20a%20different%20scenario%20is%20unveiled%20in%20tumors.%20Solid%20tumors%20and%20lymphomas%20are%20infiltrated%20by%20a%20majority%20of%20TCRV%5Cu03b3non9%20%5Cu03b3%5Cu03b4%20T%20cells%20which%20are%20quantitatively%20correlated%20and%20remarkably%20aligned%20with%20T%20CD8%20for%20differentiation%2C%20exhaustion%2C%20gene%20expression%20profile%2C%20and%20response%20to%20immune%20checkpoint%20therapy.%20This%20cancer-wide%20association%20is%20critical%20for%20developing%20cancer%20immunotherapies.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2021.1939518%22%2C%22ISSN%22%3A%222162-402X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A29%3A22Z%22%7D%7D%2C%7B%22key%22%3A%2242XYGNIA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ysebaert%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EYsebaert%2C%20Loic%2C%20Anne%20Quillet-Mary%2C%20Marie%20Tosolini%2C%20Frederic%20Pont%2C%20Camille%20Laurent%2C%20and%20Jean-Jacques%20Fourni%26%23xE9%3B.%20%26%23x201C%3BLymphoma%20Heterogeneity%20Unraveled%20by%20Single-Cell%20Transcriptomics.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2012%20%282021%29%3A%20597651.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.597651%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.597651%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lymphoma%20Heterogeneity%20Unraveled%20by%20Single-Cell%20Transcriptomics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22High-definition%20transcriptomic%20studies%20through%20single-cell%20RNA%20sequencing%20%28scRNA-Seq%29%20have%20revealed%20the%20heterogeneity%20and%20functionality%20of%20the%20various%20microenvironments%20across%20numerous%20solid%20tumors.%20Those%20pioneer%20studies%20have%20highlighted%20different%20cellular%20signatures%20correlated%20with%20clinical%20response%20to%20immune%20checkpoint%20inhibitors.%20scRNA-Seq%20offers%20also%20a%20unique%20opportunity%20to%20unravel%20the%20intimate%20heterogeneity%20of%20the%20ecosystems%20across%20different%20lymphoma%20entities.%20In%20this%20review%2C%20we%20will%20first%20cover%20the%20basics%20and%20future%20developments%20of%20the%20technology%2C%20and%20we%20will%20discuss%20its%20input%20in%20the%20field%20of%20translational%20lymphoma%20research%2C%20from%20determination%20of%20cell-of-origin%20and%20functional%20diversity%2C%20to%20monitoring%20of%20anti-cancer%20targeted%20drugs%20response%20and%20toxicities%2C%20and%20how%20new%20improvements%20in%20both%20data%20collection%20and%20interpretation%20will%20further%20foster%20precision%20medicine%20in%20the%20upcoming%20years.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2021.597651%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A22%3A11Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Domagala, Marcin, Loïc Ysebaert, Laetitia Ligat, Frederic Lopez, Jean-Jacques Fournié, Camille Laurent, and Mary Poupot. “IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells.” Cancers<\/i> 14, no. 1 (December 21, 2021): 16. https:\/\/doi.org\/10.3390\/cancers14010016<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lapierre, Leopoldine, Sarah Pericart, Caroline Protin, Cecile Borel, Loic Ysebaert, Camille Laurent, and Lucie Oberic. “Nivolumab in Refractory Cerebral Relapse of Hodgkin’s Lymphoma.” Leukemia & Lymphoma<\/i> 62, no. 12 (December 2021): 3063–65. https:\/\/doi.org\/10.1080\/10428194.2021.1950711<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Syrykh, Charlotte, Pauline Gorez, Sarah Péricart, David Grand, Frédéric Escudié, Bastien Cabarrou, Lucie Obéric, et al. “Molecular Diagnosis of T-Cell Lymphoma: A Correlative Study of PCR-Based T-Cell Clonality Assessment and Targeted NGS.” Blood Advances<\/i> 5, no. 22 (November 23, 2021): 4590–93. https:\/\/doi.org\/10.1182\/bloodadvances.2021005249<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cerapio, Juan Pablo, Marion Perrier, Fréderic Pont, Marie Tosolini, Camille Laurent, Stéphane Bertani, and Jean-Jacques Fournie. “Single-Cell RNAseq Profiling of Human Γδ T Lymphocytes in Virus-Related Cancers and COVID-19 Disease.” Viruses<\/i> 13, no. 11 (November 3, 2021): 2212. https:\/\/doi.org\/10.3390\/v13112212<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Caputo, Sandrine M., Lisa Golmard, Mélanie Léone, Francesca Damiola, Marine Guillaud-Bataille, Françoise Revillion, Etienne Rouleau, et al. “Classification of 101 BRCA1 and BRCA2 Variants of Uncertain Significance by Cosegregation Study: A Powerful Approach.” American Journal of Human Genetics<\/i> 108, no. 10 (October 7, 2021): 1907–23. https:\/\/doi.org\/10.1016\/j.ajhg.2021.09.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, José Adélaïde, Arnaud Guille, Bruno Tesson, Elodie Gat, Solene Evrard, Frederic Escudié, et al. “High-Grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.” The American Journal of Surgical Pathology<\/i> 45, no. 10 (October 1, 2021): 1324–36. https:\/\/doi.org\/10.1097\/PAS.0000000000001726<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Oberic, Lucie, Faustine Delzor, Caroline Protin, Sophie Perriat, Camille Laurent, Anaïs Grand, Jean Marie Canonge, et al. “Brentuximab Vedotin in Real Life, a Seven Year Experience in Patients with Refractory\/Relapsed CD30+ T Cell Lymphoma.” Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners<\/i> 27, no. 7 (October 2021): 1730–35. https:\/\/doi.org\/10.1177\/1078155220968615<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lavalée, Margot, Nicolas Curdy, Camille Laurent, Jean-Jacques Fournié, and Don-Marc Franchini. “Cancer Cell Adaptability: Turning Ribonucleoprotein Granules into Targets.” Trends in Cancer<\/i> 7, no. 10 (October 2021): 902–15. https:\/\/doi.org\/10.1016\/j.trecan.2021.05.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Polivka, Laura, Veronique Parietti, Julie Bruneau, Erinn Soucie, Marine Madrange, Elisa Bayard, Rachel Rignault, et al. “The Association of Greig Syndrome and Mastocytosis Reveals the Involvement of Hedgehog Pathway in Advanced Mastocytosis.” Blood<\/i>, August 23, 2021, blood.2020010207. https:\/\/doi.org\/10.1182\/blood.2020010207<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Franchet, Camille, Lounes Djerroudi, Aurélie Maran-Gonzalez, Olivia Abramovici, Martine Antoine, Véronique Becette, Anca Berghian, et al. “[2021 update of the GEFPICS’ recommendations for HER2 status assessment in invasive breast cancer in France].” Annales De Pathologie<\/i>, August 12, 2021, S0242-6498(21)00191-7. https:\/\/doi.org\/10.1016\/j.annpat.2021.07.014<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bezombes, Christine, and Patricia Pérez-Galán. “Immunotherapies in Non-Hodgkin’s Lymphoma.” Cancers<\/i> 13, no. 14 (July 20, 2021): 3625. https:\/\/doi.org\/10.3390\/cancers13143625<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Syrykh, Charlotte, Sarah Péricart, Claire Lamaison, Frédéric Escudié, Pierre Brousset, and Camille Laurent. “Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features.” Cancers<\/i> 13, no. 13 (July 1, 2021): 3315. https:\/\/doi.org\/10.3390\/cancers13133315<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laplagne, Chloé, Laetitia Ligat, Juliet Foote, Frederic Lopez, Jean-Jacques Fournié, Camille Laurent, Salvatore Valitutti, and Mary Poupot. “Self-Activation of Vγ9Vδ2 T Cells by Exogenous Phosphoantigens Involves TCR and Butyrophilins.” Cellular & Molecular Immunology<\/i>, June 28, 2021. https:\/\/doi.org\/10.1038\/s41423-021-00720-w<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Syrykh, Charlotte, Loïc Ysebaert, Sarah Péricart, Solène M. Evrard, Fabienne Meggetto, Salim Kanoun, Pierre Brousset, and Camille Laurent. “ALK-Positive Histiocytosis Associated with Chronic Lymphocytic Leukaemia\/Small Lymphocytic Lymphoma: A Multitarget Response under Ibrutinib.” Virchows Archiv: An International Journal of Pathology<\/i> 478, no. 4 (April 2021): 779–83. https:\/\/doi.org\/10.1007\/s00428-020-02937-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bommier, Côme, Claire Mauduit, Juliette Fontaine, Estelle Bourbon, Pierre Sujobert, Sarah Huet, Lucile Baseggio, et al. “Real-Life Targeted next-Generation Sequencing for Lymphoma Diagnosis over 1 Year from the French Lymphoma Network.” British Journal of Haematology<\/i>, March 25, 2021. https:\/\/doi.org\/10.1111\/bjh.17395<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gava, Fabien, Carla Faria, Pauline Gravelle, Juan G. Valero, Cèlia Dobaño-López, Renaud Morin, Marine Norlund, et al. “3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma.” Cancers<\/i> 13, no. 7 (March 24, 2021). https:\/\/doi.org\/10.3390\/cancers13071490<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cerapio, Juan Pablo, Agnès Marchio, Luis Cano, Ignacio López, Jean-Jacques Fournié, Béatrice Régnault, Sandro Casavilca-Zambrano, et al. “Global DNA Hypermethylation Pattern and Unique Gene Expression Signature in Liver Cancer from Patients with Indigenous American Ancestry.” Oncotarget<\/i> 12, no. 5 (March 2, 2021): 475–92. https:\/\/doi.org\/10.18632\/oncotarget.27890<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ghesquières, Hervé, Cédric Rossi, Fanny Cherblanc, Sandra Le Guyader-Peyrou, Fontanet Bijou, Pierre Sujobert, Pascale Fabbro-Peray, et al. “A French Multicentric Prospective Prognostic Cohort with Epidemiological, Clinical, Biological and Treatment Information to Improve Knowledge on Lymphoma Patients: Study Protocol of the ‘REal World DAta in LYmphoma and Survival in Adults’ (REALYSA) Cohort.” BMC Public Health<\/i> 21, no. 1 (March 2, 2021): 432. https:\/\/doi.org\/10.1186\/s12889-021-10433-4<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Poupot, Mary. “Why Target Innate Immune Cells in Cancers?” Cancers<\/i> 13, no. 4 (February 9, 2021). https:\/\/doi.org\/10.3390\/cancers13040690<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Curdy, Nicolas, Olivia Lanvin, Sarah Cadot, Camille Laurent, Jean-Jacques Fournié, and Don-Marc Franchini. “Stress Granules in the Post-Transcriptional Regulation of Immune Cells.” Frontiers in Cell and Developmental Biology<\/i> 8 (February 2, 2021): 611185. https:\/\/doi.org\/10.3389\/fcell.2020.611185<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Burlet, Bénédicte, Selim Ramla, Cyril Fournier, Maria Jimena Abrey-Recalde, Camille Sauter, Marie-Lorraine Chrétien, Cédric Rossi, et al. “Identification of Novel, Clonally Stable, Somatic Mutations Targeting Transcription Factors PAX5 and NKX2-3, the Epigenetic Regulator LRIF1, and BRAF in a Case of Atypical B-Cell Chronic Lymphocytic Leukemia Harboring a t(14;18)(Q32;Q21).” Cold Spring Harbor Molecular Case Studies<\/i> 7, no. 1 (February 2021). https:\/\/doi.org\/10.1101\/mcs.a005934<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Quelen, Cathy, David Grand, Emeline Sarot, Laurence Brugières, David Sibon, Anne Pradines, Camille Laurent, Pierre Brousset, and Laurence Lamant. “Minimal Residual Disease Monitoring Using a 3’ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: DdPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.” The Journal of Molecular Diagnostics: JMD<\/i> 23, no. 2 (February 2021): 131–39. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.11.002<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Domagala, Marcin, Chloé Laplagne, Edouard Leveque, Camille Laurent, Jean-Jacques Fournié, Eric Espinosa, and Mary Poupot. “Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells.” Cancers<\/i> 13, no. 2 (January 6, 2021). https:\/\/doi.org\/10.3390\/cancers13020165<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cerapio, Juan-Pablo, Marion Perrier, Camille-Charlotte Balança, Pauline Gravelle, Fréderic Pont, Christel Devaud, Don-Marc Franchini, et al. “Phased Differentiation of Γδ T and T CD8 Tumor-Infiltrating Lymphocytes Revealed by Single-Cell Transcriptomics of Human Cancers.” Oncoimmunology<\/i> 10, no. 1 (2021): 1939518. https:\/\/doi.org\/10.1080\/2162402X.2021.1939518<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ysebaert, Loic, Anne Quillet-Mary, Marie Tosolini, Frederic Pont, Camille Laurent, and Jean-Jacques Fournié. “Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics.” Frontiers in Immunology<\/i> 12 (2021): 597651. https:\/\/doi.org\/10.3389\/fimmu.2021.597651<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2020″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2020<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-82f27562b1d3d118f48288bbde628383%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TZDYZ79F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balan%5Cu00e7a%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBalan%26%23xE7%3Ba%2C%20Camille-Charlotte%2C%20Anna%20Salvioni%2C%20Clara-Maria%20Scarlata%2C%20Marie%20Michelas%2C%20Carlos%20Martinez-Gomez%2C%20Carlos%20Gomez-Roca%2C%20Victor%20Sarradin%2C%20et%20al.%20%26%23x201C%3BPD-1%20Blockade%20Restores%20Helper%20Activity%20of%20Tumor-Infiltrating%20Exhausted%20PD-1hiCD39%2B%20CD4%20T%20Cells.%26%23x201D%3B%20%3Ci%3EJCI%20Insight%3C%5C%2Fi%3E%2C%20December%2017%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2Fjci.insight.142513%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2Fjci.insight.142513%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PD-1%20blockade%20restores%20helper%20activity%20of%20tumor-infiltrating%20exhausted%20PD-1hiCD39%2B%20CD4%20T%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Salvioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez-Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Sarradin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-12-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1172%5C%2Fjci.insight.142513%22%2C%22ISSN%22%3A%222379-3708%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Finsight.jci.org%5C%2Farticles%5C%2Fview%5C%2F142513%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22WVCHCN8C%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22A6DTNMSW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marku%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMarku%2C%20Malvina%2C%20Nina%20Verstraete%2C%20Flavien%20Raynal%2C%20Miguel%20Madrid-Menc%26%23xED%3Ba%2C%20Marcin%20Domagala%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Mary%20Poupot%2C%20and%20Vera%20Pancaldi.%20%26%23x201C%3BInsights%20on%20TAM%20Formation%20from%20a%20Boolean%20Model%20of%20Macrophage%20Polarization%20Based%20on%20In%20Vitro%20Studies.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%2012%20%28December%207%2C%202020%29%3A%203664.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12123664%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12123664%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Insights%20on%20TAM%20Formation%20from%20a%20Boolean%20Model%20of%20Macrophage%20Polarization%20Based%20on%20In%20Vitro%20Studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malvina%22%2C%22lastName%22%3A%22Marku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Verstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavien%22%2C%22lastName%22%3A%22Raynal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Madrid-Menc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%5D%2C%22abstractNote%22%3A%22The%20tumour%20microenvironment%20is%20the%20surrounding%20of%20a%20tumour%2C%20including%20blood%20vessels%2C%20fibroblasts%2C%20signaling%20molecules%2C%20the%20extracellular%20matrix%20and%20immune%20cells%2C%20especially%20neutrophils%20and%20monocyte-derived%20macrophages.%20In%20a%20tumour%20setting%2C%20macrophages%20encompass%20a%20spectrum%20between%20a%20tumour-suppressive%20%28M1%29%20or%20tumour-promoting%20%28M2%29%20state.%20The%20biology%20of%20macrophages%20found%20in%20tumours%20%28Tumour%20Associated%20Macrophages%29%20remains%20unclear%2C%20but%20understanding%20their%20impact%20on%20tumour%20progression%20is%20highly%20important.%20In%20this%20paper%2C%20we%20perform%20a%20comprehensive%20analysis%20of%20a%20macrophage%20polarization%20network%2C%20following%20two%20lines%20of%20enquiry%3A%20%28i%29%20we%20reconstruct%20the%20macrophage%20polarization%20network%20based%20on%20literature%2C%20extending%20it%20to%20include%20important%20stimuli%20in%20a%20tumour%20setting%2C%20and%20%28ii%29%20we%20build%20a%20dynamical%20model%20able%20to%20reproduce%20macrophage%20polarization%20in%20the%20presence%20of%20different%20stimuli%2C%20including%20the%20contact%20with%20cancer%20cells.%20Our%20simulations%20recapitulate%20the%20documented%20macrophage%20phenotypes%20and%20their%20dependencies%20on%20specific%20receptors%20and%20transcription%20factors%2C%20while%20also%20unravelling%20the%20formation%20of%20a%20special%20type%20of%20tumour%20associated%20macrophages%20in%20an%20in%20vitro%20model%20of%20chronic%20lymphocytic%20leukaemia.%20This%20model%20constitutes%20the%20first%20step%20towards%20elucidating%20the%20cross-talk%20between%20immune%20and%20cancer%20cells%20inside%20tumours%2C%20with%20the%20ultimate%20goal%20of%20identifying%20new%20therapeutic%20targets%20that%20could%20control%20the%20formation%20of%20tumour%20associated%20macrophages%20in%20patients.%22%2C%22date%22%3A%222020-12-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12123664%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F12%5C%2F3664%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%226FNA338P%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22K3QGFDCZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gauthier%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGauthier%2C%20Martin%2C%20Jean-Baptiste%20Rieu%2C%20Camille%20Laurent%2C%20and%20Fran%26%23xE7%3Bois%20Vergez.%20%26%23x201C%3BEye-Catching%20Spindle-Shaped%20Mast%20Cells%20without%20Sinister%20Significance.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Haematology%3C%5C%2Fi%3E%2C%20November%2021%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.17207%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.17207%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Eye-catching%20spindle-shaped%20mast%20cells%20without%20sinister%20significance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-11-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbjh.17207%22%2C%22ISSN%22%3A%221365-2141%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22WRVHEXEX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mouchel%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMouchel%2C%20Pierre%26%23x2010%3BLuc%2C%20Charlotte%20Syrykh%2C%20Camille%20Laurent%2C%20Suzanne%20Tavitian%2C%20and%20Martin%20Gauthier.%20%26%23x201C%3BFirst%20Case%20of%20Classical%20Hodgkin%26%23x2010%3Blike%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3EEBV%3C%5C%2Fspan%3E%20%26%23x2010%3Bpositive%20Lymphoproliferative%20Disorder%20under%20Ruxolitinib%20Therapy.%26%23x201D%3B%20%3Ci%3EAmerican%20Journal%20of%20Hematology%3C%5C%2Fi%3E%2C%20November%206%2C%202020%2C%20ajh.26026.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fajh.26026%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fajh.26026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22First%20case%20of%20classical%20Hodgkin%5Cu2010like%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3EEBV%3C%5C%2Fspan%3E%20%5Cu2010positive%20lymphoproliferative%20disorder%20under%20ruxolitinib%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%5Cu2010Luc%22%2C%22lastName%22%3A%22Mouchel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-11-06%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fajh.26026%22%2C%22ISSN%22%3A%220361-8609%2C%201096-8652%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fajh.26026%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A48Z%22%7D%7D%2C%7B%22key%22%3A%224VWME9AG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bordes%20et%20al.%22%2C%22parsedDate%22%3A%222020-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBordes%2C%20Julien%2C%20S%26%23xE9%3Bbastien%20Incerti%2C%20Erick%20Mora-Ramirez%2C%20Jonathan%20Tranel%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20Christine%20Bezombes%2C%20Julie%20Bordenave%2C%20Manuel%20Bardi%26%23xE8%3Bs%2C%20Richard%20Brown%2C%20and%20Marie-Claude%20Bordage.%20%26%23x201C%3BMonte%20Carlo%20Dosimetry%20of%20a%20Realistic%20Multicellular%20Model%20of%20Follicular%20Lymphoma%20in%20a%20Context%20of%20Radioimmunotherapy.%26%23x201D%3B%20%3Ci%3EMedical%20Physics%3C%5C%2Fi%3E%2047%2C%20no.%2010%20%28October%202020%29%3A%205222%26%23x2013%3B34.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmp.14370%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmp.14370%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Monte%20Carlo%20dosimetry%20of%20a%20realistic%20multicellular%20model%20of%20follicular%20lymphoma%20in%20a%20context%20of%20radioimmunotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Bordes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Incerti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erick%22%2C%22lastName%22%3A%22Mora-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Tranel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bordenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardi%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claude%22%2C%22lastName%22%3A%22Bordage%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Small-scale%20dosimetry%20studies%20generally%20consider%20an%20artificial%20environment%20where%20the%20tumors%20are%20spherical%20and%20the%20radionuclides%20are%20homogeneously%20biodistributed.%20However%2C%20tumor%20shapes%20are%20irregular%20and%20radiopharmaceutical%20biodistributions%20are%20heterogeneous%2C%20impacting%20the%20energy%20deposition%20in%20targeted%20radionuclide%20therapy.%20To%20bring%20realism%2C%20we%20developed%20a%20dosimetric%20methodology%20based%20on%20a%20three-dimensional%20in%20vitro%20model%20of%20follicular%20lymphoma%20incubated%20with%20rituximab%2C%20an%20anti-CD20%20monoclonal%20antibody%20used%20in%20the%20treatment%20of%20non-Hodgkin%20lymphomas%2C%20which%20might%20be%20combined%20with%20a%20radionuclide.%20The%20effects%20of%20the%20realistic%20geometry%20and%20biodistribution%20on%20the%20absorbed%20dose%20were%20highlighted%20by%20comparison%20with%20literature%20data.%20Additionally%2C%20to%20illustrate%20the%20possibilities%20of%20this%20methodology%2C%20the%20effect%20of%20different%20radionuclides%20on%20the%20absorbed%20dose%20distribution%20delivered%20to%20the%20in%20vitro%20tumor%20were%20compared.%5CnMETHODS%3A%20The%20starting%20point%20was%20a%20model%20named%20multicellular%20aggregates%20of%20lymphoma%20cells%20%28MALC%29.%20Three%20MALCs%20of%20different%20dimensions%20and%20their%20rituximab%20biodistribution%20were%20considered.%20Geometry%2C%20antibody%20location%20and%20concentration%20were%20extracted%20from%20selective%20plane%20illumination%20microscopy.%20Assuming%20antibody%20radiolabeling%20with%20Auger%20electron%20%28125%20I%20and%20111%20In%29%20and%20%5Cu03b2-%20particle%20emitters%20%28177%20Lu%2C%20131%20I%20and%2090%20Y%29%2C%20we%20simulated%20energy%20deposition%20in%20MALCs%20using%20two%20Monte%20Carlo%20codes%3A%20Geant4-DNA%20with%20%5C%22CPA100%5C%22%20physics%20models%20for%20Auger%20electron%20emitters%20and%20Geant4%20with%20%5C%22Livermore%5C%22%20physics%20models%20for%20%5Cu03b2-%20particle%20emitters.%5CnRESULTS%3A%20MALCs%20had%20ellipsoid-like%20shapes%20with%20major%20radii%2C%20r%2C%20of%20~0.25%2C%20~0.5%20and%20~1.3%5Cu00a0mm.%20Rituximab%20was%20concentrated%20in%20the%20periphery%20of%20the%20MALCs.%20The%20absorbed%20doses%20delivered%20by%20177%20Lu%2C%20131%20I%20and%2090%20Y%20in%20MALCs%20were%20compared%20with%20literature%20data%20for%20spheres%20with%20two%20types%20of%20homogeneous%20biodistributions%20%28on%20the%20surface%20or%20throughout%20the%20volume%29.%20Compared%20to%20the%20MALCs%2C%20the%20mean%20absorbed%20doses%20delivered%20in%20spheres%20with%20surface%20biodistributions%20were%20between%2018%25%20and%2038%25%20lower%2C%20while%20with%20volume%20biodistribution%20they%20were%20between%2015%25%20and%2029%25%20higher.%20Regarding%20the%20radionuclides%20comparison%2C%20the%20relationship%20between%20MALC%20dimensions%2C%20rituximab%20biodistribution%20and%20energy%20released%20per%20decay%20impacted%20the%20absorbed%20doses.%20Despite%20releasing%20less%20energy%2C%20125%20I%20delivered%20a%20greater%20absorbed%20dose%20per%20decay%20than%20111%20In%20in%20the%20r%5Cu00a0~%5Cu00a00.25%5Cu00a0mm%20MALC%20%286.78%5Cu00b710-2%20vs%206.26%5Cu00b710-2%20%5Cu00a0%5Cu00b5Gy%5Cu00b7Bq-1%20%5Cu00b7s-1%20%29.%20Similarly%2C%20the%20absorbed%20doses%20per%20decay%20in%20the%20r%5Cu00a0~%5Cu00a00.5%5Cu00a0mm%20MALC%20for%20177%20Lu%20%282.41%5Cu00b710-2%20%5Cu00a0%5Cu00b5Gy%5Cu00b7Bq-1%20%5Cu00b7s-1%20%29%20and%20131%20I%20%282.46%5Cu00b710-2%20%5Cu00a0%5Cu00b5Gy%5Cu00b7Bq-1%20%5Cu00b7s-1%20%29%20are%20higher%20than%20for%2090%20Y%20%281.98%5Cu00b710-2%20%5Cu00a0%5Cu00b5Gy%5Cu00b7Bq-1%20%5Cu00b7s-1%20%29.%20Furthermore%2C%20radionuclides%20releasing%20more%20energy%20per%20decay%20delivered%20absorbed%20dose%20more%20uniformly%20through%20the%20MALCs.%20Finally%2C%20when%20considering%20the%20radiopharmaceutical%20effective%20half-life%2C%20due%20to%20the%20biological%20half-life%20of%20rituximab%20being%20best%20matched%20by%20the%20physical%20half-life%20of%20177%20Lu%20and%20131%20I%20compared%20to%2090%20Y%2C%20the%20first%20two%20radionuclides%20delivered%20higher%20absorbed%20doses.%5CnCONCLUSION%3A%20In%20the%20simulated%20configurations%2C%20%5Cu03b2-%20emitters%20delivered%20higher%20and%20more%20uniform%20absorbed%20dose%20than%20Auger%20electron%20emitters.%20When%20considering%20radiopharmaceutical%20half-lives%2C%20177%20Lu%20and%20131%20I%20delivered%20absorbed%20doses%20higher%20than%2090%20Y.%20In%20view%20of%20real%20irradiation%20of%20MALCs%2C%20such%20a%20work%20may%20be%20useful%20to%20select%20suited%20radionuclides%20and%20to%20help%20explain%20the%20biological%20effects.%22%2C%22date%22%3A%222020-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmp.14370%22%2C%22ISSN%22%3A%222473-4209%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22MF3AVPF2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarkozy%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESarkozy%2C%20Clementine%2C%20Stacy%20S.%20Hung%2C%20Elizabeth%20A.%20Chavez%2C%20Gerben%20Duns%2C%20Katsuyoshi%20Takata%2C%20Lauren%20C.%20Chong%2C%20Tomohiro%20Aoki%2C%20et%20al.%20%26%23x201C%3BMutational%20Landscape%20of%20Grey%20Zone%20Lymphoma.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%2C%20September%2022%2C%202020%2C%20blood.2020007507.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020007507%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020007507%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mutational%20Landscape%20of%20Grey%20Zone%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clementine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stacy%20S.%22%2C%22lastName%22%3A%22Hung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Chavez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerben%22%2C%22lastName%22%3A%22Duns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsuyoshi%22%2C%22lastName%22%3A%22Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20C.%22%2C%22lastName%22%3A%22Chong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohiro%22%2C%22lastName%22%3A%22Aoki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aixiang%22%2C%22lastName%22%3A%22Jiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomoko%22%2C%22lastName%22%3A%22Miyata-Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%5Cu00e8le%22%2C%22lastName%22%3A%22Telenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%20W.%22%2C%22lastName%22%3A%22Slack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%20Jo%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%22%2C%22lastName%22%3A%22Ben-Neriah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Farinha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Dartigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Mottok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%20Andre%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rene-Olivier%22%2C%22lastName%22%3A%22Casasnovas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20J.%22%2C%22lastName%22%3A%22Savage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Steidl%22%7D%5D%2C%22abstractNote%22%3A%22The%20mutational%20landscape%20of%20grey%20zone%20lymphoma%20%28GZL%29%20has%20not%20yet%20been%20established%20and%20differences%20to%20related%20entities%20are%20largely%20unknown.%20Here%2C%20we%20studied%20coding%20sequence%20mutations%20of%2050%20EBV-negative%20GZL%20and%2020%20polymorphic%20EBV-positive%20DLBCL%20NOS%20%28poly-EBV-L%29%20in%20comparison%20to%20classical%20Hodgkin%20lymphoma%20%28cHL%29%2C%20primary%20mediastinal%20large%20B%20cell%20lymphoma%20%28PMBCL%29%2C%20and%20diffuse%20large%20B%20cell%20lymphoma%20%28DLBCL%29.%20Exomes%20of%2021%20GZL%20and%207%20poly-EBV-L%20cases%20along%20with%20paired%20normals%20were%20analyzed%20as%20a%20discovery%20cohort%20followed%20by%20targeted%20sequencing%20of%20217%20genes%20in%20an%20extension%20cohort%20of%2029%20GZL%20and%2013%20poly-EBV-L%20cases.%20GZL%20cases%20with%20thymic%20niche%20involvement%20%28anterior%20mediastinal%20mass%29%20displayed%20a%20mutation%20profile%20closely%20resembling%20cHL%20and%20PMBCL%2C%20with%20SOCS1%20%2845%25%29%2C%20B2M%20%2845%25%29%2C%20TNFAIP3%20%2835%25%29%2C%20GNA13%20%2835%25%29%2C%20LRRN3%20%2832%25%29%20and%20NFKBIA%20%2829%25%29%20being%20the%20most%20recurrently%20mutated%20genes.%20In%20contrast%2C%20GZL%20cases%20without%20thymic%20niche%20involvement%20%28N%3D18%29%20had%20a%20significantly%20distinct%20pattern%2C%20enriched%20in%20mutations%20related%20to%20apoptosis%20defects%20%28TP53%20%2839%25%29%2C%20BCL2%20%2828%25%29%2C%20BIRC6%20%2822%25%29%29%20and%20depleted%20in%20GNA13%2C%20XPO1or%20NFKB%20signaling%20pathway%20mutations%20%28TNFAIP3%2C%20NFKBIE%2C%20IKBKB%2C%20NFKBIA%29.%20They%20also%20presented%20more%20BCL2%5C%2FBCL6%20rearrangements%20as%20opposed%20to%20thymic%20GZL.%20Poly-EBV-L%20cases%20presented%20a%20distinct%20mutational%20profile%20including%20STAT3%20mutations%20and%20a%20significantly%20lower%20coding-mutation%20load%20in%20comparison%20to%20EBV-negative%20GZL.%20Our%20study%20highlights%20characteristic%20mutational%20patterns%20in%20GZL%20associated%20with%20presentation%20in%20the%20thymic%20niche%20suggesting%20a%20common%20cell%20of%20origin%20with%20disease%20evolution%20overlapping%20with%20related%20anterior%20mediastinal%20lymphomas.%22%2C%22date%22%3A%222020-09-22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2020007507%22%2C%22ISSN%22%3A%220006-4971%2C%201528-0020%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fashpublications.org%5C%2Fblood%5C%2Farticle%5C%2Fdoi%5C%2F10.1182%5C%2Fblood.2020007507%5C%2F463845%5C%2FMutational-Landscape-of-Grey-Zone-Lymphoma%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22RJ7D838C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gallais%20et%20al.%22%2C%22parsedDate%22%3A%222020-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGallais%2C%20Fanny%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Fabien%20Despas%2C%20Sandra%20De%20Barros%2C%20Lo%26%23xEF%3Bc%20Dupr%26%23xE9%3B%2C%20Anne%20Quillet-Mary%2C%20Caroline%20Protin%2C%20et%20al.%20%26%23x201C%3BPopulation%20Pharmacokinetics%20of%20Ibrutinib%20and%20Its%20Dihydrodiol%20Metabolite%20in%20Patients%20with%20Lymphoid%20Malignancies.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2059%2C%20no.%209%20%28September%202020%29%3A%201171%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-020-00884-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-020-00884-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population%20Pharmacokinetics%20of%20Ibrutinib%20and%20Its%20Dihydrodiol%20Metabolite%20in%20Patients%20with%20Lymphoid%20Malignancies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Gallais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVE%3A%20Ibrutinib%20is%20used%20for%20the%20treatment%20of%20chronic%20lymphocytic%20leukemia%20and%20other%20lymphoid%20malignancies.%20The%20aim%20of%20this%20work%20is%20to%20develop%20a%20population%20pharmacokinetic%20model%20for%20ibrutinib%20and%20its%20dihydrodiol%20metabolite%20to%20quantify%20pharmacokinetic%20inter-%20and%20intra-individual%20variability%2C%20to%20evaluate%20the%20impact%20of%20several%20covariates%20on%20ibrutinib%20pharmacokinetic%20parameters%2C%20and%20to%20examine%20the%20relationship%20between%20exposure%20and%20clinical%20outcome.%5CnMETHODS%3A%20Patients%20treated%20with%20ibrutinib%20were%20included%20in%20the%20study%20and%20followed%20up%20for%202%5Cu00a0years.%20Pharmacokinetic%20blood%20samples%20were%20taken%20from%20months%201%20to%2012%20after%20inclusion.%20Ibrutinib%20and%20dihydrodiol-ibrutinib%20concentrations%20were%20assessed%20using%20ultra-performance%20liquid%20chromatography%20tandem%20mass%20spectrometry.%20A%20population%20pharmacokinetic%20model%20was%20developed%20using%20NONMEM%20version%207.4.%5CnRESULTS%3A%20A%20total%20of%2089%20patients%20and%201501%20plasma%20concentrations%20were%20included%20in%20the%20pharmacokinetic%20analysis.%20The%20best%20model%20consisted%20in%20two%20compartments%20for%20each%20molecule.%20Absorption%20was%20described%20by%20a%20sequential%20zero%20first-order%20process%20and%20a%20lag%20time.%20Ibrutinib%20was%20either%20metabolised%20into%20dihydrodiol-ibrutinib%20or%20excreted%20through%20other%20elimination%20routes.%20A%20link%20between%20the%20dosing%20compartment%20and%20the%20dihydrodiol-ibrutinib%20central%20compartment%20was%20added%20to%20assess%20for%20high%20first-pass%20hepatic%20metabolism.%20Ibrutinib%20clearance%20had%2067%25%20and%2047%25%20inter-%20and%20intra-individual%20variability%2C%20respectively%2C%20while%20dihydrodiol-ibrutinib%20clearance%20had%2051%25%20and%2026%25%20inter-%20and%20intra-individual%20variability%2C%20respectively.%20Observed%20ibrutinib%20exposure%20is%20significantly%20higher%20in%20patients%20carrying%20one%20copy%20of%20the%20cytochrome%20P450%203A4%2A22%20variant%20%281167%20ng.h%5C%2FmL%20vs%20743%20ng.h%5C%2FmL%2C%20respectively%2C%20p%20%3D%200.024%29.%20However%2C%20no%20covariates%20with%20a%20clinically%20relevant%20effect%20on%20ibrutinib%20or%20dihydrodiol-ibrutinib%20exposure%20were%20identified%20in%20the%20PK%20model.%20An%20external%20evaluation%20of%20the%20model%20was%20performed.%20Clinical%20outcome%20was%20expressed%20as%20the%20continuation%20or%20discontinuation%20of%20ibrutinib%20therapy%201%5Cu00a0year%20after%20treatment%20initiation.%20Patients%20who%20had%20treatment%20discontinuation%20because%20of%20toxicity%20had%20significantly%20higher%20ibrutinib%20area%20under%20the%20curve%20%28p%5Cu2009%3D%5Cu20090.047%29.%20No%20association%20was%20found%20between%20cessation%20of%20therapy%20due%20to%20disease%20progression%20and%20ibrutinib%20area%20under%20the%20curve%20in%20patients%20with%20chronic%20lymphocytic%20leukemia.%20For%20the%20seven%20patients%20with%20mantle%20cell%20lymphoma%20studied%2C%20an%20association%20trend%20was%20observed%20between%20disease%20progression%20and%20low%20exposure%20to%20ibrutinib.%5CnCONCLUSIONS%3A%20We%20present%20the%20first%20population%20pharmacokinetic%20model%20describing%20ibrutinib%20and%20dihydrodiol-ibrutinib%20concentrations%20simultaneously.%20Large%20inter-individual%20variability%20and%20substantial%20intra-individual%20variability%20were%20estimated%20and%20could%20not%20be%20explained%20by%20any%20covariate.%20Higher%20plasma%20exposure%20to%20ibrutinib%20is%20associated%20with%20cessation%20of%20therapy%20due%20to%20the%20occurrence%20of%20adverse%20events%20within%20the%20first%20year%20of%20treatment.%20The%20association%20between%20disease%20progression%20and%20ibrutinib%20exposure%20in%20patients%20with%20mantle%20cell%20lymphoma%20should%20be%20further%20investigated.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20no.%20NCT02824159.%22%2C%22date%22%3A%222020-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-020-00884-0%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%2C%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22S6D7NUE5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jacquier%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJacquier%2C%20Anthony%2C%20Charlotte%20Syrykh%2C%20Isabelle%20Bedgedjian%2C%20Franck%20Monnien%2C%20Camille%20Laurent%2C%20S%26%23xE9%3Bverine%20Valmary-Degano%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3BImmunohistochemistry%20with%20Anti-MAL%20Antibody%20and%20RNAscope%20with%20MAL%20Probes%20Are%20Complementary%20Techniques%20for%20Diagnosis%20of%20Primary%20Mediastinal%20Large%20B-Cell%20Lymphoma.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Pathology%3C%5C%2Fi%3E%2C%20August%2024%2C%202020%2C%20jclinpath-2020-206747.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjclinpath-2020-206747%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjclinpath-2020-206747%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immunohistochemistry%20with%20anti-MAL%20antibody%20and%20RNAscope%20with%20MAL%20probes%20are%20complementary%20techniques%20for%20diagnosis%20of%20primary%20mediastinal%20large%20B-cell%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Jacquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bedgedjian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Monnien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Valmary-Degano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Primary%20mediastinal%20large%20B-cell%20lymphoma%20%28PMBL%29%20diagnosis%20can%20be%20challenging%20on%20needle%20biopsies.%20Robust%20techniques%20are%20needed%20to%20ensure%20diagnosis%20of%20this%20lymphoma%20which%20is%20highly%20sensitive%20to%20recently%20developed%20therapy%20protocols.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20study%2C%20we%20sought%20to%20determine%20precise%20PMBL%20phenotype%2C%20compared%20with%20diffuse%20large%20B-cell%20lymphoma%20not%20otherwise%20specified%2C%20by%20combining%20immunohistochemistry%20with%20anti-MAL%20antibody%20and%20RNA%20in%20situ%20hybridisation%20%28RNAscope%29%20with%20specific%20MAL%20probes.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20overall%20MAL%20positivity%20level%20reached%2093%25%20%2814%5C%2F15%29%20of%20cases%20of%20PMBL.%20Among%20the%2015%20cases%20enrolled%20in%20the%20study%2C%2011%20were%20undoubtedly%20positive%20for%20MAL%20immunostaining%20whereas%2013%20were%20positive%20by%20RNA%20in%20situ%20hybridisation.%20Interestingly%2C%20one%20case%20that%20was%20negative%20by%20in%20situ%20hybridisation%20turned%20out%20to%20be%20positive%20by%20immunohistochemistry.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Taken%20together%2C%20our%20results%20demonstrate%20that%20in%20situ%20detection%20of%20both%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MAL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20transcripts%20and%20protein%20are%20complementary%20and%20increase%20the%20sensitivity%20and%20specificity%20of%20PMBL%20diagnosis.%22%2C%22date%22%3A%222020-08-24%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjclinpath-2020-206747%22%2C%22ISSN%22%3A%220021-9746%2C%201472-4146%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjcp.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fjclinpath-2020-206747%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22IX26P3VT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zam%5Cu00f2%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZam%26%23xF2%3B%2C%20Alberto%2C%20Peter%20Johnston%2C%20Ayoma%20D%20Attygalle%2C%20Camille%20Laurent%2C%20Daniel%20A%20Arber%2C%20and%20Falko%20Fend.%20%26%23x201C%3BAggressive%20B%26%23x2010%3Bcell%20Lymphomas%20with%20a%20Primary%20Bone%20Marrow%20Presentation.%26%23x201D%3B%20%3Ci%3EHistopathology%3C%5C%2Fi%3E%2C%20July%2014%2C%202020%2C%20his.14124.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14124%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14124%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Aggressive%20B%5Cu2010cell%20lymphomas%20with%20a%20primary%20bone%20marrow%20presentation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Zam%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayoma%20D%22%2C%22lastName%22%3A%22Attygalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20A%22%2C%22lastName%22%3A%22Arber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Falko%22%2C%22lastName%22%3A%22Fend%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-07-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.14124%22%2C%22ISSN%22%3A%220309-0167%2C%201365-2559%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fhis.14124%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22FSU7AR9V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aroua%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAroua%2C%20Nesrine%2C%20Emeline%20Boet%2C%20Margherita%20Ghisi%2C%20Marie-Laure%20Nicolau-Travers%2C%20Estelle%20Saland%2C%20Ryan%20Gwilliam%2C%20Fabienne%20de%20Toni%2C%20et%20al.%20%26%23x201C%3BExtracellular%20ATP%20and%20CD39%20Activate%20CAMP-Mediated%20Mitochondrial%20Stress%20Response%20to%20Promote%20Cytarabine%20Resistance%20in%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3ECancer%20Discovery%3C%5C%2Fi%3E%2C%20July%208%2C%202020%2C%20CD-19-1008.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2159-8290.CD-19-1008%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2159-8290.CD-19-1008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extracellular%20ATP%20and%20CD39%20activate%20cAMP-mediated%20mitochondrial%20stress%20response%20to%20promote%20cytarabine%20resistance%20in%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesrine%22%2C%22lastName%22%3A%22Aroua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Boet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margherita%22%2C%22lastName%22%3A%22Ghisi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Nicolau-Travers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Saland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%22%2C%22lastName%22%3A%22Gwilliam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22de%20Toni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohsen%22%2C%22lastName%22%3A%22Hosseini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Luc%22%2C%22lastName%22%3A%22Mouchel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Farge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudie%22%2C%22lastName%22%3A%22Bosc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucille%22%2C%22lastName%22%3A%22Stuani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Sabatier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fetta%22%2C%22lastName%22%3A%22Mazed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clement%22%2C%22lastName%22%3A%22Larrue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Latifa%22%2C%22lastName%22%3A%22Jarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Gandarillas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimiliano%22%2C%22lastName%22%3A%22Bardotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Gotanegre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bonnefoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriant%22%2C%22lastName%22%3A%22Bellvert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Charles%22%2C%22lastName%22%3A%22Portais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Nicot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Azuaje%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Kaoma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Joffre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Tamburini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Recher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Emmanuel%22%2C%22lastName%22%3A%22Sarry%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-07-08%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F2159-8290.CD-19-1008%22%2C%22ISSN%22%3A%222159-8274%2C%202159-8290%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcancerdiscovery.aacrjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1158%5C%2F2159-8290.CD-19-1008%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%228HPIVX5A%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22DL2Y5WG7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laplagne%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaplagne%2C%20Chlo%26%23xE9%3B%2C%20Sarah%20Meddour%2C%20Sarah%20Figarol%2C%20Marie%20Michelas%2C%20Olivier%20Calvayrac%2C%20Gilles%20Favre%2C%20Camille%20Laurent%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20St%26%23xE9%3Bphanie%20Cabantous%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BV%26%23x3B3%3B9V%26%23x3B4%3B2%20T%20Cells%20Activation%20Through%20Phosphoantigens%20Can%20Be%20Impaired%20by%20a%20RHOB%20Rerouting%20in%20Lung%20Cancer.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2011%20%28July%207%2C%202020%29%3A%201396.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.01396%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.01396%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22V%5Cu03b39V%5Cu03b42%20T%20Cells%20Activation%20Through%20Phosphoantigens%20Can%20Be%20Impaired%20by%20a%20RHOB%20Rerouting%20in%20Lung%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Laplagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Meddour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Figarol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Calvayrac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Cabantous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-7-7%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.01396%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffimmu.2020.01396%5C%2Ffull%22%2C%22collections%22%3A%5B%22W973EZ5X%22%2C%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22LJQSY8VX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balan%5Cu00e7a%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBalan%26%23xE7%3Ba%2C%20Camille-Charlotte%2C%20Clara-Maria%20Scarlata%2C%20Marie%20Michelas%2C%20Christel%20Devaud%2C%20Victor%20Sarradin%2C%20Camille%20Franchet%2C%20Carlos%20Martinez%20Gomez%2C%20et%20al.%20%26%23x201C%3BDual%20Relief%20of%20T-Lymphocyte%20Proliferation%20and%20Effector%20Function%20Underlies%20Response%20to%20PD-1%20Blockade%20in%20Epithelial%20Malignancies.%26%23x201D%3B%20%3Ci%3ECancer%20Immunology%20Research%3C%5C%2Fi%3E%208%2C%20no.%207%20%28July%202020%29%3A%20869%26%23x2013%3B82.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-19-0855%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-19-0855%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dual%20Relief%20of%20T-lymphocyte%20Proliferation%20and%20Effector%20Function%20Underlies%20Response%20to%20PD-1%20Blockade%20in%20Epithelial%20Malignancies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Sarradin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Heaugwane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizcaino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Mir-Mesnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22F%5Cu00e9liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Motton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Tanguy%20Le%20Gac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Sarini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Vairel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried-Vergnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22Although%20understanding%20of%20T-cell%20exhaustion%20is%20widely%20based%20on%20mouse%20models%2C%20its%20analysis%20in%20patients%20with%20cancer%20could%20provide%20clues%20indicating%20tumor%20sensitivity%20to%20immune%20checkpoint%20blockade%20%28ICB%29.%20Data%20suggest%20a%20role%20for%20costimulatory%20pathways%2C%20particularly%20CD28%2C%20in%20exhausted%20T-cell%20responsiveness%20to%20PD-1%5C%2FPD-L1%20blockade.%20Here%2C%20we%20used%20single-cell%20transcriptomic%2C%20phenotypic%2C%20and%20functional%20approaches%20to%20dissect%20the%20relation%20between%20CD8%2B%20T-cell%20exhaustion%2C%20CD28%20costimulation%2C%20and%20tumor%20specificity%20in%20head%20and%20neck%2C%20cervical%2C%20and%20ovarian%20cancers.%20We%20found%20that%20memory%20tumor-specific%20CD8%2B%20T%20cells%2C%20but%20not%20bystander%20cells%2C%20sequentially%20express%20immune%20checkpoints%20once%20they%20infiltrate%20tumors%2C%20leading%2C%20in%20situ%2C%20to%20a%20functionally%20exhausted%20population.%20Exhausted%20T%20cells%20were%20nonetheless%20endowed%20with%20effector%20and%20tumor%20residency%20potential%20but%20exhibited%20loss%20of%20the%20costimulatory%20receptor%20CD28%20in%20comparison%20with%20their%20circulating%20memory%20counterparts.%20Accordingly%2C%20PD-1%20inhibition%20improved%20proliferation%20of%20circulating%20tumor-specific%20CD8%2B%20T%20cells%20and%20reversed%20functional%20exhaustion%20of%20specific%20T%20cells%20at%20tumor%20sites.%20In%20agreement%20with%20their%20tumor%20specificity%2C%20high%20infiltration%20of%20tumors%20by%20exhausted%20cells%20was%20predictive%20of%20response%20to%20therapy%20and%20survival%20in%20ICB-treated%20patients%20with%20head%20and%20neck%20cancer.%20Our%20results%20showed%20that%20PD-1%20blockade-mediated%20proliferation%5C%2Freinvigoration%20of%20circulating%20memory%20T%20cells%20and%20local%20reversion%20of%20exhaustion%20occur%20concurrently%20to%20control%20tumors.%22%2C%22date%22%3A%22Jul%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-19-0855%22%2C%22ISSN%22%3A%222326-6074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22WVCHCN8C%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22HD7YQQ6T%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Attygalle%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAttygalle%2C%20Ayoma%20D.%2C%20Alberto%20Zam%26%23xF2%3B%2C%20Falko%20Fend%2C%20Peter%20Johnston%2C%20Daniel%20A.%20Arber%2C%20and%20Camille%20Laurent.%20%26%23x201C%3BChallenges%20and%20Limitations%20in%20the%20Primary%20Diagnosis%20of%20T-Cell%20and%20Natural%20Killer%20Cell%5C%2FT-Cell%20Lymphoma%20in%20Bone%20Marrow%20Biopsy.%26%23x201D%3B%20%3Ci%3EHistopathology%3C%5C%2Fi%3E%2077%2C%20no.%201%20%28July%202020%29%3A%202%26%23x2013%3B17.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14093%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14093%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20and%20limitations%20in%20the%20primary%20diagnosis%20of%20T-cell%20and%20natural%20killer%20cell%5C%2FT-cell%20lymphoma%20in%20bone%20marrow%20biopsy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayoma%20D.%22%2C%22lastName%22%3A%22Attygalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Zam%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Falko%22%2C%22lastName%22%3A%22Fend%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20A.%22%2C%22lastName%22%3A%22Arber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jul%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.14093%22%2C%22ISSN%22%3A%221365-2559%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22R4RJX8KK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarkozy%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESarkozy%2C%20Cl%26%23xE9%3Bmentine%2C%20Lauren%20Chong%2C%20Katsuyoshi%20Takata%2C%20Elizabeth%20A.%20Chavez%2C%20Tomoko%20Miyata-Takata%2C%20Gerben%20Duns%2C%20Ad%26%23xE8%3Ble%20Telenius%2C%20et%20al.%20%26%23x201C%3BGene%20Expression%20Profiling%20of%20Gray%20Zone%20Lymphoma.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%204%2C%20no.%2011%20%28June%209%2C%202020%29%3A%202523%26%23x2013%3B35.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2020001923%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2020001923%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Gene%20expression%20profiling%20of%20gray%20zone%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Chong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsuyoshi%22%2C%22lastName%22%3A%22Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Chavez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomoko%22%2C%22lastName%22%3A%22Miyata-Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerben%22%2C%22lastName%22%3A%22Duns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%5Cu00e8le%22%2C%22lastName%22%3A%22Telenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Merrill%22%2C%22lastName%22%3A%22Boyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%20W.%22%2C%22lastName%22%3A%22Slack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Farinha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%20J.%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%20A.%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Mottok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20J.%22%2C%22lastName%22%3A%22Savage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Steidl%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Gray%20zone%20lymphoma%20%28GZL%29%2C%20a%20B-cell%20lymphoma%20with%20features%20intermediate%20between%20large%20B-cell%20lymphoma%20%28LBCL%29%20and%20classic%20Hodgkin%20lymphoma%20%28cHL%29%2C%20is%20a%20rare%20and%20poorly%20defined%20entity.%20Alongside%20GZL%2C%20a%20subset%20of%20Epstein-Barr%20virus%20%28EBV%29%5Cu2013positive%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%20has%20been%20described%20with%20polymorphic%5C%2FGZL-like%20morphology%20%28polymorphic-EBV-L%29.%20To%20fill%20the%20important%20gap%20in%20our%20understanding%20of%20the%20pathogenic%20process%20underlying%20these%20entities%2C%20we%20performed%20a%20gene%20expression%20study%20of%20a%20large%20international%20cohort%20of%20GZL%20and%20polymorphic-EBV-L%2C%20combined%20with%20cHL%20and%20primary%20mediastinal%20large%20B-cell%20lymphoma%20%28PMBCL%29%20cases.%20In%20an%20unsupervised%20principal%20component%20analysis%2C%20GZL%20cases%20presented%20with%20intermediate%20scores%20in%20a%20spectrum%20between%20cHL%20and%20PMBCL%2C%20whereas%20polymorphic-EBV-L%20clustered%20distinctly.%20The%20main%20biological%20pathways%20underlying%20the%20GZL%20spectrum%20were%20related%20to%20cell%20cycle%2C%20reflecting%20tumor%20cell%20content%2C%20and%20extracellular%20matrix%20signatures%20related%20to%20the%20cellular%20tumor%20microenvironment.%20Differential%20expression%20analysis%20and%20phenotypic%20characterization%20of%20the%20tumor%20microenvironment%20highlighted%20the%20predominance%20of%20regulatory%20macrophages%20in%20GZL%20compared%20with%20cHL%20and%20PMBCL.%20Two%20distinct%20subtypes%20of%20GZL%20were%20distinguishable%20that%20were%20phenotypically%20reminiscent%20of%20PMBCL%20and%20DLBCL%2C%20and%20we%20observed%20an%20association%20of%20PMBCL-type%20GZL%20with%20clinical%20presentation%20in%20the%20%5Cu201cthymic%5Cu201d%20anatomic%20niche.%20In%20summary%2C%20gene%20expression%20profiling%20%28GEP%29%20enabled%20us%20to%20add%20precision%20to%20the%20GZL%20spectrum%2C%20describe%20the%20biological%20distinction%20compared%20with%20polymorphic-EBV-L%2C%20and%20distinguish%20cases%20with%20and%20without%20thymic%20involvement%20as%202%20subgroups%20of%20GZL%2C%20namely%20PMBCL-like%20and%20DLBCL-like%20GZL.%22%2C%22date%22%3A%222020-06-09%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2020001923%22%2C%22ISSN%22%3A%222473-9529%2C%202473-9537%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fashpublications.org%5C%2Fbloodadvances%5C%2Farticle%5C%2F4%5C%2F11%5C%2F2523%5C%2F460732%5C%2FGene-expression-profiling-of-gray-zone-lymphoma%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22YK5T475M%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pont%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPont%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Marie%20Tosolini%2C%20Qing%20Gao%2C%20Marion%20Perrier%2C%20Miguel%20Madrid-Menc%26%23xED%3Ba%2C%20Tse%26%23xA0%3BShun%20Huang%2C%20Pierre%20Neuvial%2C%20Maha%20Ayyoub%2C%20Kristopher%20Nazor%2C%20and%20Jean-Jacques%20Fourni%26%23xE9%3B.%20%26%23x201C%3BSingle-Cell%20Virtual%20Cytometer%20Allows%20User-Friendly%20and%20Versatile%20Analysis%20and%20Visualization%20of%20Multimodal%20Single%20Cell%20RNAseq%20Datasets.%26%23x201D%3B%20%3Ci%3ENAR%20Genomics%20and%20Bioinformatics%3C%5C%2Fi%3E%202%2C%20no.%202%20%28June%201%2C%202020%29%3A%20lqaa025.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-Cell%20Virtual%20Cytometer%20allows%20user-friendly%20and%20versatile%20analysis%20and%20visualization%20of%20multimodal%20single%20cell%20RNAseq%20datasets%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qing%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Madrid-Menc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tse%5Cu00a0Shun%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Neuvial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristopher%22%2C%22lastName%22%3A%22Nazor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20The%20development%20of%20single-cell%20transcriptomic%20technologies%20yields%20large%20datasets%20comprising%20multimodal%20informations%2C%20such%20as%20transcriptomes%20and%20immunophenotypes.%20Despite%20the%20current%20explosion%20of%20methods%20for%20pre-processing%20and%20integrating%20multimodal%20single-cell%20data%2C%20there%20is%20currently%20no%20user-friendly%20software%20to%20display%20easily%20and%20simultaneously%20both%20immunophenotype%20and%20transcriptome-based%20UMAP%5C%2Ft-SNE%20plots%20from%20the%20pre-processed%20data.%20Here%2C%20we%20introduce%20Single-Cell%20Virtual%20Cytometer%2C%20an%20open-source%20software%20for%20flow%20cytometry-like%20visualization%20and%20exploration%20of%20pre-processed%20multi-omics%20single%20cell%20datasets.%20Using%20an%20original%20CITE-seq%20dataset%20of%20PBMC%20from%20an%20healthy%20donor%2C%20we%20illustrate%20its%20use%20for%20the%20integrated%20analysis%20of%20transcriptomes%20and%20epitopes%20of%20functional%20maturation%20in%20human%20peripheral%20T%20lymphocytes.%20So%20this%20free%20and%20open-source%20algorithm%20constitutes%20a%20unique%20resource%20for%20biologists%20seeking%20for%20a%20user-friendly%20analytic%20tool%20for%20multimodal%20single%20cell%20datasets.%22%2C%22date%22%3A%222020-06-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fnargab%5C%2Flqaa025%22%2C%22ISSN%22%3A%222631-9268%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fnargab%5C%2Farticle%5C%2Fdoi%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%5C%2F5822687%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A23Z%22%7D%7D%2C%7B%22key%22%3A%226CWIID96%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mescam%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMescam%2C%20L%26%23xE9%3Bna%26%23xEF%3Bg%2C%20Vincent%20Camus%2C%20Jean-Marc%20Schiano%2C%20Jos%26%23xE9%3B%20Ad%26%23xE9%3Bla%26%23xEF%3Bde%2C%20Jean-Michel%20Picquenot%2C%20Arnaud%20Guille%2C%20Marie%20Bannier%2C%20et%20al.%20%26%23x201C%3BEBV%2B%20Diffuse%20Large%20B-Cell%20Lymphoma%20Associated%20with%20Chronic%20Inflammation%20Expands%20the%20Spectrum%20of%20Breast%20Implant-Related%20Lymphomas.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20135%2C%20no.%2022%20%28May%2028%2C%202020%29%3A%202004%26%23x2013%3B9.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019003408%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019003408%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22EBV%2B%20diffuse%20large%20B-cell%20lymphoma%20associated%20with%20chronic%20inflammation%20expands%20the%20spectrum%20of%20breast%20implant-related%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9na%5Cu00efg%22%2C%22lastName%22%3A%22Mescam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Camus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Schiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Ad%5Cu00e9la%5Cu00efde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Picquenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Guille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Ruminy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Julien%22%2C%22lastName%22%3A%22Viailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reda%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Brenot-Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Bohers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrielle%22%2C%22lastName%22%3A%22Robe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Birnbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Wotherspoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%2028%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2019003408%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22SM7XA2ZV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22P%5Cu00e9ricart%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EP%26%23xE9%3Bricart%2C%20Sarah%2C%20Charlotte%20Syrykh%2C%20Nadia%20Amara%2C%20Camille%20Franchet%2C%20Bernard%20Malavaud%2C%20Philippe%20Gaulard%2C%20Jean-Philippe%20Girard%2C%20Loic%20Ysebaert%2C%20Camille%20Laurent%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3BExclusive%20B-Cell%20Phenotype%20of%20Primary%20Prostatic%20Lymphomas%3A%20A%20Potential%20Role%20of%20Chronic%20Prostatitis.%26%23x201D%3B%20%3Ci%3EHistopathology%3C%5C%2Fi%3E%2076%2C%20no.%205%20%28April%202020%29%3A%20767%26%23x2013%3B73.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14045%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14045%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exclusive%20B-cell%20phenotype%20of%20primary%20prostatic%20lymphomas%3A%20a%20potential%20role%20of%20chronic%20prostatitis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Amara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Malavaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Primary%20prostatic%20lymphomas%20%28PPL%29%20is%20exceedingly%20rare.%20The%20aim%20of%20this%20study%20was%20to%20investigate%20the%20largest%20series%20of%20PPL%20obtained%20from%20a%20nationwide%20expert%20pathologist%20network%2C%20and%20thus%20try%20to%20understand%20the%20pathophysiology%20of%20these%20tumours.%5CnMETHODS%20AND%20RESULTS%3A%20Up%20to%2066%5Cu00a0000%20lymphoma%20cases%20have%20been%20collected%20and%20submitted%20for%20central%20expert%20review%20by%20the%20French%20Lymphopath%20network.%20We%20confirm%20the%20low%20frequency%20of%20PPL%20%28n%5Cu00a0%3D%5Cu00a077%3B%200.12%25%29%2C%20all%20cases%20being%20of%20B-cell%20origin.%20Diffuse%20large%20B-cell%20lymphoma%20and%20small%20lymphocytic%20lymphoma%20were%20the%20most%20frequent%20subtypes%2C%20comprising%2031%25%20and%2026%25%20of%20cases%20respectively%2C%20followed%20by%20mucosa-associated%20lymphoid%20tissue%20%28MALT%29%5C%2Flymphoplasmacytic%20lymphoma%20%2819%25%29%2C%20follicular%20lymphoma%20%2812%25%29%2C%20mantle%20cell%20lymphoma%20%286%25%29%2C%20Burkitt%20lymphoma%20%284%25%29%2C%20and%20unclassified%20lymphoma%20%281%25%29.%20Clinical%20data%20obtained%20in%2025%20cases%20suggests%20that%20PPLs%20are%20rather%20indolent%20tumours.%20Our%20hypothesis%20for%20B-cell%20recruitment%20in%20the%20prostatic%20tissue%20was%20derived%20from%20the%20observation%20in%20chronic%20inflammation%20%28prostatitis%29%20of%20frequent%20heterotopic%20proliferation%20of%20high%20endothelial%20venules%20%28HEVs%29.%20The%20latter%20are%20dedicated%20to%20lymphocyte%20entry%20into%20secondary%20lymphoid%20organs%2C%20here%20putatively%20driving%20circulating%20clonal%20B-lymphocytes%20from%20the%20blood%20into%20the%20inflamed%20prostate.%20This%20may%20account%20for%20the%20relatively%20high%20incidence%20of%20small%20lymphocytic%20lymphoma%20consistently%20reported%20in%20series%20of%20primary%20or%20secondary%20prostatic%20lymphoma.%20As%20in%20other%20organs%20or%20glands%2C%20chronic%20inflammation%20may%20promote%20antigen-dependent%20intraprostatic%20MALT%20lymphoma%20and%20diffuse%20large%20B-cell%20lymphoma%20development.%5CnCONCLUSIONS%3A%20PPLs%20are%20exclusively%20of%20B-cell%20origin%2C%20and%20chronic%20inflammation%20resulting%20from%20the%20proliferation%20of%20high%20endothelial%20venules%20could%20play%20some%20role%20in%20their%20development.%22%2C%22date%22%3A%22Apr%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.14045%22%2C%22ISSN%22%3A%221365-2559%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A29%3A21Z%22%7D%7D%2C%7B%22key%22%3A%222JNQ2ETS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aussedat%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAussedat%2C%20Guillaume%2C%20Alexandra%20Traverse-Glehen%2C%20Aspasia%20Stamatoullas%2C%20Thierry%20Molina%2C%20Violaine%20Safar%2C%20Camille%20Laurent%2C%20Jean-Marie%20Michot%2C%20et%20al.%20%26%23x201C%3BComposite%20and%20Sequential%20Lymphoma%20between%20Classical%20Hodgkin%20Lymphoma%20and%20Primary%20Mediastinal%20Lymphoma%5C%2FDiffuse%20Large%20B-Cell%20Lymphoma%2C%20a%20Clinico-Pathological%20Series%20of%2025%20Cases.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20189%2C%20no.%202%20%28April%202020%29%3A%20244%26%23x2013%3B56.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.16331%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.16331%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Composite%20and%20sequential%20lymphoma%20between%20classical%20Hodgkin%20lymphoma%20and%20primary%20mediastinal%20lymphoma%5C%2Fdiffuse%20large%20B-cell%20lymphoma%2C%20a%20clinico-pathological%20series%20of%2025%20cases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Aussedat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aspasia%22%2C%22lastName%22%3A%22Stamatoullas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Violaine%22%2C%22lastName%22%3A%22Safar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marie%22%2C%22lastName%22%3A%22Michot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Nicolas-Virelizier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Lamure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Regny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Picquenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albane%22%2C%22lastName%22%3A%22Ledoux-Pilon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Tas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Cl%5Cu00e9ment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Manson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lemal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Le%20Cann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%5D%2C%22abstractNote%22%3A%22Composite%20and%20sequential%20lymphomas%20involving%20both%20classical%20Hodgkin%20lymphoma%20%28CHL%29%20and%20primary%20mediastinal%20B-cell%20lymphoma%20%28PMBCL%29%20are%20rare%20phenomena.%20Beyond%20the%20relevant%20biological%20interest%20raised%20by%20these%20cases%2C%20treatments%20and%20outcome%20data%20are%20poorly%20covered%20in%20the%20recent%20literature.%20This%20retrospective%20analysis%20describes%20the%20pathological%20and%20clinical%20characteristics%20of%2010%20composite%20and%2015%20sequential%20cases%20included%20after%20a%20central%20pathological%20review.%20At%20diagnosis%2C%2070%25%20of%20the%20composite%20lymphomas%20presented%20a%20disseminated%20and%20extranodal%20disease.%20Among%20the%2015%20sequential%20lymphomas%2C%2012%20were%20CHL%20at%20first%20occurrence%20and%20three%20were%20PMBCL.%20Based%20on%20their%20clinical%20evolution%2C%20these%20sequential%20lymphomas%20could%20be%20divided%20into%20early%20%28i.e.%2C%20diagnosis%20of%20second%20lymphoma%20within%20a%20year%29%20and%20late%20%5B%28i.e.%2C%20a%20second%20lymphoma%20occurrence%20occurring%20after%20a%20long%20period%20of%20complete%20remission%5D%29.%20All%20composite%20cases%20were%20alive%20in%20complete%20remission%20after%20a%20median%20follow-up%20of%2034%5Cu00a0months.%20If%20the%20early%20sequential%20lymphoma%20presented%20a%20particularly%20poor%20outcome%20with%20a%20median%20overall%20survival%20shorter%20than%20one%5Cu00a0year%2C%20the%20late%20cases%20were%20efficiently%20salvaged.%20Further%20molecular%20studies%20are%20needed%20to%20describe%20the%20underlying%20biology%20of%20these%20rare%20diseases%2C%20possibly%20representing%20the%20extreme%20of%20tumour%20cell%20plasticity%20found%20in%20grey-zone%20lymphoma.%22%2C%22date%22%3A%22Apr%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbjh.16331%22%2C%22ISSN%22%3A%221365-2141%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%227VSWTTP7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vidal-Crespo%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVidal-Crespo%2C%20Anna%2C%20Alba%20Matas-C%26%23xE9%3Bspedes%2C%20Vanina%20Rodriguez%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20Juan%20G.%20Valero%2C%20Neus%20Serrat%2C%20Alejandra%20Sanjuan-Pla%2C%20et%20al.%20%26%23x201C%3BDaratumumab%20Displays%20in%20Vitro%20and%20in%20Vivo%20Anti-Tumor%20Activity%20in%20Models%20of%20B-Cell%20Non-Hodgkin%20Lymphoma%20and%20Improves%20Responses%20to%20Standard%20Chemo-Immunotherapy%20Regimens.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%20105%2C%20no.%204%20%28April%202020%29%3A%201032%26%23x2013%3B41.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2018.211904%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2018.211904%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Daratumumab%20displays%20in%20vitro%20and%20in%20vivo%20anti-tumor%20activity%20in%20models%20of%20B-cell%20non-Hodgkin%20lymphoma%20and%20improves%20responses%20to%20standard%20chemo-immunotherapy%20regimens%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Vidal-Crespo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alba%22%2C%22lastName%22%3A%22Matas-C%5Cu00e9spedes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanina%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neus%22%2C%22lastName%22%3A%22Serrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Sanjuan-Pla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Men%5Cu00e9ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebl%22%2C%22lastName%22%3A%22Rou%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armando%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Guillermo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gin%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22El%5Cu00edas%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolors%22%2C%22lastName%22%3A%22Colomer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20Lammerts%22%2C%22lastName%22%3A%22van%20Bueren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Chiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Parul%22%2C%22lastName%22%3A%22Doshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Gal%5Cu00e1n%22%7D%5D%2C%22abstractNote%22%3A%22CD38%20is%20expressed%20in%20several%20types%20of%20non-Hodgkin%20lymphoma%20%28NHL%29%20and%20constitutes%20a%20promising%20target%20for%20antibody-based%20therapy.%20Daratumumab%20%28Darzalex%29%20is%20a%20first-in-class%20anti-CD38%20antibody%20approved%20for%20the%20treatment%20of%20relapsed%5C%2Frefractory%20%28R%5C%2FR%29%20multiple%20myeloma%20%28MM%29.%20It%20has%20also%20demonstrated%20clinical%20activity%20in%20Waldenstr%5Cu00f6m%20macroglobulinaemia%20and%20amyloidosis.%20Here%2C%20we%20have%20evaluated%20the%20activity%20and%20mechanism%20of%20action%20of%20daratumumab%20in%20preclinical%20in%20vitro%20and%20in%20vivo%20models%20of%20mantle%20cell%20lymphoma%20%28MCL%29%2C%20follicular%20lymphoma%20%28FL%29%20and%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%2C%20as%20monotherapy%20or%20in%20combination%20with%20standard%20chemo-immunotherapy.%20In%20vitro%2C%20daratumumab%20engages%20Fc-mediated%20cytotoxicity%20by%20antibody-dependent%20cell%20cytotoxicity%20and%20antibody-dependent%20cell%20phagocytosis%20in%20all%20lymphoma%20subtypes.%20In%20the%20presence%20of%20human%20serum%2C%20complement-dependent%20cell%20cytotoxicity%20was%20marginally%20engaged.%20We%20demonstrated%20by%20Selective%20Plane%20Illumination%20Microscopy%20that%20daratumumab%20fully%20penetrated%20a%20three-dimensional%20%283D%29%20lymphoma%20organoid%20and%20decreased%20organoid%20volume.%20In%20vivo%2C%20daratumumab%20completely%20prevents%20tumor%20outgrowth%20in%20models%20of%20MCL%20and%20FL%2C%20and%20shows%20comparable%20activity%20to%20rituximab%20in%20a%20disseminated%20in%20vivo%20model%20of%20blastic%20MCL.%20Moreover%2C%20daratumumab%20improves%20overall%20survival%20%28OS%29%20in%20a%20mouse%20model%20of%20transformed%20CD20dim%20FL%2C%20where%20rituximab%20showed%20limited%20activity.%20Daratumumab%20potentiates%20the%20antitumor%20activity%20of%20CHOP%20and%20R-CHOP%20in%20MCL%20and%20FL%20xenografts.%20Furthermore%2C%20in%20a%20patient-derived%20DLBCL%20xenograft%20model%2C%20daratumumab%20anti-tumor%20activity%20was%20comparable%20to%20R-CHOP%20and%20the%20addition%20of%20daratumumab%20to%20either%20CHOP%20or%20R-CHOP%20led%20to%20full%20tumor%20regression.%20In%20summary%2C%20daratumumab%20constitutes%20a%20novel%20therapeutic%20opportunity%20in%20certain%20scenarios%20and%20these%20results%20warrant%20further%20clinical%20development.%22%2C%22date%22%3A%222020-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2018.211904%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22R69BB3FG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Camille%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECamille%2C%20Claire%2C%20Chlo%26%23xE9%3B%20Dimeglio%2C%20Antoine%20Yrondi%2C%20Gis%26%23xE8%3Ble%20Compaci%2C%20Emmanuelle%20Delmas%2C%20M%26%23xE9%3Blanie%20Gauch%26%23xE9%3B%2C%20Guy%20Laurent%2C%20and%20Philippe%20Birmes.%20%26%23x201C%3BPosttraumatic%20Stress%20Disorder%20Symptoms%20in%20Lymphoma%20Patients%3A%20A%20Prospective%20Study.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Psychiatry%3C%5C%2Fi%3E%2011%20%28March%2011%2C%202020%29%3A%20201.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffpsyt.2020.00201%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffpsyt.2020.00201%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Posttraumatic%20Stress%20Disorder%20Symptoms%20in%20Lymphoma%20Patients%3A%20A%20Prospective%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Camille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Dimeglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Yrondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gis%5Cu00e8le%22%2C%22lastName%22%3A%22Compaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Gauch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Birmes%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-3-11%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffpsyt.2020.00201%22%2C%22ISSN%22%3A%221664-0640%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffpsyt.2020.00201%5C%2Ffull%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22TZ2GT4UI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-30%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Alina%20Nicolae%2C%20C%26%23xE9%3Bcile%20Laurent%2C%20Fabien%20Le%20Bras%2C%20Corinne%20Haioun%2C%20Virginie%20Fataccioli%2C%20Nadia%20Amara%2C%20et%20al.%20%26%23x201C%3BGene%20Alterations%20in%20Epigenetic%20Modifiers%20and%20JAK-STAT%20Signaling%20Are%20Frequent%20in%20Breast%20Implant-Associated%20ALCL.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20135%2C%20no.%205%20%28January%2030%2C%202020%29%3A%20360%26%23x2013%3B70.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019001904%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019001904%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Gene%20alterations%20in%20epigenetic%20modifiers%20and%20JAK-STAT%20signaling%20are%20frequent%20in%20breast%20implant-associated%20ALCL%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alina%22%2C%22lastName%22%3A%22Nicolae%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Le%20Bras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Haioun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Fataccioli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Amara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Ad%5Cu00e9la%5Cu00efde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Guille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Schiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Tesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Chenard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9na%5Cu00efg%22%2C%22lastName%22%3A%22Mescam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Clement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan%22%2C%22lastName%22%3A%22Somja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Escudi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Hamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Reyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nais%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Xavier%22%2C%22lastName%22%3A%22Fr%5Cu00e9nois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asma%22%2C%22lastName%22%3A%22Beldi-Ferchiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Helene%22%2C%22lastName%22%3A%22Delfau-Larue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reda%22%2C%22lastName%22%3A%22Bouabdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Birnbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%5D%2C%22abstractNote%22%3A%22The%20oncogenic%20events%20involved%20in%20breast%20implant-associated%20anaplastic%20large%20cell%20lymphoma%20%28BI-ALCL%29%20remain%20elusive.%20To%20clarify%20this%20point%2C%20we%20have%20characterized%20the%20genomic%20landscape%20of%2034%20BI-ALCLs%20%2815%20tumor%20and%2019%20in%20situ%20subtypes%29%20collected%20from%2054%20BI-ALCL%20patients%20diagnosed%20through%20the%20French%20Lymphopath%20network.%20Whole-exome%20sequencing%20%28n%20%3D%2022%2C%20with%20paired%20tumor%5C%2Fgermline%20DNA%29%20and%5C%2For%20targeted%20deep%20sequencing%20%28n%20%3D%2024%29%20showed%20recurrent%20mutations%20of%20epigenetic%20modifiers%20in%2074%25%20of%20cases%2C%20involving%20notably%20KMT2C%20%2826%25%29%2C%20KMT2D%20%289%25%29%2C%20CHD2%20%2815%25%29%2C%20and%20CREBBP%20%2815%25%29.%20KMT2D%20and%20KMT2C%20mutations%20correlated%20with%20a%20loss%20of%20H3K4%20mono-%20and%20trimethylation%20by%20immunohistochemistry.%20Twenty%20cases%20%2859%25%29%20showed%20mutations%20in%20%5Cu22651%20member%20of%20the%20JAK%5C%2FSTAT%20pathway%2C%20including%20STAT3%20%2838%25%29%2C%20JAK1%20%2818%25%29%2C%20and%20STAT5B%20%283%25%29%2C%20and%20in%20negative%20regulators%2C%20including%20SOCS3%20%286%25%29%2C%20SOCS1%20%283%25%29%2C%20and%20PTPN1%20%283%25%29.%20These%20mutations%20were%20more%20frequent%20in%20tumor-type%20samples%20than%20in%20situ%20samples%20%28P%20%3D%20.038%29.%20All%20BI-ALCLs%20expressed%20pSTAT3%2C%20regardless%20of%20the%20mutational%20status%20of%20genes%20in%20the%20JAK%5C%2FSTAT%20pathway.%20Mutations%20in%20the%20EOMES%20gene%20%2812%25%29%20involved%20in%20lymphocyte%20development%2C%20PI3K-AKT%5C%2FmTOR%20%286%25%29%2C%20and%20loss-of-function%20mutations%20in%20TP53%20%2812%25%29%20were%20also%20identified.%20Copy-number%20aberration%20%28CNA%29%20analysis%20identified%20recurrent%20alterations%2C%20including%20gains%20on%20chromosomes%202%2C%209p%2C%2012p%2C%20and%2021%20and%20losses%20on%204q%2C%208p%2C%2015%2C%2016%2C%20and%2020.%20Regions%20of%20CNA%20encompassed%20genes%20involved%20in%20the%20JAK%5C%2FSTAT%20pathway%20and%20epigenetic%20regulators.%20Our%20results%20show%20that%20the%20BI-ALCL%20genomic%20landscape%20is%20characterized%20by%20not%20only%20JAK%5C%2FSTAT%20activating%20mutations%20but%20also%20loss-of-function%20alterations%20of%20epigenetic%20modifiers.%22%2C%22date%22%3A%222020-01-30%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2019001904%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A27%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22Z5XNH69R%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roussel%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoussel%2C%20Mikael%2C%20Faustine%20Lhomme%2C%20Caroline%20E.%20Roe%2C%20Todd%20Bartkowiak%2C%20Pauline%20Gravelle%2C%20Camille%20Laurent%2C%20Thierry%20Fest%2C%20and%20Jonathan%20M.%20Irish.%20%26%23x201C%3BMass%20Cytometry%20Defines%20Distinct%20Immune%20Profile%20in%20Germinal%20Center%20B-Cell%20Lymphomas.%26%23x201D%3B%20%3Ci%3ECancer%20Immunology%2C%20Immunotherapy%3A%20CII%3C%5C%2Fi%3E%2C%20January%209%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00262-019-02464-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00262-019-02464-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mass%20cytometry%20defines%20distinct%20immune%20profile%20in%20germinal%20center%20B-cell%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faustine%22%2C%22lastName%22%3A%22Lhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%20E.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Todd%22%2C%22lastName%22%3A%22Bartkowiak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Fest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20M.%22%2C%22lastName%22%3A%22Irish%22%7D%5D%2C%22abstractNote%22%3A%22Tumor-associated%20macrophage%20and%20T-cell%20subsets%20are%20implicated%20in%20the%20pathogenesis%20of%20diffuse%20large%20B-cell%20lymphoma%2C%20follicular%20lymphoma%2C%20and%20classical%20Hodgkin%20lymphoma.%20Macrophages%20provide%20essential%20mechanisms%20of%20tumor%20immune%20evasion%20through%20checkpoint%20ligand%20expression%20and%20secretion%20of%20suppressive%20cytokines.%20However%2C%20normal%20and%20tumor-associated%20macrophage%20phenotypes%20are%20less%20well%20characterized%20than%20those%20of%20tumor-infiltrating%20T-cell%20subsets%2C%20and%20it%20would%20be%20especially%20valuable%20to%20know%20whether%20the%20polarization%20state%20of%20macrophages%20differs%20across%20lymphoma%20tumor%20microenvironments.%20Here%2C%20an%20established%20mass%20cytometry%20panel%20designed%20to%20characterize%20myeloid-derived%20suppressor%20cells%20and%20known%20macrophage%20maturation%20and%20polarization%20states%20was%20applied%20to%20characterize%20B-lymphoma%20tumors%20and%20non-malignant%20human%20tissue.%20High-dimensional%20single-cell%20analyses%20were%20performed%20using%20dimensionality%20reduction%20and%20clustering%20tools.%20Phenotypically%20distinct%20intra-tumor%20macrophage%20subsets%20were%20identified%20based%20on%20abnormal%20marker%20expression%20profiles%20that%20were%20associated%20with%20lymphoma%20tumor%20types.%20While%20it%20had%20been%20proposed%20that%20measurement%20of%20CD163%20and%20CD68%20might%20be%20sufficient%20to%20reveal%20macrophage%20subsets%20in%20tumors%2C%20results%20here%20indicated%20that%20S100A9%2C%20CCR2%2C%20CD36%2C%20Slan%2C%20and%20CD32%20should%20also%20be%20measured%20to%20effectively%20characterize%20lymphoma-specific%20tumor%20macrophages.%20Additionally%2C%20the%20presence%20of%20phenotypically%20distinct%2C%20abnormal%20macrophage%20populations%20was%20closely%20linked%20to%20the%20phenotype%20of%20intra-tumor%20T-cell%20populations%2C%20including%20PD-1%20expressing%20T%20cells.%20These%20results%20further%20support%20the%20close%20links%20between%20macrophage%20polarization%20and%20T-cell%20functional%20state%2C%20as%20well%20as%20the%20rationale%20for%20targeting%20tumor-associated%20macrophages%20in%20cancer%20immunotherapies.%22%2C%22date%22%3A%22Jan%2009%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00262-019-02464-z%22%2C%22ISSN%22%3A%221432-0851%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22T2C5KIYF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cadot%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECadot%2C%20Sarah%2C%20Carine%20Valle%2C%20Marie%20Tosolini%2C%20Frederic%20Pont%2C%20Laetitia%20Largeaud%2C%20Camille%20Laurent%2C%20Jean%20Jacques%20Fournie%2C%20Loic%20Ysebaert%2C%20and%20Anne%20Quillet-Mary.%20%26%23x201C%3BLongitudinal%20CITE-Seq%20Profiling%20of%20Chronic%20Lymphocytic%20Leukemia%20during%20Ibrutinib%20Treatment%3A%20Evolution%20of%20Leukemic%20and%20Immune%20Cells%20at%20Relapse.%26%23x201D%3B%20%3Ci%3EBiomarker%20Research%3C%5C%2Fi%3E%208%2C%20no.%201%20%282020%29%3A%2072.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40364-020-00253-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40364-020-00253-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Longitudinal%20CITE-Seq%20profiling%20of%20chronic%20lymphocytic%20leukemia%20during%20ibrutinib%20treatment%3A%20evolution%20of%20leukemic%20and%20immune%20cells%20at%20relapse%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Cadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Jacques%22%2C%22lastName%22%3A%22Fournie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Ibrutinib%2C%20an%20irreversible%20Bruton%20Tyrosine%20Kinase%20%28BTK%29%20inhibitor%2C%20has%20revolutionized%20Chronic%20Lymphocytic%20Leukemia%20%28CLL%29%20treatment%2C%20but%20resistances%20to%20ibrutinib%20have%20emerged%2C%20whether%20related%20or%20not%20to%20BTK%20mutations.%20Patterns%20of%20CLL%20evolution%20under%20ibrutinib%20therapy%20are%20well%20characterized%20for%20the%20leukemic%20cells%20but%20not%20for%20their%20microenvironment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Here%2C%20we%20addressed%20this%20question%20at%20the%20single%20cell%20level%20of%20both%20transcriptome%20and%20immune-phenotype.%20The%20PBMCs%20from%20a%20CLL%20patient%20were%20monitored%20during%20ibrutinib%20treatment%20using%20Cellular%20Indexing%20of%20Transcriptomes%20and%20Epitopes%20by%20sequencing%20%28CITE-Seq%29%20technology.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20unveiled%20that%20the%20short%20clinical%20relapse%20of%20this%20patient%20driven%20by%20BTK%20mutation%20is%20associated%20with%20intraclonal%20heterogeneity%20in%20B%20leukemic%20cells%20and%20up-regulation%20of%20common%20signaling%20pathways%20induced%20by%20ibrutinib%20in%20both%20B%20leukemic%20cells%20and%20immune%20cells.%20This%20approach%20also%20pinpointed%20a%20subset%20of%20leukemic%20cells%20present%20before%20treatment%20and%20highly%20enriched%20during%20progression%20under%20ibrutinib.%20These%20latter%20exhibit%20an%20original%20gene%20signature%20including%20up-regulated%20BCR%2C%20MYC-activated%2C%20and%20other%20targetable%20pathways.%20Meanwhile%2C%20although%20ibrutinib%20differentially%20affected%20the%20exhaustion%20of%20T%20lymphocytes%2C%20this%20treatment%20enhanced%20the%20T%20cell%20cytotoxicity%20even%20during%20disease%20progression.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20These%20results%20could%20open%20new%20alternative%20of%20therapeutic%20strategies%20for%20ibrutinib-refractory%20CLL%20patients%2C%20based%20on%20immunotherapy%20or%20targeting%20B%20leukemic%20cells%20themselves.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40364-020-00253-w%22%2C%22ISSN%22%3A%222050-7771%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbiomarkerres.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs40364-020-00253-w%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22FHE2PHI2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Syrykh%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESyrykh%2C%20Charlotte%2C%20Arnaud%20Abreu%2C%20Nadia%20Amara%2C%20Aurore%20Siegfried%2C%20V%26%23xE9%3Bronique%20Maisongrosse%2C%20Fran%26%23xE7%3Bois%20X.%20Frenois%2C%20Laurent%20Martin%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20Camille%20Laurent%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3BAccurate%20Diagnosis%20of%20Lymphoma%20on%20Whole-Slide%20Histopathology%20Images%20Using%20Deep%20Learning.%26%23x201D%3B%20%3Ci%3ENpj%20Digital%20Medicine%3C%5C%2Fi%3E%203%2C%20no.%201%20%282020%29%3A%2063.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41746-020-0272-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41746-020-0272-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Accurate%20diagnosis%20of%20lymphoma%20on%20whole-slide%20histopathology%20images%20using%20deep%20learning%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Syrykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Abreu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Amara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Maisongrosse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%20X.%22%2C%22lastName%22%3A%22Frenois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41746-020-0272-0%22%2C%22ISSN%22%3A%222398-6352%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41746-020-0272-0%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22AUETBIYI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22El%20Halabi%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEl%20Halabi%2C%20Layal%2C%20Julien%20Adam%2C%20Pauline%20Gravelle%2C%20Virginie%20Marty%2C%20Alina%20Danu%2C%20Julien%20Lazarovici%2C%20Vincent%20Ribrag%2C%20et%20al.%20%26%23x201C%3BExpression%20of%20the%20Immune%20Checkpoint%20Regulators%20LAG-3%20and%20TIM-3%20in%20Classical%20Hodgkin%20Lymphoma.%26%23x201D%3B%20%3Ci%3EClinical%20Lymphoma%20Myeloma%20and%20Leukemia%3C%5C%2Fi%3E%2C%202020%2C%20S2152265020306339.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clml.2020.11.009%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clml.2020.11.009%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expression%20of%20the%20Immune%20Checkpoint%20Regulators%20LAG-3%20and%20TIM-3%20in%20Classical%20Hodgkin%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Layal%22%2C%22lastName%22%3A%22El%20Halabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Adam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Marty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alina%22%2C%22lastName%22%3A%22Danu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Lazarovici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Ribrag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Bosq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Camara-Clayette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ghez%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2211%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.clml.2020.11.009%22%2C%22ISSN%22%3A%2221522650%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2152265020306339%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22E95GCYPB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20Daniel%20A.%20Arber%2C%20Peter%20Johnston%2C%20Falko%20Fend%2C%20Alberto%20Zamo%2C%20and%20Ayoma%20D.%20Attygalle.%20%26%23x201C%3BDiagnosis%20of%20Classic%20Hodgkin%20Lymphoma%20on%20Bone%20Marrow%20Biopsy.%26%23x201D%3B%20%3Ci%3EHistopathology%3C%5C%2Fi%3E%2076%2C%20no.%207%20%282020%29%3A%20934%26%23x2013%3B41.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14085%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14085%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20of%20classic%20Hodgkin%20lymphoma%20on%20bone%20marrow%20biopsy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20A.%22%2C%22lastName%22%3A%22Arber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Falko%22%2C%22lastName%22%3A%22Fend%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Zamo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayoma%20D.%22%2C%22lastName%22%3A%22Attygalle%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2206%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.14085%22%2C%22ISSN%22%3A%221365-2559%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A40Z%22%7D%7D%2C%7B%22key%22%3A%2285FPEP3S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brunac%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrunac%2C%20Anne%26%23x2010%3BC%26%23xE9%3Bcile%2C%20Anne%20Laprie%2C%20Marie%26%23x2010%3BPierre%20Castex%2C%20Camille%20Laurent%2C%20Fran%26%23xE7%3Bois%20Le%20Loarer%2C%20Marie%20Karanian%2C%20Sophie%20Le%20Guellec%2C%20Delphine%20Guillemot%2C%20Gaelle%20Pierron%2C%20and%20Anne%20Gomez%26%23x2010%3BBrouchet.%20%26%23x201C%3BThe%20Combination%20of%20Radiotherapy%20and%20ALK%20Inhibitors%20Is%20Effective%20in%20the%20Treatment%20of%20Intraosseous%20Rhabdomyosarcoma%20with%20%3Ci%3EFUS%26%23x2010%3BTFCP2%3C%5C%2Fi%3E%20Fusion%20Transcript.%26%23x201D%3B%20%3Ci%3EPediatric%20Blood%20%26amp%3B%20Cancer%3C%5C%2Fi%3E%2067%2C%20no.%205%20%282020%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.28185%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.28185%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20combination%20of%20radiotherapy%20and%20ALK%20inhibitors%20is%20effective%20in%20the%20treatment%20of%20intraosseous%20rhabdomyosarcoma%20with%20%3Ci%3EFUS%5Cu2010TFCP2%3C%5C%2Fi%3E%20fusion%20transcript%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%5Cu2010C%5Cu00e9cile%22%2C%22lastName%22%3A%22Brunac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%5Cu2010Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez%5Cu2010Brouchet%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2205%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.28185%22%2C%22ISSN%22%3A%221545-5009%2C%201545-5017%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fpbc.28185%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A16Z%22%7D%7D%2C%7B%22key%22%3A%226B64776A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Egan%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEgan%2C%20Caoimhe%2C%20Camille%20Laurent%2C%20Julie%20C.%20Alejo%2C%20Stefano%20Pileri%2C%20Elias%20Campo%2C%20Steven%20H.%20Swerdlow%2C%20Miguel%20Piris%2C%20et%20al.%20%26%23x201C%3BExpansion%20of%20PD1-Positive%20T%20Cells%20in%20Nodal%20Marginal%20Zone%20Lymphoma%3A%20A%20Potential%20Diagnostic%20Pitfall.%26%23x201D%3B%20%3Ci%3EThe%20American%20Journal%20of%20Surgical%20Pathology%3C%5C%2Fi%3E%2044%2C%20no.%205%20%282020%29%3A%20657%26%23x2013%3B64.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001414%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001414%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expansion%20of%20PD1-positive%20T%20Cells%20in%20Nodal%20Marginal%20Zone%20Lymphoma%3A%20A%20Potential%20Diagnostic%20Pitfall%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caoimhe%22%2C%22lastName%22%3A%22Egan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%20C.%22%2C%22lastName%22%3A%22Alejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Pileri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elias%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20H.%22%2C%22lastName%22%3A%22Swerdlow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Piris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wing%20C.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Warnke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Randy%20D.%22%2C%22lastName%22%3A%22Gascoyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liqiang%22%2C%22lastName%22%3A%22Xi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Raffeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Pittaluga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elaine%20S.%22%2C%22lastName%22%3A%22Jaffe%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2205%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001414%22%2C%22ISSN%22%3A%220147-5185%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F10.1097%5C%2FPAS.0000000000001414%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A28%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22YWW677H9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Philippe%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPhilippe%2C%20Laure%2C%20Remi%20Lancar%2C%20Camille%20Laurent%2C%20Michele%20Algarte%26%23x2010%3BGenin%2C%20Catherine%20Chassagne%26%23x2010%3BCl%26%23xE9%3Bment%2C%20Bettina%20Fabiani%2C%20Marie%20Pierre%20Chenard%2C%20et%20al.%20%26%23x201C%3BBCL2%20Expression%20Is%20an%20Independent%20Prognostic%20Factor%20in%20HIV%26%23x2010%3Bassociated%20DLBCL%2C%20a%20LYMPHOVIR%20Cohort%20Study.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20188%2C%20no.%203%20%282020%29%3A%20413%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.16176%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjh.16176%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22BCL2%20expression%20is%20an%20independent%20prognostic%20factor%20in%20HIV%5Cu2010associated%20DLBCL%2C%20a%20LYMPHOVIR%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Philippe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remi%22%2C%22lastName%22%3A%22Lancar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Algarte%5Cu2010Genin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne%5Cu2010Cl%5Cu00e9ment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Fabiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Pierre%20Chenard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lazure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Parrens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Charlotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Delattre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gibault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederique%22%2C%22lastName%22%3A%22Capron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Goubin%5Cu2010Versini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Petitjean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bou%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regis%22%2C%22lastName%22%3A%22Costello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Costagliola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Prevot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ANRS%5Cu2010CO16%20LYMPHOVIR%20Cohort%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fbjh.16176%22%2C%22ISSN%22%3A%220007-1048%2C%201365-2141%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fbjh.16176%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A28%3A19Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Balança, Camille-Charlotte, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, et al. “PD-1 Blockade Restores Helper Activity of Tumor-Infiltrating Exhausted PD-1hiCD39+ CD4 T Cells.” JCI Insight<\/i>, December 17, 2020. https:\/\/doi.org\/10.1172\/jci.insight.142513<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Marku, Malvina, Nina Verstraete, Flavien Raynal, Miguel Madrid-Mencía, Marcin Domagala, Jean-Jacques Fournié, Loïc Ysebaert, Mary Poupot, and Vera Pancaldi. “Insights on TAM Formation from a Boolean Model of Macrophage Polarization Based on In Vitro Studies.” Cancers<\/i> 12, no. 12 (December 7, 2020): 3664. https:\/\/doi.org\/10.3390\/cancers12123664<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gauthier, Martin, Jean-Baptiste Rieu, Camille Laurent, and François Vergez. “Eye-Catching Spindle-Shaped Mast Cells without Sinister Significance.” British Journal of Haematology<\/i>, November 21, 2020. https:\/\/doi.org\/10.1111\/bjh.17207<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Mouchel, Pierre‐Luc, Charlotte Syrykh, Camille Laurent, Suzanne Tavitian, and Martin Gauthier. “First Case of Classical Hodgkin‐like EBV<\/span> ‐positive Lymphoproliferative Disorder under Ruxolitinib Therapy.” American Journal of Hematology<\/i>, November 6, 2020, ajh.26026. https:\/\/doi.org\/10.1002\/ajh.26026<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bordes, Julien, Sébastien Incerti, Erick Mora-Ramirez, Jonathan Tranel, Cédric Rossi, Christine Bezombes, Julie Bordenave, Manuel Bardiès, Richard Brown, and Marie-Claude Bordage. “Monte Carlo Dosimetry of a Realistic Multicellular Model of Follicular Lymphoma in a Context of Radioimmunotherapy.” Medical Physics<\/i> 47, no. 10 (October 2020): 5222–34. https:\/\/doi.org\/10.1002\/mp.14370<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sarkozy, Clementine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns, Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. “Mutational Landscape of Grey Zone Lymphoma.” Blood<\/i>, September 22, 2020, blood.2020007507. https:\/\/doi.org\/10.1182\/blood.2020007507<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, et al. “Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.” Clinical Pharmacokinetics<\/i> 59, no. 9 (September 2020): 1171–83. https:\/\/doi.org\/10.1007\/s40262-020-00884-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Jacquier, Anthony, Charlotte Syrykh, Isabelle Bedgedjian, Franck Monnien, Camille Laurent, Séverine Valmary-Degano, and Pierre Brousset. “Immunohistochemistry with Anti-MAL Antibody and RNAscope with MAL Probes Are Complementary Techniques for Diagnosis of Primary Mediastinal Large B-Cell Lymphoma.” Journal of Clinical Pathology<\/i>, August 24, 2020, jclinpath-2020-206747. https:\/\/doi.org\/10.1136\/jclinpath-2020-206747<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Zamò, Alberto, Peter Johnston, Ayoma D Attygalle, Camille Laurent, Daniel A Arber, and Falko Fend. “Aggressive B‐cell Lymphomas with a Primary Bone Marrow Presentation.” Histopathology<\/i>, July 14, 2020, his.14124. https:\/\/doi.org\/10.1111\/his.14124<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Aroua, Nesrine, Emeline Boet, Margherita Ghisi, Marie-Laure Nicolau-Travers, Estelle Saland, Ryan Gwilliam, Fabienne de Toni, et al. “Extracellular ATP and CD39 Activate CAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia.” Cancer Discovery<\/i>, July 8, 2020, CD-19-1008. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1008<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laplagne, Chloé, Sarah Meddour, Sarah Figarol, Marie Michelas, Olivier Calvayrac, Gilles Favre, Camille Laurent, Jean-Jacques Fournié, Stéphanie Cabantous, and Mary Poupot. “Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.” Frontiers in Immunology<\/i> 11 (July 7, 2020): 1396. https:\/\/doi.org\/10.3389\/fimmu.2020.01396<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Balança, Camille-Charlotte, Clara-Maria Scarlata, Marie Michelas, Christel Devaud, Victor Sarradin, Camille Franchet, Carlos Martinez Gomez, et al. “Dual Relief of T-Lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.” Cancer Immunology Research<\/i> 8, no. 7 (July 2020): 869–82. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0855<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Attygalle, Ayoma D., Alberto Zamò, Falko Fend, Peter Johnston, Daniel A. Arber, and Camille Laurent. “Challenges and Limitations in the Primary Diagnosis of T-Cell and Natural Killer Cell\/T-Cell Lymphoma in Bone Marrow Biopsy.” Histopathology<\/i> 77, no. 1 (July 2020): 2–17. https:\/\/doi.org\/10.1111\/his.14093<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sarkozy, Clémentine, Lauren Chong, Katsuyoshi Takata, Elizabeth A. Chavez, Tomoko Miyata-Takata, Gerben Duns, Adèle Telenius, et al. “Gene Expression Profiling of Gray Zone Lymphoma.” Blood Advances<\/i> 4, no. 11 (June 9, 2020): 2523–35. https:\/\/doi.org\/10.1182\/bloodadvances.2020001923<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pont, Frédéric, Marie Tosolini, Qing Gao, Marion Perrier, Miguel Madrid-Mencía, Tse Shun Huang, Pierre Neuvial, Maha Ayyoub, Kristopher Nazor, and Jean-Jacques Fournié. “Single-Cell Virtual Cytometer Allows User-Friendly and Versatile Analysis and Visualization of Multimodal Single Cell RNAseq Datasets.” NAR Genomics and Bioinformatics<\/i> 2, no. 2 (June 1, 2020): lqaa025. https:\/\/doi.org\/10.1093\/nargab\/lqaa025<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Mescam, Lénaïg, Vincent Camus, Jean-Marc Schiano, José Adélaïde, Jean-Michel Picquenot, Arnaud Guille, Marie Bannier, et al. “EBV+ Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation Expands the Spectrum of Breast Implant-Related Lymphomas.” Blood<\/i> 135, no. 22 (May 28, 2020): 2004–9. https:\/\/doi.org\/10.1182\/blood.2019003408<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Péricart, Sarah, Charlotte Syrykh, Nadia Amara, Camille Franchet, Bernard Malavaud, Philippe Gaulard, Jean-Philippe Girard, Loic Ysebaert, Camille Laurent, and Pierre Brousset. “Exclusive B-Cell Phenotype of Primary Prostatic Lymphomas: A Potential Role of Chronic Prostatitis.” Histopathology<\/i> 76, no. 5 (April 2020): 767–73. https:\/\/doi.org\/10.1111\/his.14045<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Aussedat, Guillaume, Alexandra Traverse-Glehen, Aspasia Stamatoullas, Thierry Molina, Violaine Safar, Camille Laurent, Jean-Marie Michot, et al. “Composite and Sequential Lymphoma between Classical Hodgkin Lymphoma and Primary Mediastinal Lymphoma\/Diffuse Large B-Cell Lymphoma, a Clinico-Pathological Series of 25 Cases.” British Journal of Haematology<\/i> 189, no. 2 (April 2020): 244–56. https:\/\/doi.org\/10.1111\/bjh.16331<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Vidal-Crespo, Anna, Alba Matas-Céspedes, Vanina Rodriguez, Cédric Rossi, Juan G. Valero, Neus Serrat, Alejandra Sanjuan-Pla, et al. “Daratumumab Displays in Vitro and in Vivo Anti-Tumor Activity in Models of B-Cell Non-Hodgkin Lymphoma and Improves Responses to Standard Chemo-Immunotherapy Regimens.” Haematologica<\/i> 105, no. 4 (April 2020): 1032–41. https:\/\/doi.org\/10.3324\/haematol.2018.211904<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Camille, Claire, Chloé Dimeglio, Antoine Yrondi, Gisèle Compaci, Emmanuelle Delmas, Mélanie Gauché, Guy Laurent, and Philippe Birmes. “Posttraumatic Stress Disorder Symptoms in Lymphoma Patients: A Prospective Study.” Frontiers in Psychiatry<\/i> 11 (March 11, 2020): 201. https:\/\/doi.org\/10.3389\/fpsyt.2020.00201<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, Alina Nicolae, Cécile Laurent, Fabien Le Bras, Corinne Haioun, Virginie Fataccioli, Nadia Amara, et al. “Gene Alterations in Epigenetic Modifiers and JAK-STAT Signaling Are Frequent in Breast Implant-Associated ALCL.” Blood<\/i> 135, no. 5 (January 30, 2020): 360–70. https:\/\/doi.org\/10.1182\/blood.2019001904<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Roussel, Mikael, Faustine Lhomme, Caroline E. Roe, Todd Bartkowiak, Pauline Gravelle, Camille Laurent, Thierry Fest, and Jonathan M. Irish. “Mass Cytometry Defines Distinct Immune Profile in Germinal Center B-Cell Lymphomas.” Cancer Immunology, Immunotherapy: CII<\/i>, January 9, 2020. https:\/\/doi.org\/10.1007\/s00262-019-02464-z<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cadot, Sarah, Carine Valle, Marie Tosolini, Frederic Pont, Laetitia Largeaud, Camille Laurent, Jean Jacques Fournie, Loic Ysebaert, and Anne Quillet-Mary. “Longitudinal CITE-Seq Profiling of Chronic Lymphocytic Leukemia during Ibrutinib Treatment: Evolution of Leukemic and Immune Cells at Relapse.” Biomarker Research<\/i> 8, no. 1 (2020): 72. https:\/\/doi.org\/10.1186\/s40364-020-00253-w<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Syrykh, Charlotte, Arnaud Abreu, Nadia Amara, Aurore Siegfried, Véronique Maisongrosse, François X. Frenois, Laurent Martin, Cédric Rossi, Camille Laurent, and Pierre Brousset. “Accurate Diagnosis of Lymphoma on Whole-Slide Histopathology Images Using Deep Learning.” Npj Digital Medicine<\/i> 3, no. 1 (2020): 63. https:\/\/doi.org\/10.1038\/s41746-020-0272-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
El Halabi, Layal, Julien Adam, Pauline Gravelle, Virginie Marty, Alina Danu, Julien Lazarovici, Vincent Ribrag, et al. “Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.” Clinical Lymphoma Myeloma and Leukemia<\/i>, 2020, S2152265020306339. https:\/\/doi.org\/10.1016\/j.clml.2020.11.009<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, Daniel A. Arber, Peter Johnston, Falko Fend, Alberto Zamo, and Ayoma D. Attygalle. “Diagnosis of Classic Hodgkin Lymphoma on Bone Marrow Biopsy.” Histopathology<\/i> 76, no. 7 (2020): 934–41. https:\/\/doi.org\/10.1111\/his.14085<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Brunac, Anne‐Cécile, Anne Laprie, Marie‐Pierre Castex, Camille Laurent, François Le Loarer, Marie Karanian, Sophie Le Guellec, Delphine Guillemot, Gaelle Pierron, and Anne Gomez‐Brouchet. “The Combination of Radiotherapy and ALK Inhibitors Is Effective in the Treatment of Intraosseous Rhabdomyosarcoma with FUS‐TFCP2<\/i> Fusion Transcript.” Pediatric Blood & Cancer<\/i> 67, no. 5 (2020). https:\/\/doi.org\/10.1002\/pbc.28185<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Egan, Caoimhe, Camille Laurent, Julie C. Alejo, Stefano Pileri, Elias Campo, Steven H. Swerdlow, Miguel Piris, et al. “Expansion of PD1-Positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall.” The American Journal of Surgical Pathology<\/i> 44, no. 5 (2020): 657–64. https:\/\/doi.org\/10.1097\/PAS.0000000000001414<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Philippe, Laure, Remi Lancar, Camille Laurent, Michele Algarte‐Genin, Catherine Chassagne‐Clément, Bettina Fabiani, Marie Pierre Chenard, et al. “BCL2 Expression Is an Independent Prognostic Factor in HIV‐associated DLBCL, a LYMPHOVIR Cohort Study.” British Journal of Haematology<\/i> 188, no. 3 (2020): 413–23. https:\/\/doi.org\/10.1111\/bjh.16176<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2019″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tQS3I9WIA<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2019<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2232<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-37f6d356cd9770942b719022275ca07e%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XZPZPTJ6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22P%5Cu00e9ricart%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EP%26%23xE9%3Bricart%2C%20Sarah%2C%20Charlotte%20Waysse%2C%20Aurore%20Siegfried%2C%20Stephanie%20Struski%2C%20Eric%20Delabesse%2C%20Camille%20Laurent%2C%20and%20Sol%26%23xE8%3Bne%20Evrard.%20%26%23x201C%3BSubsequent%20Development%20of%20Histiocytic%20Sarcoma%20and%20Follicular%20Lymphoma%3A%20Cytogenetics%20and%20next-Generation%20Sequencing%20Analyses%20Provide%20Evidence%20for%20Transdifferentiation%20of%20Early%20Common%20Lymphoid%20Precursor-a%20Case%20Report%20and%20Review%20of%20Literature.%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%2C%20December%205%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Subsequent%20development%20of%20histiocytic%20sarcoma%20and%20follicular%20lymphoma%3A%20cytogenetics%20and%20next-generation%20sequencing%20analyses%20provide%20evidence%20for%20transdifferentiation%20of%20early%20common%20lymphoid%20precursor-a%20case%20report%20and%20review%20of%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Waysse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Struski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22Histiocytic%20sarcoma%20%28HS%29%20is%20a%20rare%20aggressive%20hematologic%20neoplasm%20that%20can%20be%20associated%20with%20low-grade%20B%20cell%20lymphoma.%20The%20development%20of%20both%20neoplasms%20is%20currently%20being%20considered%20a%20transdifferentiation%20mechanism%20but%20remains%20elusive.%20We%20report%20the%20case%20of%20a%2065-year-old%20patient%20with%20synchronous%20development%20of%20peritoneal%5C%2Fabdominal%20HS%20and%20grade%201-2%20follicular%20lymphoma%20%28FL%29.%20Cytogenetic%20analysis%20and%20targeted%20next-generation%20sequencing%20of%20both%20FL%20and%20HS%20tumors%20identified%20common%20genomic%20alterations%20such%20as%20IGH-BCL2%20rearrangement%2C%20CREBBP%20and%20KMT2D%2C%20and%20aberrations%20of%20chromosomes%209q%20and%2019q.%20However%2C%20only%20the%20HS%20tumor%20had%20a%20KRAS%20mutation%20while%20the%20lymph%20node%20involved%20by%20FL%20harbored%20a%20TNFAIP3%20mutation%20and%20both%20tumors%20also%20showed%20distinct%20chromosomal%20alterations.%20This%20report%20strengthens%20the%20hypothesis%20of%20a%20common%20lymphoid%20progenitor%20which%20accumulates%20genetic%20alterations%20leading%20to%20two%20different%20hematologic%20malignant%20diseases%20with%20significantly%20distinct%20prognoses.%22%2C%22date%22%3A%22Dec%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-019-02691-w%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22ZJZR8A4N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarkozy%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESarkozy%2C%20Clementine%2C%20Stacy%20Hung%2C%20Katsuyoshi%20Takata%2C%20Elizabeth%20Chavez%2C%20Tomohiro%20Aoki%2C%20Gerben%20Duns%2C%20Graham%20W.%20Slack%2C%20et%20al.%20%26%23x201C%3BMutational%20Landscape%20of%20Grey%20Zone%20Lymphoma.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20134%2C%20no.%20Supplement_1%20%28November%2013%2C%202019%29%3A%2021.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-127375%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-127375%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mutational%20Landscape%20of%20Grey%20Zone%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clementine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stacy%22%2C%22lastName%22%3A%22Hung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsuyoshi%22%2C%22lastName%22%3A%22Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Chavez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohiro%22%2C%22lastName%22%3A%22Aoki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerben%22%2C%22lastName%22%3A%22Duns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%20W.%22%2C%22lastName%22%3A%22Slack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adele%22%2C%22lastName%22%3A%22Telenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomoko%22%2C%22lastName%22%3A%22Miyata-Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Vigan%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%20Jo%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%22%2C%22lastName%22%3A%22Ben-Neriah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Mottok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20J.%22%2C%22lastName%22%3A%22Savage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Steidl%22%7D%5D%2C%22abstractNote%22%3A%22DISCLOSURES%3A%20Sarkozy%3A%20Takeda%3A%20Research%20Funding.%20Salles%3AMerck%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%27s%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Novartis%2C%20Servier%2C%20AbbVie%2C%20Karyopharm%2C%20Kite%2C%20MorphoSys%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%27s%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events%3B%20Autolus%3A%20Consultancy%2C%20Membership%20on%20an%20entity%27s%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Takeda%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%27s%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events%3B%20Epizyme%3A%20Consultancy%2C%20Honoraria%3B%20BMS%3A%20Honoraria%3B%20Amgen%3A%20Honoraria%2C%20Other%3A%20Educational%20events%3B%20Roche%2C%20Janssen%2C%20Gilead%2C%20Celgene%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%27s%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events.%20Savage%3ABMS%2C%20Merck%2C%20Novartis%2C%20Verastem%2C%20Abbvie%2C%20Servier%2C%20and%20Seattle%20Genetics%3A%20Consultancy%2C%20Honoraria%3B%20Seattle%20Genetics%2C%20Inc.%3A%20Consultancy%2C%20Honoraria%2C%20Research%20Funding.%20Scott%3ACelgene%3A%20Consultancy%3B%20Roche%5C%2FGenentech%3A%20Research%20Funding%3B%20Janssen%3A%20Consultancy%2C%20Research%20Funding%3B%20NanoString%3A%20Patents%20%26%20Royalties%3A%20Named%20inventor%20on%20a%20patent%20licensed%20to%20NanoSting%20%5BInstitution%5D%2C%20Research%20Funding.%20Steidl%3AJuno%20Therapeutics%3A%20Consultancy%3B%20Tioma%3A%20Research%20Funding%3B%20Roche%3A%20Consultancy%3B%20Bristol-Myers%20Squibb%3A%20Research%20Funding%3B%20Nanostring%3A%20Patents%20%26%20Royalties%3A%20Filed%20patent%20on%20behalf%20of%20BC%20Cancer%3B%20Seattle%20Genetics%3A%20Consultancy%3B%20Bayer%3A%20Consultancy.%22%2C%22date%22%3A%22Nov%2013%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood-2019-127375%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A44Z%22%7D%7D%2C%7B%22key%22%3A%224BTE4RWA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laplagne%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaplagne%2C%20Chlo%26%23xE9%3B%2C%20Marcin%20Domagala%2C%20Augustin%20Le%20Naour%2C%20Christophe%20Quemerais%2C%20Dimitri%20Hamel%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Bettina%20Couderc%2C%20Corinne%20Bousquet%2C%20Audrey%20Ferrand%2C%20and%20Mary%20Poupot.%20%26%23x201C%3BLatest%20Advances%20in%20Targeting%20the%20Tumor%20Microenvironment%20for%20Tumor%20Suppression.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2020%2C%20no.%2019%20%28September%2023%2C%202019%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20194719%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20194719%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Latest%20Advances%20in%20Targeting%20the%20Tumor%20Microenvironment%20for%20Tumor%20Suppression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Laplagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Domagala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Le%20Naour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Quemerais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Hamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Couderc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Bousquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%5D%2C%22abstractNote%22%3A%22The%20tumor%20bulk%20is%20composed%20of%20a%20highly%20heterogeneous%20population%20of%20cancer%20cells%2C%20as%20well%20as%20a%20large%20variety%20of%20resident%20and%20infiltrating%20host%20cells%2C%20extracellular%20matrix%20proteins%2C%20and%20secreted%20proteins%2C%20collectively%20known%20as%20the%20tumor%20microenvironment%20%28TME%29.%20The%20TME%20is%20essential%20for%20driving%20tumor%20development%20by%20promoting%20cancer%20cell%20survival%2C%20migration%2C%20metastasis%2C%20chemoresistance%2C%20and%20the%20ability%20to%20evade%20the%20immune%20system%20responses.%20Therapeutically%20targeting%20tumor-associated%20macrophages%20%28TAMs%29%2C%20cancer-associated%20fibroblasts%20%28CAFs%29%2C%20regulatory%20T-cells%20%28T-regs%29%2C%20and%20mesenchymal%20stromal%5C%2Fstem%20cells%20%28MSCs%29%20is%20likely%20to%20have%20an%20impact%20in%20cancer%20treatment.%20In%20this%20review%2C%20we%20focus%20on%20describing%20the%20normal%20physiological%20functions%20of%20each%20of%20these%20cell%20types%20and%20their%20behavior%20in%20the%20cancer%20setting.%20Relying%20on%20the%20specific%20surface%20markers%20and%20secreted%20molecules%20in%20this%20context%2C%20we%20review%20the%20potential%20targeting%20of%20these%20cells%20inducing%20their%20depletion%2C%20reprogramming%2C%20or%20differentiation%2C%20or%20inhibiting%20their%20pro-tumor%20functions%20or%20recruitment.%20Different%20approaches%20were%20developed%20for%20this%20targeting%2C%20namely%2C%20immunotherapies%2C%20vaccines%2C%20small%20interfering%20RNA%2C%20or%20small%20molecules.%22%2C%22date%22%3A%22Sep%2023%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms20194719%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22NPEV4ECN%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22YINBPDTY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mondrag%5Cu00f3n%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMondrag%26%23xF3%3Bn%2C%20Laura%2C%20Rana%20Mhaidly%2C%20Gian%20Marco%20De%20Donatis%2C%20Marie%20Tosolini%2C%20Pascal%20Dao%2C%20Anthony%20R.%20Martin%2C%20Caroline%20Pons%2C%20et%20al.%20%26%23x201C%3BGAPDH%20Overexpression%20in%20the%20T%20Cell%20Lineage%20Promotes%20Angioimmunoblastic%20T%20Cell%20Lymphoma%20through%20an%20NF-%26%23x39A%3BB-Dependent%20Mechanism.%26%23x201D%3B%20%3Ci%3ECancer%20Cell%3C%5C%2Fi%3E%2C%20August%2020%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ccell.2019.07.008%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ccell.2019.07.008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22GAPDH%20Overexpression%20in%20the%20T%20Cell%20Lineage%20Promotes%20Angioimmunoblastic%20T%20Cell%20Lymphoma%20through%20an%20NF-%5Cu03baB-Dependent%20Mechanism%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mondrag%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rana%22%2C%22lastName%22%3A%22Mhaidly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Marco%22%2C%22lastName%22%3A%22De%20Donatis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Dao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20R.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Pons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Chiche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Jacquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Pro%5Cu00efcs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Doye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Luciano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaap%20G.%22%2C%22lastName%22%3A%22Neels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Coutant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Fabien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Sormani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camila%22%2C%22lastName%22%3A%22Rubio-Pati%5Cu00f1o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jozef%20P.%22%2C%22lastName%22%3A%22Bossowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Marchetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Villa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Peyron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Asnafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Genestier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Benhida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Passeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Ehrland%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Verhoeyen%22%7D%5D%2C%22abstractNote%22%3A%22GAPDH%20is%20emerging%20as%20a%20key%20player%20in%20T%5Cu00a0cell%20development%20and%20function.%20To%20investigate%20the%20role%20of%20GAPDH%20in%20T%5Cu00a0cells%2C%20we%20generated%20a%20transgenic%20mouse%20model%20overexpressing%20GAPDH%20in%20the%20T%5Cu00a0cell%20lineage.%20Aged%20mice%20developed%20a%20peripheral%20Tfh-like%20lymphoma%20that%20recapitulated%20key%20molecular%2C%20pathological%2C%20and%20immunophenotypic%20features%20of%20human%20angioimmunoblastic%20T%5Cu00a0cell%20lymphoma%20%28AITL%29.%20GAPDH%20induced%20non-canonical%20NF-%5Cu03baB%20pathway%20activation%20in%20mouse%20T%5Cu00a0cells%2C%20which%20was%20strongly%20activated%20in%20human%20AITL.%20We%20developed%20a%20NIK%20inhibitor%20to%20reveal%20that%20targeting%20the%20NF-%5Cu03baB%20pathway%20prolonged%20AITL-bearing%20mouse%20survival%20alone%20and%20in%20combination%20with%20anti-PD-1.%20These%20findings%20suggest%20the%20therapeutic%20potential%20of%20targeting%20NF-%5Cu03baB%20signaling%20in%20AITL%20and%20provide%20a%20model%20for%20future%20AITL%20therapeutic%20investigations.%22%2C%22date%22%3A%22Aug%2020%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ccell.2019.07.008%22%2C%22ISSN%22%3A%221878-3686%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22ZWP5MRV4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gauthier%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-14%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGauthier%2C%20Martin%2C%20Fran%26%23xE7%3Boise%20Durrieu%2C%20Elodie%20Martin%2C%20Michael%20Peres%2C%20Fran%26%23xE7%3Bois%20Vergez%2C%20Thomas%20Filleron%2C%20Lucie%20Ob%26%23xE9%3Bric%2C%20Fontanet%20Bijou%2C%20Anne%20Quillet%20Mary%2C%20and%20Loic%20Ysebaert.%20%26%23x201C%3BPrognostic%20Role%20of%20CD4%20T-Cell%20Depletion%20after%20Frontline%20Fludarabine%2C%20Cyclophosphamide%20and%20Rituximab%20in%20Chronic%20Lymphocytic%20Leukaemia.%26%23x201D%3B%20%3Ci%3EBMC%20Cancer%3C%5C%2Fi%3E%2019%2C%20no.%201%20%28August%2014%2C%202019%29%3A%20809.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-5971-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-5971-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20role%20of%20CD4%20T-cell%20depletion%20after%20frontline%20fludarabine%2C%20cyclophosphamide%20and%20rituximab%20in%20chronic%20lymphocytic%20leukaemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durrieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fontanet%22%2C%22lastName%22%3A%22Bijou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet%20Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Eradication%20of%20minimal%20residual%20disease%20%28MRD%29%2C%20at%20the%20end%20of%20Fludarabine-Cyclophosphamide-Rituximab%20%28FCR%29%20treatment%2C%20is%20a%20validated%20surrogate%20marker%20for%20progression-free%20and%20overall%20survival%20in%20chronic%20lymphocytic%20leukaemia.%20But%20such%20deep%20responses%20are%20also%20associated%20with%20severe%20immuno-depletion%2C%20leading%20to%20infections%20and%20the%20development%20of%20secondary%20cancers.%5CnMETHODS%3A%20We%20assessed%2C%20blood%20MRD%20and%20normal%20immune%20cell%20levels%20at%20the%20end%20of%20treatment%2C%20in%20162%20first-line%20FCR%20patients%2C%20and%20analysed%20survival%20and%20adverse%20event.%5CnRESULTS%3A%20Multivariate%20Landmark%20analysis%203%5Cu2009months%20after%20FCR%20completion%20identified%20unmutated%20IGHV%20status%20%28HR%2C%202.03%2C%20p%5Cu2009%3D%5Cu20090.043%29%2C%20the%20level%20of%20MRD%20reached%20%28intermediate%20versus%20low%2C%20HR%2C%202.43%2C%20p%5Cu2009%3D%5Cu20090.002%3B%20high%20versus%20low%2C%20HR%2C%204.56%2C%20p%5Cu2009%3D%5Cu20090.002%29%20and%20CD4%5Cu2009%3E%5Cu2009200%5C%2Fmm3%20%28HR%2C%203.30%2C%20p%5Cu2009%3C%5Cu2009%5Cu00a00.001%29%20as%20factors%20independently%20associated%20with%20progression-free%20survival%20%28PFS%29%3B%20neither%20CD8%20nor%20NK%20counts%20were%20associated%20with%20PFS.%20The%20CD4%20count%20was%20associated%20with%20PFS%20irrespective%20of%20IGHV%20mutational%20status%2C%20but%20only%20in%20patients%20with%20detectable%20MRD%20%28HR%2C%203.51%2C%20p%5Cu2009%3D%5Cu20090.0004%2C%20whereas%20it%20had%20no%20prognostic%20impact%20in%20MRD%5Cu2009%3C%5Cu200910-%5Cu20094%20patients%3A%20p%5Cu2009%3D%5Cu20090.6998%29.%20We%20next%20used%20a%20competitive%20risk%20model%20to%20investigate%20whether%20immune%20cell%20subsets%20could%20be%20associated%20with%20the%20risk%20of%20infection%20and%20found%20no%20association%20between%20CD4%2C%20CD8%20and%20NK%20cells%20and%20infection.%5CnCONCLUSIONS%3A%20Consolidation%5C%2Fmaintenance%20trials%20based%20on%20detectable%20MRD%20after%20FCR%20should%20investigate%20CD4%20T-cell%20numbers%20both%20as%20a%20selection%20and%20a%20response%20criterion%2C%20and%20consolidation%20treatments%20should%20target%20B-cell%5C%2FT-cell%20interactions.%22%2C%22date%22%3A%222019-08-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-019-5971-z%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22UY5Z4Y4P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20and%20Brousset%22%2C%22parsedDate%22%3A%222019-08-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3B%5BNew%20entities%20and%20new%20tools%20in%20hematopathology%20as%20proposed%20by%20the%202016%20WHO%20classification%3A%20Case%207%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2C%20August%209%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2019.05.004%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2019.05.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BNew%20entities%20and%20new%20tools%20in%20hematopathology%20as%20proposed%20by%20the%202016%20WHO%20classification%3A%20Case%207%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Aug%2009%2C%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2019.05.004%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A33Z%22%7D%7D%2C%7B%22key%22%3A%2232MC8SYW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20and%20Brousset%22%2C%22parsedDate%22%3A%222019-08-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Camille%2C%20and%20Pierre%20Brousset.%20%26%23x201C%3B%5BNew%20entities%20and%20new%20tools%20in%20hematopathology%20as%20proposed%20by%20the%202016%20WHO%20classification%3A%20Case%206%5D.%26%23x201D%3B%20%3Ci%3EAnnales%20De%20Pathologie%3C%5C%2Fi%3E%2C%20August%209%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2019.05.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2019.05.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BNew%20entities%20and%20new%20tools%20in%20hematopathology%20as%20proposed%20by%20the%202016%20WHO%20classification%3A%20Case%206%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Aug%2009%2C%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2019.05.003%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A34Z%22%7D%7D%2C%7B%22key%22%3A%222X4FEW3U%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Loarer%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Loarer%2C%20Fran%26%23xE7%3Bois%2C%20Arjen%20H.%20G.%20Cleven%2C%20Corinne%20Bouvier%2C%20Marie-Pierre%20Castex%2C%20Cleofe%20Romagosa%2C%20Anne%20Moreau%2C%20S%26%23xE9%3Bbastien%20Salas%2C%20et%20al.%20%26%23x201C%3BA%20Subset%20of%20Epithelioid%20and%20Spindle%20Cell%20Rhabdomyosarcomas%20Is%20Associated%20with%20TFCP2%20Fusions%20and%20Common%20ALK%20Upregulation.%26%23x201D%3B%20%3Ci%3EModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%3C%5C%2Fi%3E%2C%20August%205%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0323-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0323-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20subset%20of%20epithelioid%20and%20spindle%20cell%20rhabdomyosarcomas%20is%20associated%20with%20TFCP2%20fusions%20and%20common%20ALK%20upregulation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arjen%20H.%20G.%22%2C%22lastName%22%3A%22Cleven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Bouvier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleofe%22%2C%22lastName%22%3A%22Romagosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Bonhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Audard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irma%22%2C%22lastName%22%3A%22Ramos-Oliver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Cleton-Jansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dilara%20C.%22%2C%22lastName%22%3A%22Savci-Heijink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herman%20M.%22%2C%22lastName%22%3A%22Kroon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Pissaloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anand%22%2C%22lastName%22%3A%22Sherwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20V.%20M.%20G.%22%2C%22lastName%22%3A%22Bov%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Larousserie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Tirode%22%7D%5D%2C%22abstractNote%22%3A%22Rhabdomyosarcomas%20with%20TFCP2%20fusions%20represent%20an%20emerging%20subtype%20of%20tumors%2C%20initially%20discovered%20by%20RNA-sequencing.%20We%20report%20herein%20the%20clinicopathological%2C%20transcriptional%2C%20and%20genomic%20features%20of%20a%20series%20of%2014%20cases.%20Cases%20were%20retrospectively%20and%20prospectively%20recruited%20and%20studied%20by%20immunohistochemistry%20%28MYF4%2C%20MYOD1%2C%20S100%2C%20AE1%5C%2FE3%2C%20ALK%29%2C%20fluorescence%20in%20situ%20hybridization%20with%20TFCP2%20break-apart%20probe%20%28n%5Cu2009%3D%5Cu200910%5C%2F14%29%2C%20array-comparative%20genomic%20hybridization%20%28Agilent%29%2C%20whole%20RNA-sequencing%20%28Truseq%20Exome%2C%20Illumina%29%2C%20or%20anchored%20multiplex%20PCR-based%20targeted%20next-generation%20sequencing%20%28Archer%5Cu00ae%20FusionPlex%5Cu00ae%20Sarcoma%20kit%29.%20Patient%27s%20age%20ranged%20between%2011%20and%2086%20years%2C%20including%205%20pediatric%20cases.%20Tumors%20were%20located%20in%20the%20bone%20%28n%5Cu2009%3D%5Cu200912%5C%2F14%29%20and%20soft%20tissue%20%28n%5Cu2009%3D%5Cu20092%5C%2F14%29.%20Most%20bone%20tumors%20invaded%20surrounding%20soft%20tissue.%20Craniofacial%20bones%20were%20over-represented%20%28n%5Cu2009%3D%5Cu20098%5C%2F12%29.%20Median%20survival%20was%208%20months%20and%20five%20patients%20are%20currently%20alive%20with%20a%20median%20follow-up%20of%2020%20months.%20Most%20tumors%20displayed%20a%20mixed%20spindle%20cell%20and%20epithelioid%20pattern%20with%20frequent%20vesicular%20nuclei.%20All%20tumors%20expressed%20keratins%20and%20showed%20a%20rhabdomyogenic%20phenotype%20%28defined%20as%20expression%20of%20MYF4%20and%5C%2For%20MYOD1%29.%20ALK%20was%20overexpressed%20in%20all%20but%20three%20cases%20without%20underlying%20ALK%20fusion%20on%20break-apart%20FISH%20%28n%5Cu2009%3D%5Cu20095%29%20nor%20next-generation%20sequencing%20%28n%5Cu2009%3D%5Cu200914%29.%20ALK%20upregulation%20was%20frequently%20associated%20with%20an%20internal%20deletion%20at%20genomic%20level.%20TFCP2%20was%20fused%20in%205%27%20either%20to%20EWSR1%20%28n%5Cu2009%3D%5Cu20096%29%20or%20FUS%20%28n%5Cu2009%3D%5Cu20098%29.%20EWSR1%20was%20involved%20in%20both%20soft%20tissue%20cases.%20FISH%20with%20TFCP2%20break-apart%20probe%20was%20positive%20in%20all%20tested%20cases%20%28n%5Cu2009%3D%5Cu20098%29%2C%20including%20one%20case%20with%20unbalanced%20signal.%20On%20array-CGH%2C%20all%20tested%20tumors%20displayed%20complex%20genetic%20profiles%20with%20genomic%20indexes%20ranging%20from%5Cu00a013%20to%20107.55%5Cu00a0and%20recurrent%20CDKN2A%20deletions.%20FET-TFCP2%20rhabdomyosarcomas%20clustered%20together%20and%20distinctly%20from%20other%20rhabdomyosarcomas%20subgroups.%20Altogether%2C%20our%20data%20confirm%20and%20expand%20the%20spectrum%20of%20the%20new%20family%20of%20FET-TFCP2%20rhabdomyosarcomas%2C%20which%20are%20associated%20with%20a%20predilection%20for%20the%20craniofacial%20bones%2C%20an%20aggressive%20course%2C%20and%20recurrent%20pathological%20features.%20Their%20association%20with%20ALK%20overexpression%20might%20represent%20a%20therapeutic%20vulnerability.%22%2C%22date%22%3A%22Aug%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-019-0323-8%22%2C%22ISSN%22%3A%221530-0285%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22YP4DNRFH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Branco%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBranco%2C%20Beno%26%23xEE%3Bt%2C%20Thibault%20Comont%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Muriel%20Picard%2C%20Camille%20Laurent%2C%20and%20Lucie%20Oberic.%20%26%23x201C%3BTargeted%20Therapy%20of%20BRAF%20V600E-Mutant%20Histiocytic%20Sarcoma%3A%20A%20Case%20Report%20and%20Review%20of%20the%20Literature.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Haematology%3C%5C%2Fi%3E%2C%20August%202%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13303%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13303%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeted%20therapy%20of%20BRAF%20V600E-mutant%20histiocytic%20sarcoma%3A%20A%20case%20report%20and%20review%20of%20the%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Branco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Comont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Aug%2002%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fejh.13303%22%2C%22ISSN%22%3A%221600-0609%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22W69M8XBU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Curdy%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECurdy%2C%20Nicolas%2C%20Olivia%20Lanvin%2C%20Camille%20Laurent%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20and%20Don-Marc%20Franchini.%20%26%23x201C%3BRegulatory%20Mechanisms%20of%20Inhibitory%20Immune%20Checkpoint%20Receptors%20Expression.%26%23x201D%3B%20%3Ci%3ETrends%20in%20Cell%20Biology%3C%5C%2Fi%3E%2C%20August%201%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tcb.2019.07.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tcb.2019.07.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Regulatory%20Mechanisms%20of%20Inhibitory%20Immune%20Checkpoint%20Receptors%20Expression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Curdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%5D%2C%22abstractNote%22%3A%22T%20cells%20responding%20to%20persistent%20tumor%20or%20viral%20antigens%20progressively%20lose%20their%20functional%20properties%2C%20a%20feature%20known%20as%20exhaustion.%20This%20state%20is%20also%20characterized%20by%20cell-surface%20expression%20of%20multiple%20inhibitory%20immune%20checkpoint%20receptors%20%28IRs%29.%20Cancer%20immunotherapy%20by%20immune%20checkpoint%20targeting%20has%20shown%20impressive%20clinical%20outcomes%2C%20but%20requires%20substantial%20improvement%20given%20the%20limited%20number%20of%20patients%20who%20benefit%20from%20the%20treatment.%20Targeting%20the%20mechanisms%20controlling%20immune%20checkpoint%20expression%20could%20represent%20a%20step%20towards%20this%20aim.%20Accumulating%20data%20indicate%20that%20this%20strategy%20can%20limit%20immune%20checkpoint%20expression%2C%20in%20some%20instances%20simultaneously%20inhibiting%20several%20immune%20checkpoints.%20This%20review%20discusses%20various%20mechanisms%20through%20which%20IRs%20are%20activated%20or%20regulated%2C%20and%20ways%20these%20mechanisms%20could%20be%20exploited%20to%20develop%20more%20effective%20future%20immunotherapies.%22%2C%22date%22%3A%22Aug%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.tcb.2019.07.002%22%2C%22ISSN%22%3A%221879-3088%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22USVJNI86%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franchini%20et%20al.%22%2C%22parsedDate%22%3A%222019-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFranchini%2C%20Don-Marc%2C%20Olivia%20Lanvin%2C%20Nicolas%20Curdy%2C%20and%20Jean-Jacques%20Fourni%26%23xE9%3B.%20%26%23x201C%3B%5BControl%20of%20lymphocyte%20activity%20by%20stress%20granules.%20New%20targets%20for%20immunotherapy%26%23x202F%3B%3F%5D.%26%23x201D%3B%20%3Ci%3EMedecine%20Sciences%3A%20M%5C%2FS%3C%5C%2Fi%3E%2035%2C%20no.%206%26%23x2013%3B7%20%28July%202019%29%3A%20507%26%23x2013%3B9.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2019109%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2019109%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BControl%20of%20lymphocyte%20activity%20by%20stress%20granules.%20New%20targets%20for%20immunotherapy%20%3F%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Curdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019%20Jun-Jul%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1051%5C%2Fmedsci%5C%2F2019109%22%2C%22ISSN%22%3A%221958-5381%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22JBQXQ3TV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Flinn%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-27%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFlinn%2C%20Ian%20W.%2C%20John%20G.%20Gribben%2C%20Martin%20J.%20S.%20Dyer%2C%20William%20Wierda%2C%20Michael%20B.%20Maris%2C%20Richard%20R.%20Furman%2C%20Peter%20Hillmen%2C%20et%20al.%20%26%23x201C%3BPhase%201b%20Study%20of%20Venetoclax-Obinutuzumab%20in%20Previously%20Untreated%20and%20Relapsed%5C%2FRefractory%20Chronic%20Lymphocytic%20Leukemia.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20133%2C%20no.%2026%20%28June%2027%2C%202019%29%3A%202765%26%23x2013%3B75.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-01-896290%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-01-896290%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phase%201b%20study%20of%20venetoclax-obinutuzumab%20in%20previously%20untreated%20and%20relapsed%5C%2Frefractory%20chronic%20lymphocytic%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20W.%22%2C%22lastName%22%3A%22Flinn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20G.%22%2C%22lastName%22%3A%22Gribben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20J.%20S.%22%2C%22lastName%22%3A%22Dyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Wierda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20B.%22%2C%22lastName%22%3A%22Maris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20R.%22%2C%22lastName%22%3A%22Furman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Hillmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20A.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Swaminathan%20Padmanabhan%22%2C%22lastName%22%3A%22Iyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriet%20S.%22%2C%22lastName%22%3A%22Walter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Verdugo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huang%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanwen%22%2C%22lastName%22%3A%22Jiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Lozanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20Soriano%22%2C%22lastName%22%3A%22Pignataro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehrdad%22%2C%22lastName%22%3A%22Mobasher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20J.%22%2C%22lastName%22%3A%22Kipps%22%7D%5D%2C%22abstractNote%22%3A%22This%20single-arm%2C%20open-label%2C%20phase%201b%20study%20evaluated%20the%20maximum%20tolerated%20dose%20%28MTD%29%20of%20venetoclax%20when%20given%20with%20obinutuzumab%20and%20its%20safety%20and%20tolerability%20in%20patients%20with%20relapsed%5C%2Frefractory%20%28R%5C%2FR%29%20or%20previously%20untreated%20%28first%20line%20%5B1L%5D%29%20chronic%20lymphocytic%20leukemia%20%28CLL%29.%20Venetoclax%20dose%20initially%20was%20escalated%20%28100-400%20mg%29%20in%20a%203%5Cu2009%2B%5Cu20093%20design%20to%20define%20MTD%20combined%20with%20standard-dose%20obinutuzumab.%20Patients%20received%20venetoclax%20%28schedule%20A%29%20or%20obinutuzumab%20%28schedule%20B%29%20first%20to%20compare%20safety%20and%20determine%20dose%5C%2Fschedule%20for%20expansion.%20Venetoclax-obinutuzumab%20was%20administered%20for%206%20cycles%2C%20followed%20by%20venetoclax%20monotherapy%20until%20disease%20progression%20%28R%5C%2FR%29%20or%20fixed%20duration%201-year%20treatment%20%281L%29.%20Fifty%20R%5C%2FR%20and%2032%201L%20patients%20were%20enrolled.%20No%20dose-limiting%20toxicities%20were%20observed.%20Safety%2C%20including%20incidence%20of%20tumor%20lysis%20syndrome%20%28TLS%29%2C%20did%20not%20differ%20between%20schedules%20%282%20laboratory%20TLSs%20per%20schedule%29.%20Schedule%20B%20and%20a%20400-mg%20dose%20of%20venetoclax%20were%20chosen%20for%20expansion.%20The%20most%20common%20grade%203-4%20adverse%20event%20was%20neutropenia%20%28R%5C%2FR%2C%2058%25%20of%20patients%3B%201L%2C%2053%25%29.%20Rates%20of%20grade%203-4%20infections%20were%2029%25%20%28R%5C%2FR%29%20and%2013%25%20%281L%29%3B%20no%20fatal%20infections%20occurred%20in%201L.%20All%20infusion-related%20reactions%20were%20grade%201-2%2C%20except%20for%202%20grade%203%20events.%20No%20clinical%20TLS%20was%20observed.%20Overall%20best%20response%20rate%20was%2095%25%20in%20R%5C%2FR%20%28complete%20response%20%5BCR%5D%5C%2FCR%20with%20incomplete%20marrow%20recovery%20%5BCRi%5D%2C%2037%25%29%20and%20100%25%20in%201L%20%28CR%5C%2FCRi%2C%2078%25%29%20patients.%20Rate%20of%20undetectable%20%28%3C10-4%29%20minimal%20residual%20disease%20%28uMRD%29%20in%20peripheral%20blood%20for%20R%5C%2FR%20and%201L%20patients%2C%20respectively%2C%20was%2064%25%20and%2091%25%20%5Cu22653%20months%20after%20last%20obinutuzumab%20dose.%20Venetoclax%20and%20obinutuzumab%20therapy%20had%20an%20acceptable%20safety%20profile%20and%20elicited%20durable%20responses%20and%20high%20rates%20of%20uMRD.%20This%20trial%20was%20registered%20at%20www.clinicaltrials.gov%20as%20%23NCT01685892.%22%2C%22date%22%3A%222019-06-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood-2019-01-896290%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22YNCQN7WI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vaysse%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVaysse%2C%20Charlotte%2C%20Camille%20Laurent%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Elodie%20Chantalat%2C%20and%20Benoit%20Chaput.%20%26%23x201C%3BFrance%3A%20The%20First%20Country%20to%20Ban%20a%20Type%20of%20Breast%20Implant%20Linked%20to%20Anaplastic%20Large%20Cell%20Lymphoma.%26%23x201D%3B%20%3Ci%3EAesthetic%20Surgery%20Journal%3C%5C%2Fi%3E%2C%20June%201%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fasj%5C%2Fsjz142%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fasj%5C%2Fsjz142%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22France%3A%20The%20First%20Country%20to%20Ban%20a%20Type%20of%20Breast%20Implant%20Linked%20to%20Anaplastic%20Large%20Cell%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Vaysse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Chantalat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Chaput%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jun%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fasj%5C%2Fsjz142%22%2C%22ISSN%22%3A%221527-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A17Z%22%7D%7D%2C%7B%22key%22%3A%2226Q8PTNH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pizzolato%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPizzolato%2C%20Gabriele%2C%20Hannah%20Kaminski%2C%20Marie%20Tosolini%2C%20Don-Marc%20Franchini%2C%20Fr%26%23xE9%3Bderic%20Pont%2C%20Fr%26%23xE9%3Bderic%20Martins%2C%20Carine%20Valle%2C%20et%20al.%20%26%23x201C%3BSingle-Cell%20RNA%20Sequencing%20Unveils%20the%20Shared%20and%20the%20Distinct%20Cytotoxic%20Hallmarks%20of%20Human%20TCRV%26%23x3B4%3B1%20and%20TCRV%26%23x3B4%3B2%20%26%23x393%3B%26%23x3B4%3B%20T%20Lymphocytes.%26%23x201D%3B%20%3Ci%3EProceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America%3C%5C%2Fi%3E%2C%20May%2022%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.1818488116%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.1818488116%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-cell%20RNA%20sequencing%20unveils%20the%20shared%20and%20the%20distinct%20cytotoxic%20hallmarks%20of%20human%20TCRV%5Cu03b41%20and%20TCRV%5Cu03b42%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriele%22%2C%22lastName%22%3A%22Pizzolato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannah%22%2C%22lastName%22%3A%22Kaminski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Martins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Labourdette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Cadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serena%22%2C%22lastName%22%3A%22Meraviglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Dieli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Merville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Milpied%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22D%5Cu00e9chanet-Merville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22%5Cu03b3%5Cu03b4%20T%20lymphocytes%20represent%20%5Cu223c1%25%20of%20human%20peripheral%20blood%20mononuclear%20cells%20and%20even%20more%20cells%20in%20most%20tissues%20of%20vertebrates.%20Although%20they%20have%20important%20anticancer%20functions%2C%20most%20current%20single-cell%20RNA%20sequencing%20%28scRNA-seq%29%20studies%20do%20not%20identify%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20because%20their%20transcriptomes%20at%20the%20single-cell%20level%20are%20unknown.%20Here%20we%20show%20that%20high-resolution%20clustering%20of%20large%20scRNA-seq%20datasets%20and%20a%20combination%20of%20gene%20signatures%20allow%20the%20specific%20detection%20of%20human%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20and%20identification%20of%20their%20T%20cell%20receptor%20%28TCR%29V%5Cu03b41%20and%20TCRV%5Cu03b42%20subsets%20in%20large%20datasets%20from%20complex%20cell%20mixtures.%20In%20t-distributed%20stochastic%20neighbor%20embedding%20plots%20from%20blood%20and%20tumor%20samples%2C%20the%20few%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20appear%20collectively%20embedded%20between%20cytotoxic%20CD8%20T%20and%20NK%20cells.%20Their%20TCRV%5Cu03b41%20and%20TCRV%5Cu03b42%20subsets%20form%20close%20yet%20distinct%20subclusters%2C%20respectively%20neighboring%20NK%20and%20CD8%20T%20cells%20because%20of%20expression%20of%20shared%20and%20distinct%20cytotoxic%20maturation%20genes.%20Similar%20pseudotime%20maturation%20trajectories%20of%20TCRV%5Cu03b41%20and%20TCRV%5Cu03b42%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20were%20discovered%2C%20unveiling%20in%20both%20subsets%20an%20unattended%20pool%20of%20terminally%20differentiated%20effector%20memory%20cells%20with%20preserved%20proliferative%20capacity%2C%20a%20finding%20confirmed%20by%20in%20vitro%20proliferation%20assays.%20Overall%2C%20the%20single-cell%20transcriptomes%20of%20thousands%20of%20individual%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20from%20different%20CMV%2B%20and%20CMV-%20donors%20reflect%20cytotoxic%20maturation%20stages%20driven%20by%20the%20immunological%20history%20of%20donors.%20This%20landmark%20study%20establishes%20the%20rationale%20for%20identification%2C%20subtyping%2C%20and%20deep%20characterization%20of%20human%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20in%20further%20scRNA-seq%20studies%20of%20complex%20tissues%20in%20physiological%20and%20disease%20conditions.%22%2C%22date%22%3A%22May%2022%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1073%5C%2Fpnas.1818488116%22%2C%22ISSN%22%3A%221091-6490%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A18Z%22%7D%7D%2C%7B%22key%22%3A%227IJWM4K6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Quintyn%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQuintyn%2C%20Jean-Claude%2C%20Priscille%20Olle%2C%20Monique%20Courtade-Saidi%2C%20Camille%20Laurent%2C%20Lucie%20Ob%26%23xE9%3Bric%2C%20and%20Marie-Laure%20Quintyn-Ranty.%20%26%23x201C%3BCytological%20Diagnosis%20of%20Vitreoretinal%20Lymphomas%3A%20A%20Case%20Series.%26%23x201D%3B%20%3Ci%3ECytopathology%3A%20Official%20Journal%20of%20the%20British%20Society%20for%20Clinical%20Cytology%3C%5C%2Fi%3E%2C%20April%2029%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fcyt.12711%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fcyt.12711%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cytological%20diagnosis%20of%20vitreoretinal%20lymphomas%3A%20A%20case%20series%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Quintyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priscille%22%2C%22lastName%22%3A%22Olle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Courtade-Saidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Quintyn-Ranty%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20cytological%20diagnosis%20and%20follow-up%20of%20patients%20suffering%20from%20vitreoretinal%20lymphoma%20%28VRL%29%20diagnosed%20in%20our%20institution.%5CnMETHODS%20AND%20RESULTS%3A%20From%20January%202010%20to%20June%202017%2C%20we%20collected%2015%20patients%20with%20VRL.%20Twelve%20patients%20had%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%3B%20of%20these%2C%2011%20had%20primary%20central%20nervous%20system%20%28CNS%29%20DLBCL%2C%20one%20had%20ocular%20localization%20of%20follicular%20lymphoma%2C%20one%20had%20extranodal%20NK%5C%2FT-cell%20nasal%20type%20lymphoma%20and%20one%20had%20chronic%20lymphocytic%20leukaemia.%20The%20results%20of%20the%20cytological%20examination%20%28cell%20morphology%20and%20immunocytochemistry%29%20of%20the%20vitreous%20fluid%20were%20available%20for%209%5C%2F15%20VRL.%20The%20IL-10%5C%2FIL-6%20ratio%20was%20%3E%201%20in%208%20of%2012%20DLBCL.%20Molecular%20testing%20was%20useful%20in%206%5C%2F15%20cases%20%28clonality%20evaluationor%20MYD88%20L265P%20mutation%20testing%29.%20Eight%20out%20of%2011%20primary%20CNS%20DLBCL%20patients%20had%20CNS%20involvement%2C%20with%20twenty-two-month%20progression-free%20survival.%20In%20our%20series%2C%20only%202%20out%20of%2011%20CNS%20DLBCL%20patients%20died%20of%20disease%20after%202%20and%205%20years%2C%20respectively.%5CnCONCLUSIONS%3A%20The%20short%20delay%20to%20assert%20the%20diagnosis%20of%20VRL%20could%20explain%20the%20quite%20good%20prognosis%20in%20our%20series%2C%20which%20highlights%20the%20need%20to%20consider%20a%20diagnosis%20of%20DLBCL%20as%20first%20step.%20The%20cytological%20features%2C%20as%20a%20reliable%20way%20to%20identify%20vitreoretinal%20lymphoma%2C%20must%20always%20guide%20the%20choice%20of%20techniques%20for%20further%20investigations%20given%20the%20small%20amount%20of%20vitreous%20fluid%20available%20for%20analysis.%20This%20article%20is%20protected%20by%20copyright.%20All%20rights%20reserved.%22%2C%22date%22%3A%22Apr%2029%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fcyt.12711%22%2C%22ISSN%22%3A%221365-2303%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22XJWGJ626%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guinard%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuinard%2C%20Elisabeth%2C%20Fawaz%20Alenezi%2C%20Laurence%20Lamant%2C%20Vanessa%20Szablewski%2C%20Emilie%20Tournier%2C%20Camille%20Laurent%2C%20Carle%20Paul%2C%20Nicolas%20Meyer%2C%20Olivier%20Dereure%2C%20and%20Serge%20Boulinguez.%20%26%23x201C%3BStaging%20of%20Primary%20Cutaneous%20Follicle%20Centre%20B-Cell%20Lymphoma%3A%20Bone%20Marrow%20Biopsy%2C%20CD10%2C%20BCL2%20and%20t%2814%3B18%29%20Are%20Not%20Relevant%20Prognostic%20Factors.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Dermatology%3A%20EJD%3C%5C%2Fi%3E%2C%20April%2017%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fejd.2018.3489%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fejd.2018.3489%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Staging%20of%20primary%20cutaneous%20follicle%20centre%20B-cell%20lymphoma%3A%20bone%20marrow%20biopsy%2C%20CD10%2C%20BCL2%20and%20t%2814%3B18%29%20are%20not%20relevant%20prognostic%20factors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Guinard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fawaz%22%2C%22lastName%22%3A%22Alenezi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Szablewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Tournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carle%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dereure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Boulinguez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20There%20is%20a%20certain%20degree%20of%20controversy%20as%20to%20whether%20bone%20marrow%20biopsy%20is%20required%20during%20the%20staging%20procedures%20for%20primary%20cutaneous%20follicle%20centre%20B-cell%20lymphoma%20%28PCFCCL%29.%5CnOBJECTIVES%3A%20Firstly%2C%20to%20determine%20extra-cutaneous%20involvement%20at%20initial%20diagnosis%2C%20in%20particular%2C%20based%20on%20bone%20marrow%20biopsy%2C%20and%20secondly%2C%20evaluate%20the%20phenotypic%20features%20associated%20with%20extra-cutaneous%20involvement%20during%20follow-up%20%28in%20particular%2C%20the%20predictive%20value%20of%20BCL2%20and%20CD10%20coexpression%20and%20identification%20of%20t%5B14%3B18%5D%20in%20skin%20lesions%2C%20as%20well%20as%20bone%20marrow%20biopsy%20involvement%20at%20initial%20staging%29%20in%20a%20cohort%20of%20patients%20with%20PCFCCL.%5CnMATERIALS%20%26%20METHODS%3A%20A%20bicentric%20retrospective%20study%20was%20established%20to%20investigate%2075%20cases%20of%20PCFCCL%2C%20for%20which%2044%20bone%20marrow%20biopsies%20were%20performed.%5CnRESULTS%3A%20Two%20of%2044%20%285%25%29%20patients%20had%20bone%20marrow%20involvement.%20These%20two%20patients%20had%20no%20relapse%20during%20follow-up%2C%20either%20cutaneous%20or%20extra-cutaneous.%20BCL2%20staining%20in%20B%5Cu00a0cells%20was%20positive%20in%2039%5C%2F75%20%2852%25%29%20cases%20and%20CD10%20was%20positive%20in%2039%5C%2F73%20%2853%25%29.%20Only%204%5C%2F26%20%2815%25%29%20cases%20showed%20t%2814%3B18%29%20based%20on%20fluorescence%20in%20situ%20hybridisation.%5CnCONCLUSIONS%3A%20Our%20study%20combined%20with%20data%20from%20the%20literature%20suggests%20that%20systematic%20bone%20marrow%20biopsy%20at%20initial%20staging%20for%20putative%20PCFCCL%20is%20not%20to%20be%20recommended.%20Moreover%2C%20BCL2%20or%20CD10%20expression%20does%20not%20currently%20represent%20a%20reliable%20basis%20to%20introduce%20significant%20changes%20in%20initial%20therapy%20or%20the%20follow-up%20strategy.%22%2C%22date%22%3A%22Apr%2017%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1684%5C%2Fejd.2018.3489%22%2C%22ISSN%22%3A%221952-4013%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22DR8XZCR5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perchey%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPerchey%2C%20Renaud%20T.%2C%20Laure%20Tonini%2C%20Marie%20Tosolini%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Lopez%2C%20Arnaud%20Besson%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Pont.%20%26%23x201C%3BPTMselect%3A%20Optimization%20of%20Protein%20Modifications%20Discovery%20by%20Mass%20Spectrometry.%26%23x201D%3B%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%209%2C%20no.%201%20%28March%2012%2C%202019%29%3A%204181.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-019-40873-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-019-40873-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PTMselect%3A%20optimization%20of%20protein%20modifications%20discovery%20by%20mass%20spectrometry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%20T.%22%2C%22lastName%22%3A%22Perchey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Tonini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%5D%2C%22abstractNote%22%3A%22Discovery%20of%20protein%20modification%20sites%20relies%20on%20protein%20digestion%20by%20proteases%20and%20mass%20spectrometry%20%28MS%29%20identification%20of%20the%20modified%20peptides.%20Depending%20on%20proteases%20used%20and%20target%20protein%20sequence%2C%20this%20method%20yields%20highly%20variable%20coverage%20of%20modification%20sites.%20We%20introduce%20PTMselect%2C%20a%20digestion-simulating%20software%20which%20tailors%20the%20optimal%20set%20of%20proteases%20for%20discovery%20of%20global%20or%20targeted%20modification%20from%20any%20single%20or%20multiple%20proteins.%22%2C%22date%22%3A%22Mar%2012%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-019-40873-3%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22DXNAE4ND%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarkozy%20et%20al.%22%2C%22parsedDate%22%3A%222019-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESarkozy%2C%20Cl%26%23xE9%3Bmentine%2C%20Christiane%20Copie-Bergman%2C%20Diane%20Damotte%2C%20Susana%20Ben-Neriah%2C%20Barbara%20Burroni%2C%20J%26%23xE9%3Brome%20Cornillon%2C%20Richard%20Lemal%2C%20et%20al.%20%26%23x201C%3BGray-Zone%20Lymphoma%20Between%20CHL%20and%20Large%20B-Cell%20Lymphoma%3A%20A%20Histopathologic%20Series%20From%20the%20LYSA.%26%23x201D%3B%20%3Ci%3EThe%20American%20Journal%20of%20Surgical%20Pathology%3C%5C%2Fi%3E%2043%2C%20no.%203%20%28March%202019%29%3A%20341%26%23x2013%3B51.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001198%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001198%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Gray-zone%20Lymphoma%20Between%20cHL%20and%20Large%20B-Cell%20Lymphoma%3A%20A%20Histopathologic%20Series%20From%20the%20LYSA%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%22%2C%22lastName%22%3A%22Ben-Neriah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Burroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22Cornillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lemal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Golfier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Fabiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Chassagne-Cl%5Cu00e9ment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Parrens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Herbaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Xerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Bossard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Cheminant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Cabecadas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Steidl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Ghesqui%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Mottok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%5D%2C%22abstractNote%22%3A%22Gray-zone%20lymphoma%20%28GZL%29%20with%20features%20intermediate%20between%20classic%20Hodgkin%20lymphoma%20%28cHL%29%20and%20large%20B-cell%20lymphoma%20%28LBCL%29%20was%20introduced%20as%20a%20provisional%20entity%20into%20the%20World%20Health%20Organization%20classification%20in%202008.%20However%2C%20as%20diagnostic%20criteria%20are%20imprecise%2C%20reliable%20identification%20of%20GZL%20cases%20remains%20challenging.%20Here%2C%20we%20describe%20the%20histopathologic%20features%20of%20139%20GZL%20cases%20from%20a%20retrospective%20Lymphoma%20Study%20Association%20%28LYSA%29%20study%20with%20the%20goal%20to%20improve%20classification%20accuracy.%20Inclusion%20criteria%20were%20based%20on%20literature%20review%20and%20an%20expert%20consensus%20opinion%20of%20the%20LYSA%20hematopathologist%20panel.%20We%20observed%2086%20cases%20with%20a%20morphology%20more%20closely%20related%20to%20cHL%2C%20but%20with%20an%20LBCL%20immunophenotype%20based%20on%20strong%20and%20homogenous%20B-cell%20marker%20expression%20%28CD20%20and%5C%2For%20CD79a%2C%20OCT2%2C%20BOB1%2C%20PAX5%29%20on%20all%20tumor%20cells%20%28cHL-like%20GZL%29.%20Fifty-three%20cases%20were%20morphologically%20more%20closely%20related%20to%20LBCL%20but%20harbored%20a%20cHL%20immunophenotype%20%28LBCL-like%20GZL%29.%20Importantly%2C%20we%20observed%20a%20continuous%20morphologic%20and%20immunophenotypic%20spectrum%20within%20these%202%20GZL%20categories.%20The%20majority%20of%20cases%20presented%20genetic%20immune%20escape%20features%20with%20CD274%5C%2FPDCD1LG2%20and%5C%2For%20CIITA%20structural%20variants%20by%20fluorescence%20in%20situ%20hybridization.%20Patients%20without%20mediastinal%20involvement%20at%20diagnosis%20%2817%25%29%20were%20older%20than%20those%20with%20mediastinal%20tumors%20%28median%3A%2056%20vs.%2039%5Cu2009y%29.%20Cases%20associated%20with%20Epstein-Barr%20virus%20%2824%25%29%20presented%20with%20similar%20patient%20characteristics%20and%20outcome%20as%20Epstein-Barr%20virus%20negative%20cases.%20In%20summary%2C%20we%20provide%20refined%20diagnostic%20criteria%20that%20contribute%20to%20a%20more%20precise%20pathologic%20and%20clinical%20characterization%20of%20GZL%20within%20a%20broad%20spectrum%20from%20cHL-like%20to%20LBCL-like%20disease.%22%2C%22date%22%3A%22Mar%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001198%22%2C%22ISSN%22%3A%221532-0979%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A47%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22YVP6CVLM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baseggio%20et%20al.%22%2C%22parsedDate%22%3A%222019-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBaseggio%2C%20Lucile%2C%20Alexandra%20Travers-Glehen%2C%20Emmanuel%20Bachy%2C%20and%20Camille%20Laurent.%20%26%23x201C%3BBreast%20Implant-Associated%20Anaplastic%20Large%20Cell%20Lymphoma.%26%23x201D%3B%20%3Ci%3EBlood%20Research%3C%5C%2Fi%3E%2054%2C%20no.%201%20%28March%202019%29%3A%203.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5045%5C%2Fbr.2019.54.1.3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5045%5C%2Fbr.2019.54.1.3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Breast%20implant-associated%20anaplastic%20large%20cell%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Baseggio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Travers-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Bachy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Mar%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5045%5C%2Fbr.2019.54.1.3%22%2C%22ISSN%22%3A%222287-979X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A08Z%22%7D%7D%2C%7B%22key%22%3A%227WHZTJE8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Phonesouk%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-07%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPhonesouk%2C%20Erick%2C%20S%26%23xE9%3Bverine%20Lechevallier%2C%20Audrey%20Ferrand%2C%20Marie-Pierre%20Rols%2C%20Christine%20Bezombes%2C%20Marc%20Verelst%2C%20and%20Muriel%20Golzio.%20%26%23x201C%3BIncreasing%20Uptake%20of%20Silica%20Nanoparticles%20with%20Electroporation%3A%20From%20Cellular%20Characterization%20to%20Potential%20Applications.%26%23x201D%3B%20%3Ci%3EMaterials%20%28Basel%2C%20Switzerland%29%3C%5C%2Fi%3E%2012%2C%20no.%201%20%28January%207%2C%202019%29%3A%20E179.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fma12010179%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fma12010179%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increasing%20Uptake%20of%20Silica%20Nanoparticles%20with%20Electroporation%3A%20From%20Cellular%20Characterization%20to%20Potential%20Applications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erick%22%2C%22lastName%22%3A%22Phonesouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Lechevallier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Rols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Verelst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Golzio%22%7D%5D%2C%22abstractNote%22%3A%22In%20the%20fields%20of%20biology%20and%20medicine%2C%20nanoproducts%20such%20as%20nanoparticles%20%28NPs%29%20are%20specifically%20interesting%20as%20theranostic%20tools%2C%20since%20they%20offer%20the%20double%20capacity%20to%20locally%20deliver%20active%20drugs%20and%20to%20image%20exactly%20where%20the%20product%20is%20delivered.%20Among%20the%20many%20described%20possibilities%2C%20silica%20nanoparticles%20%28SiNPs%29%20represent%20a%20good%20choice%20because%20of%20their%20ease%20of%20synthesis%2C%20the%20possibility%20of%20their%20vast%20functionalization%2C%20and%20their%20good%20biocompatibility.%20However%2C%20SiNPs%27%20passive%20cell%20internalization%20by%20endocytosis%20only%20distributes%20NPs%20into%20the%20cell%20cytoplasm%20and%20is%20unable%20to%20target%20the%20nucleus%20if%20SiNPs%20are%20larger%20than%20a%20few%20nanometers.%20In%20this%20study%2C%20we%20demonstrate%20that%20the%20cell%20penetration%20of%20SiNPs%20of%2028%5Cu207b30%20nm%20in%20diameter%20can%20be%20strongly%20enhanced%20using%20a%20physical%20method%2C%20called%20electroporation%20or%20electropermeabilization%20%28EP%29.%20The%20uptake%20of%20fluorescently%20labelled%20silica%20nanoparticles%20was%20improved%20in%20two%20different%20cancer%20cell%20lines%2C%20namely%2C%20HCT-116%20%28human%20colon%20cancer%29%20cells%20and%20RL%20%28B-lymphoma%29%20cells.%20First%2C%20we%20studied%20cells%27%20capability%20for%20the%20regular%20passive%20uptake%20of%20SiNPs%20in%20vitro.%20Then%2C%20we%20set%20EP%20parameters%20in%20order%20to%20induce%20a%20more%20efficient%20and%20rapid%20cell%20loading%2C%20also%20comprising%20the%20nuclear%20compartment%2C%20while%20preserving%20the%20cell%20viability.%20In%20the%20final%20approach%2C%20we%20performed%20in%20vivo%20experiments%2C%20and%20evidenced%20that%20the%20labeling%20was%20long-lasting%2C%20as%20confirmed%20by%20fluorescence%20imaging%20of%20labeled%20tumors%2C%20which%20enabled%20a%2030-day%20follow-up.%20This%20kind%20of%20SiNPs%20delivery%2C%20achieved%20by%20EP%2C%20could%20be%20employed%20to%20load%20extensive%20amounts%20of%20active%20ingredients%20into%20the%20cell%20nucleus%2C%20and%20concomitantly%20allow%20the%20monitoring%20of%20the%20long-term%20fate%20of%20nanoparticles.%22%2C%22date%22%3A%222019-01-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fma12010179%22%2C%22ISSN%22%3A%221996-1944%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A10Z%22%7D%7D%2C%7B%22key%22%3A%229NBPDPBB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franchini%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFranchini%2C%20Don-Marc%2C%20Olivia%20Lanvin%2C%20Marie%20Tosolini%2C%20Emilie%20Patras%20de%20Campaigno%2C%20Anne%20Cammas%2C%20Sarah%20P%26%23xE9%3Bricart%2C%20Clara-Maria%20Scarlata%2C%20et%20al.%20%26%23x201C%3BMicrotubule-Driven%20Stress%20Granule%20Dynamics%20Regulate%20Inhibitory%20Immune%20Checkpoint%20Expression%20in%20T%20Cells.%26%23x201D%3B%20%3Ci%3ECell%20Reports%3C%5C%2Fi%3E%2026%2C%20no.%201%20%28January%202%2C%202019%29%3A%2094-107.e7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2018.12.014%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2018.12.014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Microtubule-Driven%20Stress%20Granule%20Dynamics%20Regulate%20Inhibitory%20Immune%20Checkpoint%20Expression%20in%20T%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Patras%20de%20Campaigno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Cammas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Lebras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20B.%22%2C%22lastName%22%3A%22Arimondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Lapeyre-Mestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Millevoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20clinical%20success%20of%20blocking%20inhibitory%20immune%20checkpoint%20receptors%20such%20as%20programmed%20cell%20death-1%20%28PD-1%29%20in%20cancer%2C%20the%20mechanisms%20controlling%20the%20expression%20of%20these%20receptors%20have%20not%20been%20fully%20elucidated.%20Here%2C%20we%20identify%20a%20post-transcriptional%20mechanism%20regulating%20PD-1%20expression%20in%20T%5Cu00a0cells.%20Upon%20activation%2C%20the%20PDCD1%20mRNA%20and%20ribonucleoprotein%20complexes%20coalesce%20into%20stress%20granules%20that%20require%20microtubules%20and%20the%20kinesin%5Cu00a01%20molecular%20motor%20to%20proceed%20to%20translation.%20Hence%2C%20PD-1%20expression%20is%20highly%20sensitive%20to%20microtubule%20or%20stress%20granule%20inhibitors%20targeting%20this%20pathway.%20Evidence%20from%20healthy%20donors%20and%20cancer%20patients%20reveals%20a%20common%20regulation%20for%20the%20translation%20of%20CTLA4%2C%20LAG3%2C%20TIM3%2C%20TIGIT%2C%20and%20BTLA%20but%20not%20of%20the%20stimulatory%20co-receptors%20OX40%2C%20GITR%2C%20and%204-1BB%20mRNAs.%20In%20patients%2C%20disproportionality%20analysis%20of%20immune-related%20adverse%20events%20for%20currently%20used%20microtubule%20drugs%20unveils%20a%20significantly%20higher%20risk%20of%20autoimmunity.%20Our%20findings%20reveal%20a%20fundamental%20mechanism%20of%20immunoregulation%20with%20great%20importance%20in%20cancer%20immunotherapy.%22%2C%22date%22%3A%22Jan%2002%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.celrep.2018.12.014%22%2C%22ISSN%22%3A%222211-1247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22WVCHCN8C%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22LEVHN8UC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Decaup%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDecaup%2C%20Emilie%2C%20C%26%23xE9%3Bdric%20Rossi%2C%20Pauline%20Gravelle%2C%20Camille%20Laurent%2C%20Julie%20Bordenave%2C%20Marie%20Tosolini%2C%20Anne%20Tourette%2C%20et%20al.%20%26%23x201C%3BA%20Tridimensional%20Model%20for%20NK%20Cell-Mediated%20ADCC%20of%20Follicular%20Lymphoma.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2010%20%282019%29%3A%201943.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.01943%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.01943%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Tridimensional%20Model%20for%20NK%20Cell-Mediated%20ADCC%20of%20Follicular%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Decaup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bordenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Tourette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Perrial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Dumontet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariel%22%2C%22lastName%22%3A%22Savina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20is%20the%20second%20most%20frequent%20subtype%20of%20B%20non-Hodgkin%27s%20lymphomas%20%28NHL%29%20for%20which%20the%20treatment%20is%20based%20on%20the%20use%20of%20anti-CD20%20mAbs.%20NK%20cells%20play%20a%20crucial%20role%20in%20their%20mechanism%20of%20action%20and%20the%20number%20of%20these%20cells%20mediating%20antibody-dependent%20cell%20cycotoxicity%20%28ADCC%29%20in%20the%20peripheral%20blood%20of%20FL%20patients%20predict%20the%20outcome.%20However%2C%20their%20presence%20in%20FL%20biopsies%2C%20their%20activation%20and%20their%20role%20have%20been%20poorly%20investigated.%20Moreover%2C%20in%20vitro%20studies%20have%20not%20deciphered%20the%20exact%20signaling%20cascades%20triggered%20by%20NK%20cells%20in%20presence%20of%20anti-CD20%20mAbs%20on%20both%20effector%20and%20target%20cells%20in%20a%20relevant%20FL%20model.%20We%20performed%20in%20silico%20analyses%20and%20ex%20vivo%20functional%20assays%20to%20determine%20the%20presence%20and%20the%20activation%20status%20of%20NK%20cells%20in%20FL%20biopsies.%20We%20modelized%20ADCC%20phenomenon%20by%20developing%20a%20co-culture%20model%20composed%20by%203D-cultured%20FL%20cells%20and%20NK%20cells.%20Thus%2C%20we%20investigated%20the%20biological%20effect%20of%20anti-CD20%20mAbs%20by%20fluorescent%20microscopy%20and%20the%20phosphorylation%20status%20of%20survival%20pathways%20by%20cell%20bar%20coding%20phosphoflow%20in%20target%20cells.%20In%20parallel%2C%20we%20measured%20the%20status%20of%20activation%20of%20downstream%20Fc%5Cu03b3RIIIa%20signaling%20pathways%20in%20effector%20cells%20and%20their%20activation%20%28CD69%2C%20perforin%2C%20granzyme%20B%2C%20IFN%5Cu03b3%29%20by%20flow%20cytometry.%20We%20determined%20by%20in%20vivo%20experiments%20the%20effects%20of%20anti-CD20%20mAbs%20in%20presence%20of%20NK%20cells%20in%20SCID-Beige%20engrafted%20FL%20mice.%20Here%2C%20we%20show%20that%20functional%20NK%20cells%20infiltrate%20FL%20biopsies%2C%20and%20that%20their%20presence%20tends%20to%20correlate%20with%20the%20survival%20of%20FL%20patients.%20Using%20our%203D%20co-culture%20model%2C%20we%20show%20that%20rituximab%20and%20GA101%20are%20able%20to%20promote%20degranulation%2C%20CD69%20expression%2C%20IFN%5Cu03b3%20production%20and%20activate%20Fc%5Cu03b3RIIIa%20signaling%20cascade%20in%20NK%20cells%2C%20and%20inhibit%20survival%20pathways%20and%20induce%20apoptosis%20in%20FL%20cells.%20The%20effect%20of%20GA101%20seems%20to%20be%20more%20pronounced%20as%20observed%20in%20vivo%20in%20a%20xenograft%20FL%20model.%20This%20study%20strongly%20supports%20the%20role%20of%20NK%20cells%20in%20FL%20and%20highlights%20the%20application%20of%20the%203D%20co-culture%20model%20for%20in%20vitro%20validation.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2019.01943%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22QHYGXK9A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rossi%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERossi%2C%20C%26%23xE9%3Bdric%2C%20Pauline%20Gravelle%2C%20Emilie%20Decaup%2C%20Julie%20Bordenave%2C%20Mary%20Poupot%2C%20Marie%20Tosolini%2C%20Don-Marc%20Franchini%2C%20et%20al.%20%26%23x201C%3BBoosting%20%26%23x393%3B%26%23x3B4%3B%20T%20Cell-Mediated%20Antibody-Dependent%20Cellular%20Cytotoxicity%20by%20PD-1%20Blockade%20in%20Follicular%20Lymphoma.%26%23x201D%3B%20%3Ci%3EOncoimmunology%3C%5C%2Fi%3E%208%2C%20no.%203%20%282019%29%3A%201554175.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2018.1554175%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2018.1554175%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Boosting%20%5Cu03b3%5Cu03b4%20T%20cell-mediated%20antibody-dependent%20cellular%20cytotoxicity%20by%20PD-1%20blockade%20in%20follicular%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Decaup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bordenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Poupot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Jean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariel%22%2C%22lastName%22%3A%22Savina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alba%20Matas%22%2C%22lastName%22%3A%22C%5Cu00e9spedes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Perez-Galan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bezombes%22%7D%5D%2C%22abstractNote%22%3A%22Follicular%20lymphoma%20%28FL%29%20is%20a%20common%20non%20Hodgkin%27s%20lymphoma%20subtype%20in%20which%20immune%20escape%20mechanisms%20are%20implicated%20in%20resistance%20to%20chemo-immunotherapy.%20Although%20molecular%20studies%20point%20to%20qualitative%20and%20quantitative%20deregulation%20of%20immune%20checkpoints%2C%20in%20depth%20cellular%20analysis%20of%20FL%20immune%20escape%20is%20lacking.%20Here%2C%20by%20functional%20assays%20and%20in%20silico%20analyses%20we%20show%20that%20a%20subset%20of%20FL%20patients%20displays%20a%20%27high%27%20immune%20escape%20phenotype.%20These%20FL%20cases%20are%20characterized%20by%20abundant%20infiltration%20of%20PD1%2B%20CD16%2B%20TCRV%5Cu03b39V%5Cu03b42%20%5Cu03b3%5Cu03b4%20T%20lymphocytes.%20In%20a%203D%20co-culture%20assay%20%28MALC%29%2C%20%5Cu03b3%5Cu03b4%20T%20cells%20mediate%20both%20direct%20and%20indirect%20%28ADCC%20in%20the%20presence%20of%20anti-CD20%20mAbs%29%20cytolytic%20activity%20against%20FL%20cell%20aggregates.%20Importantly%2C%20PD-1%2C%20which%20is%20expressed%20by%20most%20FL-infiltrating%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20with%20ADCC%20capacity%2C%20impairs%20these%20functions.%20In%20conclusion%2C%20we%20identify%20a%20PD1-regulated%20%5Cu03b3%5Cu03b4%20T%20cell%20cytolytic%20immune%20component%20in%20FL.%20Our%20data%20provide%20a%20treatment%20rational%20by%20PD-1%20blockade%20aimed%20at%20boosting%20%5Cu03b3%5Cu03b4%20T%20cell%20anti-tumor%20functions%20in%20FL.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2018.1554175%22%2C%22ISSN%22%3A%222162-4011%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A59Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Péricart, Sarah, Charlotte Waysse, Aurore Siegfried, Stephanie Struski, Eric Delabesse, Camille Laurent, and Solène Evrard. “Subsequent Development of Histiocytic Sarcoma and Follicular Lymphoma: Cytogenetics and next-Generation Sequencing Analyses Provide Evidence for Transdifferentiation of Early Common Lymphoid Precursor-a Case Report and Review of Literature.” Virchows Archiv: An International Journal of Pathology<\/i>, December 5, 2019. https:\/\/doi.org\/10.1007\/s00428-019-02691-w<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sarkozy, Clementine, Stacy Hung, Katsuyoshi Takata, Elizabeth Chavez, Tomohiro Aoki, Gerben Duns, Graham W. Slack, et al. “Mutational Landscape of Grey Zone Lymphoma.” Blood<\/i> 134, no. Supplement_1 (November 13, 2019): 21. https:\/\/doi.org\/10.1182\/blood-2019-127375<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laplagne, Chloé, Marcin Domagala, Augustin Le Naour, Christophe Quemerais, Dimitri Hamel, Jean-Jacques Fournié, Bettina Couderc, Corinne Bousquet, Audrey Ferrand, and Mary Poupot. “Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.” International Journal of Molecular Sciences<\/i> 20, no. 19 (September 23, 2019). https:\/\/doi.org\/10.3390\/ijms20194719<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Mondragón, Laura, Rana Mhaidly, Gian Marco De Donatis, Marie Tosolini, Pascal Dao, Anthony R. Martin, Caroline Pons, et al. “GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-ΚB-Dependent Mechanism.” Cancer Cell<\/i>, August 20, 2019. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.008<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gauthier, Martin, Françoise Durrieu, Elodie Martin, Michael Peres, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet Mary, and Loic Ysebaert. “Prognostic Role of CD4 T-Cell Depletion after Frontline Fludarabine, Cyclophosphamide and Rituximab in Chronic Lymphocytic Leukaemia.” BMC Cancer<\/i> 19, no. 1 (August 14, 2019): 809. https:\/\/doi.org\/10.1186\/s12885-019-5971-z<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, and Pierre Brousset. “[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 7].” Annales De Pathologie<\/i>, August 9, 2019. https:\/\/doi.org\/10.1016\/j.annpat.2019.05.004<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Camille, and Pierre Brousset. “[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 6].” Annales De Pathologie<\/i>, August 9, 2019. https:\/\/doi.org\/10.1016\/j.annpat.2019.05.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Loarer, François, Arjen H. G. Cleven, Corinne Bouvier, Marie-Pierre Castex, Cleofe Romagosa, Anne Moreau, Sébastien Salas, et al. “A Subset of Epithelioid and Spindle Cell Rhabdomyosarcomas Is Associated with TFCP2 Fusions and Common ALK Upregulation.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc<\/i>, August 5, 2019. https:\/\/doi.org\/10.1038\/s41379-019-0323-8<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Branco, Benoît, Thibault Comont, Loïc Ysebaert, Muriel Picard, Camille Laurent, and Lucie Oberic. “Targeted Therapy of BRAF V600E-Mutant Histiocytic Sarcoma: A Case Report and Review of the Literature.” European Journal of Haematology<\/i>, August 2, 2019. https:\/\/doi.org\/10.1111\/ejh.13303<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Curdy, Nicolas, Olivia Lanvin, Camille Laurent, Jean-Jacques Fournié, and Don-Marc Franchini. “Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression.” Trends in Cell Biology<\/i>, August 1, 2019. https:\/\/doi.org\/10.1016\/j.tcb.2019.07.002<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Franchini, Don-Marc, Olivia Lanvin, Nicolas Curdy, and Jean-Jacques Fournié. “[Control of lymphocyte activity by stress granules. New targets for immunotherapy ?].” Medecine Sciences: M\/S<\/i> 35, no. 6–7 (July 2019): 507–9. https:\/\/doi.org\/10.1051\/medsci\/2019109<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Flinn, Ian W., John G. Gribben, Martin J. S. Dyer, William Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, et al. “Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed\/Refractory Chronic Lymphocytic Leukemia.” Blood<\/i> 133, no. 26 (June 27, 2019): 2765–75. https:\/\/doi.org\/10.1182\/blood-2019-01-896290<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Vaysse, Charlotte, Camille Laurent, Loïc Ysebaert, Elodie Chantalat, and Benoit Chaput. “France: The First Country to Ban a Type of Breast Implant Linked to Anaplastic Large Cell Lymphoma.” Aesthetic Surgery Journal<\/i>, June 1, 2019. https:\/\/doi.org\/10.1093\/asj\/sjz142<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pizzolato, Gabriele, Hannah Kaminski, Marie Tosolini, Don-Marc Franchini, Fréderic Pont, Fréderic Martins, Carine Valle, et al. “Single-Cell RNA Sequencing Unveils the Shared and the Distinct Cytotoxic Hallmarks of Human TCRVδ1 and TCRVδ2 Γδ T Lymphocytes.” Proceedings of the National Academy of Sciences of the United States of America<\/i>, May 22, 2019. https:\/\/doi.org\/10.1073\/pnas.1818488116<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Quintyn, Jean-Claude, Priscille Olle, Monique Courtade-Saidi, Camille Laurent, Lucie Obéric, and Marie-Laure Quintyn-Ranty. “Cytological Diagnosis of Vitreoretinal Lymphomas: A Case Series.” Cytopathology: Official Journal of the British Society for Clinical Cytology<\/i>, April 29, 2019. https:\/\/doi.org\/10.1111\/cyt.12711<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Guinard, Elisabeth, Fawaz Alenezi, Laurence Lamant, Vanessa Szablewski, Emilie Tournier, Camille Laurent, Carle Paul, Nicolas Meyer, Olivier Dereure, and Serge Boulinguez. “Staging of Primary Cutaneous Follicle Centre B-Cell Lymphoma: Bone Marrow Biopsy, CD10, BCL2 and t(14;18) Are Not Relevant Prognostic Factors.” European Journal of Dermatology: EJD<\/i>, April 17, 2019. https:\/\/doi.org\/10.1684\/ejd.2018.3489<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Perchey, Renaud T., Laure Tonini, Marie Tosolini, Jean-Jacques Fournié, Frédéric Lopez, Arnaud Besson, and Frédéric Pont. “PTMselect: Optimization of Protein Modifications Discovery by Mass Spectrometry.” Scientific Reports<\/i> 9, no. 1 (March 12, 2019): 4181. https:\/\/doi.org\/10.1038\/s41598-019-40873-3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sarkozy, Clémentine, Christiane Copie-Bergman, Diane Damotte, Susana Ben-Neriah, Barbara Burroni, Jérome Cornillon, Richard Lemal, et al. “Gray-Zone Lymphoma Between CHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.” The American Journal of Surgical Pathology<\/i> 43, no. 3 (March 2019): 341–51. https:\/\/doi.org\/10.1097\/PAS.0000000000001198<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Baseggio, Lucile, Alexandra Travers-Glehen, Emmanuel Bachy, and Camille Laurent. “Breast Implant-Associated Anaplastic Large Cell Lymphoma.” Blood Research<\/i> 54, no. 1 (March 2019): 3. https:\/\/doi.org\/10.5045\/br.2019.54.1.3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Phonesouk, Erick, Séverine Lechevallier, Audrey Ferrand, Marie-Pierre Rols, Christine Bezombes, Marc Verelst, and Muriel Golzio. “Increasing Uptake of Silica Nanoparticles with Electroporation: From Cellular Characterization to Potential Applications.” Materials (Basel, Switzerland)<\/i> 12, no. 1 (January 7, 2019): E179. https:\/\/doi.org\/10.3390\/ma12010179<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Franchini, Don-Marc, Olivia Lanvin, Marie Tosolini, Emilie Patras de Campaigno, Anne Cammas, Sarah Péricart, Clara-Maria Scarlata, et al. “Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells.” Cell Reports<\/i> 26, no. 1 (January 2, 2019): 94-107.e7. https:\/\/doi.org\/10.1016\/j.celrep.2018.12.014<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Decaup, Emilie, Cédric Rossi, Pauline Gravelle, Camille Laurent, Julie Bordenave, Marie Tosolini, Anne Tourette, et al. “A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.” Frontiers in Immunology<\/i> 10 (2019): 1943. https:\/\/doi.org\/10.3389\/fimmu.2019.01943<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rossi, Cédric, Pauline Gravelle, Emilie Decaup, Julie Bordenave, Mary Poupot, Marie Tosolini, Don-Marc Franchini, et al. “Boosting Γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by PD-1 Blockade in Follicular Lymphoma.” Oncoimmunology<\/i> 8, no. 3 (2019): 1554175. https:\/\/doi.org\/10.1080\/2162402X.2018.1554175<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES MEMBRES DE L\u2019\u00c9QUIPE<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider color=”#F19532″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\n
<\/div>\n\n\n
\n
\n
\n
\n
\n
\"\"<\/a><\/div>\n
Mathylda Brachais<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sonia Quertinmont<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Marie Tosolini<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
L\u00e9a Rimailho<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Fabien Gava<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Camille LAURENT<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Cathy Quelen<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
christine Bezombes<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Anne Quillet-Mary<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Don-Marc Franchini<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Olivia Lanvin<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Pauline Gravelle<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n <\/div>\n<\/div><\/div>\n\n